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ABSTRACT 
 
 
BACKGROUND: In the context of the progressive movement towards patient-
centred care, patient-specific decision support is an important focus of interest. Many 
diagnostic and treatment patient decision aids (PDAs) are now available to help 
patients make informed choice decisions. An increasing number of these are 
software-based, with some available online. Multi-Criteria Decision Analysis 
(MCDA) is a potentially useful technique on which to base a software-assisted PDA, 
especially when the decision is complex - as is the case in choosing the best 
treatment for non-small cell lung cancer – but it has so far been relatively little 
exploited in this area. The use of any from a number of existing MCDA-based 
software applications in the development and delivery of a MCDA-based interactive 
PDA can be an effective way of achieving “best-practice” or normative standards of 
decision making, such as 1) a well-constructed set of decision criteria or 2) logically 
consistent patient preferences. However, it also involves the use of resources such as 
the time and cognitive effort involved in decision-making. The comparative 
evaluation of alternative MCDA-based software applications in developing and 
delivering a PDA therefore involves trade-offs between decision effectiveness and 
decision resource criteria moving from the normative to the prescriptive. MCDA is 
an ideal tool for this meta-evaluation task as well as for the adoption decision itself. 
AIM: To analyse, as proof of concept, the use of MCDA for the development, 
implementation and evaluation of interactive PDAs in routine clinical practice. 
OBJECTIVES: 
1. To assess the use with clinicians in the Spanish NHS of two alternative MCDA 
software applications which implement dissimilar MCDA techniques in the 
development of a PDA in routine clinical practice; 
2. To assess the use with clinicians in the Spanish NHS of the same two alternative 
MCDA software applications in the implementation of a PDA in an environment 
replicating actual clinical consultations; 
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3. To build a meta-multi-criteria decision model based on the Decision Resources 
Decision Effectiveness Analysis (DRDEA) framework and assess the use of this 
model by clinicians in the Spanish NHS to make the choice between the two MCDA 
applications as the basis for a PDA. 
METHODS: 
1) Two dissimilar MCDA software applications served as a basis for the 
development of a lung cancer clinical management PDA in close collaboration with 
two different groups of three clinicians from two different Spanish NHS hospitals 
(H1 and H2): 1) Expert Choice, which implements the Analytic Hierarchy Process 
(AHP) MCDA approach; 2) Annalisa in Elicia (ALEL), which implements the 
Simple Attribute Weighting (SAW) MCDA approach. The process of co-
development of the PDA in hospitals H1 and H2 was documented; 
2) Expert Choice was used to implement (i.e. deliver) the lung cancer clinical 
management PDA in three hypothetical consultations in hospital H1. In each 
consultation, one of the three clinicians involved in the development of the tool, with 
support by this researcher, guided a proxy patient (a non-clinical member of hospital 
staff) through the PDA. The same process was repeated with the MCDA software 
ALEL in hospital H2. The process of delivery of the PDA in hospitals H1 and H2 was 
documented; 
3) This researcher built a meta-multi-criteria decision model based on the DRDEA 
framework to help clinicians choose between different MCDA software applications 
as the basis of a PDA. The MCDA approach used for this meta-model was Multi-
Attribute Value Theory (MAVT). The model was implemented, using the software 
HiView 3, with three clinicians from hospital H3 for the choice between Expert 
Choice and ALEL as the basis of a lung cancer clinical management PDA. 
RESULTS: 
The thesis makes a three-fold contribution to research in patient-centred decision 
support. First, it presents two new MCDA software-based approaches to clinical 
decision support, based on joint work with clinicians in the Spanish NHS, for 
developing an interactive PDA for the clinical management of non-small cell lung 
cancer. Second, it describes the use of these decision support tools in the delivery of 
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an interactive PDA for the clinical management of non-small cell lung cancer in a 
hospital environment via simulated consultations between actual clinicians, with 
support from this researcher, and proxy lung cancer patients. Third, it presents and 
applies a new MCDA-based methodology for evaluating the use of alternative 
MCDA software applications in the development and delivery of interactive PDAs. 
 
  
6 
 
AKNOWLEDGEMENTS 
The conversation that this thesis originated from took place on the street in 
Johannesburg, South Africa, several years ago. Much has happened since then. 
Throughout the years that led to this day, Zaid Chalabi and Jack Dowie have been a 
constant source of knowledge and support. Thank you. As Jack said to me once, 
quoting Shoeless Joe Jackson, “if you build it they will come”, and he was right. 
Apart from Zaid and Jack, other friends have illuminated the way. Some quite 
literally, as they are the wonderful clinicians that participated in this research: Angel 
Salvatierra, Eduard Monsó, Jaume Sauleda, Miguel Angel Martín, Isidoro Barneto, 
Teresa Morán, Pedro López de Castro, Mónica Guillot, and Miguel Angel Carvajal. 
In addition to them, my friends Angel López Encuentra and Víctor Abraira provided 
me with extremely valuable insights at a difficult moment. 
Light also came from Hilary, Caroline, Alvaro, Douglas, Charlotte, Angel, Rosa, 
Luciano, Miguel, Alex, Sara, James, Clara, Yoel, Thanassis, Isabelle, Chris, Sandra, 
Andy, Melisa, Triantafyllos, Mariana, Catriona, Sotiris, Karima, Alessandra, Ana, 
Milica, David, Fernando, Leandro, Alejandra, and Yoshimi. Thank you. 
Judy, thank you! Karl, merci bien! 
Paco and Wigberta, my parents, continue giving to me unconditionally, and so do 
Gonzalo and María, Daniel, and Ula. Thank you.  
This thesis is dedicated to my wife Stephanie, my daughter Clara, and my son Eloy. 
  
7 
 
Table of Contents. 
List of Figures. ............................................................................................................. 9 
List of Tables: ............................................................................................................. 12 
Introduction: ............................................................................................................... 15 
Chapter 1. Literature review. ...................................................................................... 21 
Chapter 2: Using Expert Choice and Annalisa in Elicia to develop, with clinicians in 
the Spanish NHS, a patient decision aid for the clinical management of Stage IIIA3 
non-small cell lung cancer. ....................................................................................... 109 
Chapter 3: Using Expert Choice and Annalisa in Elicia to deliver, with clinicians in 
the Spanish NHS, a patient decision aid for the clinical management of Stage IIIA3 
non-small cell lung cancer in an environment replicating actual clinical consultations.
 .................................................................................................................................. 166 
Chapter 4: Using a meta-multi-criteria decision model to make the choice between 
alternative templates for developing and delivering a patient decision aid in routine 
clinical practice. ........................................................................................................ 208 
Chapter 5: Discussion ............................................................................................... 249 
Appendix 1: Initial hierarchies of criteria for the Expert Choice-based PDA and the 
ALEL-based PDA. .................................................................................................... 265 
Appendix 2: Description of the criteria of the final hierarchy common to the Expert 
Choice-based PDA and the ALEL-based PDA. ........................................................ 267 
Appendix 3: Literature search of published clinical studies evaluating the outcomes 
of the three clinical decision options. ....................................................................... 272 
Appendix 4: Expert Choice Evidence-Generation Questionnaire (EC-EGQ), 
clinicians’ judgments about the performance levels of the options on the bottom-level 
criteria of the hierarchy and single-criterion scores of the options on these criteria for 
hospital H1 ............................................................................................................... 284 
Appendix 5: ALEL Evidence-Generation Questionnaire (ALEL-EGQ), clinicians’ 
judgments about the performance levels of the options on the bottom-level criteria of 
the hierarchy and single-criterion scores of the options on these criteria for ALEL-
based PDA ................................................................................................................ 295 
Appendix 6. Visual representation of the sequence of delivery steps using the Expert 
Choice-based PDA (hospital H1) ............................................................................. 306 
Appendix 7. Visual representation of the sequence of delivery steps using the ALEL-
based PDA (hospital H2) .......................................................................................... 309 
Appendix 8: Spanish version of the top-level criteria and of the treatment 
descriptions for the Expert Choice-based PDA ........................................................ 312 
Appendix 9: Spanish version of the top-level criteria and of the treatment 
descriptions for the ALEL-based PDA ..................................................................... 314 
8 
 
Appendix 10: STATA output. .................................................................................. 316 
References: ............................................................................................................... 321 
 
  
9 
 
List of Figures. 
Figure 2.1. Pathway of possible clinical interventions under option 𝐴1, neoadjuvant 
chemotherapy with resective intent. .................................................................................... 113 
Figure 2.2. Pathway of possible clinical interventions under option A2, concurrent chemo-
radiotherapy. ........................................................................................................................ 114 
Figure 2.3. Final hierarchy of criteria for the Expert Choice-based PDA and the ALEL-based 
PDA ..................................................................................................................................... 117 
Figure 2.4. Calculation of the priorities 𝑠𝑖,𝑘 of the options 𝐴𝑖(𝑖 = 1,2,3) on criteria 
𝐶 𝑘(b) (𝑘 = 3,4,5,6) (Expert Choice-based PDA) ............................................................. 134 
Figure 2.5. Transformation of the levels of performance 𝑥𝑖,𝑘 of the options 𝐴𝑖(𝑖 = 1,2,3) on 
criteria 𝐶𝑘(b) (𝑘 = 1,2,7,8 … 24) into priorities 𝑠𝑖,𝑘 (Expert Choice-based PDA) ............. 135 
Figure 2.6. Schematic representation of the Stage IIIA3 non-small cell lung cancer Markov 
model ................................................................................................................................... 140 
Figure 2.7. Calculating the priorities of the options on the top-level criteria (Expert Choice-
based PDA) .......................................................................................................................... 143 
Figure 2.8. Priorities of the options on the top-level criteria (Expert Choice-based PDA) . 144 
Figure 2.9. Transformation of the levels of performance 𝑥𝑖,𝑘 of the options 𝐴𝑖(𝑖 = 1,2,3) on 
criteria 𝐶𝑘(b) (𝑘 = 1,2,7,8 … 24) into ratings 𝑠𝑖,𝑘 (ALEL-based PDA) .............................. 149 
Figure 2.10. Transformation of the levels of performance 𝑥𝑖,𝑘 of the options 𝐴𝑖(𝑖 = 1,2,3) 
into ratings on 𝐶3(𝑏)- 𝐶6(𝑏) (ALEL-based PDA) ................................................................ 152 
Figure 2.11: Weighted sums required in order to calculate the ratinss of the options on the 
parent top-level criteria (ALEL-based PDA) ........................................................................ 155 
Figure 2.12. Calculating the ratings of the options on the top-level criteria (ALEL-based 
PDA) .................................................................................................................................... 156 
Figure 2.13. Visual representation of the scores (priorities/ratings) of the options on the six 
top-level criteria ................................................................................................................... 160 
Figure 2.14. Comparing the performance levels and the scores (priorities/ratings) of the 
options on the bottom-level criteria ..................................................................................... 161 
Figure 3.1. Sequence of delivery steps of the Expert Choice-based and ALEL-based PDAs
 ............................................................................................................................................. 168 
Figure 3.2. Results of delivering the Expert Choice-based PDA in hypothetical consultation 
1 with Clinician 1 and a proxy patient (hospital H1) ........................................................... 187 
Figure 3.3. Results of delivering the Expert Choice-based PDA in hypothetical consultation 
2 with Clinician 2 and a proxy patient (hospital H1) ........................................................... 188 
Figure 3.4. Results of delivering the Expert Choice-based PDA in hypothetical consultation 
3 with Clinician 3 and a proxy patient (hospital H1) ........................................................... 189 
Figure 3.5. Results of delivering the ALEL-based PDA in hypothetical consultation 1 with 
Clinician 1 and a proxy patient (hospital H2) ...................................................................... 190 
10 
 
Figure 3.6. Results of delivering the ALEL-based PDA in hypothetical consultation 2 with 
Clinician 2 and a proxy patient (hospital H2) ...................................................................... 191 
Figure 3.7. Results of delivering the ALEL-based PDA in hypothetical consultation 3 with 
Clinician 3 and a proxy patient (hospital H2) ...................................................................... 192 
Figure 3.8. Plot of the MDQ scores (Expert Choice-based PDA and ALEL-based PDA) ... 196 
Figure 3.9. Criteria weights assigned by the proxy patients in the hypothetical consultations
 ............................................................................................................................................. 200 
Figure 4.1. Normativity in the development of a MCDA-based PDA: parent criterion and 
sub-criteria ........................................................................................................................... 214 
Figure 4.2. Practicality in the delivery of the template-based PDA: parent criterion and sub-
criteria .................................................................................................................................. 215 
Figure 4.3. Ease of use of the template interface: parent criterion and sub-criteria ............ 216 
Figure 4.4. Acceptability of the template-based PDA: parent criterion and sub-criteria ..... 216 
Figure 4.5. Full hierarchy of decision criteria for the meta-decision model ........................ 217 
Figure 4.6. Example of a diagram illustrating each of the single-criterion value functions for 
criteria 𝐶𝑘(b)(𝑘 = 1 … 11) .................................................................................................. 218 
Figure 4.7. Value function for criterion normativity in the model structuring (𝐶1(𝑏)) ...... 220 
Figure 4.8. Value function for criterion logical consistency of the preferences  (𝐶2(𝑏)) ... 221 
Figure 4.9. Value function for criterion empirical accuracy of the preferences  (𝐶3(b)) ... 223 
Figure 4.10. Value function for criterion normativity in the evidence generation/ 
representation (𝐶4(𝑏)) ......................................................................................................... 224 
Figure 4.11. Value function for criterion practicality in the communication of the model 
structure and outputs (𝐶5(𝑏)) .............................................................................................. 225 
Figure 4.12. Clinician-specific value functions for criterion practicality in the 
communication of the model structure and outputs (𝐶5(𝑏)) ............................................... 226 
Figure 4.13. Clinician-specific value functions for criterion practicality in the preference 
elicitation ((𝐶6(𝑏))............................................................................................................... 229 
Figure 4.14. Clinician-specific value functions for criterion practicality in the preference 
elicitation ((𝐶7(𝑏)) .............................................................................................................. 232 
Figure 4.15. Value function for criterion ease of use of the template interface by clinicians 
(𝐶8(b))................................................................................................................................. 234 
Figure 4.16. Value function for criterion ease of use of the template interface by patients 
(𝐶9(b)) ................................................................................................................................. 236 
Figure 4.17. Value function for criterion cost of the template (𝐶10(𝑏)) ............................. 239 
Figure 4.18. Value function for criterion organisational fit (𝐶11(𝑏) ................................... 240 
Figure 4.19. Results of the meta-decision model (clinician 1) ............................................ 242 
Figure 4.20. Results of the meta-decision model (clinician 2) ............................................ 244 
11 
 
Figure 4.21. Results of the meta-decision model (clinician 3) ............................................ 245 
Figure 5.1. DRDEA MAUT formulation. Using high DE templates to develop a PDA: 
sacrifice in DE ..................................................................................................................... 252 
Figure 5.2. DRDEA MAUT formulation. Using high DE templates to develop a PDA: no 
sacrifice in DE ..................................................................................................................... 253 
Figure A1.1. Initial hierarchy of criteria for the Expert Choice-based PDA ....................... 265 
Figure A1.2. Initial hierarchy of criteria for the ALEL-based PDA .................................... 266 
Figure A2.1. Sub-hierarchy of quality of life in the medium term sub-criteria (Expert Choice-
based PDA and ALEL-based PDA) ..................................................................................... 269 
Figure A2.2. Sub-hierarchy of treatment-related adverse effects sub-criteria (Expert Choice-
based PDA and ALEL-based PDA) ..................................................................................... 270 
Figure A2.3. Sub-hierarchy of health care experience between the start of treatment and the 
medium term sub-criteria (Expert Choice-based PDA and ALEL-based PDA) .................. 271 
Figure A3.1. Full final hierarchy of criteria for the Expert Choice-based PDA and the ALEL-
based PDA ........................................................................................................................... 273 
Figure A6.1. Communication of the criteria ........................................................................ 306 
Figure A6.2. Pair-wise comparisons screen ......................................................................... 306 
Figure A6.3. Communication of the options ....................................................................... 307 
Figure A6.4. Communication of the results of the decision ................................................ 307 
Figure A6.5. Communication of the evidence for the quality of life in the medium term 
criterion ................................................................................................................................ 307 
Figure A6.6. Dynamic sensitivity analysis screen ............................................................... 308 
Figure A7.1. Communication of the criteria ........................................................................ 309 
Figure A7.2. Elicia screen to assess the criteria weights ..................................................... 309 
Figure A7.3. Weightings panel in the Annalisa topic screen ............................................... 310 
Figure A7.4. Information pop-up for criterion financial burden due to the disease in the 
medium term ........................................................................................................................ 310 
Figure A7.5. Communication of the options ....................................................................... 310 
Figure A7.6. Communication of results ............................................................................... 311 
Figure A7.7. Communication of the evidence ..................................................................... 311 
Figure A7.8 Sensitivity analysis of the criteria weights ...................................................... 311 
 
  
12 
 
List of Tables: 
Table 1.1. IPDAS definition of PDA effectiveness. .............................................................. 27 
Table 1.2. AHP scale of intensity of dominance. .................................................................. 66 
Table 1.3. Software applications for MCDA: methods implemented, decision support 
features and group decision support. ..................................................................................... 83 
Table 1.4. Software applications for MCDA: problem structuring. ...................................... 85 
Table 1.5. Software applications for MCDA: scoring options on the individual criteria ...... 87 
Table 1.6. Software applications for MCDA: weight elicitation. .......................................... 92 
Table 1.7. Software applications for MCDA: analysis of results and sensitivity analysis. ... 94 
Table 2.1.  Description of the pair-wise comparisons used to obtain the priorities of the 
options on criteria 𝐶3(𝑏)-𝐶6(𝑏) ........................................................................................... 121 
Table 2.2. Description of the variables used to measure the levels of performance 𝑥𝑖,𝑘 of the 
options 𝐴𝑖(𝑖 = 1,2,3) on criteria 𝐶 𝑘(b)(𝑘 = 1,2,7,8 … 24) ............................................... 122 
Table 2.3. Description of the variables measuring the levels of the options on the criteria 
𝐶3(𝑏)-𝐶6(𝑏) (ALEL-based PDA) ........................................................................................ 147 
Table 2.4. Inter-rater reliability ............................................................................................ 162 
Table 3.1. Communication of the criteria to the proxy patient (Expert Choice-based PDA)
 ............................................................................................................................................. 171 
Table 3.2. 1-9 AHP scale of intensity of dominance. .......................................................... 172 
Table 3.3. Textual content of the three option descriptions (Expert Choice-based PDA) ... 174 
Table 3.4. Levels of criterion importance and associated weights (ALEL-based PDA) ..... 179 
Table 3.5. Content of the criterion information pop-ups (ALEL-based PDA) .................... 180 
Table 3.6. Possible levels of importance and corresponding weights of the decision quality 
criteria (MDQ) ..................................................................................................................... 184 
Table 3.7. Ratings on the decision criteria (MDQ) .............................................................. 185 
Table 3.8. Overall scores (ranking of options) for the options in hypothetical consultations
 ............................................................................................................................................. 197 
Table 3.9. Highest scoring option on each criterion for each hypothetical consultations ... 198 
Table 3.10. Impact on rankings and overall scores of adding option A2* to the set of options
 ............................................................................................................................................. 202 
Table 3.11. Impact on rankings and overall scores of subtracting option A2 from the set of 
options .................................................................................................................................. 203 
Table 3.12. Impact on rankings and overall scores of subtracting option A3 from the set of 
options .................................................................................................................................. 204 
Table 4.1. Levels 𝑥𝑖,1(𝑖 = 1,2) and value scores 𝑣𝑖,1(𝑖 = 1,2) of the two templates 𝐴𝑖  (𝑖 =
1,2) on criterion normativity in the model structuring (𝐶1(b)) .......................................... 220 
13 
 
Table 4.2. Levels 𝑥𝑖,2(𝑖 = 1,2) and value scores 𝑣𝑖,2(𝑖 = 1,2) of the two templates 𝐴𝑖  (𝑖 =
1,2) on criterion logical consistency of the preferences  (𝐶2(𝑏)) ....................................... 222 
Table 4.3. Levels 𝑥𝑖,3(𝑖 = 1,2) and value scores 𝑣𝑖,3(𝑖 = 1,2) of the two templates 𝐴𝑖  (𝑖 =
1,2) on empirical accuracy of the preferences  (𝐶3(𝑏)) ...................................................... 223 
Table 4.4. Levels 𝑥𝑖,4(𝑖 = 1,2) and value scores 𝑣𝑖,4(𝑖 = 1,2) of the two templates 𝐴𝑖  (𝑖 =
1,2) on normativity in the evidence generation/ representation (𝐶4(𝑏)) ............................ 224 
Table 4.5. Levels 𝑥𝑖,5(𝑖 = 1,2) and value scores 𝑣𝑖,5(𝑖 = 1,2) of the two templates 𝐴𝑖  (𝑖 =
1,2) on criterion practicality in the communication of the model structure and outputs 
(𝐶5(𝑏)) ................................................................................................................................ 228 
Table 4.6. Levels 𝑥𝑖,6(𝑖 = 1,2) and value scores 𝑣𝑖,6(𝑖 = 1,2) of the two templates 𝐴𝑖  (𝑖 =
1,2) on criterion practicality in the preference elicitation ((𝐶6(𝑏)) .................................... 230 
Table 4.7. Levels 𝑥𝑖,7(𝑖 = 1,2) and value scores 𝑣𝑖,7(𝑖 = 1,2) of the two templates 𝐴𝑖  (𝑖 =
1,2) on criterion practicality in the preference elicitation ((𝐶7(𝑏)) .................................... 233 
Table 4.8. Levels 𝑥𝑖,8(𝑖 = 1,2) and value scores 𝑣𝑖,8(𝑖 = 1,2) of the two templates 𝐴𝑖  (𝑖 =
1,2) on criterion ease of use of the template interface by clinicians (𝐶8(𝑏))...................... 235 
Table 4.9. Levels 𝑥𝑖,9(𝑖 = 1,2) and value scores 𝑣𝑖,9(𝑖 = 1,2) of the two templates 𝐴𝑖(𝑖 =
1,2) on criterion ease of use of the template interface by patients (𝐶9(𝑏))......................... 237 
Table 4.10. Single user standard licenses available and their cost for six commonly used 
MCDA templates (in year 2013).......................................................................................... 238 
Table 4.11. Levels 𝑥𝑖,10(𝑖 = 1,2) and value scores 𝑣𝑖,10(𝑖 = 1,2) of the two templates 
𝐴𝑖(𝑖 = 1,2) on criterion cost of the template (𝐶10(𝑏)) ....................................................... 239 
Table 4.12. Levels 𝑥𝑖,11(𝑖 = 1,2) and value scores 𝑣𝑖,11(𝑖 = 1,2) of the two templates 
𝐴𝑖  (𝑖 = 1,2) on criterion organisational fit (𝐶11(𝑏))........................................................... 241 
Table 4.13. Short names of the meta-decision model criteria .............................................. 242 
Table A3.1: Search strategy ................................................................................................. 274 
Table A3.2: Results of the literature search. Treatment option: neoadjuvant chemotherapy 
with resective intent (𝐴1) .................................................................................................... 277 
Table A3.3: Results of the literature search. Treatment option: concurrent chemo-
radiotherapy (𝐴2) ................................................................................................................ 281 
Table A4.1: Expert Choice Evidence Generation Questionnaire (EC-EGC) ...................... 284 
Table A4.2. Levels of the three options 𝐴𝑖 (𝑖 = 1 … 3) on the bottom-level criteria of the full 
final hierarchy for each of the three clinicians (Expert Choice-based PDA) ....................... 287 
Table A4.3. Transition probability matrices for the Stage IIIA3 NSCLC Markov model 
elicited from the three clinicians in hospital H1 (Expert Choice-based PDA) .................... 291 
Table A4.4. Levels 𝑥𝑖,2 (𝑖 = 1 … 3) of the three options 𝐴𝑖 (𝑖 = 1 … 3) on criterion life 
expectancy 𝐶2(𝑏), in years (Expert Choice-based PDA) .................................................... 291 
Table A4.5. Non-idealised scores (idealised scores) of the options 𝐴𝑖(𝑖 = 1 … 3) on the 
bottom-level criteria 𝐶𝑘(𝑏)(𝑘 = 1 … 24) resulting from clinicians’ judgments (Expert 
Choice-based PDA) ............................................................................................................. 292 
14 
 
Table A5.1. ALEL-based evidence generation questionnaire (ALEL-EGC) ...................... 295 
Table A5.2. Levels of the three options 𝐴𝑖 (𝑖 = 1 … 3) on the bottom-level criteria of the full 
final hierarchy for each of the three clinicians (ALEL-based PDA) ................................... 298 
Table A5.3. Transition probability matrices for the Stage IIIA3 NSCLC Markov model 
elicited from the three clinicians in hospital H2 (ALEL-based PDA) ................................. 302 
Table A5.4. Levels 𝑥𝑖,2 (𝑖 = 1 … 3) of the three options 𝐴𝑖 (𝑖 = 1 … 3) on criterion life 
expectancy 𝐶2(𝑏), in years (ALEL-based PDA) ................................................................. 302 
Table A5.5. Non-idealised scores (idealised scores) of the options 𝐴𝑖(𝑖 = 1 … 3) on the 
bottom-level criteria 𝐶𝑘(𝑏)(𝑘 = 1 … 24) resulting from clinicians’ judgments (ALEL-based 
PDA) .................................................................................................................................... 303 
Table A8.1. Renaming in Spanish the top-level criteria for communication to the patient . 312 
Table A8.2. Textual content in Spanish of the three treatment descriptions ....................... 313 
Table A9.1: Renaming in Spanish the top-level criteria for communication to the patient . 314 
Table A9.2: Textual content in Spanish of the three treatment descriptions ....................... 315 
  
15 
 
Introduction: 
 
In recent years there has been an increased emphasis in involving patients in making 
decisions about their own health care [1]. Different models of clinical decision 
making where the patient is an active participant in the decision making process have 
been proposed. One model that has gained high policy support is Shared Decision 
Making (SDM) [2, 3]. SDM is a concept variably and loosely defined [4]. In a 
review of the literature on alternative definitions of SDM, Makoul and Clayman [4] 
proposed that an integrative model of SDM would have the following elements:  a 
discussion between the patient and the clinician of the problem to be addressed, the 
options available, and their pros and cons; an explication of the patient’s values and 
preferences, as well as of the physician’s knowledge and recommendations; an 
assessment of patient self-efficacy to adhere to a plan of action; an explicit decision 
(or an explicit deferment of a decision) and follow-up [2]. 
SDM can be facilitated by the use of patient decision aids [5]. Patient decision aids 
(PDAs) are “evidence-based tools designed to help patients participate in making 
specific and deliberated choices among health care options” [5]. In general, they 
provide decision support to patients by 1) making explicit the decision that needs to 
be made, 2) providing evidence-based information about the condition, the options, 
the consequences (benefits, harms), their probabilities and the uncertainties related to 
each of the health care options under consideration, and 3) helping patients express 
their values/ preferences with regards to the benefits, harms and uncertainties of the 
options [6]. PDAs are available in different formats [7]. A number of them are 
available on the internet. They can be self-administered by patients or used with 
practitioners in the consultation [7].  
A systematic review of randomised clinical trials (RCT) of PDA effectiveness 
provides enough evidence that PDAs improve decision making (in terms e.g. of 
improving patient knowledge, reducing decisional conflict and increasing the 
consistency between patient values and the chosen option) so as to warrant their use 
in clinical practice [5]. However, the routine implementation of these tools to support 
SDM has challenges [7]. Among the barriers cited in the literature by practitioners 
are 1) the lack of skills to practice shared decision making, 2) an organisational 
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culture that hinders the uptake of PDAs, 3) the perception that PDAs are 
inappropriate and/or too complex for use with certain groups of patients, 4) problems 
with workflow fit [7]. These barriers highlight the importance of developing “tools, 
processes and systems of care which make SDM feasible given the constraints of 
routine clinical practice” [8].  
Multi-Criteria Decision Analysis (MCDA) can be the used as the basis for such tools 
[8]. MCDA is “an umbrella term for a collection of formal approaches which 
explicitly seek to take into account of multiple criteria in helping individuals or 
groups explore decisions that matter” [9]. In preference-sensitive choice decision 
situations such as those which are often the subject of SDM, a number of MCDA 
techniques are available to provide decision support. For these decisions, the MCDA 
process usually involves the following steps: 1) Identifying the decision problem, 2) 
clearly specifying the options, 3) Identifying the objectives of the decision and 
related measureable criteria, 4) measuring the consequences of the options on each of 
the criteria and, depending on the specific MCDA technique used, scoring these 
consequences on a common scale, and 5) assigning weights of relative importance to 
the criteria [10]. Formal procedures are used to combine the information from steps 
4) and 5) to provide a recommendation for the decision, usually in the form of a 
ranking of the options from most to least preferred. A sixth step in the process 
involves analysing the robustness of the results to changes in inputs that are not 
defined or measured precisely. The main role of MCDA is to help decision-makers 
manage large amounts of complex information in a way that is consistent [10].  
Examples of well-known MCDA approaches include Multi-Attribute Value Theory 
(MAVT) [11], the Analytic Hierarchy Process (AHP) [12], the family of methods 
Election et Choix Traduisant la Realite (ELECTRE) [13] and the family of methods 
Preference Ranking Organisation Method for Enriched Evaluation (PROMETHEE) 
[14]. The implementation of these methods is usually done using decision analytic 
software applications. For example, HiView 3 [15] implements MAVT, and Expert 
Choice [16] implements the AHP. 
MCDA can and has been used in decision support for complex clinical decisions, 
such as in oncology [17]. In addition, some MCDA approaches have been shown to 
be acceptable to patients and within their capabilities [18].  
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Clinicians can use different software applications for developing and implementing 
MCDA-based PDAs for complex clinical decisions in their day-to-day clinical 
practice environment. According to the Decision resource-decision effectiveness 
analysis (DRDEA) framework [19], the choice by clinicians between alternative 
software applications or “templates” for developing and implementing MCDA-based 
PDAs in routine clinical practice is a multi-criterion meta-decision that can be 
expressed in terms of the trade-offs between two types of criteria: 1) decision 
resources (DR) criteria expressing the resource requirements associated with using 
each template (e.g. time required, cognitive effort required, or financial cost [19]) 
and 2) decision effectiveness (DE) criteria expressing the benefits of using each 
template (e.g. theoretical grounding, evidential strength and coverage, transparency 
[19]). This choice depends on the specific context in which clinicians operate and it 
is preference-sensitive, i.e. it depends on how clinicians trade-off DR and DE 
criteria. According to DRDEA [19], MCDA is the appropriate technique to make this 
choice. 
Aim: To analyse, as proof of concept, the use of MCDA for the development, 
implementation and evaluation of interactive patient decision aids in routine clinical 
practice 
Objectives.  
1. To assess the use with clinicians in the Spanish NHS of two alternative MCDA 
software applications which implement dissimilar MCDA techniques in the 
development of a PDA in routine clinical practice; 
2. To assess the use with clinicians in the Spanish NHS of the same two alternative 
MCDA software applications in the implementation of a PDA in an environment 
replicating actual clinical consultations  
3. To build a meta-multi-criteria decision model based on the DRDEA framework 
and assess the use of this model by clinicians in the Spanish NHS to make the choice 
between the two MCDA applications as the basis for a PDA. 
The case study. 
The case study in this research is a hypothetical 69 year-old patient recently 
diagnosed with stage IIIA3 non-small cell lung cancer and with lung and 
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cardiovascular comorbidities who will use an MCDA-based PDA to choose between 
a set of available clinical management strategies for his condition.  
Methods.  
1. The two MCDA software applications which served as a basis for the development 
of the lung cancer PDA were 1) Expert Choice [16], which implements the Analytic 
Hierarchy Process (AHP) MCDA approach, and Annalisa in Elicia (ALEL) [20], 
which implements the Simple Additive Weighting (SAW) MCDA approach.  
Expert Choice was used by this researcher to co-develop with 3 clinicians (one 
oncologist, one pulmonologist, one thoracic surgeon) from hospital H1 in the 
Spanish NHS a Stage IIIA3 lung cancer clinical management PDA. The same process 
was repeated with a different group of 3 clinicians working in hospital H2 in the 
Spanish NHS using ALEL. 
The process of co-development of each PDA with clinicians was documented by this 
researcher.  This process included the following steps: 1) determining the options, 2) 
determining the relevant criteria for the decision, 3) measuring the consequences of 
the options on the criteria, and 4) scoring these consequences. 
2. ALEL was used to implement (i.e. deliver) the lung cancer clinical management 
PDA in 3 hypothetical consultations in hospital H1. In each consultation, one of the 
three clinicians involved in the development of the tool, with support by this 
researcher, guided a proxy patient (a non-clinical member of hospital staff) through 
the PDA. The same process was repeated with the MCDA software Expert Choice in 
hospital H2.  
The process of implementation of each PDA in each hypothetical consultation, 
documented by this researcher, included the following steps: 1) communication of 
the criteria, 2) preference elicitation, 3) communication of the options, 4) 
communication of the results of the decision, 5) communication of the evidence, 6) 
sensitivity analysis. In addition, at the end of each consultation the perceived quality 
of the decision of both the physician and the patient was assessed using the “My 
Decision Quality” (MDQ) questionnaire [21]. 
3. This researcher built a meta-multi-criteria decision model based on the DRDEA 
framework to help clinicians choose between different MCDA software applications 
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as the basis of a PDA. The MCDA approach used for this meta-model was Multi-
Attribute Value Theory [11]. The model was implemented with 3 clinicians (one 
oncologist, one pulmonologist, one thoracic surgeon) from hospital H3 in the 
Spanish NHS for the choice between ALEL and Expert Choice as the basis of a lung 
cancer management PDA. The MCDA software used to implement the meta-model 
was HiView 3 [15]. 
The process of development of the meta-model by this researcher had four steps: 1) 
determining the options, 2) determining the relevant decision effectiveness (DE) and 
decision resources (DR) criteria, 3) measuring the consequences of the options on the 
criteria, and 4) scoring these options. The implementation of the meta-model with 
each of the 3 clinicians from hospital H3 had three steps: 1) preference elicitation for 
the different DE and DR criteria, 2) review of results, 3) sensitivity analysis. 
This research project was considerably informed by the concept of engaged 
scholarship, which involves generating knowledge in collaboration with practitioners 
(in this case, clinicians from three hospitals in the Spanish NHS) that can jointly 
advance the scientific enterprise and enlighten the community of those practitioners 
[22]. In this sense, the methods used were context-led. That is, they evolved in 
response to the conditions found in the context of clinical practice where the research 
was conducted. Particularly, in response to the time constraints posed to the 
clinicians involved. This should not be considered a limitation but the essence of this 
study. 
Structure of the thesis. 
This thesis is structured to analyse, as proof of concept, the use of MCDA for the 
development, implementation and evaluation of patient decision aids in routine 
clinical practice. Chapter 1 presents a literature review of interactive PDAs. This 
includes a review of the current status in the field of PDAs with a focus on successful 
empirical applications, a review of MCDA methods, and a review of software 
applications supporting MCDA. The chapter ends with a justification of the case 
study for this thesis: a hypothetical 69 year-old patient recently diagnosed with stage 
IIIA3 non-small cell lung cancer and with lung and cardiovascular comorbidities who 
will use an MCDA-based PDA to choose between a set of available clinical 
management strategies for his condition. Chapter 2 describes the process and results 
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of using Expert Choice and ALEL with clinicians to develop a Stage IIIA3 lung 
cancer clinical management PDA in routine clinical practice. Chapter 3 describes the 
process and results of using Expert Choice and ALEL with clinicians to implement a 
Stage IIIA3 lung cancer clinical management PDA in an environment replicating 
actual clinical consultations. Chapter 4 describes the process and results of 
developing and implementing a meta-multi-criteria decision model based on the 
DRDEA framework to help clinicians choose between Expert Choice and ALEL as 
the basis for a Stage IIIA3 lung cancer clinical management PDA. The chapter shows 
that the decision is preference-sensitive: it depends on the trade-offs clinicians are 
willing to make between “decision resources” and “decision effectiveness” criteria. 
Chapter 5 brings all the elements of the thesis together by presenting a discussion of 
the main findings and lessons learnt, as well as suggestions for further research. 
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Chapter 1. Literature review. 
 
1. What is and what is not a PDA.  
PDAs are tools to help patients participate in making decisions about health care 
options [5]. They contain, at least, information about the health care options and 
about their consequences (e.g. benefits and harms) on an individual’s health [6]. In 
addition, they may provide 1) information on the condition, 2) the chances (i.e. 
probabilities) that the patient will experience these consequences, 3) an explicit 
exercise to help patients clarify their preferences (i.e. values) over the consequences 
of the options, 4) other’s testimonials, and 5) assistance through the decision-making 
process [6].  
PDAs are most often used to help patients make preference-sensitive decisions, i.e. 
decisions for which the choice of option is not clear (e.g. because several options 
with similar efficacy are available) and thus depend on the patient’s valuation of the 
different consequences of the options [23]. They support the process of Shared 
Decision Making, a mode of decision making in which both clinicians and patients 
share information in order to reach a consensus about the preferred treatment [24]. 
The above definition of PDAs excludes 1) passive informed consent materials, 2) 
educational interventions which are not targeted to making a specific decision, 3) 
interventions to increase adherence to a particular option. It also excludes 
computerised decision support systems (CDSS). CDSS are information technology 
(IT)-based systems that use algorithms to provide specific recommendations to 
clinicians about a particular patient or his/her condition [25], including, inter alia, 
computerised physician order entry systems, reminder systems, alert systems, and 
medical calculators. CDSS are not patient-centred but clinician-centred systems. 
2. Origin, growth, drivers. 
The early development of PDAs was influenced by work on decision support tools 
based on Decision Analysis [23], a quantitative approach to decision making first 
used in patient counselling in the late 1970s [26, 27]. In the 1980s, the work by 
Mulley, Wennberg and others [28, 29] on interactive multimedia programmes for the 
treatment on benign prostate hyperplasia was influential in the development of the 
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field [23]. PDAs are primarily developed and used in Australia, North America and 
Europe [5]. In the last 15 years their number has proliferated rapidly [5]. While in 
1999 only 15 PDAs had been developed by researchers [30], in 2007 O’Connor 
reported the existence of more than 450 PDAs and that the previous year more than 8 
million hits were made on the websites of the main PDA providers [31]. In 2014, the 
Ottawa Decision Aid Repository, a comprehensive collection of PDAs available on 
the internet, received more than 80,000 visits and provided information about 647 
PDAs [32]. 
Several factors have influenced the development of PDAs, among which are the 
following: 
1. An acknowledgement that, with the rapid expansion of health care interventions in 
recent years, several options are often available for a particular clinical decision, and 
that the choice of option will often depend on the trade-offs between the harms, 
benefits, and uncertainties related to each of these options [1]; 
2. The search for interventions to help reduce unwarranted variations in the provision 
of health care (i.e. variation in the provision of care that could not be explained by 
the need for these interventions) [23, 33]. In this sense, the use of PDAs is intended 
to spur patient self-interest in avoiding those interventions [23]; 
3. The increased importance of the ethical principle of respect for patient autonomy 
[23], which promotes that patients make choices understanding all the relevant 
information about the options and which has prompted changes in the legal 
requirements for informed consent [34]. These changes highlight the importance that 
patients are fully informed of the consequences of the different health care options 
available to them before they make a decision [34]. PDAs are tools which may 
support this process; 
4. The influence of the evidence-based medicine (EBM) movement [6]. EBM 
highlights the importance of making available and taking into account information 
about the outcomes of different health care interventions in clinical decision making.  
3. Types of PDAs. 
PDAs are heterogeneous tools. In terms of their scope, they vary in: 
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- The health care condition they address, ranging from allergies to depression, from 
cancer to end of life care [32];  
- The type of decision they support, such as choice of screening test, choice of 
treatment, or choice of self-management strategy [1]; 
In terms of their characteristics, they differ, inter alia, in terms of: 
- Their format, including booklets (see, for example Labrecque et al. [35] or Legare 
et al. [36]), audiotape workbooks (e.g. Hunter et al. [37]), videos (e.g. Partin et al. 
[38] and Pignone et al. [39]), and internet-based applications such as those provided 
by the following online resources: Patient [40], NHS Rightcare [41], Healthwise 
[42], Mayo Clinic Shared Decision Making National Resource Center [43]; 
- Their mode of delivery, either self-administered by patients or used with clinicians 
in the consultation [7]; 
- Their components, which may or may not include probabilistic information about 
the consequences of the options, visual representations of this probabilistic 
information, explicit value clarification exercises, personal stories (e.g. testimonials 
of other patients) or guidance through the decision-making process [5];  
- The theory or model of decision making which informs their design and 
development [26], e.g. Decision Analysis under Expected Utility Theory (e.g. Bekker 
at al. [44] or Montgomery et al. [45]), Multi-Criteria Decision Analysis (e.g. Dolan 
and Frisina [46]), the Ottawa Decision Support Framework (e.g. Hunter et al. [37] or 
Lalonde et al. [47]), the Health Belief Model (e.g. Schapira and VanRuiswyk [48]), 
or no theory or model of decision making (e.g. Auvinen et al. [49] or Deschamps et 
al. [50]). 
For the purposes of this thesis, one type of PDAs is particularly relevant: 
computerised PDAs. These PDAs use a computerised medium, and their format 
includes video-discs, CD-ROM or computer-based programmes, and websites [51]. 
Computerised PDAs have a number of advantages over other types of PDAs: 1) they 
allow for interactivity and for the use of visual features which can facilitate patient 
involvement, 2) they can include information tailored to specific patients, 3) they can 
provide feedback to increase understanding and 4) they can facilitate the 
dissemination of information [51]. PDAs are increasingly computerised [51]. 
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4. What makes a good PDA? Different views on the most appropriate measure 
of PDA effectiveness. 
In principle a good PDA is a PDA that leads to a good decision. However, there are 
different views about what constitutes a good decision [5]. These different views are 
reflected in the literature in a debate around what should be the focus of the 
evaluation of PDAs, i.e. what is the most appropriate measure of the effectiveness of 
PDAs [52].  
Studies measuring the effectiveness of PDAs have used a wide range of outcomes. 
The next five sections provide an overview of these outcomes. Incorporated in the 
narrative are any salient criticisms and justifications in the literature for the use of 
these outcomes as measures of effectiveness of PDAs. 
4.1. Outcomes related with decision-making. 
Decision-making using a PDA involves patients engaging in a decision-making 
process to make a choice. The next two sub-sections explores PDA effectiveness 
outcomes related with 1) the decision making process and 2) the choice made. A 
third sub-section section explores a number of constructs of decision quality, which 
are multidimensional measures of PDA effectiveness.  
4.1.1. Outcomes related with the decision-making process. 
Outcomes related with the decision-making process include variables such as 1) 
preparation for decision-making, 2) satisfaction with decision-making, 3) 
communication between the patient and the practitioner, 4) patient involvement in 
decision making, and 5) decisional conflict [5]. 
Preparation for decision-making refers to the patient’s perception of the usefulness of 
a PDA in helping him/her prepare to communicate with the practitioner and to make 
a decision [53]. It has been measured using e.g. the Preparation for Decision Making 
Scale [5, 53].  
Different measures of satisfaction include self-reported satisfaction with the option 
chosen and satisfaction with the process of decision-making [5]. These measures 
have been criticised by some authors as inadequate measures of PDA effectiveness 
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because satisfaction depends on a patient’s expectations [54] rather than in the 
quality of decision support [55].  
Communication between the patient and the practitioner has been measured [5] using 
instruments such as the Observing Patient Involvement in Decision Making 
(OPTION) scale [56] or the Informed Decision Making instrument [57].  
Patient involvement in decision making has been measured [5] using e.g. the Control 
Preferences Scale (CPS), which identifies the preferred role of the patient in terms of 
decisional control (active, shared with the clinician, or passive)  [58]. Measures 
highlighting patient participation in the consultation have been considered by some 
researchers as unsuitable for primary measures of PDA effectiveness on the grounds 
that the role of PDAs is not to promote any particular model of decision-making [52]. 
Decisional conflict is a construct measuring an individual’s “level of personal 
uncertainty about the course of action to take” [59]. Factors influencing decisional 
conflict in patients include the absence of information about the health care options 
and their consequences, values which are not clear, insufficient skills in decision-
making or in putting decisions into practice, emotional distress, and the perception 
that significant others exercise pressure to impose their views on the decision [59]. A 
commonly used measure of decisional conflict is the Decisional Conflict Scale 
(DCS), an instrument composed of 16 items grouped into five subscales measuring 
patients’ perceptions in terms of the following domains: feeling uncertain in making 
a choice, feeling uninformed, feeling unclear about values, feeling unsupported in 
decision making, feeling that the decision was effective [60]. Decisional conflict has 
been criticised as a measure of PDA effectiveness by some authors on the grounds 
that focusing on reducing decisional conflict penalises decision processes which 
create in patients a state of warranted equipoise with regards to the decision [21]. 
4.1.2. Outcomes related with the choice made. 
Outcomes related with the choice made include 1) knowledge acquired by the patient 
about the condition, the options and their consequences and 2) accuracy in the 
patient’s perceived probabilities of the options’ consequences and 3) concordance 
between the option chosen and the patient’s values [5].  
26 
 
Knowledge is measured using knowledge questionnaires, generally based on 
multiple choice or true/false questions and usually designed specifically for each 
study [61]. Perceived probabilities of the options’ consequences are measured using 
e.g. probability scales [62, 63], which are then matched to the actual probabilities 
presented in the PDAs to assess their accuracy. Some authors have argued against 
knowledge and accuracy in perceived probabilities, two types of knowledge 
outcomes [52], as being the most appropriate measures of PDA effectiveness [36, 
64]. Knowledge makes patients more informed and thus helps them deliberate about 
their preferences, but it does not ensure, by itself, that patients will be more involved 
in decision making or that they will get the option that they desire [36]. In addition, 
knowledge as a key element of a good decision is not a concept easy to 
operationalise [64]. For example, does there exist an amount of knowledge which is 
both necessary and sufficient for each decision question or should patients determine 
when they know enough? [64]. 
Achieving concordance between the option chosen and the patient’s values has been 
described as one important measure of PDA effectiveness [52] and increasingly 
identified as a key goal of PDAs [65], in line with the argument that PDAs should 
primarily help patients make personalised choices between options [52]. Studies have 
measured value-choice concordance using different approaches, e.g. calculating the 
percentage of patients getting a treatment that matched their stated preferences or 
eliciting patients’ preferences and using regression models to predict patients choices 
based on those preferences [5]. 
4.1.3. Constructs of decision quality 
A number of constructs of decision quality have been proposed in the literature to 
measure the effectiveness of PDAs. Perhaps the most well-known of these constructs 
is the one developed by the International Patient Decision Aids (IPDAS) 
Collaboration. The IPDAS Collaboration, founded in 2003, is an international group 
of researchers, PDA developers and other stakeholders with the main task of 
developing a framework to improve the content, development, implementation and 
evaluation of PDAs [66]. The IPDAS Collaboration has developed a consensus 
definition of PDA effectiveness based on two main components: 1) the quality of the 
decision-making process and 2) the quality of the choice made [30]. According to 
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this definition, a PDA fosters a high quality decision process if it helps patients 
“recognise that a decision needs to be made”, “feel informed about the options and 
their features”, “understand that values affect the decision”, “be clear about the 
option-features that matter most”, “discuss values with their practitioner”, and 
“become involved in their preferred ways” [67]. A PDA fosters a high quality choice 
if it “improves the match between the chosen option and the patients’ values” [67]. 
The IPDAS definition of PDA effectiveness combines different outcomes of the 
decision making process and of the choice made explored in previous sub-sections. 
Table 1.1 shows the different elements of the IPDAS definition of PDA effectiveness 
against the outcomes that map onto these elements [5, 53, 61]. 
Table 1.1. IPDAS definition of PDA effectiveness.  
Elements of the definition Outcomes of PDA effectiveness 
mapping onto the elements of the 
definition 
Quality of the decision-making process: 
 
 
1. “Recognise that a decision needs to be 
made” 
1. Preparation for decision-making  
2. “Feel informed about the options and their 
features” 
2. Decisional conflict (feeling 
uninformed) 
3. “Understand that values affect the decision” 3. Preparation for decision-making 
4. “Be clear about the option-features that 
matter most” 
4. Decisional conflict (feeling unclear 
about values) 
5. “Discuss values with their practitioner” 5. Patient-practitioner communication 
6. “Become involved in their preferred ways” 
 
6. Patient involvement in decision-
making 
Quality of the choice made: 
7. “Improve the match between the chosen 
option and the patients’ values” 
 
7.1. Knowledge 
7.2. Accuracy in the patient’s perceived 
probabilities 
7.3. Concordance between chosen option 
and patient’s values 
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The different elements of decision quality of the IPDAs definition have been 
measured in studies evaluating PDA effectiveness using different measurement 
instruments such as the Preparation for Decision Making Scale, the Decisional 
Conflict Scale and the Control Preferences Scale [61]. There is considerable 
consensus that PDAs should be evaluated according to the IPDAS criteria of PDA 
effectiveness [61]. 
There are other definitions of decision quality. For example, Sepucha et al. [68] have 
defined decision quality as “the extent to which a decision reflects the considered 
preferences of a well-informed patient, and is implemented” [55, 68]. This definition 
emphasises similar outcomes of quality of the choice made as does the IPDAS 
definition (namely, knowledge outcomes and concordance between the chosen 
option and the patient’s values), but it makes an additional decision quality 
requirement: that the choice is implemented. The team led by Dr Sepucha in the 
Health Sciences Centre of the Massachusetts General Hospital has developed a set of 
Decision Quality Instruments (DQI) for a number of health care conditions such as 
back pain or breast cancer [69]. Each DQI, completed by a patient, assesses 1) the 
knowledge of the patient, 2) the concordance of the patient’s choice with the 
patient’s values, and 3) the extent to which the patient was involved in shared 
decision-making with his/her clinician [69].  
Kaltoft et al. [21] have criticised existing measurements of decision quality 
(including the DQIs) mainly on the grounds that they do not incorporate patients’ 
preferences for the different aspects of decision-making [21]. They have proposed to 
measure decision quality using a tool called My Decision Quality (MDQ) [21]. MDQ 
asks the patient, after making a health care decision, to first rate and then assign 
preference weights to the following eight decision quality criteria: 1) clarity about 
the options, 2) clarity about the likely effects and consequences of the options, 3) 
clarity about the importance of the effects and consequences of the options, 4) clarity 
about the chances of these effects and consequences, 5) trust in having received the 
best possible information, 6) receiving the desired level of decision support, 7) 
feeling in control of the decision to the desired extent, and 8) committing to 
implementing the choice [21]. MDQ, implemented using the multi-criteria decision 
analysis (MCDA) software Annalisa in Elicia, combines a patient’s ratings and 
preference weights over the above eight criteria into an overall score of decision 
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quality which reflects how important each aspect of decision-making is for him/her 
personally [21]. 
4.1.4. Health outcomes. 
Health outcomes include general health status (e.g. as measured by the 36 item Short 
Form Health Survey or by the EuroQoL EQ-5D instrument), condition-specific 
health outcomes (such as back pain, angina or bleeding), depression, anxiety and 
regret [5]. Some authors have argued that considering the main goal of health care is 
to improve health, the main measure of effect of PDAs should be their impact on 
health outcomes [70, 71] . Other authors argue that judging the success of PDAs 
primarily by whether or not their use leads to better health outcomes is inappropriate 
[61, 64]. This is so because: 1) PDAs are used in preference-sensitive decision 
situations involving the choice between alternative health care options none of which 
is clearly superior to the others in terms of health outcomes, 2) these decisions are 
made under conditions of uncertainty, which implies that beneficial or adverse health 
outcomes may be due to chance and 3) focusing on improving health outcomes 
ignores the possibility that patients may value other outcomes more than health 
outcomes [61].  
4.1.5. Outcomes related with patient behaviour after using the PDA. 
Behaviour-related outcomes include 1) the option implemented by the patient and 2) 
patient adherence to the chosen option [5]. The main criticism made with respect to 
using this type of outcomes as a basis for measuring the effectiveness of PDAs is that 
PDAs are not intended to promote one health care option over another; instead, the 
appropriate choice of option for a patient will depend on his/her preferences for the 
different consequences of these options [52].  
4.1.6. Health systems outcomes. 
These outcomes include the length of the consultation using a PDA, the costs 
incurred as a results of using a PDA, and the cost-effectiveness of using a PDA [5]. 
Including these outcomes as measures (but not as sole measures) of PDA 
effectiveness is important from the perspective of the health service provider [61]. 
This is so because if health systems are to fund access to PDAs, it is important to 
know the impact of these tools on costs and cost-effectiveness [61].  
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4.1.7. Conclusion. 
As has been shown in the previous sections, there is debate in the literature about 
what is the most appropriate measure of effectiveness of PDAs. The definition of the 
IPDAS PDA effectiveness criteria, which results from a consensual effort by 
researchers, PDA developers and other stakeholders to develop common standards 
for the evaluation of PDAs, indicates that there is considerable agreement that, 
notwithstanding other goals (such as improving health), PDAs primarily aim to 
support decision processes which are conducive to patients making decisions that are 
consistent with their informed preferences. 
5. What should a good PDA contain and how should it be developed? 
5.1. IPDAS criteria to assess the quality of the PDA content and of the PDA 
development process. 
Along with the IPDAS criteria of PDA effectiveness, the IPDAS Collaboration 
developed a consensus checklist of criteria for assessing the quality of the content of 
PDAs and the quality of the PDA development process [67].    
Quality criteria regarding the content of PDAs are grouped into four dimensions: 
1. “Provide information in sufficient detail for decision making” [67]. Patients should 
be provided with sufficient information to generate the knowledge that allows them 
to make preference-based choices [72]. Such information should include a 
description of the condition and the health care options involved, a description of 
how the condition would evolve if it is not treated, the likely benefits, the likely 
harms, and probabilistic information about both [72]. Other patient information 
needs should be identified [72]; 
2. “Present probabilities of outcomes in an unbiased and understandable way” [67]. 
Trevena et al [73] developed an expert consensus summary of relevant issues in the 
presentation of probabilistic information of the options’ consequences in PDAs, as 
well as evidence-based guidance on how to best address these issues. The issues and 
guidance presented in the summary are numerous and are described in section 6.5.1 
of this review. 
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3. “Include methods for clarifying and expressing patients’ values.” [67] Value 
clarification methods aim to help patients to, inter alia: retrieve their preferences for 
relevant option consequences that may be overlooked, make holistic comparisons 
between options, and make preference trade-offs between option consequences [74]. 
Value clarification methods can be implicit or explicit [75]. Implicit value 
clarification methods are not interactive and include 1) vivid descriptions of the 
physical or mental impact of the consequences of the options and 2) other patients’ 
testimonials of their attitudes towards the options’ consequences [75]. Explicit value 
clarification methods are interactive and include 1) utility-based techniques [75] such 
as the standard gamble [76] and 2) non-utility-based approaches [75] (e.g. comparing 
the pros and cons of the options [77], the balance technique [78], the time trade-off 
technique [79], conjoint analysis [80], rank ordering the importance of consequences 
[77], or assigning importance weights on a visual analogue scale [77]).  
4. “Include structured guidance in deliberation and communication” [67]. This 
dimension includes coaching (support through decision-making by a trained 
individual) and guidance (an explicit component of the decision support material 
aimed at facilitating the decision process) [81]. Coaching and guidance can aid 
patients to reflect on the steps of making a decision, anticipate and help to prevent 
cognitive biases in patients’ judgments, and engage patients in the process of 
learning about the decision [81]. Coaching and guidance can also increase patient-
clinician communication, e.g. by helping patients prepare questions or by training 
patients to raise difficult issues [81]. 
Quality criteria regarding the PDA development process are grouped around six 
dimensions: 
1. “Presentation of information and options in a balanced manner” [67]. The 
presentation of information in PDAs is balanced if it is complete (including all 
relevant options and all relevant option-related information such as possible benefits 
and harms and probabilistic information), if it is non-directive (i.e. giving equal 
weight to positive and negative aspects), and if it avoids bias in the processing of 
information by the patient [82]. Balanced presentation of information in PDAs is 
important, among other reasons, to avoid cognitive biases that may affect patient 
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knowledge and perceptions of benefits and harms, and ultimately their preferences 
[82];  
2. “Systematic PDA development process” [67]. To inform this dimension, Coulter 
et al [83] suggested, based on a literature review of previous experiences that a 
systematic development process for a PDA should include the following steps: 1) a 
scoping stage to determine the decision, the target audience and the theoretical 
framework informing the PDA; 2) a design stage to determine patient needs for 
information, the format and content of the PDA and how the PDA will be delivered, 
3) an alpha-testing stage to determine the comprehensibility and usability of the 
PDA, 4) a beta-testing stage to determine its feasibility in real practice [83]; 
3. “Use scientific evidence that is cited in a reference section” [67]. Informed consent 
requirements, quality of care principles and evidence-based medicine all suggest that 
the development of a high quality PDAs should incorporate comprehensive, up-to-
date and critically appraised (“best available”) evidence on the options and on the 
probabilistic information regarding the consequences of these options for patients 
[84]; 
4. “Disclose conflicts of interest” [67]. PDAs should report prominently and in clear 
language 1) sources of funding for their development and distribution and 2) whether 
the people or institutions involved in the development of the PDA can incur in gains 
or losses derived from the choices patients make using the PDAs [85]. In addition, 
PDAs should report that no organisations with a commercial interest in the options 
included in the PDA have provided funding for the development and distribution of 
PDAs [85];  
5. Quality criteria for PDAs including patient stories [67]. Patient stories (e.g. 
testimonials of other patients, or narratives of health practitioners discussing the 
experience of patients making the same decision [86]) can be a useful means to 
communicate decision-related information in PDAs [86]. The content of patient 
stories included in PDAs should report both positive and negative experiences [67]. 
PDAs should not include testimonials (or other narratives) of patients without their 
explicit consent and should report the reasons (financial or not) for patients agreeing 
to share their stories [67]; 
33 
 
6. Quality criteria for PDAs delivered online [67]. PDAs delivered over the internet 
should 1) be navigable one step at a time, 2) be easy to return to if navigated away 
from, 2) permit searches for key words, 3) provide safeguards for (and feedback on) 
any personal health data entered into them, and 4) be printable as a sole document 
[67]. 
The IPDAS checklist is being promoted as guidance for the development of PDAs 
[87] and is increasingly used by PDA developers to inform the development and 
evaluation of PDAs [87]. An instrument (IPDASi [88]) is available to assess 
quantitatively the different IPDAS quality dimensions. 
5.2. Criticisms of the IPDAS quality checklist. 
Some criticisms have been made of the IPDAS checklist of PDA quality criteria. 
McDonald et al [89], focusing on the quality dimension “presenting probabilities in 
an unbiased and understandable way”, found that 1) some of the key concepts 
underlying this dimension have not been defined and that 2) that there are gaps in the 
empirical evidence and in the theoretical basis supporting the use of specific criteria 
within this dimension [89]. Bekker [87] has pointed out that the IPDAS checklist was 
developed by expert consensus as “much of the evidence-base to underpin each 
IPDAS domain was weak” [87]. In particular, Bekker argues that there is insufficient 
evidence about what are the active components of PDAs which facilitate decision-
making [87]. In this sense, different theories of decision-making emphasise different 
active components [87]. Elwyn et al. [90] illustrate this debate by considering how 
different theories of decision-making can inform the design of PDAs [91]. For 
example, the design of a deliberation component (the element of PDA that supports 
patients in deliberating about their choice [90]) would differ across theories of 
decision-making (e.g. Prospect Theory [91], Fuzzy-trace Theory [92] or the Rational-
emotional Theory of Decision Avoidance[93]) [90].  
5.3. Conclusion. 
The development by the IPDAS Collaboration of a consensus checklist to assess the 
quality of PDAs was prompted by concerns regarding the quality of existing PDAs 
[30]. The checklist provides agreed standards for assessing the quality of the content 
and of the development process of PDAs, and is increasingly used by PDA 
developers. In 2014, the IPDAS checklist was proposed as the basis for a set of 
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standards for the certification of PDAs [94]. However, it should be used with caution 
[87]. First, the evidence underlying the recommendations of the checklist is not 
entirely clear, as shown by McDonald et al [89]. Second, the checklist does not 
adequately reflect the existing debate in the decision sciences regarding what are the 
active components of PDAs which facilitate decision-making, as discussed by 
Bekker [87]. 
6. Evidence of the effectiveness of PDAs. 
6.1. The Cochrane systematic review of trials evaluating PDA effectiveness. 
The Cochrane Collaboration published in 2014 the latest update of a systematic 
review of clinical trials evaluating the effectiveness of PDAs [5]. This review 
synthesised the evidence of PDA effectiveness for 115 studies covering 46 health 
conditions [5].  
From the review, PDAs have proven to have a number of benefits on variables 
mapping onto the IPDAS criteria of PDA effectiveness [5]. First, compared to 
standard consultations the use of PDAs leads to patients having higher levels of 
knowledge with respect to the options and their outcomes [5]. In addition, the use of 
PDAs which include the probabilities of the consequences of the options leads to an 
increase in the accuracy of the perceived probabilities by patients [5]. These two 
results highlight the limitations of standard clinical consultations in terms of 
providing the necessary information for helping patients make preference-sensitive 
decisions [5]. Third, the use of PDAs versus standard consultations results in lower 
decisional conflict with respect to feeling uninformed and feeling unclear about 
values [5]. Fourth, compared to standard consultations, the use of PDAs leads to a 
reduction in practitioner-controlled decision-making: patients who use PDAs have a 
higher level of involvement in making decisions [5]. Fifth, compared to standard 
consultations, using PDAs leads to higher levels of consistency between the options 
chosen by patients and patients’ values [5]. The review states that, in addition, PDAs 
with explicit value clarification exercises lead to an increase in values-based choice 
compared to PDAs without these exercises [5]: however, this is not entirely clear, as 
some of the studies reporting this effect use a variation of the Multidimensional 
Measure of Informed Choice [95] which does not measure directly the consistency 
between patients’ values and their choices [61]. Other variables of proven PDA 
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effectiveness include overall decisional conflict, proportion of patients undecided 
and patient-practitioner communication [5].  
PDAs have limited effects in terms of increased satisfaction, either with the decision 
or with the decision-making process [5]. Also, PDAs have limited effects in terms of 
improved health outcomes, which is unsurprising given that they are often used in 
preference-sensitive decision situations where no option has a distinct advantage 
over other options [5]. While the effects of PDAs on the options chosen by patients 
and on the length of the clinical encounter are variable [5], little is known about how 
the use of PDAs impacts on other measures of PDA effectiveness such as adherence 
to the chosen option or cost-effectiveness [5]. 
Although the 2014 update of the Cochrane systematic review provides an in-depth 
analysis of the effectiveness of PDAs, it does not distinguish between different PDA 
formats, different modes of PDA delivery, or different theoretical frameworks 
underlying the development of PDAs. With respect to specific PDA components, 
apart from describing the benefits of 1) including probabilities of the consequences 
into PDAs and of 2) including explicit value clarification exercises into PDAs, the 
Cochrane review only provides additional results of PDA effectiveness for studies 
comparing detailed with simple PDAs. From the review, compared to simple 
decision aids, the use of detailed decision aids results in 1) higher levels of 
knowledge of the options and outcomes and 2) lower levels of overall decisional 
conflict and of decisional conflict related to feeling uninformed [5].  
6.2. Effectiveness of different PDA formats. 
In terms of the effectiveness of PDAs by different formats, two reviews of the 
literature were found: a review by Hoffman et al. [96] exploring the effectiveness of 
PDAs delivered over the internet and a systematic review of the effectiveness of 
computerised PDAs (which include internet applications) by Sheehan et al. [51]. 
The review by Hoffman et al. [96] found some evidence that internet-delivered PDAs 
led to an increase in knowledge, improved preparation for decision-making and 
lower decisional conflict, as well as, for screening PDAs, an increase in the 
likelihood of screening [96]. However, these results were based on few clinical trials 
which did not control for potential confounders (e.g. whether or not patients had 
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previous experience of decision support) and hence should be interpreted with 
caution [96]. 
The systematic review by Sheehan et al. [51] provides some insight on the 
effectiveness of computerised PDAs (including internet applications) compared with 
simpler PDAs. The results of this review suggest that the use of computerised PDAs 
1) lead to a very small effect on increasing knowledge of the options and outcomes 
unless they include feedback and self-test features and 2) lead to a lower level of 
decisional conflict with respect to feeling uninformed and unclear about values 
immediately after using the PDA (although not after 3 months) [51].  
6.3. Effectiveness of different modes of PDA delivery. 
No reviews were found exploring the effectiveness of PDAs by mode of delivery. 
One clinical trial has explored the relative effectiveness of giving patients 1) a PDA 
and 2) an information pamphlet under two distinct delivery modes: A) when both the 
PDA and the pamphlet are delivered by a clinician during the consultation and B) 
when a researcher delivers both the PDA and the pamphlet before the clinical 
encounter [97]. The study found that, compared with patients getting the pamphlet, 
those patients to whom the PDA was delivered during the clinical consultation had a 
higher level of knowledge than those patients to whom the PDA was delivered before 
the clinical encounter [97]. The authors point out among the limitations of the study 
that the PDA was designed for delivery during the consultation, so the results may 
not apply to PDAs designed for use outside the consultation [97]. 
6.4. Effectiveness of PDAs with different underlying theoretical frameworks. 
Durand et al [26] identified and described the theoretical frameworks of PDAs 
included in the 2009 update of the Cochrane systematic review of PDA effectiveness. 
Although they did not undertake a comparative analysis of PDA effectiveness by 
type of framework, they found that two thirds of PDAs included in the Cochrane 
review were not based on any theory or model of decision-making [26]. Of those 
PDAs that were, there was little evidence that the design, development and 
evaluation of these PDAs was in accordance with the theory or model on which they 
were based [26]. Only one review was found of studies explicitly comparing the 
relative effectiveness of PDAs by type of underlying theory or model of decision 
making. This was a systematic review (previously mentioned in this text) of the 
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effectiveness of computerised PDAs [51]. In this review, the authors did not find any 
unequivocal evidence that the use of theoretically-based computerised PDAs, 
compared to a-theoretical PDAs can lead to increased levels of effectiveness [51].  
6.5. Effectiveness of specific components of PDAs. 
6.5.1. Effective presentation of probabilistic information. 
Section 6.1. showed that there is evidence that the inclusion of probabilities in PDAs 
leads to an increase in the accuracy of the perceived probabilities by patients [5]. 
Trevena et al [73] developed an expert consensus document distilling the evidence 
regarding best practices in the presentation of probabilistic information in PDAs. A 
summary of this evidence includes the following points: 
1. Appropriate numeric formats for the presentation of probabilistic information 
differ across tasks [73]. To illustrate this point with four examples:  
A) for the task of presenting probabilistic information for two events which are 
independent (e.g. the probability of migraine symptom relief within 24 hours with 
treatment versus placebo) percentages (e.g. 90% versus 0%) are easier to understand 
than simple frequencies (e.g. 90 in 100 versus 0 in 100) [73];  
B) for the task of presenting changes in probabilistic information (e.g. changes in the 
probability of disease before and after treatment), the absolute risk reduction (the 
probability of disease after the treatment minus the probability of disease before the 
treatment) is preferable to the relative risk reduction (the absolute risk reduction 
divided by the probability of disease before the treatment), as this last measure tends 
to bias (magnify) patients’ perceptions of the change in probabilities and is not easy 
to understand [73];  
C) for the task of presenting probabilistic information about connected events (e.g. 
the probability of disease given an irregular test result), natural frequencies (a step-by 
step description of the calculation of the posterior probability of an event based on 
the way individuals would learn it in real life [98, 99]) are proposed as the best 
format to help patients understand these probabilities [73];  
D) for the task of presenting probabilistic information regarding options’ 
consequences that occur over time, different approaches can be used when data is 
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available (which is usually a problem [73]), such as presenting such probabilistic 
information at one point in the future (e.g. the probability of cardiovascular disease 
in 10 years if a particular treatment is taken), at several points in the future, 
presenting the cumulative probability of the consequences over a patient’s lifetime, 
or presenting survival and/or mortality graphs [73]. 
2. The reference class (i.e. the denominator of the probabilistic information 
presented) should be defined and used consistently throughout the PDA [73]; 
3. Presenting probabilistic information about the context (e.g. the probability of death 
from major causes other than the condition at hand) helps patients get a wider 
perspective of the risk of disease [73]. Labels qualifying probabilities (e.g. how 
“bad” a particular probability is) should be used with care, as they can affect 
patients’ perceptions of risk [73];  
4. There is little consensus about the best way to communicate uncertainty around 
probabilistic estimates [73]. Representations of randomness (the unpredictability of 
future outcomes) [100] can be made using icon arrays showing the number of 
individuals affected in a scattered rather than sequential fashion [73, 100]. These 
representations do not seem to significantly affect patients’ perception of risk [73], 
but it is not clear whether or not they increase patients’ understanding of uncertainty 
[73]. Representations of ambiguity (uncertainty about how reliable, credible, or 
adequate the probabilistic information is [73, 101]) can be made presenting 
confidence intervals around probability point estimates [73], e.g. via textual 
statements or visual aids (solid or blurred bars) [101]. The communication of 
ambiguity in PDAs may lead to ambiguity aversion [73]; 
5. Visual displays of probabilistic information may help in increasing the accuracy of 
the probabilistic information perceived by patients [73].  The types of visual displays 
which are more easily understood by patients include vertical and horizontal bars as 
well as pictographs (i.e. icon arrays) [73]; 
6. The impact of tailoring probabilistic information to individual patient 
characteristics (e.g. by whether or not that particular patient has specific risk factors) 
on PDA effectiveness is not clear [73]; 
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7. The effect of interactive features for presenting probabilistic information in web-
based PDAs is not well known [73]. 
6.5.2. Effectiveness of PDAs using value clarification methods. 
Section 6.1 reported the evidence from the Cochrane systematic review of trials of 
PDA effectiveness regarding the positive impact of explicit value clarification 
exercises on value-choice consistency [5] and the problems with this evidence [61]. 
Fagerlin et al. [74] reviewed, based on the results of an previous, unpublished 
systematic review [102], the empirical evidence of the effects of including value 
clarification methods in PDAs. This study showed that: 
1. The most frequently used value clarification methods were comparisons of the 
pros and cons of options (46% of studies), utility elicitation (18% of studies), 
prioritisation (i.e. rank ordering of consequences) (11%) and rating scales (11%) 
[74]; 
2. Only 13 trials compared the effectiveness of PDAs with value clarification 
exercises with PDAs without value clarification exercises [77]. Decision processes 
improved in five trials, but other PDA effectiveness outcomes were not measured 
with enough frequency to draw conclusions about the positive impact of value 
clarification methods on PDA effectiveness [77].   
6.5.3. Effectiveness of PDAs using personal stories. 
Bekker et al. [86] reviewed the evidence regarding the comparative effectiveness of 
PDAs with and without patient stories. The review found that the inclusion of patient 
stories in PDAs has an effect on both 1) deliberative and 2) heuristic (i.e. intuitively-
experiential) strategies of information processing in patients [86]. With respect to the 
deliberative strategies, the review found, inter alia, an increase in patients’ 
perceptions of making 1) informed decisions and 2) decisions based on their own 
values, as well as more stable choices, knowledge and preferences over time [86]. 
With respect to the heuristic strategies, the review found, inter alia, a decrease in 
counterfactual reasoning and an increase in emotional perceptions (e.g. fear of 
illness) [86]. However, the review found insufficient evidence about what are the 
active ingredients in personal stories which may facilitate decision-making [86]. 
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6.5.4. Effectiveness of including structured guidance and coaching in 
deliberation and communication in PDAs. 
Stacey et al. [81] reviewed the evidence available regarding the effectiveness of 
including coaching and guidance in PDAs. No trials were found isolating the 
effectiveness of guidance in PDAs [81]. Coaching added to a PDA improved 
knowledge and decreased costs compared to standard consultations [81]. Only four 
trials compared 1) coaching plus a PDA with 2) a PDA alone [81]. Hence, the 
evidence of the impact of coaching on the effectiveness of PDAs is limited [81]. 
Within these trials, one study found that the addition of coaching to a PDA increased 
participation in decision-making and decreased anxiety [103] and another study 
found that adding coaching to a PDA decreased costs [104].  
6.6. Conclusion. 
There is substantial evidence that PDAs, compared to usual care (i.e. standard 
consultations), are effective in terms of improving a number of criteria of quality of 
the decision-making process  (e.g. decisional conflict, patient involvement in 
decision-making) and in terms of improving key elements of the quality of the choice 
made (knowledge outcomes and value-choice consistency)   [5]. There is evidence 
that, compared to simpler PDAs, more detailed PDAs have a positive effect on 
knowledge and decisional conflict [5]. There is also evidence that the inclusion of 
probabilities in PDAs increases patient knowledge [5]. The literature on risk 
communication provides a number of evidence-based recommendations about best 
practices in the presentation of probabilistic information in PDAs to improve patient 
understanding of this information [73].  
It is unclear whether or not the inclusion of value clarification methods in PDAs 
leads to improved decision-making process [74] or to increased value-choice 
consistency [61] compared to PDAs that do not include these exercises. It is also 
unclear whether including patient stories in PDAs facilitates decision-making [86], 
and whether or not guidance and coaching increase PDA effectiveness [81]. Finally, 
it is not clear whether the use of theoretically-based PDAs, such as MCDA-based 
PDAs, leads to increased levels of PDA effectiveness compared to a-theoretical 
PDAs.   
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7. Implementing PDAs in practice. 
Although PDAs have shown to be effective across a number of outcomes [5], their 
implementation in routine clinical practice has been achieved to a level that is “less 
than expected” [105]. PDA implementation is challenging [7, 105]: indeed, a number 
of implementation barriers have been identified in the literature that hamper the 
widespread adoption of these tools. These barriers, and suggested solutions, include:  
1. Clinicians’ concerns about the content of PDAs [7, 105], including concerns that 
1) this content is not comprehensive enough and that 2) it is out of date [7, 106]. 
Ensuring the comprehensiveness of the content of PDAs can be achieved by 
promoting the uptake of PDA quality standards [7], such as those included in IPDAS 
Collaboration checklist [7, 66]. With respect to the outdatedness of PDAs, it is clear 
that new evidence regarding the consequences of the options is quickly available for 
many clinical decisions and it needs to be regularly incorporated into existing PDAs 
[7]: stronger connections between PDA developers and those who generate, 
synthesise and analyse the evidence can help achieve this aim [7]; 
2. Lack of awareness in physicians regarding the availability of PDAs [7] and lack of 
training in the use of PDAs and Shared Decision Making (SDM) [7, 105, 107]. 
Training in decision support may help overcome these barriers [7, 108]. An 
environmental scan of training programmes in SDM [109] found, between 1996 and 
2011, that 54 SDM programmes (most often targeting licensed health care 
practitioners) had been put into practice [109]. These programmes varied 
substantially in their content and were often not evaluated [109], suggesting the need 
for accreditation mechanisms [107];  
3. Competing demands and time constraints on physicians [105]. These constraints 
limit the success of PDA implementation strategies that depend on clinicians 
identifying patients for using these tools [105]. One more successful strategy is to 
use system-based approaches for distributing PDAs to patients [105], such as 1) 
mailing PDAs to all eligible patients or 2) getting practitioners to hand PDAs to 
eligible patients to be filled at home [110]. Studies using this strategy have still found 
large differences between patients identified as eligible and patients actually using 
PDAs  [105]. 
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4. Clinicians’ concerns about the adequacy of PDAs for some groups of patients [7]. 
Clinicians perceive that different groups of patients have different abilities and/or 
willingness to use PDAs [7] and to engage in SDM [107, 111]. In fact, vulnerable 
patients (such as elderly patients or patients with little education), compared with 
other patients, report less interest in participating in SDM [107]. PDAs aiming to 
provide decision support to these patients should address their health literacy needs 
[112]. Successful strategies used in the design of PDAs to improve understanding in 
patients with low levels of health literacy include 1) presenting numerical data in 
tabular or graphical formats instead of text and 2) including videos to reinforce the 
message presented with verbal narratives [112]. 
Important facilitators for the implementation of PDAs identified in the literature 
include 1) training practitioners in the use of PDAs, 2) the (already mentioned here) 
availability of system-wide methods to initiate PDA use in patients and 2) the 
availability of a “clinical champion” to lead on implementing these tools [105]. 
8. Multi-Criteria Decision Analysis (MCDA) and medical decision making. 
Multi-Criteria Decision Analysis (MCDA) [113], Multiple Criteria Decision 
Analysis [9, 114], Multi-Criteria Analysis [10], and Multiple-Criteria Decision 
Making [115] are all terms that make reference to a collection of formal methods that 
can be used to solve decision problems involving multiple, often conflicting, criteria. 
In this thesis the term Multi-Criteria Decision Analysis (MCDA) is used to refer to 
such collection of methods. In MCDA, an initial distinction can be made between 1) 
decisions involving the appraisal of a finite number of options and 2) decisions 
involving the design of optimal options from an infinite potential set [10]. This thesis 
focuses on MCDA methods that can be used to make decisions involving the choice 
of one alternative from a set of finite, well-defined options, as these are the kind of 
decision situations typically confronted by patients making health care decisions.  
8.1. Overview of MCDA methods. 
The role of MCDA methods in supporting clinical decision making has been 
advocated by several authors, e.g. Dolan [116] and Dowie et al. [19]. MCDA 
methods are designed to provide decision support in complex circumstances like 
those arising in many typical patient management decision situations [116], i.e. 
decision situations where the choice of option depends on making trade-offs between 
43 
 
the consequences of the options [116]. MCDA has been identified by Durand et al. 
[26] as one of the several decision-making theories informing the design of PDAs. 
8.1.1. Steps of the MCDA process. 
MCDA methods provide guidance to the decision maker(s) in exploring a particular 
decision problem [10]. When applied in full, the MCDA process involves the 
following eight steps [10]:  
1) Establishment of the decision context [10]. An important element of establishing 
the decision context involves determining who is responsible for making the decision 
[10]. Is it a single individual? Is it a group of individuals? If the second is the case, it 
will be appropriate to use applications of MCDA which are suited for group 
decision-making, e.g. those reviewed in Kilgour et al. [117]. Another important 
element of establishing the decision context is understanding the main overarching 
objective of the decision [10]. Establishing the main objective is important in order 
to be able to establish lower sub-objectives which will be the basis for defining the 
measureable criteria on which the performance of the options can be evaluated [10]. 
Value-focused thinking [118] is a good approach to facilitate this process. 
2) Identification of the options [10]. Options are important insofar as they are of 
value to achieve the objectives of the decision [10] and so, when they are not given, 
they should be established after the objectives of the decision are developed [10, 
118]. This point is of limited relevance for MCDA in patient decision support using 
PDAs, where the health care options (including doing nothing) are normally given. 
3) Identification of the objectives and of the criteria which show the value of the 
options’ consequences [10]. Establishing the criteria on which to measure the 
performance of the options is an important part of MCDA. For this task it is useful to 
first determine the fundamental (i.e. important in themselves) sub-objectives to 
achieve the main decision objective and structuring these in a hierarchy or “value 
tree” [10], as for example is done using the value-focused thinking approach [118]. 
The value tree of criteria measuring these objectives, should: 
- Be complete, i.e. it should include all the relevant criteria for making the decision 
[10]; 
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- Be of adequate size, i.e. include as few criteria as possible so that it is “no larger 
than it needs to be” [10]; 
- Be non-redundant (i.e. it should not include criteria which are not important in 
making the decision) and not incur in double-counting of criteria [10]; 
- Be operational, i.e. all the criteria included in the value tree should be defined 
clearly enough to be assessed from both an objective and a value perspective [10]; 
- Adequately factor-in the impact of time, e.g. by defining the criteria with respect to 
a specific time horizon [10]; 
- Be such that all the criteria are mutually preferentially independent, i.e. the 
preference of the decision maker over different levels of performance on each 
criterion should not depend on the performance levels of the other criteria [10]. 
4) Description of the expected performances of the options on the criteria and- in the 
case of those methods involving steps 5) and 6) below - calculating scores [10]. The 
variables measuring the performances of the options on the criteria can be, for 
example, continuous quantitative (e.g. cost of treatment in GBP), categorical (e.g. 
presence or absence of side effects), ordinal (e.g. low/medium/high efficacy), and 
interval (e.g. three levels of cost of treatment: “between 0 and 100 GBP”/ “between 
100 and 500 GBP”/ “more than 500 GBP”). The performance levels of the options on 
each of the criteria are normally represented as cells in a performance matrix with 
options in rows and criteria in columns [10]. Scores normally reflect the value (e.g. 
on a scale between 0 and 100) to the decision maker of the different performance 
levels of each criterion. These scores can be calculated using different methods, e.g. 
estimating value functions or via direct rating [10]. The type of scales on which the 
scores are calculated (e.g. interval or ratio scales) differ depending on the MCDA 
method. The extremes (the two points representing respectively a value of “0” and a 
value of “100”) of the score scales used can be assigned by reference to the local set 
of options (the options taken into account by the decision-maker) or to a global set of 
options (i.e. a set of options including options not taken into account by the decision 
maker) [10];   
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5) Assignation of weights (N.B. or other inter-criteria parameters) reflecting the 
relative importance of the criteria [10]. The calculation of criteria weights (and other 
inter-criteria parameters) differs across MCDA methods; 
6) Integration of the performances and the weights to obtain an overall value for each 
option [10]. Different MCDA methods perform this integration in different ways;   
7) Examination of results [10], e.g. assessing the overall ranking of the options and 
any other information that is relevant for making recommendations about the relative 
performance of the options on the criteria; 
8) Sensitivity analysis [10] e.g. to assess how changes in imprecise criteria weights 
affect the final results. 
8.1.2. Types of MCDA methods. 
A possible typology of the many MCDA methods available includes the following: 
1. MCDA methods based exclusively on the analysis of the performance matrix [10, 
119]. These basic forms of MCDA are non-compensatory, i.e. for a specific option 
they do not allow for bad performance in one criterion to be compensated by good 
performance in another criterion. They include: 1) dominance analysis, which 
involves eliminating dominated options, i.e. those options which perform no better 
than any other options on any of the criteria and worse than all other options on some 
criteria [10]; 2) disjunctive/conjunctive selection procedures, which respectively  
eliminate options if they fail to reach a threshold level on some or all the criteria and 
include options for further consideration if they reach threshold levels on some or all 
the criteria [10]; 3) the lexicographic ordering approach, which involves selecting the 
highest performing option on the most important criterion unless there is more than 
one option with the same highest performance, in which case the process is repeated 
with this subset of options for the next most important criterion until either there is 
only one option left or there are no more criteria left [10]; 4) elimination by aspects 
[10], which sequentially eliminates all options but one based on whether or not the 
options meet specific aspects, i.e. values or characteristics related with the criteria 
(e.g. when buying a car, a threshold lower price, or automatic versus manual 
transmission [120]) or arbitrary features that do not correspond to any of the criteria 
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[120]. All of these methods very much limit the incorporation of the decision 
maker’s preferences into the decision [10];   
2. Full aggregation MCDA approaches [113]. Typically, the way these approaches 
operate involves first scoring each option on each criterion and then combining these 
scores into a global score for each option. These approaches are fully compensatory 
[113]. In this group are such well-known methods as Multi-Attribute Value/Utility 
Theory (MAUT/MAVT) [11] and extensions of MAVT based on linear additive 
multi-attribute value functions such as the Simple Multi-Attribute Rating Technique 
(SMART), SMART with swings (SMARTS), and SMART exploiting ranks 
(SMARTER) [121]. This group also includes other simple linear additive models 
such as the Simple Additive Weighting (SAW) approach; it also includes the 
Analytic Hierarchy Process (AHP)[122] and its extension the Analytic Network 
Process (ANP) [123], Measuring Attractiveness by a Categorical Based Evaluation 
Technique (MACBETH) [124], and the family of UTA (“UTilites Additives”) 
methods [125]; 
3. Outranking MCDA methods [113]. These methods are based on making sequential 
pairwise comparisons of the options (taking into account their performances on the 
criteria) so as to determine what is the preference relation that can be established 
between every option pair [126]. In contrast with full aggregation MCDA methods, 
these approaches may lead to cases of incomparability between options, and hence 
require additional exploitation procedures to be able to rank the options [126]. These 
methods are partially compensatory [113]. The most widely used outranking methods 
are the Election et Choix Traduisant la Realité (ELECTRE) [13] family of methods 
and the Preference Ranking Organisation Method for Enriched Evaluation 
(PROMETHEE) [14] family of methods, but there are others [127]; 
4. Goal, aspiration or reference-level MCDA methods [113]. These approaches 
operate by first defining a goal, ideal or reference level on each of the criteria and 
then identifying the option which is closest to that level [113]. Such methods, under 
the general rubric of goal programming [128] are often used in design multi-criteria 
problems where the objective is to identify (i.e. design) an optimal option from an 
infinite (or very large) potential set of options. For choice multi-criteria decision 
problems where the options are pre-determined (the subject of this thesis), several 
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MCDA methods based on this logic are available. One of these, Technique for Order 
Preference by Similarity to an Ideal Solution (TOPSIS), is based on ranking the 
available options by calculating an index of closeness to an ideal solution [129]. 
Other methods of this type can be interactive, such as the Visual Reference Direction 
approach [130]. This approach proceeds in an iterative fashion [130]. At each 
iteration, the decision maker identifies one preferred option and his/her aspiration 
levels on the criteria; with this information, an achievement function (based on the 
reference direction, i.e. the vector connecting the preferred option with the decision 
maker’s aspiration levels) is minimised, leading to the selection of a (smaller in each 
iteration) subset of the options available; the process is finished when the decision 
maker is unable to find a more preferred option [130]. Other aspiration-level MCDA 
methods which use achievement functions include approaches based on the objective 
ranking of options [131]. In these approaches, the aspiration levels of the criteria are 
not determined via the preferences of the decision maker, but as objectively as 
possible [131].   
5. Other methods.  
5.1. Fuzzy MCDA methods [132]. In set theory, “fuzziness” refers to classes of 
objects in which there are grades of membership to a set [133]. These grades of 
membership are expressed using membership functions, defined between 0 (when the 
object definitely does not belong to the set) and 1 (when the object definitely belongs 
to the set) [133]. “Fuzziness” can be used to explicitly model imprecision in 
information or in knowledge into MCDA. For example, membership functions can 
be used to account for imprecision in the measurement of criteria performance levels 
when these are defined qualitatively (e.g. “fair” or “good”) [134]. Membership 
functions can also be used to incorporate imprecision in the assessment of preference 
weights [134]. Fuzzy MCDA methods differ in terms of the way they integrate 
performance levels and preference weights to obtain an overall rating for each 
option, but a common procedure to perform this integration is the weighted average 
sum method (i.e. multiplying the performance level of each option on each criterion 
by the normalised weight of that criterion and adding across criteria) [135]. Since the 
resulting ratings can be fuzzy, it is often necessary to use additional procedures to be 
able to rank the options from most to least preferred [135]. Fuzzy approaches have 
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been developed for a number of MCDA methods, e.g. the AHP [136], outranking 
methods [137] and MAUT [138];   
5.2. Stochastic Multicriteria Acceptability Analysis (SMAA) [139]. SMAA is a 
family of MCDA methods which explicitly deal with uncertainty, imprecision and/or 
missing information in 1) the performance levels of the options on the criteria and in 
2) the preference weights of the criteria. In SMAA, the decision problem is 
represented in a stochastic fashion, i.e. defining suitable joint probability 
distributions for the uncertain/imprecise/missing variables (namely, the variables 
measuring the performance levels of the options on the criteria and the criteria 
weights) [139]. A decision model is then assumed for ranking, sorting or classifying 
options [139]. For example, for ranking options, SMAA-2 assumes a multi-attribute 
value function [140]. Monte-Carlo simulations are then used to draw many samples 
from the joint probability distribution of performance levels and weights and to 
generate results in terms of the assumed decision model - results which can be 
summarised statistically and/or graphically to draw conclusions [139]. For example 
SMAA-2 calculates a rank acceptability index measuring the percentage of all 
combinations of preference weights which give a particular option a specific rank: 
the best options are those with high rank acceptability indexes for the best ranks 
[139]. Other descriptive measures provided by SMAA-2 are 1) the central weight 
vector (representing the preferences of a “typical” decision maker choosing a 
particular option) [139] and the confidence factor (the probability that an option 
ranks first when its central weight vector is selected) [139]; 
5.3. Dominance-based rough set approach (DRSA) [141]. DRSA approaches are 
based on modelling the preferences of the decision maker(s) in terms of “if…then…” 
rules [141]. To explain DRSA for a choice decision problem, it is useful to first 
explain DRSA for a classification problem, i.e. a decision problem involving the 
classification of options into different categories. For a classification problem, the 
DRSA analysis starts with a data table, a table with options in rows, criteria in 
columns and evaluations (either quantitative or qualitative) of the options on the 
criteria in cells [141]. The DRSA data table is different from a performance matrix in 
that it contains two types of criteria: 1) condition criteria (N.B. the individual criteria 
relevant for the decision) and 2) decision criteria (one for each decision maker 
involved in the decision) which provide comprehensive evaluations of each of the 
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options [141]. When the decision involves only one decision maker (the example 
discussed here), then there is only one decision criterion. A key element of DRSA is 
the dominance principle, which states that if one option is at least as good as another 
option on a subset of condition criteria, then the first option should have a 
comprehensive evaluation (on the decision criterion) which is at least just as good as 
that of the second option [141]. DRSA uses rough sets (i.e. approximations of crisp 
sets, where a crisp set is a conventional collections of objects) and the dominance 
principle in order to derive “if…then…” decision rules [141], or decision rules 
linking the evaluations of the options on the condition criteria with their 
comprehensive evaluations on the decision criterion. For an example adapted from 
Greco et al [141], one such rule might be: “if the evaluation of an option in criterion 
1 is at least ‘fair’ and its evaluation on criterion 2 is at least ‘fair’, then the option is 
comprehensively evaluated as at least ‘fair’ (i.e. ‘fair’ or ‘good’)”. To modify DRSA 
to help solve choice multi-criteria decision problems, the data table needs to include 
pair-wise comparisons of options’ evaluations and the dominance principles needs to 
be defined with respect to these pair-wise comparisons [141]; 
5.4. Verbal decision analysis (VDA) [142]. In choice decision problems, VDA (as 
implemented by the most well-known VDA method, ZAPROS [143]) ranks options 
by constructing a decision rule which is based on comparing verbal formulations 
(e.g. “below average”, “average”, above average” [142]) of the performance levels of 
the options on the criteria [142]. The procedure involves several steps. In the first 
step, the decision maker is asked to make trade-offs between all pairs of hypothetical 
criteria vectors where each vector contains the best possible performance level on 
every criterion but one. This allows, under certain conditions1 [142], to construct a 
joint ordinal scale (a scale which provides a rank order of its elements and no 
information about the relative position of these elements) for these vectors [143]. For 
example, in a decision problem with two criteria, the joint ordinal scale might be: 
first ranked, hypothetical criterion vector (“average”, “above average”); second 
ranked, hypothetical criterion vector (“above average”, “average”); third ranked, 
hypothetical criterion vector (“below average”, “above average”); fourth ranked, 
hypothetical criterion vector (“above average”, “below average”). The next step in 
VDA involves considering the criterion vector of each real option and substituting 
                                                          
1 Transitivity and mutual preferential independence of the decision makers preferences  
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the performance level of this option on each criterion by its rank order in the joint 
ordinal scale [143]. For example, consider two options: option 1 with criterion vector 
(“above average”, “below average”); option 2 with criterion vector (“average”, 
“average”). Substituting each performance level by its rank order on the joint ordinal 
scale yields respectively vectors (2,4) and (1,2). From this operation, it is clear that 
option 2 is preferred to option 1.   
8.1.3. Conclusion. 
In this overview of MCDA methods, the general process of MCDA has been 
identified. It is a step-wise process which guides the decision-maker through the 
steps of making the decision. The general steps of the MCDA process include: 
identifying the decision context, identifying the options, identifying and adequately 
structuring the objectives and their measureable criteria, developing the matrix of 
performance levels of the options on the criteria, integrating the information from the 
performance matrix to make a choice, analysing the results and performing 
sensitivity analysis.  
In addition, a typology of MCDA methods has been presented and each type broadly 
described. A discussion of the relative merits of all these methods is beyond the 
scope of this review. However, the next section explores a selection of these MCDA 
approaches. This selection is based on 1) a number of long-established [126] full 
aggregation MCDA methods and a number of well-known outranking methods, 2) 
existing applications of these MCDA methods in the area of diagnosis and treatment 
of diseases, based on a recent systematic review and bibliometric analysis [144]. The 
selected MCDA approaches are:  
1) Full aggregation MCDA methods. 
1.1. Value and utility function methods, including: a) Multiattribute Value/Utility 
Theory (MAVT/MAUT), b) the Simple Multiattribute Rating Technique with 
Swings (SMARTS), c) the Simple Multiattribute Rating Technique Exploiting Ranks 
(SMARTER), d) Measuring Attractiveness by a Categorical Based Evaluation 
Technique (MACBETH);  
1.2. Simple Attribute Weighting (SAW); 
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1.3. The Analytic Hierarchy Process (AHP) and its generalisation the Analytic 
Network Process (ANP);  
2) Outranking methods, including two of the most well-known [126]: a) Election et 
Choix Traduisant la Realité (ELECTRE) and b) Preference Ranking Organisation 
Method for Enriched Evaluation (PROMETHEE);  
3) The Technique for Order of Preference by Similarity to an Ideal Solution 
(TOPSIS). 
8.2. Exploring a selection of MCDA methods. 
8.2.1. Value and utility function methods. 
8.2.1.1. Multi-attribute Value/Utility Theory (MAVT/MAUT) and its extensions 
SMARTS and SMARTER. 
MAVT/MAUT is a MCDA approach developed by Keeney and Raiffa [11] which is 
based on a number of axioms about rational decision making (for a description of 
these axioms, see Keeney and Raiffa [11]). A full aggregation MCDA approach, for 
a specific decision problem MAVT/MAUT combines 1) the performance levels of 
the options on the criteria and 2) the decision maker’s preferences over the criteria 
via the construction of a multi-attribute value function, MAVF (under certainty in the 
consequences of the options) or a multi-attribute utility function, MAUF (under 
uncertainty in the options’ consequences). Given a choice decision problem under 
certainty, each option i is assigned an aggregate score 𝑆𝑖 on a MAVF. Similarly, for a 
choice decision problem under uncertainty, each option is assigned an aggregate 
score 𝑆𝑖 on a MAUF. In each case, consideration of the aggregate scores of all the 
options allows for a full ranking of all these options from most to least preferred. 
Multi-Attribute Value Theory (MAVT). 
For a given choice decision problem under certainty in the performance levels of the 
options on the criteria, the main task in MAVT involves constructing a MAVF 
assigning a unique score to each option with multi-attribute consequences [11]. The 
MAVF is usually represented as a function of criterion-specific value functions. 
Depending on the structure of the decision maker’s preferences, MAFVs may have 
different forms, e.g. multiplicative on the criterion-specific value functions or 
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additive on these functions [11]. Constructing a MAVF involves a sequence of tasks 
which can be quite complex, but which is substantially facilitated for an additive 
MAVF. In order to be able to assert that the preferences of the decision maker can be 
expressed with an additive MAVF, a particular assumption about the preference of 
the decision maker needs to hold, i.e. mutual preference independence of the criteria 
(MPIC) [145]. In essence, MPIC requires that any subset of criteria C is 
preferentially independent of its complementary set C’, i.e. that in any subset of 
criteria C the preferences of the decision maker between any pair of options differing 
on the levels of criteria in C do not depend on the levels of the criteria in C’ [11]. If 
this condition holds, the aggregate score 𝑆𝑖 of any option i on the (linear additive) 
MAVF can be written as: 
𝑆𝑖 = ∑ 𝑤𝑘𝑣𝑖,𝑘
𝐾
𝑘=1
         𝑖 = 1,2, … 𝑙 
(1.1) 
In equation 2.1, 𝑣𝑖,𝑘  are the value scores of the local options (i.e. the options 
included by the decision maker as part of the choice decision) 𝐴𝑖  (𝑖 = 1,2, … 𝑙) on K 
single-criterion value functions scaled between 0 and 1, and 𝑤𝑘 are K criterion-
specific scaling constants adding to 1. The resulting MAVF is an ordinal MAVF 
which does not provide information about the strength of preference of the decision 
maker between the options. Note that mutual preference independence is a concept 
unrelated to statistical correlation between criteria. Statistical correlation is a measure 
of the extent to which two quantities fluctuate together. Two criteria can be 
correlated and be preference independent. 
In order to construct the additive ordinal MAVF, the steps are [11]: 1) verifying that 
MPIC holds, which requires checking that the rates at which the decision maker 
substitutes the levels of one criterion for the levels of another criterion do not depend 
on the level of the remaining criteria, 2) constructing the single-criterion value 
functions using techniques based on indifference judgments such as the mid-value 
splitting technique [11], and 3) calculating the scaling constants using trade-off 
methods [11, 146]. Calculating the value scores of the options on the criteria and 
entering this information into equation 1.1 solves for 𝑆𝑖. 
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The additive MAVF is measurable, i.e. provides information about the strength of the 
decision maker’s preferences over the options, if difference independence (DI) holds 
[145]. In essence, DI holds if, once it is verified that MPIC holds, the preference 
difference between any pair of options differing on the levels of one criterion do not 
depend on the common levels of the remaining criteria [145, 147]. The additive 
measurable MAVF has the same formula shown in equation (1.1). 
The resulting measureable MAVF is built on an interval scale of measurement [9]: 
comparisons between the overall value scores of the options are made using 
differences in overall value. The first step in constructing a linear measureable 
MAVF is checking the required preference independence conditions. The second one 
is building K single-criterion value functions. Here, simpler methods than techniques 
based on indifference judgments can be used to build the single-criterion value 
functions. These methods include indirect assessment of the value function, 
constructing a value scale and direct rating [9]. The criteria weights 𝑤𝑘 can be 
calculated, notwithstanding their calculation using trade-off methods (as for the 
additive ordinal MAVF) [145] using simpler methods, e.g. swing weights [9] or 
direct rating [147] (also termed “importance weights” [9]). Other approaches for 
weight elicitation include point allocation or rank order methods [146]. 
When the criteria are structured as a hierarchy or value tree, the simultaneous 
assessment of all the bottom-level criteria (e.g. via swing weights) can be a 
cumbersome task. This task can be simplified by assessing the weights at each level 
of the hierarchy.  
A number of software tools can be used for decision support using MAVT, 
including: HiView [15], V.I.S.A. [148], and Logical Decisions [149]. 
Multi-Attribute Utility Theory (MAUT). 
For a given choice decision problem under uncertainty in the performance levels of 
the options on the criteria, the main task in MAUT involves constructing a multi-
attribute utility function (MAUF) [11]. The MAUFs (as the MAVFs in MAVT) are 
usually represented as functions on criterion-specific utility functions. In order for 
the decision maker’s preferences to be represented by an additive MAUF, the 
assumption of additive independence of the criteria (AI) must hold [11]. To illustrate 
AI for the case of a decision problem with two criteria, AI holds if the decision 
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maker is indifferent between A) all lotteries involving with equal probability 1) 
variable levels x and y of two criteria and 2) arbitrarily fixed levels x’ and y’ of these 
two criteria and B) all lotteries involving with equal probability 1) variable levels of 
x on the first criterion and an arbitrarily fixed level y’ of the second criterion and 2) 
an arbitrarily fixed level of x’ on the first criterion and variable levels y of the second 
criterion [11]. In other words, AI holds if there is absolutely no interaction of 
preferences among criteria [150]. If AI holds, then: 
𝑆𝑖 = ∑ 𝑤𝑘𝑢𝑖,𝑘
𝐾
𝑘=1
         𝑖 = 1,2, … 𝑙 
(1.2) 
In equation 2.2, 𝑢𝑖,𝑘 are values on K single-criterion utility functions and 𝑤𝑘 are K 
scaling constants.  
The steps for constructing a MAUF can be simplified as follows [11]: 1) defining the 
region of values over which the utilities of the criteria will be assessed, 2) setting up 
relevant lotteries to verify AI, 3) if AI holds, constructing single-attribute utility 
functions (e.g. using the variable probability method or the variable certainty 
equivalent approach [151]), 4) calculating the scaling constants using trade-off 
methods.  
MAUT is supported by the Generic Multiattribute Analysis (GMAA) software tool 
[152]. 
Simple Multiattribute Rating Technique with Swings (SMARTS) and SMART 
Exploiting Ranks (SMARTER). 
Edwards developed the Simple Multiattribute Rating Technique (SMART) method in 
part out of concern regarding the difficulty and instability of the indifference 
judgments required to construct multiattribute preference structures in Keeney and 
Raiffa [11, 121]. The original procedure used to calculate criteria weights in SMART 
(ranking the criteria in order of importance, assigning the most important criterion a 
reference weight of 100 and assigning weights to the other criteria relative to this 
reference weight) had the limitation that it ignored the ranges in the values of the 
criteria to determine criteria weights so SMART is not recommended any more 
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[121]. Two improvements have been suggested: SMART with Swings (SMARTS) 
and SMART Exploiting Ranks (SMARTER) [121]. SMARTS and SMARTER both 
provide simple approaches to building MAVFs based on a “strategy of heroic 
approximation” [121] which involves identifying “the simplest possible judgments 
that have any hope of meeting the underlying requirements of multiattribute utility 
measurement, and try to determine whether they will lead to substantial suboptimal 
choices in the problem at hand” [121].  
In SMARTS, 9 steps are proposed for solving a multi-criterion decision problem 
[121]:  
1) Establish the purpose of the value elicitation and identify the decision maker(s);  
2) Construct a value tree. If more than one decision maker is involved in making the 
decision, a group exercise can be useful to get agreement from all the decision 
makers on the final structure of the value tree (if possible be limited in size to twelve 
criteria and avoiding criteria duplicates and criteria overlaps) and on the labels of the 
criteria (which should be unambiguous) [121].    
3) Identify the options. If the options are not known in advance, the value tree can be 
used to generate a set of real or hypothetical options - it is useful to anticipate the 
range of performance levels of these hypothetical options on the criteria so it is not 
too narrow [121];  
4) Construct the performance matrix. If physical measures can be used to measure 
the performance levels of the options on the criteria, they should be used [121]; 
5) Eliminate dominated options. When, after eliminating dominated options, the 
range of the performance levels on a particular criterion is greatly reduced, consider 
eliminating that criterion [121]; 
6) Calculate single-criterion utilities for the elements of the performance matrix. If 
possible, single-criterion utility functions linear on the performance levels of the 
criteria should be used, as they are easy to calculate [121]. To check the linearity 
assumption for a particular single-criterion utility function, a first check involves 
testing the monotonicity of the function eliciting internal maxima/minima [121]; a 
second check involves testing the curvature of the function, e.g. by eliciting the 
changes in value induced by small changes in the performance levels at several 
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points in their range [121]. If the linearity assumption does not hold, single-criterion 
utility elicitation methods which do not rely on making indifference judgments 
between lotteries can be used [121]. A final test in this steps involves checking for 
conditional monotonicity (CM) to verify that an additive value model on the single-
criterion utilities is adequate [121]. CM is not met in instances in which the direction 
of the decision maker’s preferences for the levels on one criterion changes for 
different levels of another criterion [121]. If CM is not met, a non-additive value 
model should be used [121]. 
Steps 7 and 9 involve the calculation of swing weights [121]. 
7) Rank order of the criteria weights. This step is implemented as follows [121]. 
First, selecting the most important criterion by imagining a hypothetical option 
which has no value (i.e. a value of 0) on all the criteria except on a criterion of 
choice, where it has the highest value possible (i.e. a value of 100). The criterion 
chosen by the decision maker is the most important. This procedure is then repeated 
for the remaining criteria. 
8) Elicit swing weights using direct estimates of their magnitude and calculate the 
multiattribute utility of each option. To elicit the swing weights, the following 
procedure can be used [121]. First, assign the most important criterion a weight of 
100. Next, elicit, for the second most important criterion, the worth (in terms of a 
number between 0 and 100) to the decision maker of a swing in value between 0 and 
100 in this criterion compared with a swing in value between 0 and 100 in the most 
important criterion. The resulting number is the weight of the second most important 
criterion. The procedure is then repeated for the remaining criteria. To obtain the 
final weights 𝑤𝑘 of the K criteria, they are normalised to add up to 100. To calculate 
the multiattribute utility of each option, the weights and the performance levels of the 
option on the criterion are combined using the relevant (i.e. either additive or non-
additive) value model identified in step 6. 
9) Decide. 
SMART Exploiting Ranks (SMARTER) follows the same steps as SMARTS except 
for the elicitation of weights, i.e. step 8) [121]. In SMARTER, the weights 𝑤𝑘 of the 
K criteria are rank order centroid (ROC) weights [121]. These weights are calculated 
57 
 
by solving a system of equations on the hypersurface (or simplex) of weights defined 
by these weights adding up to 1 [121]. The formula for each weight 𝑤𝑘 is: 
𝑤𝑘 = (
1
𝐾
) ∑ (
1
𝑗
)
𝐾
𝑗=𝑘
 
(1.3) 
SMART with Swings (SMARTS) is supported by software applications such as 
Logical Decisions; SMARTER is supported by e.g. Web-HIPRE and Logical 
Decisions.     
8.2.1.2. Measuring Attractiveness by a Categorical Based Evaluation Technique 
(MACBETH). 
The MACBETH approach separately elicits single-criterion value functions and 
criteria weights and aggregates both using an additive value model. The aggregate 
scores 𝑆𝑖 of the options are defined on a cardinal value scale [153]. However, it uses 
a different approach to MAVT/MAUT for eliciting the inputs of the decision model.  
The MACBETH approach to calculating each single single-criterion value function 
is based on making pairwise comparisons of difference in attractiveness between 
either 1) performance levels (expressed either qualitatively or quantitatively) on the 
criterion or, if the decision maker so wishes, 2) between the options themselves [113, 
153]. For the remainder of this section, the assumption is that the performance levels 
are expressed qualitatively. The pairwise comparisons between the levels are done on 
a 7-point semantic scale of differences in attractiveness with the following categories 
[113]: 1) “none”, 2) “very weak”, 3) “weak”, 4) “moderate”, 5) “strong”, 6) “very 
strong”, 7) “extreme”. To construct each single criterion value function, it is useful to 
provide a description (in terms of their performance levels on that criterion) of two 
reference options [153], e.g. one “neutral” (neither satisfying nor satisfying) [153] 
and one “good” (undoubtedly satisfying) [153], which will serve to anchor the value 
scale and later to facilitate the calculation of the criteria weights [153]. Assuming 
this is done, the next step is to perform the pairwise comparisons of difference in 
attractiveness between pairs of performance levels. These pairwise comparisons can 
be performed in any order, although it is recommended to rank the performance 
levels in order of decreasing attractiveness [113]. Linear programming techniques are 
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used to calculate the single-criterion value function [153], which can have negative 
values and values higher than 100 if the reference options are not the worst and the 
best on that particular criterion [153].  
The criteria weights are calculated based on pairwise comparisons of differences in 
attractiveness between the criteria [113, 153]. The performance levels of the 
reference options on the criteria (described above) can be used as the basis for 
eliciting swings in differences of attractiveness between criteria [153]. Linear 
programming is used to calculate the actual weights [113].  
MACBETH can be implemented using the dedicated software M-MACBETH [154]. 
In MACBETH, it is important to verify that the judgments of the decision maker are 
consistent [113]. The software M-MACBETH highlights inconsistencies in 
judgements and supports the decision maker in correcting these inconsistencies.     
As with other value function models presented here, MACBETH allows for 
structuring the decision problem in terms of a value tree, but unlike these, it does not 
allow for more than one parent criterion (i.e. a criterion composed of several sub-
criteria) at the same level of the hierarchy [113]. 
8.2.1.3. Assessment of MAUT/MAVT and MACBETH. 
Value function methods calculate the aggregate score 𝑆𝑖 of each option 𝐴𝑖  (𝑖 =
1,2, … 𝑙) as an overall score between 0 and 1 on a multi-attribute value (or utility) 
function (MAVF/MAUF). Such a function is built on an interval scale. Differences 
in overall option scores reflect differences in the strength of preference between 
options. To compare options, ratios of the overall scores of the options 
(corresponding to statements of the type “option 𝐴1  is twice as preferred as option 
𝐴2 “) are not meaningful [9]. 
Riabacke [146], citing French and Rios Insua [155], described prescriptive decision 
analysis as a method which should be: 1) grounded on an axiomatic basis accepted 
by users, 2) feasible, i.e. practical in its implementation , 3) robust, in the sense that 
the sensitivity to changes in the inputs should be understood, 4) transparent to users, 
and 5) compatible with a wider philosophy, i.e. with the user’s view of the context. 
The work by Keeney and Raiffa [11] resulting in MAVT/MAUT is an early 
prescriptive approach in the field of decision analysis with multiple criteria [146]. An 
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important strength of this approach is that it is based on constructing the 
MAVF/MAUF in a feasible way while respecting an axiomatic basis of rational 
decision making. However, as mentioned above, the elicitation procedures in 
MAVT/MAUT are still relatively complex and sometimes unstable. SMARTS and 
SMARTER use a strategy of heroic approximation to facilitate the MAVT/MAUT 
approach as much as possible while respecting its axiomatic basis. MACBETH was 
also developed in response to the complexities of the elicitation procedures required 
in MAVT/MAUT [124]. In MACBETH, the calculation of MAVFs, based on 
integrating a series of qualitative judgments of difference in preference 
(systematically checked for consistency) using linear programming techniques, 
eschews the complexity of the MAVT elicitation procedures proposed by Keeney 
and Raiffa. 
In terms of the single-attribute value or utility functions, the elicitation of preferences 
is a task that is cognitively demanding and prone to error [146]. Different procedures 
for eliciting values/utilities (like the ones that have been described here) with the 
same normative basis should yield the same ordering of preferences (the assumption 
of procedural invariance [156]), but empirical studies have shown that this may not 
be the case [146]. Approaches have been proposed to choose the most appropriate 
preference elicitation method depending on the specific situation [157]. 
In linear additive MAVFs/MAUFs (a commonly used MAVT/MAUT model), the 
weight of a particular criterion is “a scaling factor which relates a unit on its 
measurement scale to a unit on the measurement scale for any other criterion” [158]. 
The elicitation of the criteria weights can be undertaken using 1) ratio weight 
approaches such as direct rating, swing weights, trade-off methods and point 
allocation [146] and 2) imprecise weight elicitation methods, e.g. rank order methods 
or methods based on semantic scales (as in MACBETH) [146]. When the decision 
problem is structured as a value tree, the weight of each criterion at an intermediate 
level of the tree is interpreted as the total weight of its sub-criteria [158]. 
Ratio weight methods are hard to obtain accurately [146]. In the elicitation of these 
types of weights, the range of the value scale on each criterion needs to be taken into 
account. When the top and bottom values of the value scales are fixed based on best 
and worst performance levels of the options available locally, the value scale is 
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termed a local scale [159]. When the top and bottom values of the value scales are 
fixed based on the best and worst values according to the decision maker’s 
“experience, aspirations or imagination” [159], the value scale is termed a global 
scale [159]. Importance weights have been shown to be inappropriate with local 
scales in which the ranges of the values on the criteria are small and hence swing 
weights are advocated when these scales are used [159]. However, empirical studies 
have shown that people often do not adjust properly for the ranges in the criteria 
[146]. Several methods (including the generalised use of global scales [159]) have 
been suggested to improve this adjustment [146]. 
Within imprecise weight elicitation methods, two will be briefly discussed here with 
reference to the value function methods discussed above: rank order methods and 
methods based on semantic scales. Rank order methods, used e.g. in SMARTER, 
have been proposed on the basis that they adequately identify the best option 
between 75% and 85% of the time [10, 121]. The use of semantic scales with verbal 
terms in elicitation has the general problem that the same verbal expression may have 
different meanings for different people [146]: the interpretation of the numerical 
weights resulting from these verbal expressions can be difficult. 
In summary, value function methods have the advantage that they are solidly 
grounded in axioms of rational decision making. Classic MAVT/MAUT methods are 
can be complex to use, even if the criteria are value/utility independent, but good 
prescriptive approximations are available (SMARTS and SMARTER). MACBETH 
is an alternative to MAVT that relies 1) on pairwise comparisons of difference in 
preference between options (or option performance levels) and criteria and 2) on an 
iterative, software-supported, consistency-checking process. The elicitations of 
values, utilities, and weights can be subject to error, so they should be done with 
care. Careful examination of results and their validity is important, as is conducting 
sensitivity analysis on the inputs of the decision model [10].  
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8.2.1.4. Application of value function methods in the area of diagnosis and 
treatment of diseases. 
In their systematic review of MCDA applications in health care, Adunlin et al. [144] 
report several applications of value function methods in the area of diagnosis and 
treatment of diseases. Van Til et al. [160] studied  the applicability of different 
weight elicitation techniques, including those of SMART and SMARTS, in patients 
with mild cognitive impairment being treated for a stroke-related disability. They 
found that these individuals are willing (as well as able) to use these weighting 
approaches in a decision situation, although they did not express a preference for a 
particular method [160]. Chang et al. [161] used multi-attribute utility model to 
assess the factors that predict womens’ decisions to receive epidural analgesia. 
Pinheiro et a. [162] use MACBETH and Bayesian networks to determine what 
clinical aspects are most relevant in the diagnosis of Alzheimer’s disease. Shaw et al. 
[163] used importance weights to develop a patient preference-based scale for 
assessing health outcomes in women with menorrhagia. De Bock et al. [164] 
assessed how well a multi-attribute value model with rank order weights predicted 
general practitioners’ clinical decisions regarding the management of patient with 
suspected sinusitis. They found, inter alia, that the concordance between the model 
results and the actual decision was 80% in clear-cut cases of sinusitis and 50% in 
dubious cases [164]. Bettinger et al. [165] developed and solved a MAVT model for 
choosing between atypical antipsychotic treatments. Suehs and Bettinger [166] 
developed a MAVT model for the choice between mood-stabilizing medicines for 
bipolar disorder, and used a survey to obtain criteria preference weights from a large 
sample of specialists in psychiatric pharmacy to determine the preferred medication. 
After reviewing all studies included in the Cochrane review of PDA effectiveness 
which used computerised decision aids, we found one trials which made explicit 
reference to MCDA, and both referred to MAVT. In a previous RCT with the same 
tool, Schwartz et al. found that, within the group of women undecided about the 
breast cancer management option, the PDA (compared to usual care) led to an higher 
likelihood of reaching a decision, lower decisional conflict and higher decisional 
satisfaction. This study by Schwartz et al. [167] is an RCT of a 1) MAVT-based 
PDA for choosing between breast cancer management options in women carrying a 
BRCA 1/2 gene mutation versus 2) usual care. The authors found that, within the 
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group of women undecided about the breast cancer management option, the PDA led 
to a higher likelihood of reaching a decision, lower decisional conflict and higher 
decisional satisfaction [167]. In a subsequent study using the same PDA, Hooker et 
al. [168] found that women using the PDA experienced more distress than those that 
did not in the short term (at one month) but not in the longer term (at one year after).  
8.2.2. The Simple Additive Weighting (SAW) method. 
SAW is probably one of the best-known and widespread MCDA methods [169]. 
Suppose a choice decision problem with options 𝐴𝑖  (𝑖 = 1,2, … 𝑙) and criteria 
𝐶𝑘 (𝑘 = 1,2, … 𝐾). The performance levels of the options on the criteria 𝑥𝑖,𝑘 are 
measured quantitatively. The SAW method provides a ranking of the options using 
the following steps [169]: 
1) Elicit weights 𝑤𝑘 expressing the relative importance of the criteria. A number of 
approaches for eliciting the weights are available [169, 170], e.g. based on rating the 
importance of the criteria on a numerical scale or based on pairwise comparisons of 
the relative importance of the criteria [170]; 
2) Transform the performance levels 𝑥𝑖,𝑘 of the options on the criteria into scores 𝑠𝑖,𝑗 
on a common scale. If all the criteria are increasing in preference with the 
performance levels, this can be achieved by dividing the performance level 𝑥𝑖,𝑘 of 
each option by maximum performance level 𝑥𝑘
∗  [169], i.e. normalising by the score 
of the highest performing option: 
𝑠𝑖,𝑘 =
𝑥𝑖,𝑘
𝑥𝑘
∗       𝑖 = 1,2 … 𝑙; 𝑘 = 1,2 … 𝐾 
(1.4) 
If all the criteria which are decreasing in preference with the performance levels, the 
appropriate transformation is [169]: 
𝑠𝑖,𝑘 = 1 −
𝑥𝑖,𝑘
𝑥𝑘
∗       𝑖 = 1,2 … 𝑙; 𝑘 = 1,2 … 𝐾 
(1.5) 
If both types of criteria exist, then one appropriate transformation involves using 
equation (1.5) above and calculating the scores of the options on the criteria which 
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are decreasing in preference based on the inverse of their performance levels, i.e. 
[169]: 
𝑠𝑖,𝑘 =
1
𝑥𝑖,𝑘⁄
1
𝑥𝑘
∗⁄
      𝑖 = 1,2 … 𝑙; 𝑘 = 1,2 … 𝐾 
(1.6) 
3) Use a linear additive model to aggregate weights and scores into an overall score 
𝑆𝑖 for each option [169]: 
𝑆𝑖 = ∑ 𝑤𝑘𝑠𝑖,𝑘
𝐾
𝑘=1
         𝑖 = 1,2, … 𝑙 
(1.7) 
The scores 𝑆𝑖 are used to rank the options from most to least preferred. Note that 
SAW is not designed to handle hierarchies of criteria and sub-criteria. 
8.2.2.1. Annalisa, Annalisa in Elicia and SAW. 
Annalisa is a software implementation of  the “weighted sum approach” [19], i.e. a 
software implementation of SAW. In the software Annalisa, the scores of the options 
𝑠𝑖,𝑘 on the individual criteria are termed “ratings”. The process of normalising the 
single-criterion score of the options by dividing them by the score of the highest 
performing option on that criterion is termed, in Annalisa, “idealisation”. Idealisation 
is performed to ensure that, for each option 𝐴𝑖, each of the overall scores 𝑆𝑖 
generated in the aggregation of weights 𝑤𝑘 and ratings 𝑠𝑖,𝑘 reflects 1) the weight of 
each criterion and 2) the relative performances of the options on that criterion. If the 
options’ ratings on one criterion are all very small and those on another criterion are 
all very high the part-worths in the overall options’ scores will reflect improperly the 
relative performances of the options on the criteria if the ratings are not idealised 
(Dowie, personal communication). Annalisa software files are normally embedded 
using the survey software Elicia [171], which allows for customisation and 
personalisation of the inputs into the decision model [19]. In this thesis we refer to 
the joint implementation of Annalisa files and the Elicia survey software as Annalisa 
in Elicia (ALEL). We refer to the implementation of SAW using Annalisa as “SAW 
via Annalisa”. 
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8.2.2.3. Assessment of SAW. 
SAW is a long standing MCDA method. It has the advantage that it is very easy to 
put into practice. However, it has a disadvantage: it does not have an anchoring in 
axioms of rational decision making. In one variant of the SAW method explained 
above, where the performance levels are normalised to sum to one, it has been shown 
that rank reversals may occur when options are removed or added to the option set 
[172]. This is due to the change in the denominator of the normalisation process 
when the options are added/removed, which may change the scale of the resulting 
single-criterion scores and possibly result in rank changes [113]. To avoid this rank 
reversal problem, the normalisation process should be done using always the same 
denominator in any configuration of the decision problem [113]. The implication is 
that in an open system (i.e. where options can be added or removed from the set 
under consideration), care has to be taken when using SAW.  
8.2.2.4. Application of SAW the area of diagnosis and treatment of diseases. 
Based on the studies included in the review by Adunlin et al [144], there are several 
studies implementing SAW. Van Wijk et al [173] used SAW and TOPSIS to identify 
in a sample of clinicians the best first-line antihypertensive treatment. Azar [174] 
used SAW, TOPSIS and the Weighted Product Method (WPM) to compare the 
performance of several imaging techniques for diagnosing breast cancer, and found 
that SAW was the most robust method of the three. With respect to implementations 
of SAW via Annalisa in medical decision making, Masya et al. [175] demonstrated 
the use of a patient decision aid for the choice between alternative colorectal cancer 
treatment regimes. The authors elicited, in a sample of patients and in a sample of 
clinicians (including colorectal surgeons, medical oncologists, and radiation 
oncologists), individual preferences for a number of treatment outcomes using the 
time trade-off technique [175]. These preferences were averaged for each of the two 
groups of individuals and entered into an Annalisa model where the ratings of the 
options on the outcomes had been calculated using the best available evidence [175]. 
The authors found that patients and clinicians agreed on the most important 
outcomes to avoid, and identified the best alternative for different subgroups of 
individuals. Cunich et al. [176] developed and pilot-tested with a convenience 
sample of clinicians an Annalisa-based patient decision aid for choosing whether or 
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not to take a prostate screening test. They found, inter alia, that clinicians responding 
to a survey about the patient decision aid mostly 1) agreed with positive statements 
about its ease of use of the tool and 2) that the tool would be useful for discussing 
prostate cancer screening with their patients [176]. In the field of medical decision 
making, SAW via Annalisa has also been used 1) as the basis to develop a 
preference-sensitive measure of decision quality [21] and 2) in combination with 
cluster analysis to identify optimal prostate screening interventions for subgroups of 
individuals [177]. 
8.2.3. The Analytic Hierarchy Process (AHP) and the Analytic Network Process 
(ANP). 
8.2.3.1. The Analytic Hierarchy Process (AHP). 
The AHP is an MCDA method which organises “perceptions, feelings, judgments 
and memories into a hierarchy of forces that influence decision results” [12]. For an 
axiomatic representation of the AHP, see Saaty [12] and Dolan et al. [178]. 
The AHP decomposes the decision problem into a hierarchy of levels [12]. The 
simplest hierarchy is a three-level hierarchy, composed (from top to bottom) of the 
following elements: 1) the goal of the decision question, 2) the criteria to achieve the 
goal, and 3) the options [113]. Additional sub-criteria may be added under the 
criteria for more complex decision problems. 
With a simple three-level hierarchy as illustration, the AHP operates as follows: 1) 
calculating local priorities (i.e. scores) for each option on each criterion, 2) 
calculating criteria weights, and 3) aggregating local priorities and criteria weights 
into a global priority (i.e. a score 𝑆𝑖) for each option [113]. The calculation of the 
local priorities of the options and of the criteria weights is based on comparing each 
pair of elements at the same level of the hierarchy with respect to the element 
immediately above it in the hierarchy [178]. To obtain the local priorities of the 
options, each option is compared to each other option in terms of their relative 
performance with respect to each criterion. To obtain the criteria weights, each 
criterion is compared to each other criterion in terms of their relative importance with 
respect to achieving the goal. In the original version of the AHP, the pairwise 
comparisons between elements of the hierarchy are made in terms of judgments on a 
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ratio 9-point scale of perceived intensity of dominance [12] which is shown in Table 
1.2. 
Table 1.2. AHP scale of intensity of dominance. 
Intensity of dominance Definition 
1 Equal intensity of dominance 
2 Weak intensity of dominance 
3 Moderate intensity of dominance 
4 Moderate plus intensity of dominance 
5 Strong intensity of dominance 
6 Strong-plus intensity of dominance 
7 Very strong intensity of dominance 
8 Very, very strong intensity of dominance 
9 Extreme intensity of dominance 
 
The pairwise comparisons of performance of the options with respect to each 
criterion are represented in a reciprocal matrix of comparative judgments. AHP 
allows to check the consistency of these pairwise comparisons through the 
consistency ratio (which adopts values between 0 and 1) [178]. The closer the 
consistency ratio is to 1, the closer the pairwise comparisons of performance 
correspond to a series of random judgments. In practice, a consistency ratio of 0.1 or 
less is considered acceptable [178]. If this is not the case, the pairwise comparisons 
of performance should to be reassessed until they are consistent.  
The pairwise comparisons of performance of the options can be made, instead of 
using judgments on the AHP scale above, using objective data. A good example of 
the use of direct data in pairwise comparisons in clinical decision making is Dolan 
[179]. 
The solution for the local priorities is obtained, in the original version of the AHP, 
using the eigenvector method, a procedure based on matrix calculus [178]. In 
67 
 
contrast with the single-attribute value scores derived using the value function 
methods described in the previous section, which were calculated on interval scales, 
these local priorities are calculated on a ratio scale [180].  
To calculate the criteria weights, the pairwise comparisons of their relative 
importance with respect to the goal are displayed in a reciprocal matrix of 
comparative judgments. Once their consistency is verified, the weights are calculated 
(using the eigenvector method). These weights are also calculated on a ratio scale. 
When the hierarchy contains criteria and sub-criteria, the weights of all the sub-
criteria of a parent criterion reflect their relative importance with respect to their 
parent criterion. 
The AHP uses a linear aggregation procedure to combine local priorities and criteria 
weights. Considering the local priorities 𝑝𝑖,𝑗 of the options 𝐴𝑖 (𝑖 = 1,2, … 𝑙) on the 
criteria 𝐶𝑘 (𝑘 = 1,2, … 𝐾), the aggregate AHP scores 𝑆𝑖 can be represented as: 
𝑆𝑖 = ∑ 𝑤𝑘𝑝𝑖,𝑘
𝐾
𝑘=1
         𝑖 = 1,2, … 𝑙 
(1.5) 
Note that these overall scores are also on a ratio scale. With such a scale, 
comparisons in overall scores of the type “option 𝐴1 is x times better than option 𝐴2” 
are meaningful. Importantly, in the original AHP the aggregation of local priorities 
𝑝𝑖,𝑘 across criteria is done using the distributive mode, i.e. normalising their sum to 
unity [113]. This may create rank reversal problems, discussed in section 8.2.3.3 
below.  
In an AHP hierarchy, the elements within each level of the hierarchy are assumed to 
be independent. For example, at the level of the criteria, two criteria are dependent if 
they influence each other: Ishizaka et al. [113] exemplify this type of dependence for 
criteria “speed” and “engine power” in a car choice decision. Dependence between 
options is rare [113]. Lower levels of the hierarchy are also assumed to be 
independent from higher levels. For example, dependence between the level of the 
criteria and the level of the options exists when the criteria weights depend on the 
options: Ishizaka et al [113] illustrate this type of dependence for a dress decision 
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with two criteria (“price” and “elegance”) where the weight of criterion “price” 
changes depending on the price of a particular dress. 
The AHP can be implemented with a number of software applications, e.g. Expert 
Choice  and MakeItRational [181]. 
8.2.3.2. The Analytic Network Process (ANP). 
The ANP is a generalisation of the AHP which does not make assumptions about the 
independence of the different elements of the decision problem [182], whether they 
be the goal, the criteria (and/or sub-criteria) or the options. In the ANP, the decision 
problem is not modelled as a hierarchy, but as a network of clusters, where each 
cluster is a collection of elements [182] (e.g. a criterion cluster or an options cluster). 
In a network, there are two types of dependencies: 1) dependencies between elements 
with a cluster, termed inner dependencies [113] and 2) dependencies between two 
clusters, termed outer dependencies or feedback [113].  
To model inner dependencies in the criteria cluster, the ANP requires, in addition to 
the matrix of comparative judgments of importance of all the criteria, additional 
matrices of comparative judgments [113]. For example, in the case of a car choice 
decision problem with three criteria (price, speed and engine power), two of which 
are dependent (speed and engine power), three matrices are required: 1) a matrix of 
pairwise comparisons of the relative importance of price and speed assuming that the 
importance of engine power has already been assessed, 2) a matrix of pairwise 
comparisons of the relative importance of price and engine power assuming that the 
importance of speed has already been assessed, 3) a matrix of pairwise comparisons 
of relative importance of speed and engine power assuming that the importance of 
price has already been assessed. Similar procedures are used to model inner 
dependencies in the options cluster and outer dependencies. The different matrices of 
comparative matrices are combined in a supermatrix.  
In the ANP, the impact of dependencies on the overall scores 𝑆𝑖 is modelled using a 
Markov chain process [113]. 
The ANP is supported by the software Superdecisions [183]. 
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8.2.3.3. Assessment of the AHP and the ANP. 
The AHP has an axiomatic foundation (for a description of these axioms, see Saaty 
[184]) which focuses on the required properties of elements structured as a hierarchy 
in order to derive overall priorities on a ratio scale. These axioms differ from those of 
MAVT/MAUT in not making assumptions about the choice behaviour of a rational 
decision maker and have been the subject of some debate [185, 186]. 
The elicitation of local priorities of the options on a ratio scale separates the AHP 
from MAVT/MAUT, where the single-criterion values of the options are elicited on 
an interval scale. The use of ratio scales in the AHP have been criticised by some 
authors, e.g. Belton [158]  and Dyer [185] because they require decision makers to 
(either implicitly or explicitly) establish a reference point of absolute zero overall 
value, a concept difficult to understand and which introduces ambiguity into the 
elicitation process. Harker and Vargas [180] have argued that ambiguity is a 
characteristic of all preference elicitation procedures, and highlight the role of the 
decision analyst to support decision makers in eliminating that ambiguity. 
The use of the linear AHP scale (See Table 1.2) has been criticised for imposing 
unnatural restrictions on the decision maker’s judgments, such as having an upper 
limit of 9 to express numerically how many more times one element dominates 
another element [158]. However, Harker and Vargas [180] argued that the linear 
AHP scale can be altered to suit an individual’s need. In fact, several other scales 
have been proposed which increase the upper limit of this scale, such as the square 
root scale or the power scale [113]. Although the linear scale is the one that is most 
widely used, there is debate in the literature about what is the best scale [113]. 
As has been mentioned before, in the AHP the aggregate scores 𝑆𝑖 of the options are 
calculated on a ratio scale. This means that there is an absolute zero overall score 
(and hence no option can have a negative overall score) and that the only meaningful 
comparisons in overall value between options are of the type “Option 𝐴2 is x times 
better than option 𝐴2”, or, equivalently, “Option 𝐴2 is x% better than option 𝐴2”. 
Belton argues that the interpretation of AHP scores is not intuitive, and that the 
meaning of these scores should be made clear to the decision maker at the start of the 
decision process [158]. 
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In the AHP, each criterion weight should be interpreted as an “average score 
(average over the options under consideration) on each criterion” [158]. Salo and 
Hamalainen [187] have shown that if the pairwise comparisons between elements are 
interpreted in terms of preference differences the AHP can be interpreted as a variant 
of MAVT.  
Perhaps the most important criticism of the AHP is the possibility of rank reversals 
[188]. Rank reversals of options may occur in the AHP for different reasons [113]. 
One reason is due to the right-left inconsistency in the eigenvector method (the 
method used to calculate local priorities and weights) [113]. The right-left 
inconsistency (or right-left asymmetry), identified by Johnson et al. [189], arises 
when, after replacing the pair-wise comparisons between elements (e.g. performance 
levels or criteria) with their inverse values the obtained ranking of those elements is 
not, as would logically be expected, exactly reversed [113]. Rank reversals may 
occur when both of the following occur: 1) the matrix of pairwise comparisons is 
inconsistent and 2) there are more than three elements being compared [189]. 
Methods alternative to the eigenvector method have been proposed to avoid the 
right-left inconsistency [113]. 
Rank reversals may also occur in the original, distributive AHP, if a copy/ near-copy 
of an option (respectively, an option which has the same/almost the same pairwise 
comparisons in terms of the performance levels than another option) is added to or 
subtracted from the decision model [113]. As was mentioned before, this is a 
violation of the Principle of Independence from Irrelevant Alternatives (PIIA) [190] 
and it may occur in other additive MCDA methods (such as SAW) where the 
performance levels are normalised [113, 172]. To avoid this type of rank reversal in 
the AHP, whenever options can be added to or removed from the decision model, the 
normalisation of the local priorities should be done using always the same 
denominator [113]. This is achieved dividing the local priority of each option on a 
particular criterion by the local priority of the best option on that criterion [113]: the 
resulting local priorities are termed “idealised” [191] . This is the ideal mode in AHP 
[113]. 
The ANP is a generalisation of the AHP where dependencies within and between 
levels of the hierarchy can be modelled. Although the ANP has the same theoretical 
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underpinning and the AHP [113], the procedures used to calculate the overall scores 
of options, based on the analysis of a supermatrix via a Markov Chain process, yield 
multilinear forms of aggregation of the local priorities which can be quite elaborate 
[192]. The interpretation of such multilinear forms is beyond the scope of this 
chapter. However, in terms of practical implementation, the construction of a 
supermatrix can be quite a labor intensive task in terms of the number of pairwise 
comparisons required from the decision maker. 
To summarise, the use of the AHP has the advantage over MAVT/MAUT a la 
Keeney and Raiffa [11] that it systematically checks the consistency of the decision 
maker’s judgments before aggregating the inputs of the decision model into overall 
scores. In contrast, the interpretation of these scores and of the weights is arguably 
less straightforward. Care must be taken in using the eigenvector method (which may 
lead to rank reversals if the pairwise comparisons are inconsistent). Appropriate 
procedures (e.g. using the ideal AHP mode) should be used when options can be 
added or subtracted. If there are dependencies in the model, the ANP is the 
appropriate approach. As with other MCDA methods, careful analysis of the results 
and sensitivity analysis should be used to examine the robustness of these results. 
8.2.3.4. Application of AHP/ANP in the area of diagnosis and treatment of 
diseases. 
Based on the systematic review by Adunlin et al. [144], the AHP is the most widely 
used method in the diagnosis and trea. The implementation of this method in clinical 
decision making will be illustrated with several examples, focusing in studies 
undertaken with patients of AHP as a tool for patient decision support. Dolan [18] 
pilot-tested with patients a AHP-based decision tool for the choice of colorectal 
screening regimen. He found that 90% of the patients were both willing and capable 
(where capable was understood as completing the tool in less than forty five minutes) 
of using the tool [18]. Dolan and Frisina [46] compared in a RCT 1) an AHP-based 
decision tool for choosing between alternative colorectal screening programmes with 
2) an educational intervention about colorectal cancer and the screening programs. 
They found that the tool reduced decisional conflict and that there was no difference 
between patient groups in the choice of screening test [46]. Dolan [193], in a field 
study with primary care patients of an AHP-based decision tool for choosing 
72 
 
between alternative colorectal screening procedures, found using cluster analysis that 
there was significant variation between patients in the trade-offs they made between 
the decision criteria. Liberatore et al. [194] developed and successfully implemented 
in a general practice setting an AHP-based decision aid for deciding whether or not 
to undergo a prostate screening test. Carter et al [195] solved a breast cancer 
treatment decision problem using the AHP, the ANP and a Markov model and found 
that the three models gave similar results. 
8.2.4. Outranking approaches Election et Choix Traduisant la Realité 
(ELECTRE) and Preference Ranking Organisation Method for Enriched 
Evaluation (PROMETHEE). 
Outranking approaches such as ELECTRE [13] PROMETHEE [14] are MCDA 
methods which model the decision maker’s preferences based on establishing binary 
outranking relations between options. In these methods, every pair of options is 
compared in order to establish one of the following situations: 1) the first option is 
strictly preferred to the second option, 2) the second option is strictly preferred to the 
first option, 3) the two options are indifferent, or 3) the two options are incomparable 
[13, 14]. Comparing these outranking relations between options creates a 
synthesising preference relational system [126] which, due to 1) the possibility that 
some pairwise comparisons are intransitive and 2) the possibility that some options 
are incomparable [126], may not be enough to lead to a clear answer to the decision 
question [126]. These methods use additional procedures, termed exploitation 
procedures, to make recommendations [126].  
8.2.4.1. Election et Choix Traduisant la Realite (ELECTRE). 
Different ELECTRE methods have been developed for different types of decision 
problems [13, 113]. For example, ELECTRE I, ELECTRE Iv and ELECTRE Is are 
based on selecting a subset of all the options available in such a way that only one 
option will be selected in the end [13]. ELECTRE II, ELECTRE III and ELECTRE 
IV were designed to rank from most to least preferred all the options [113]. 
ELECTRE-Tri-B and ELECTRE-Tri-C were developed to sort options into 
categories [113]. For the remainder of this section and for illustration purposes, the 
focus will be on ELECTRE III for ranking options. 
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Consider the options 𝐴𝑖 (𝑖 = 1,2 … 𝑙) and the criteria 𝐶𝑘 (𝑘 = 1,2 … 𝐾). The first 
stage in ELECTRE III is determining the outranking relation between the pair of 
options 𝐴𝑖 and 𝐴𝑗  𝑗 ≠ 𝑖 . The task can be summarised in the following steps [113]: 
1) Construct two indices on each criterion 𝐶𝑘: 1.a) a partial concordance degree 
𝑐𝑘(𝐴𝑖, 𝐴𝑗) measuring the assertion that 𝐴𝑖 is as least as good as 𝐴𝑗  (𝑗 ≠ 𝑖) on that 
criterion [113], and 1.b) a partial discordance degree 𝑑𝑘(𝐴𝑖, 𝐴𝑗) measuring the 
discordance with the assertion that 𝐴𝑖  is at least as good as 𝐴𝑗  (𝑗 ≠ 𝑖) on that 
criterion [113].  
1.a) To construct the partial concordance degree for each criterion 𝐶𝑘, indifference 
and preference thresholds are defined. The indifference threshold describes 
numerically the largest difference between the performance levels of the criterion so 
that the decision maker is indifferent between two options [113]. The preference 
threshold describes numerically the largest difference between the performance 
levels of the criterion so that the decision maker prefers one option over another 
[113]. The partial concordance degree 𝑐𝑘(𝐴𝑖, 𝐴𝑗) takes values between 0 and 1 based 
on comparing the differences in the performance of 𝐴𝑖 and 𝐴𝑗  (𝑗 ≠ 𝑖) with the 
indifference and preference thresholds: 𝑐𝑘(𝐴𝑖, 𝐴𝑗) = 0 indicates that 𝐴𝑖 is indifferent 
to 𝐴𝑗, 𝑐𝑘(𝐴𝑖 , 𝐴𝑗) = 1 indicates that 𝐴𝑖 is strictly preferred to 𝐴𝑗 [113];      
1.b) To construct the partial concordance degree for each criterion 𝐶𝑘, a veto 
threshold is defined. The veto threshold describes numerically the largest difference 
between the performance levels so that the decision maker rejects the assertion that 
that 𝐴𝑖 is at least as good as 𝐴𝑗  (𝑗 ≠ 𝑖) [113]. The partial discordance degree 
𝑑𝑘(𝐴𝑖, 𝐴𝑗) takes values between 0 and 1 based on comparing the differences in the 
performance of 𝐴𝑖 and 𝐴𝑗  with the veto thresholds: 𝑑𝑘(𝐴𝑖 , 𝐴𝑗) = 0 indicates that 
there is no reason to reject the assertion; 𝑑𝑘(𝐴𝑖, 𝐴𝑗) = 1 indicates that the assertion is 
accepted, since difference in performance between 𝐴𝑖 and 𝐴𝑗 exceeds the veto 
threshold [113]; 
2) Calculate the partial concordance degrees 𝑐𝑘(𝐴𝑖, 𝐴𝑗) and the partial discordance 
degrees 𝑑𝑘(𝐴𝑖 , 𝐴𝑗) for each pair of options 𝐴𝑖 and 𝐴𝑗  (𝑗 ≠ 𝑖); 
3) Assign importance weights to the criteria;  
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3) Calculate the global concordance degree 𝐶(𝐴𝑖, 𝐴𝑗), the weighted sum of partial 
concordance degrees 𝑐𝑘(𝐴𝑖, 𝐴𝑗) (𝑘 = 1,2, … 𝐾) for each pair of options 𝐴𝑖 and 
𝐴𝑗  (𝑗 ≠ 𝑖); 
4) Calculate the global outranking degree 𝑆(𝐴𝑖, 𝐴𝑗) for each pair of options 𝐴𝑖 and 
𝐴𝑗  (𝑗 ≠ 𝑖). This index (between 0 and 1) measures the extent to which option 𝐴𝑖 
outranks 𝐴𝑗  (𝑗 ≠ 𝑖) [113]. It modifies the global concordance degree based on the 
veto effects measured by each criterion’s partial discordance degree. 
Once the global outranking degrees between pair of options have been established, 
the second stage in ELECTRE III involves using additional exploitation procedures 
called ascending and descending distillation procedures [113] to obtain a full ranking 
of the options. 
Approaches have been developed to use ELECTRE for solving decision problems 
which are structured as a hierarchy of criteria [196]. 
Different ELECTRE methods are supported by different software applications [197]. 
ELECTRE III is supported by the software application ELECTRE III-IV [197]. 
8.2.4.2. Preference Ranking Organisation Method for Enriched Evaluation 
(PROMETHEE). 
Consider the options 𝐴𝑖 (𝑖 = 1,2 … 𝑙) and the criteria 𝐶𝑘 (𝑘 = 1,2 … 𝐾). 
PROMETHEE methods are based on making pairwise comparisons of the difference 
in the performance levels of each pair of options 𝐴𝑖 and 𝐴𝑗  (𝑗 ≠ 𝑖) on each criterion 
𝐶𝑘 [14]. To undertake these comparisons, a preference function is defined for each 
criterion. The definition of such functions, with different possible forms (e.g. linear 
or Gaussian [14, 113]) depending on the decision maker’s preferences and with 
values between 0 and 1, allows to calculate for each ordered pair of options 𝐴𝑖 and 
𝐴𝑗  (𝑗 ≠ 𝑖) a preference degree 𝑃𝑘(𝐴𝑖 , 𝐴𝑗) taking a higher value the higher the 
difference in performance between the options [113]. 
Once the criterion-specific preference degrees 𝑃𝑘(𝐴𝑖, 𝐴𝑗) (𝑘 = 1,2, . . 𝐾) are 
calculated for each ordered pair of options, PROMETHEE then calculates, for each 
option, the positive flow (an index of preference for that option with respect to all 
other options [113]), the negative flow (an index of preference of all other options 
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with respect to that option [113]), and the net flow (the difference between the 
positive and negative flow). Global flows are then calculated [113] by aggregating 
positive/negative/net flows across criteria – this is done using criteria weights (which 
can be elicited in different ways, e.g. based on pairwise comparisons of relative 
importance or on rank ordering the criteria [113]). PROMETHEE I analyses the 
global positive and negative flows to obtain a partial ranking of the options, while 
PROMETHEE II uses the net flows to obtain a complete ranking of the options [14].  
Methods exist to use PROMETHEE for solving decision problems which are 
structured as a hierarchy of criteria [196]. 
PROMETHEE methods are supported by a number of software applications, e.g. 
Visual PROMETHEE [198], D-Sight [199], and Smart Picker Pro [200]. 
8.2.4.3. Assessment of ELECTRE and PROMETHEE. 
Outranking method ELECTRE and PROMETHEE have the advantage over full 
aggregation methods (such as MAVT/MAUT or the AHP) that, allowing for 
incomparability between options, they can express more flexibly the decision 
maker’s preferences. However, some have expressed concern that the definitions and 
procedures used in these methods are rather arbitrary [10] and that MAVT is more 
transparent and provides a clearer audit trail [10]. In addition, neither PROMETHEE 
nor ELECTRE are free from rank reversals [113].   
8.2.4.4. Application of ELECTRE and PROMETHEE in the area of diagnosis 
and treatment of diseases. 
In the systematic review of studies presented in Adunlin et al. [144], two studies 
were described using ELECTRE in the area of diagnosis and treatment of diseases. 
One of these studies by Le Gales and Moatti [201] used ELECTRE IS to support a 
group of experts identify a reasonable set of screening strategies for the prevention of 
major hemoglobinopathies in France and choose the best alternative based on a 
number of criteria. The other study by Brasil Filho and Coelho [202] used ELECTRE 
IV for the classification of patients into different Alzheimer’s disease categories. 
With respect to PROMETHEE, no applications in the area of diagnosis and treatment 
were reported in the systematic review mentioned above. 
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8.2.5. Technique for Order of Preference by Similarity with an Ideal Solution 
(TOPSIS). 
TOPSIS is a reference-level MCDA method which is based on choosing options 
which are, at the same time, as close as possible to a positive-ideal option and as far 
away as possible from a negative-ideal option [129], both of which are defined by the 
decision maker [113]. TOPSIS is based on the following five steps [113, 129]: 
1) Normalising, on each criterion, the performance levels of the options (so that they 
are comparable) by the sum of the squared performance levels of the options; 
2) Weighting, on each criterion, the performance level of each option by the 
preference weight assigned to that criterion; 
3) Establishing the positive-ideal and the negative-ideal options. The positive-ideal 
option can be 1) a hypothetical option with the best (normalised) performance level 
of all the available options on each criterion, 2) an absolute ideal option independent 
of all the available options, or 3) an option between these two [113]. Similarly, the 
negative-ideal option can be 1) a hypothetical option with the worst (normalised) 
performance levels of all the available options on each criterion, 2) an absolute anti-
ideal option, or 3) an option between these two [113]; 
4) Calculating the distance from each option to the ideal and anti-ideal options: the 
standard approach is calculating, for each option, the Euclidian distance between the 
point defined by the vector of normalised performance levels of the option and the 
point defined by the vector of normalised performance levels of the positive-ideal 
and negative-ideal options [113]. Note that the Euclidian distance is a scalar; 
5) For each option, calculate the relative closeness coefficient (a number between 0 
and 1), based on dividing the distance to the anti-ideal option by the sum of the 
distance to the anti-ideal solution and the distance to the ideal solution [113]. The 
higher the relative closeness coefficient is for a particular option, the closest the 
option is to the ideal option and the furthest it is from the anti-ideal option.  
TOPSIS can be implemented using e.g. the Tryptich Excel-based software 
application [203].  
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With respect to the assessment of TOPSIS, the main advantage is that it is a simple 
method to implement. However, it has been criticised because it may give illogical 
results [113]. As with other MCDA methods, TOPSIS is not free from rank reversals, 
although modifications of the original TOPSIS algorithm have been proposed to 
avoid this problem [204]. 
The only study using TOPSIS in the area of diagnosis and treatment, as reported by 
Adunlin et al. [144], is the study by Azar et al. [174] comparing TOPSIS, SAW and 
WPM in the choice of imaging technique for breast cancer diagnosis: this study 
showed that SAW and TOPSIS yielded similar results. 
8.2.6. Conclusion. 
This section has explored in detail a number of MCDA methods which 1) are long-
established and/or 2) have been used in the area of diagnosis and treatment of 
diseases. Value function methods have the advantage that they are well-grounded on 
axioms of rational decision making. In this sense they are normatively more 
appropriate than other methods. Within these methods, MAVT/MAUT as described 
by Keeney and Raiffa [11] may be difficult to implement. For this reason, simpler 
approaches like SMARTS and SMARTER have been proposed to facilitate the 
MCDA process. Another approach, MACBETH, may be impractical when the 
decision involves many options or many criteria, as it requires to make many 
pairwise comparisons. This applies to the AHP which, although axiomatically 
anchored, does not make assumptions about the rational behaviour of the decision 
maker. The AHP has to be used with care, as in decision situations where the options 
are not fixed it can give rise to anomalous results (rank reversals) when options are 
added or removed. SAW, a very easy methods to implement, also has to be used with 
care for the same reason. TOPSIS is also easy to implement, but it may give rise to 
illogical results. ELECTRE and PROMETHEE allow to express more realistically 
the preferences of decision makers than full aggregation methods such as 
MAVT/MAUT, AHP and SAW, but they are not very transparent and may also lead 
to rank reversals.  
Based on a systematic review of studies [144] of the application of these methods in 
the area of diagnosis and treatment, the most used method in patient decision support 
is the AHP. The AHP has been described as acceptable to users and has successfully 
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been applied in a general practice setting. SAW has been successfully used by 
clinicians to choose between antihypertensive treatments. SAW via Annalisa has 
been described by clinicians as easy to use and useful to provide clinical decision 
support. Value function methods have been used by health practitioners to make 
decisions, and also to develop preference-based health outcome scales. It has been 
shown that patients are willing to use the weight elicitation procedures of SMART 
and SMARTS. ELECTRE has been used to choose between alternative screening 
programmes for prevention of major hemoglobinopathies, but not at patient level and 
to help clinicians diagnose Alzheimer’s disease patients. No information was 
reported in Adunlin et al [144] about uses of TOPSIS or PROMETHEE with patients 
or clinicians.   
8.3. Choosing an MCDA method. 
As has been shown in the previous section, different MCDA methods differ not only 
in their axiomatic basis, but also in the specific implementation of the MCDA 
process. Choosing a MCDA method is not a straightforward task [205]. Different 
approaches which have been proposed include 1) choice rules and algorithms 
(including expert systems) based on the information required by the model, 2) field 
experiments with subjects exploring their reaction to different methods in terms of 
specific criteria, and 3) comparison experiments in the form of mathematical 
simulations [206].  
Studies based on choice rules and algorithms are more useful for eliminating than for 
choosing one particular MCDA method [206]. Field studies are useful to compare 
MCDA methods in terms of user reactions, but they have limitations (e.g. they tend 
to have small sample sizes, the way information is elicited may influence the results 
more than the method used, learning effects may bias the outcomes) [206]. Existing 
simulation experiments exploring the operational aspects of different MCDA 
methods have been undertaken on a variety of these methods, and summarising this 
literature is beyond the scope of this review. Three of these studies are commented 
on here because they involve several of the methods described in the previous 
sections. Buede and Maxwell [207] performed a number of simulations to compare 
MAVT (which was used as a benchmark because it is immune to rank reversals) with 
several methods known to show rank reversals, including the AHP and TOPSIS. The 
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results showed that while the rank disagreements between MAVT and TOPSIS were 
likely, they were unlikely between MAVT and the AHP [207]. Zanakis et al. [206] 
performed simulations comparing the performance of several MCDA methods 
including SAW (used as a benchmark), Multiplicative Exponent Weighting (MEW), 
four versions of the AHP, ELECTRE and TOPSIS. They found, inter alia, that 1) the 
AHP versions performed closer to SAW than the other methods and that 2) when the 
number of options increase, the methods produce similar final weights, dissimilar 
rankings, and more rank reversals [206]. Salminen et al. [208] performed simulations 
comparing SMART, ELECTRE III and PROMETHEE I and II. They found that in 
many situations the three methods performed similarly, but that the preferred options 
can vary greatly between methods in specific situations [208].    
In a review of empirical studies comparing the results of different MCDA methods 
when applied to the same decision problem, Mysiak [209] reported that: 
- In terms of the perceived usefulness of methods by different users: methods which 
rated highly on ease of use often rated poorly in inspiring confidence in the results; 
harder methods gave more similar results across users; simpler methods were 
generally reported as less appropriate; 
- The evidence regarding the consistency of results when the same individual uses 
different MCDA methods is contradictory; 
- When the same MCDA method is used by different individuals, the results can vary 
greatly due to interpersonal differences in preferences and in experience; 
- Studies evaluating the difference in the consistency of results when both 1) the 
same individual is exposed to different methods and 2) different individuals are 
exposed to the same method found no evidence to that effect;  
The experimental validation of MCDA methods is problematic, as there is no agreed 
definition of validity [210]. In the light of this observation, is there a best MCDA 
method? Several authors suggest that the “right” method will depend on the 
characteristics of the specific decision situation [209, 211]. Salminen [208] and 
Mysiak [209] both recommend to use more than one MCDA method to solve a 
decision problem. Buede and Maxwell [207] argue that structuring the decision 
problem (in terms of the selection of options and criteria) and adequately eliciting of 
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the inputs into the decision model are as important as the choice of method. Philips 
argues that decision models are requisite when their “form and content are sufficient 
to solve a particular problem” [212]. Such decision models are constructed in an 
interactive process of consultation with a decision analyst: extensive sensitivity 
analysis is used to explore the results and reshape (if necessary) the model until no 
more intuitions arise about the problem [212]. The focus of these models is on 
analysis, and in this sense they are not necessarily prescriptive [212]. In order to 
assess the validity of requisite decision models, multi-criteria requisite evaluation 
models can be developed, where the evaluation criteria may be objective or relatively 
subjective [212]. 
8.4. Software applications for implementing MCDA methods. 
An ample variety of software applications are available to implement MCDA 
methods. Weistroffer et al. [213] provides an overview of these tools. The 2014 
Decision Analysis Software Survey by OR/MS Today [214] includes a number 
applications implementing MCDA, and also includes detailed vendor-provided 
information about their features. The International Society of Multi-Criteria Decision 
Making provides, on its website [215], links to the websites of a number of tool 
developers/vendors. 
8.4.1. Software applications: types and characteristics. 
Some applications are MCDA-method-specific, such as the aforementioned 
ELECTRE family of applications [197], Visual PROMETHEE [198], M-MACBETH 
[154] and Annalisa in Elicia (ALEL) [20]. Others allow for the combination of 
features of different MCDA methods. A good example of this second type is Web-
HIPRE [216]. Web-HIPRE uses a linear additive MAVT model but the weights can 
be elicited using a number of techniques, e.g. direct rating, swing weighting, or 
pairwise comparisons of importance as in the AHP [217]. HiView 3 [15] allows to 
use MAVT (with swing weights) but it also permits 1) the use of MACBETH to 
evaluate a whole model and 2) the use of MACBETH only for weight elicitation. 
Although many software applications implementing MCDA are generic, some have 
been designed for specific fields. For example, PurE2 [218] was developed to solve 
multi-criteria decision problems in the field of urban pollution. MCDA-Res [219] 
was designed to solve multi-criteria renewable energy decision problems. 
81 
 
Applications developed in academic institutions are often available for free (or for a 
small fee), but commercial vendors (some of which give educational discounts) can 
charge hundreds or thousands of dollars [213]. Mustajoki and Marttunen [220] 
provide relatively recent cost information for commonly used MCDA applications. 
The purpose of this section is to review different generic MCDA software 
applications for solving a particular choice decision problem. Because of the large 
number of existing applications implementing MCDA, a decision was made to focus 
on a reasonable subset. In a review of these applications and their features, Mustajoki 
and Marttunen [220] identified twenty-four applications that have “been actively 
used or that have achieved some status among the practitioners and MCDA 
community (which can be seen as an indication of the software offering such features 
that make it worth using)” [220]. The set of applications identified by these authors 
was used as a starting point for the review presented here. For inclusion in this 
review, the following software applications were eliminated: 1) those that were not 
generic; 2) in addition, those that were not based on the MCDA methods described in 
sections 8.1. and 8.2. This resulted the following applications for review: Analytica 
[221], Criterium Decision Plus [222], D-Sight, GMAA, HiView 3, Logical 
Decisions, M-MACBETH, MakeItRational, OnBalance [223], Smart Decisions 
(previously Promax) [224], V.I.S.A Decisions, and Web-HIPRE [216, 217]. Expert 
Choice was added to the set since it is a well-known AHP software and has been 
used in medical decision making. ALEL was added to the set because it has been 
used previously in medical decision making. Studies comparing MCDA applications 
were identified from the literature, i.e. French and Xu [225], Mustajoki and 
Marttunen [220], and Baizyldayeva et al. [226]. The results of these studies and and 
the OR/MS survey [214], complemented by any user guides available for each 
package and trial testing of the software (where possible) were used to assess the 
applications included in this review. The focus of the review is on how each 
application addresses the MCDA process. Information is also provided on any 
available features within the packages that provide users with support through the 
decision making process, e.g. in terms of 1) tab panels distinguishing each step of the 
decision-making process or 2) step-by-step guidance through decision-making [220]. 
Information is also provided on any explicit group decision support available with 
each package. The results of the review are summarised in five tables, respectively 
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commenting for each application on: methods supported, decision support features 
(user manuals and help menus not included, as they are common software features), 
and group decision support (Table 1.3); problem structuring (Table 1.4); scoring 
options on the individual criteria (Table 1.5); weighting criteria (Table 1.6); analysis 
of results and sensitivity analysis (Table 1.7). 
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Table 1.3. Software applications for MCDA: methods implemented, decision support 
features and group decision support.  
Software Description of method(s) implemented, decision support features, 
and explicit support for group decision making 
 
 
Analytica 
 
MAVT with additive MAUF. No decision support features. Explicit 
support for group decision making not provided. 
 
 
 
ALEL 
 
SAW. Decision support can be added through the Elicia functionality, 
which allows to tailor the steps of the decision process via a sequence 
of screens. ALEL allows for different users to work on the same 
model remotely and supports decentralised elicitation of information. 
 
Criterium 
Decision Plus 
 
SMART and AHP. No decision support features. Explicit support for 
group decision making not provided 
 
D-Sight  
MAVT/MAUT with additive MAVF/MAUF and PROMETHEE. 
Provides decision support in tabs separating the elements of the 
decision-making process. D-sight allows for different users to work 
on the same model remotely and supports decentralised elicitation of 
information. 
 
Expert Choice 
(version 11.52) 
 
AHP. No decision support. Group decision making is supported by 
creating models that can be worked on remotely by several members 
of a group. In group mode, the judgments of the different users can be 
combined. 
 
GMAA  
MAVT/MAUT with additive MAVF/MAUF. Allows for imprecision 
in value elicitation. No decision support. Explicit support for group 
decision making is not provided. 
 
  
                                                          
2 The author of this thesis did not have access to a more recent version of this software 
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Table 1.3 (cont.). Software applications for MCDA: methods implemented, decision 
support features and group decision support.  
Software 
 
Description of method(s) implemented, decision support features, 
and explicit support for group decision making 
 
HiView 3 
 
MAVT with additive MAVF. MACBETH supported. No decision 
support. Explicit support for group decision making is not provided. 
 
Logical Decisions 
 
MAVT with additive MAVF, AHP, and AHP as a value function 
approach. The “Logical Decisions Facilitator” provides information 
about the steps of the decision-making process in tab panels. Explicit 
support for group decision making is provided in Logical Decisions 
for Groups, but not in the standard version of the software. 
 
M-MACBETH 
 
MACBETH. No decision support. Explicit support for group decision 
making is not provided 
 
MakeItRational 
 
AHP. Provides decision support in tabs separating the elements of the 
decision-making process. Group decision making is supported by 
creating models that can be worked on remotely by several members 
of a group. In group mode, the judgments of the different users can be 
combined. 
 
OnBalance 
 
MAVT with linear additive MAVF. No decision support. Explicit 
support for group decision making is not provided. 
 
Smart Decisions 
 
MAVT with linear additive MAVF. Provides decision support in tabs 
separating the steps of the decision-making process. According to the 
OR/MS Survey, explicit support for group decision making is 
provided in Smart Decisions Gold [214]. 
 
V.I.S.A. 
Decisions 
 
MAVT with linear additive MAVF. Provides decision support in both 
tab panels and in a step-by-step guide of the decision process. 
Explicit support for group decision making is not provided. 
 
Web-HIPRE 
 
MAVT with linear additive MAVF and AHP as a value function 
method. No decision support. Group models can be created 
combining the weights of different users. 
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Table 1.4. Software applications for MCDA: problem structuring. 
Software 
 
Description  
 
Analytica 
 
Problems structured as influence diagrams. Hierarchies can be 
modelled and displayed. Easy to add and drag elements across the 
screen. Interfaces can be created for users to enter information 
without having to view the entire diagram 
 
ALEL 
 
Does not have an interface for structuring the decision problem. Does 
not allow for criteria hierarchies. 
  
Criterium 
Decision Plus 
 
Criteria hierarchies can be modelled and displayed. “Brainstorm 
window” to structure decision problems, where elements can easily 
be added and dragged around. The resulting model in a “Brainstorm 
window” can automatically be transformed into a hierarchy. 
Hierarchies are represented in the “Hierarchy window”. 
  
D-Sight 
 
Criteria hierarchies can be modelled and displayed. Criteria can be 
added and dragged around easily. 
 
Expert Choice 
 
Criteria hierarchies can be modelled and displayed. Two different 
interfaces: the “Cluster view” interface and the “Treeview” interface. 
Both are flexible in terms of arranging criteria. Additionally, the 
“ProCon pane” allows to set pros and cons of options and then 
convert them into criteria. 
 
GMAA 
 
Criteria hierarchies can be modelled and they are displayed from left 
to right. The problem structuring interface allows to add criteria but it 
does not allow to drag criteria around the screen  
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Table 1.4 (cont.). Software applications for MCDA: problem structuring. 
 
Software 
 
Description 
HiView 3 
 
Criteria hierarchies can be modelled and displayed vertically or 
horizontally. Criteria can be added and dragged around easily 
 
Logical 
Decisions 
 
Criteria hierarchies can be modelled and are displayed horizontally or 
vertically. “Brainstorming window” to structure the hierarchy, criteria 
can easily be added and be dragged around the screen.  
 
M-MACBETH 
 
Criteria hierarchies can be modelled and displayed from left to right. 
Hierarchies are built using “nodes”, of which there are two types: 
“non-criteria nodes” and “criteria nodes”. The first type can be used 
to structure the decision model in a hierarchy, but contain no 
information. The second time are the nodes on which the model is 
assessed. Nodes can be added but cannot be dragged around the 
screen. 
 
MakeItRational 
 
Criteria hierarchies can be modelled. In the online version, criteria 
can be added but not dragged around, and the hierarchy cannot be 
displayed graphically. In the desktop version the hierarchy can be 
displayed graphically but the criteria cannot be dragged around the 
screen 
 
OnBalance 
 
Criteria hierarchies can be modelled, and are displayed from top to 
bottom. Criteria can be added but not dragged around on the screen. 
Criteria are divided into “benefit” and “cost” criteria 
 
 
  
87 
 
Table 1.4 (cont.). Software applications for MCDA: problem structuring. 
 
Software 
 
Description 
Smart Decisions 
 
Criteria hierarchies can be modelled and displayed, criteria can be 
added but not dragged around 
 
V.I.S.A. 
Decisions  
 
Criteria hierarchies can be modelled and displayed. Criteria can be 
added and dragged around the screen easily.  
 
Web-HIPRE 
 
Criteria hierarchies can be modelled and displayed. Criteria can be 
dragged around the screen easily 
 
 
Table 1.5. Software applications for MCDA: scoring options on the individual 
criteria 
 
Software 
 
 
Description  
 
Analytica 
 
Allows for visual assessment of single-criterion value scores for each 
option. Not possible from surveys or user guide to identify the exact 
value elicitation procedures available in the software  
 
ALEL  
Single-criterion scores for each option assessed directly either in text 
or on a sliding bar 
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Table 1.5 (cont.). Software applications for MCDA: scoring options on the individual 
criteria 
 
Software 
 
Description 
Criterium 
Decision Plus 
 
Allows for visual assessment of single-criterion value scores for each 
option. Not possible from surveys to identify the exact value 
elicitation procedures available in the software. From the user 
manual, information is provided about the AHP elicitation of local 
priorities. For calculating local priorities, pairwise comparisons of 
relative performance are done on a “rating” screen which allows for 
numerical, verbal or graphical comparisons between options. 
 
D-Sight 
 
According to Mustajoki and Marttunen [220], the software does not 
allow for visually eliciting single-criterion value scores. This 
information could not be verified as this author did not have access to 
the user manual. 
 
Expert Choice 
 
Single-criterion local priorities for each option are elicited using 
pairwise comparisons of relative performance with three possible 
formats: verbal, numerical, or with sliding bars. Local priorities can 
be entered directly if data is available. Inconsistencies are displayed 
and suggestions made for their correction. The software allows to 
construct value functions, a departure from AHP 
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Table 1.5 (cont.). Software applications for MCDA: scoring options on the individual 
criteria 
 
Software 
 
Description 
GMAA 
 
Support in the elicitation of single-criterion value scores is provided 
using visual aids. Option value scores can be elicited directly using a 
vertical value scale (i.e. thermometer). For discrete performance 
levels, discrete value functions can be built entering directly the value 
scores to construct a graph. For continuous performance levels, linear 
or piecewise linear value functions can be built on a graph. Single-
attribute utility functions ca be built using certainty equivalence 
methods and probability equivalence methods with visual aids. 
Imprecision can be built into the functions. 
 
HiView 3 
Support in the elicitation of value scores is provided using visual aids. 
Option value scores can be elicited directly using vertical value scales 
(i.e. thermometers). For discrete performance levels (e.g. verbal 
levels), discrete value functions can be built using vertical value 
scales. For continuous performance levels, single-criterion linear 
value functions are the default in the software, but piecewise linear 
value functions can be constructed using interactive graphs. 
Logarithmic value functions can be used to represent uncertainty as a 
criterion. In addition, MACBETH scales can be built using a matrix 
of pairwise comparisons of difference in attractiveness (the M-
MACBETH interface) 
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Table 1.5 (cont.). Software applications for MCDA: scoring options on the individual 
criteria 
 
 
Software 
 
Description 
Logical 
Decisions 
 
Support in the elicitation of single-criterion value scores is provided 
using visual aids. Option value scores can be elicited directly using a 
screen with sliding bars. The balanced beam method (based on 
equally preferred bundles of items) can also be used to elicit option 
value scores. For continuous performance levels, linear, piecewise 
and exponential value functions can be assigned using an interactive 
screen. The mid-value splitting technique can also be used to elicit 
option value scores. Option utility scores can be assessed using 
lotteries. For eliciting local priorities using the AHP, a matrix of 
numerical pairwise comparisons is available, including consistency 
checks. The local priorities can be normalised in several ways: 1) 
assigning the highest performing option a priority of 1 and the lowest 
performing option a priority of 0; normalising priorities so they add to 
1 (the distributive AHP); normalising by the priority of the highest 
performing option, i.e. idealising (the ideal AHP)  
 
M-MACBETH 
 
Single-criterion value scores are elicited in a matrix of pairwise 
comparisons of difference in performance, with inconsistencies 
displayed and suggestions made for their correction. Several options 
are available for these pairwise comparisons: 1) comparing the local 
options, 2) comparing the local options + two reference options, 3) 
comparing qualitative performance levels, and 4) comparing 
quantitative performance levels. Allowance is made for adjusting the 
resulting scale graphically. 
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Table 1.5 (cont.). Software applications for MCDA: scoring options on the individual 
criteria 
 
Software 
 
Description 
MakeItRational 
 
Single-criterion local priorities for each option are elicited using 
pairwise comparisons of relative performance with a visual aid, with 
inconsistencies displayed and suggestions made for their correction. 
OnBalance 
Support in the elicitation of option value scores is available with 
visual aids. Option value scores can be elicited directly using vertical 
value scales (i.e. thermometers). For discrete performance levels (e.g. 
verbal levels), discrete value functions can be built using histograms. 
For continuous performance levels, single-criterion linear value 
functions can be constructed. Piecewise linear value functions can be 
elicited using interactive graphs. The software allows to visualise the 
single-criterion value scores and the performance levels in visual 
scales side by side.  
Smart Decisions 
Support in the elicitation of option value scores is available with 
visual aids. Linear single-criterion value functions are the default 
option, but piecewise linear value functions can also be created 
interactively. 
V.I.S.A. 
Decisions  
Support in the elicitation of value scores is provided using visual aids. 
Option value scores can be elicited directly using vertical value scales 
(i.e. thermometers). For discrete performance levels (e.g. verbal 
levels), discrete value functions can be built using vertical value 
scales. For continuous performance levels, single-criterion linear 
value functions and piecewise linear value functions (the latter can be 
elicited using interactive graphs) 
Web-HIPRE 
Single-criterion value scores for each option can be entered directly. 
Single-criterion value functions (linear, piecewise or exponential) can 
be elicited. Value scores can also be calculated making pairwise 
comparisons of difference in attractiveness (the AHP as a value 
function approach) 
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Table 1.6. Software applications for MCDA: weight elicitation. 
 
Software 
 
Description  
Analytica 
 
From Mustajoki et al. [220] criteria weights can be elicited in 
different ways, including swing weights. The visual aids for weight 
elicitation were not found in the software user guide  
 
ALEL 
 
Criteria weights can be entered as numbers or can be elicited on 
sliding bars 
 
Criterium 
Decision Plus 
 
From Mustajoki et al. [220], different weight elicitation procedures 
are possible, including swing weights and AHP weights. From the 
user manual, the only elicitation procedure that could be observed 
was that of pairwise comparison of relative importance of criteria 
(AHP weights). For calculating criteria weights, pairwise 
comparisons of relative importance are done on a “rating” screen 
which allows for numerical, verbal or graphical comparisons between 
criteria. 
 
D-Sight 
 
According to Mustajoki and Marttunen [220] weights can be elicited 
visually. The visual aids for weight elicitation could not be found.  
 
Expert Choice 
 
Criteria weights are elicited using pairwise comparisons of relative 
importance with three possible formats: verbal, numerical, or with 
sliding bars. Criteria weights can also be entered directly. 
Inconsistencies are highlighted by the software, which provides 
suggestions for their correction 
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Table 1.6 (cont.). Software applications for MCDA: weight elicitation. 
 
Software 
 
Description 
GMAA 
 
Weight elicitation is undertaken using trade-off methods or directly 
assigning weights (N.B. weight intervals) to each of the criteria. 
 
HiView 3 
 
Criteria weights can be entered directly and elicited using swings with 
a visual aid. Criteria weights can also be assessed using comparisons 
of difference in attractiveness with the M-MACBETH functionality. 
 
Logical 
Decisions 
 
Criteria weights can be elicited with visual aids in a number of ways, 
e.g. direct rating, the trade-off method, swing weights, rank ordering, 
pairwise comparisons of criteria importance (for the AHP, this 
approach checks consistency in judgments). 
 
M-MACBETH 
 
Criteria weights are elicited in a matrix of pairwise comparisons of 
difference in attractiveness, with inconsistencies displayed and 
suggestions made for their correction. The resulting criteria weights 
can be displayed as bar charts and adjusted within consistent levels. 
 
MakeItRational 
 
Criteria weights are elicited using pairwise comparisons of relative 
performance with a visual aid. 
 
OnBalance 
 
Criteria weights are elicited using trade-off methods or swing weights 
with visual aids 
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Table 1.6 (cont.). Software applications for MCDA: weight elicitation. 
 
Software 
 
Description 
Smart Decisions 
 
Criteria weights can entered directly in numerical form or elicited 
using swing weights with a visual aid or using numerical pairwise 
comparisons (AHP as a value function approach)  
 
 
V.I.S.A. 
Decisions 
 
 
Criteria are elicited using swings with a visual aid  
Web-HIPRE 
 
Criteria weights can be elicited using direct rating, swings, ranking of 
options + point distribution (SMART), rank ordering (SMARTER), 
and pairwise comparisons of difference in attractiveness (AHP as a 
value function approach) 
 
 
Table 1.7. Software applications for MCDA: analysis of results and sensitivity 
analysis.  
Software 
 
Description 
  
 
Analytica 
 
Overall option scores are visualised numerically, although they can 
also be viewed graphically. Sensitivity analysis on changes in 
individual weights can be undertaken for each overall score. Two-
way sensitivity analysis can also be undertaken. Tornado diagrams 
can be generated to explore the sensitivity of overall results to 
changes in several weights 
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Table 1.7 (cont.). Software applications for MCDA: analysis of results and sensitivity 
analysis. 
 
Software 
 
Description 
ALEL 
 
Overall option scores are visualised as a horizontal bar graph at the 
top of the screen, accompanied by the numerical values. The package 
allows for overall results to be idealised (normalised by the highest 
overall score) or distributed (normalised to add to 1). Stacked bars 
showing the contribution of each criterion to the overall scores. 
Although ALEL supports no sensitivity analysis screens separate from 
the main screen. The sensitivity of the overall option scores to 
changes in weights (or in single-criterion ratings) can be visualised 
directly in the main screen: as the weights (or ratings) are changed, 
the overall scores of the options change accordingly 
 
Criterium 
Decision Plus 
 
From the user manual, overall option scores are presented visually on 
a horizontal bar graph, accompanied by the numerical values. Stacked 
bar graphs can be displayed to visualise the contribution of each 
criterion to the overall score of each option. The “sensitivity by 
weights” screen plots each criterion weight against the overall scores 
of the options and allows for assessing interactively how much a 
criterion weight needs to change for a change in the overall ranking 
of the options. 
 
D-Sight 
 
From Mustajoki and Marttunen [220], visual graphs are provided and 
there is a sensitivity analysis functionality. The implementation of 
this feature could not be verified due to lack of access to the software 
or to its user manual 
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Table 1.7 (cont.). Software applications for MCDA: analysis of results and sensitivity 
analysis. 
 
Software 
 
 
Description 
 
 
 
 
 
 
 
Expert Choice 
 
Overall option scores are visualised in a horizontal bar graph with 
accompanying overall priorities, and can be presented using the ideal 
or distributive AHP mode. There are five sensitivity analysis screens: 
1) the “dynamic” screen allows the user to assess in real time the 
impact on the overall scores of the options of changing the weights of 
the top-level criteria using bar graphs; 2) the “performance” screen 
allows for a similar assessment while visualising the contribution of 
each option to each top-level weight; 3) the “gradient” screen plots 
each criterion weight against the overall scores of the options and 
allows for assessing interactively how much a criterion weight needs 
to change for a change in the overall ranking of the options; 4) the 
“two-dimensional” screen (not interactive) plots the priorities of the 
options for any pair of criteria, and allows to inspect situations of 
dominance and key trade-offs; 5) the “head to head” screen allows to 
compare two options overall and for each top-level criterion.  
 
 
 
 
 
 
 
GMAA 
 
Results are presented in a horizontal bar graph with accompanying 
numerical values. Both mean overall scores and any upper or lower 
bounds (due to the effect of imprecision in value elicitation) are 
presented. A stacked bar graph can be used to visualise the 
contribution of each criterion to the overall scores. A vertical bar 
graph allows to visualise the contribution of each criterion to the 
overall score of each option. The “compare optionss” graph allows to 
visualise differences between options along the criteria and overall. In 
terms of sensitivity analysis, weights can be changed to explore their 
effect on overall option scores, but this feature requires moving 
between screens (it is not interactive). The software has a feature to 
assess dominated and potentially optimal options. It also has a feature 
for sensitivity analysis of weights using Monte Carlo simulations. 
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Table 1.7 (cont.). Software applications for MCDA: analysis of results and sensitivity 
analysis. 
 
Software 
 
Description 
HiView 3 
 
Overall option scores are visualised in a vertical bar graph with 
accompanying numerical values and accompanying weights of the 
top-level criteria. The user can switch to visualising in stacked bars 
the contribution of each criterion to the overall score of each option. 
The impact of changing criteria weights on the overall numerical 
scores can be assessed interactively using sliding bars. The “map” 
screen plots 1) the weighted scores of the options against criteria two 
at a time and 2) the efficient frontier, allowing for assessment of 
dominance and key trade-offs. The “sorts” screen compares options 
two at a time with respect to each of the criteria. Different sensitivity 
analysis screens are available: 1) the interactive “sensitivity up” 
screen allows to visually assess how changes in each criterion weight 
impacts on the overall scores and ranking of the options; 3) the 
“sensitivity down” tool identifies with colour codes which criteria 
weights are more or less sensitive (red indicates that a criterion would 
have to increase/ decrease less than 5% for the highest ranked option 
to change, orange indicates that a criterion would have to 
increase/decrease between 5% and 10% for the highest ranked option 
to change, green indicates that a criterion would have to change by 
more than 15% for the highest ranked option to change). 
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Table 1.7 (cont.). Software applications for MCDA: analysis of results and sensitivity 
analysis. 
 
Software 
 
Description 
Logical Decisions 
 
Overall option scores are visualised in horizontal bar charts with 
accompanying numerical values. The contribution of each criterion to 
the overall scores can be visualised in stacked bars. A “scatter 
diagram” screen allows to visualise the weighted scores of each 
option on any two criteria. There are several sensitivity analysis 
screens, e.g.: 1) An interactive “dynamic sensitivity” screen allows to 
visualise with sliding bars the impact of changing weights on the 
overall scores, 2) a “compare options” screen allows to visualise in 
bar charts the differences in overall scores and single-criterion scores 
for every pair of options, 3) a “sensitivity graph” which allows to 
graphically assess the impact of changes in individual weights on the 
overall score of the options. 
 
M-MACBETH 
 
Overall option scores can be visualised on a scale. An “option 
profiles” screen allows to visualise each option’s single-criterion 
scores in relation to the lower and upper reference levels. “Difference 
profile” screens allow to visualise the difference in single-criterion 
value scores between pairs of options. “XY” maps allow to compare 
the single-criterion values of the options along pairs of criteria. There 
are several types of sensitivity analysis: 1) the “sensitivity analysis on 
weight” screen allows to visualise the effect of changing individual 
weights on the ranking of the options; 2) the “overall thermometer” 
feature allows to visualise on a scale the impact on the overall option 
scores of changing a) the value score of an option on a particular 
criterion or b) the weight of a criterion. The “robustness analysis” 
screen allows to identify dominant and additive dominant options. 
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Table 1.7 (cont.). Software applications for MCDA: analysis of results and sensitivity 
analysis. 
 
Software 
 
Description 
MakeItRational 
 
Overall option scores are visualised in a horizontal bar graph, and can 
be presented using the ideal or distributive AHP mode. Stacked bars 
can be used to visualise the contribution of each criterion to each 
overall option score. The options can be compared across criteria 
using a radar chart. The sensitivity analysis screen allows to visualise 
how changes in individual criteria weights affect the overall scores 
and the ranking of options  
 
OnBalance 
 
Overall option scores are visualised on horizontal bar graphs with or 
without their associated numerical scores. Stacked bars can be used to 
visualise the contribution of each criterion to each overall option 
score. The “map” window plots option scores on two criteria to assess 
dominance and key trade-offs. A “sensitivity on node” screen allows 
to graphically assess the impact of changes in individual weights on 
the overall score of the options. A “test robustness” window allows to 
compare options two at a time to visualise how much better (or 
worse) one option is than the other on each criterion. 
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Table 1.7 (cont.). Software applications for MCDA: analysis of results and sensitivity 
analysis. 
 
Software 
 
Description 
Smart Decisions 
 
Overall option scores are visualised on horizontal bar graphs with 
their associated numerical scores. The contribution of each criterion 
to the overall scores can be visualised in stacked bars. A “strengths 
and weaknesses” screen allows to see the differences between options 
on each of the criteria. A “scatter” screen displays scores of options 
on two criteria at a time to assess situations of dominance and key 
trade-offs. Weights of individual criteria can be plotted against 
overall option scores to assess when changes in these weights alter 
the ranking of options. It is possible to also assess for each criterion 
the range of weights over which the ranking of options will change. 
 
V.I.S.A. 
Decisions 
 
Overall option scores are visualised in a vertical bar graph. “Score 
profiles” allows to compare the weighted scores of the options for 
each criterion in a single graph. The “dominance” table allows to 
compare the options in terms of dominance. An “XY” screen allows 
to compare option scores two criteria at a time to assess dominance 
situations and key trade-offs. A “weight sensitivity” screen allows to 
visualise how changes in individual criteria weights affect the overall 
scores and the ranking of options 
 
Web-HIPRE 
 
Overall option scores are visualised in vertical bar charts with 
accompanying numerical values. The contribution of the 
criteria/options to each overall score can also be visualised. The 
sensitivity analysis screen allows to view how changes on a criterion 
weight impacts on the overall scores and on the ranking of the options 
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8.4.2. Assessment of software applications for MCDA. 
In order to choose a software application to implement the MCDA process it is 
important to consider the context of the decision and the process of the decision 
[225]. Decision context characteristics pertain to 1) the type of decision problem (e.g. 
whether it is more or less structured, the number of criteria/options to be considered), 
2) the social context (e.g. who is/are the decision maker/s and what are his/her/their 
responsibilities), and 3) the cognitive factors of the decision maker/s [225]. Decision 
process characteristics include 1) whether the final decision maker is one individual 
or several individuals with potentially conflicting goals and worldviews, 2) the time 
constraints for making the decision, 3) whether or not the results of the analysis 
needs to be communicated to stakeholders not involved in decision-making, and 4) 
how the analysis will be conducted (e.g. working through the problem with an 
analyst, as is the case in a decision conference [227], by the decision maker 
him/herself) [225]. 
This thesis focuses on the development and implementation of MCDA-based PDAs 
for complex decisions by clinicians in the environment of routine clinical practice in 
Spanish NHS hospitals. Given this, the decision context and the decision process 
have some general characteristics. With respect to the decision context:  
1) The decision problem is relatively structured, i.e. the options are limited to the 
available health care options (e.g. treatments) for the condition at hand and the 
decision criteria are limited to the consequences of the options which are relevant for 
the patient; 
2) The decision maker is a patient making a complex decision with inputs from 
his/her clinician; 
3) The cognitive features of different patients will differ, but it should not be 
assumed that an average patient has high levels of health literacy. 
With respect to the decision process: 
1) The final decision maker is the patient; 
2) Time and other resource constraints exist both in the development and in the 
implementation of MCDA-based PDAs by clinicians in routine clinical practice; 
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3) The development of an MCDA-based PDAs for a complex decision by clinicians 
in routine clinical practice is likely to involve a team of health practitioners; 
3) The main stakeholders to which the decision needs to be communicated are 
mainly the patient’s relatives and the patient’s health practitioners; 
4) In general, the presence of an analyst to support the development and delivery to 
patients of MCDA-based PDAs in routine clinical practice should not be assumed. 
The software applications described in this review share one obvious characteristic: 
they all implement MCDA. In this sense, their use has the potential to improve the 
quality of the decision process and the quality of the decision made, two key 
effectiveness measures of PDAs. They differ in a number of aspects, including: 
1) In the MCDA method implemented. The choice of software application will 
determine the MCDA method implemented unless the application supports different 
methods (e.g. Logical Decisions or Web-HIPRE). One advantage of supporting 
different methods is that the end user can choose the one which best suits his/her 
cognitive style. However, some applications (e.g. Web-HIPRE) which allow the user 
to mix methods may result in incompatibilities with the theoretical underpinnings of 
the methods [225]. Applications which implement prescriptive methods (such as 
HiView, V.I.S.A. decisions, or Logical Decisions) have a clear advantage in terms of 
best practice decision-making over those that do not (such as ALEL). Elicitation 
procedures used by different methods differ in complexity. Logical Decisions, for 
example, supports the elicitation of weights using trade-offs, which can be 
cognitively challenging. Expert Choice and M-MACBETH are based on pairwise 
comparisons, which can be tedious with many options/criteria. ALEL has an 
advantage here in requiring little elicitation effort; 
2) In the decision support features. In the context of the development and 
implementation of MCDA-based patient decision aids in routine clinical practice, 
decision support is important as patients/clinicians are usually not familiarised with 
the MCDA process. Applications which separate the steps of decision-making with 
tabs (e.g. MakeITRational, D-Sight) have an advantage over those that do not (e.g. 
Expert Choice, Analytica). Some applications provide step-by-step guidance through 
the decision-making process. This feature is in-built in V.I.S.A. Decisions. ALEL can 
incorporate this feature through the Elicia functionality, but it has to be built by the 
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tool developer as a sequence of screens. A more sophisticated approach would be the 
use of natural language generation techniques to incorporate automated explanations 
into the software, as was proposed by Papamichail and French [228]; 
3) In the type of group decision support offered. In the development stage of the 
MCDA-based PDA, a fit-for-purpose software application will facilitate the 
interaction of those involved in developing the tool, be they only health practitioners 
or health practitioners and patients. This interaction can take several forms. For 
example, a meeting (which may be a decision conference with an analyst [227]) to 
agree on the structure of the decision model. Or remote interaction to populate the 
performance matrix interface. In the case of meetings, projection of the application 
interface on a screen will facilitate interaction. Here, fit-for-purpose applications 
should have screens clear of distractions and with text and plots easy to read [225]. 
This author does not know whether any of the applications reviewed have been 
designed for projection, but in the experience of this author with trial versions of the 
software MakeITRAtional, Smart Decisions and V.I.S.A. Decisions stand out as 
clear of distractions and with texts and plots easy to read. ALEL also stands out in 
this sense, but it has the important disadvantage that it does not allow for building 
hierarchies of criteria interactively. HiView, designed to support decision 
conferencing [225], is a good alternative if an analyst is involved. Applications 
supporting remote interaction include ALEL, Expert Choice, D-Sight, and Logical 
Decisions for Groups. Applications that do support remote interaction include 
GMAA, OnBalance, and Criterium Decision Plus. Group interaction, however, might 
also be required in the implementation of MCDA-based PDAs in routine clinical 
practice. In this case, interaction will be between the patient and his/her health care 
practitioner. Applications which facilitate this interaction have minimal distractions 
and easy-to-access information, e.g. pop-ups when dragging the mouse over a 
criterion or a score. ALEL stands out in this regard.  
4) In the functionality for structuring the decision problem. In the development of 
patient decision aids by clinicians, the availability of easy to use interfaces to 
structure a hierarchy of criteria (as is the case with e.g. Criterium Decision Plus, 
HiView, V.I.S.A. Decisions, and Expert Choice) is an advantage. Here, software 
applications like Web-HIPRE which 1) display the options in the hierarchy and 
which 2) display lines connecting all the elements of the hierarchy are at a 
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disadvantage. Applications like ALEL which do not support hierarchical structuring 
of decision problems are not useful for structuring the decision problem; 
5) In the visual aids for the elicitation of inputs from the decision maker. In 
delivering PDAs to patients, visual aids should be simple and easy to access. ALEL 
ranks highly in this respect: all the inputs are elicited using sliding bars and all the 
information is contained in one screen. V.I.S.A. Decisions also ranks highly, its 
elicitation screens are uncluttered and the user can access them with a minimal 
number of clicks. In this sense, Analytica and GMAA rank poorly: they require 
substantial numerical input and navigation between screens is not designed for non-
initiated users. In OnBalance, it is not easy to navigate to the elicitation screens, but 
the visual aids for input elicitation are very clear. HiView and Expert Choice also 
have very clear elicitation screens, although navigation to these screens for non-
initiated users is not easy without support; 
6) Analysis of results and sensitivity analysis. In delivering MCDA-based PDAs to 
patients, results should be easy to visualise and understand. ALEL is one of the best 
applications here: the graph chart showing the overall scores of the options is always 
visible, it occupies one third of the computer screen and the bar for the preferred 
option is highlighted in a different colour than the bars of the other options. Here, the 
availability of screens comparing alternatives in pairs to assess how much better one 
option is to another option overall and on individual criteria is useful. Several 
applications offer this possibility, e.g. Expert Choice and Logical Decisions. The 
importance of sensitivity analysis in MCDA has been highlighted by e.g. Dodgson at 
al [10] and Phillips [212], and methods for expert users of software have been 
explored e.g. by Hodgkin et al. [229]. In the context of this thesis, sensitivity analysis 
should be informative while supporting different levels of health literacy in different 
patients. Here, screens like the “dynamic” sensitivity screen in Expert Choice, which 
shows with interactive slide bars how changes in weights affect overall scores in real 
time, are very valuable. HiView is unique in providing easy to visualise and 
informative sensitivity analysis with its “sensitivity down” screen, which identifies 
with colour codes which criteria weights are more or less sensitive. A similar feature 
to “sensitivity down” is available in Smart Decisions, but the sensitivity of criteria 
weights is represented numerically, and hence harder to interpret than if it was 
colour-coded. 
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How should clinicians choose between alternative MCDA software applications for 
developing and implementing PDAs for complex decisions in routine clinical 
practice? Jadhav and Sonar [230], in their review of methods for software selection, 
describe three studies that have considered the choice between alternative decision 
support software applications. Le Blanc and Tawfik Jelassi [231] proposed, within a 
wider procedure for the evaluation of decision support systems, the use of MCDA to 
select between applications. The proposed MCDA is based on four types of criteria: 
technical requirements (e.g. software and hardware compatibility) , functional 
requirements (e.g. user friendliness), availability of support documentation and 
training materials, and vendor information (e.g. availability of vendor support for 
installation and training in the use of the software) [231]. Ossadnik and Lange [232] 
used an AHP model to choose between three software applications implementing 
AHP (namely, Automan, Expert Choice Pro, and HIPRE+). The criteria used in the 
software selection software were: 1) criteria of software performance (including e.g. 
sub-criteria of technical functionality and sub-criteria of functions of rationalisation 
of usage) and 2) software cost criteria (including the costs of acceptance to users and 
the initial investment in acquiring the software) [232]. Phillips-Wren et al. [233] 
proposed a multi-criteria approach for the evaluation of decision support systems 
based on two types of criteria. The first type of criteria were outcomes of the 
decision-making process, e.g. proficiency in the phases of decision-making (i.e. 
intelligence, design, choice and implementation), proficiency in the steps of decision-
making (from recognising the decision problem to making a choice) and changes in 
the organisation or in the decision maker (e.g. reducing the time required for making 
decisions) [233]. The second type of criteria were outcomes of the decision, e.g. 
measures of performance in the organisation such as lower costs or increased profit 
[233]. Dowie et al. [19] have proposed the Decision Resource-Decision 
Effectiveness Analysis (DRDEA) framework. According to DRDEA [19], the 
question of choosing between alternative decision technologies (i.e. ways of making 
decisions), where decision support software applications are particular decision 
technologies [19], is a multi-criteria decision problem specific to the particular 
decision situation at hand. The decision problem can be represented by two types of 
criteria: 1) decision resource criteria expressing the resource requirements associated 
with using each decision technology (e.g. time required, cognitive effort required, or 
financial cost [19]) and 2) decision effectiveness criteria expressing the benefits of 
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using each decision technology (e.g. theoretical grounding, evidential strength and 
coverage, transparency [19]). In DRDEA, the decision of choosing between 
alternative decision technologies is preference sensitive and the appropriate 
analytical technique for solving this decision is MCDA [19].  
Le Blanc and Tawfik Jelassi [231], Ossadnik and Lange [232], Phillips-Wren et al. 
[233] and Dowie et al. [19] all highlight the use of MCDA as an appropriate 
procedure for choosing between decision support software applications. With respect 
to the criteria considered relevant for the choice in each of the four studies, the 
DRDEA framework is the only method that proposes an explicit distinction between 
two groups of criteria: 1) the benefits (i.e. decision effectiveness) and 2) the resource 
requirements or costs (i.e. decision resources of using these applications) of using 
these software applications to make decisions. The application of the DRDEA 
framework to specific decision contexts and decision processes allows to explore the 
trade-offs between these benefits and costs.     
9. Key issues. 
From the above literature review, a number of key issues of relevance to this thesis 
study have been identified: 
1. Although consensus IPDAS guidelines exist regarding the content and the 
development process of PDAs, these guidelines have been criticised for their 
limitations. Furthermore, they do not explicitly address the content and development 
process of MCDA-based PDAs. More specifically, these guidelines do not address 
the development of MCDA-based PDAs for complex decisions by clinicians within 
the constraints of their day-to-day clinical practice; 
2. Studies have shown that patients are willing and able to use some MCDA methods 
to make clinical decisions. Other studies have shown that clinicians find some 
MCDA methods easy to use and potentially useful for helping patients make 
decisions. In the few existing RCTs evaluating the impact of MCDA-based PDAs, 
compared to usual consultations these tools can be effective in terms of improving 
the quality of decision-making. However, different MCDA methods differ greatly in 
cognitive complexity. Considering 1) that the implementation of PDAs in routine 
clinical practice has not been achieved to the desired extent and 2) that barriers to 
PDA implementation include concerns about the adequacy of PDAs for some patient 
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groups (e.g. those with low health literacy) and competing demands and time 
constraints by clinicians, the use of differing MCDA methods in the development 
and implementation of MCDA-based PDAs for complex health care decisions in 
routine clinical practice should be explored; 
3. There are a large number of alternative software applications (i.e. templates) that 
may be used for developing and implementing MCDA-based PDAs. These 
applications can be more or less fit-for-purpose depending on the specific decision 
context and decision process at hand. According to the Decision Resource-Decision 
Effectiveness Analysis (DRDEA), the choice between alternative templates may be 
expressed in terms of trade-offs between decision resource (DR) and decision 
effectiveness (DE) criteria using MCDA. This framework has not been tested in the 
context of the development and implementation by clinicians of MCDA-based PDAs 
for complex decisions in routine clinical practice. 
Based on the above key issues, the aim and objectives of this thesis are described 
below. 
Aim: To analyse, as proof of concept, the use of MCDA for the development, 
implementation and evaluation of interactive patient decision aids in routine clinical 
practice 
Objectives:  
1. To assess the use with clinicians in the Spanish NHS of two alternative MCDA 
software applications which implement dissimilar MCDA techniques in the 
development of a PDA in routine clinical practice; 
2. To assess the use with clinicians in the Spanish NHS of the same two alternative 
MCDA software applications in the implementation of a PDA in an environment 
replicating actual clinical consultations;  
3. To build a meta-multi-criteria decision model based on the DRDEA framework 
and assess the use of this model by clinicians in the Spanish NHS to make the choice 
between the two MCDA applications as the basis for a PDA. 
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10. The case: a patient with lung cancer. 
This proof of concept study is built around using MCDA in the development, 
implementation and evaluation of interactive patient decision aids in routine clinical 
practice. To put the study into practice with clinicians in the Spanish NHS, a case in 
the general field of pulmonology was developed to be the subject of the MCDA-
based PDA. To establish the case, an interview was held with an experienced 
pulmonologist from a hospital (hospital H1) in the Spanish NHS. The main question 
posed to the pulmonologist was to identify a hypothetical patient who would face a 
complex decision which was of relevance in routine clinical practice in Spanish 
hospitals. The clinician identified the following hypothetical patient:  
- a 69 year-old patient recently diagnosed with stage IIIA3 non-small cell lung cancer 
(TNM stage T2N2M0 [234]) and with the following comorbidities: 1) light chronic 
obstructive pulmonary disease (COPD) with a good lung function; 2) myocardial 
infarction three years back treated with stent surgery.   
This case is complex because the treatment is not clear. According to the clinical 
guidelines for the treatment of non-small cell lung cancer patients developed in 
hospital H1 [235], and which the pulmonologist shared with this researcher, the 
recommended treatment for a patient with Stage IIIA3 T2N2M0 non-small cell lung 
cancer depends on the patient’s age and lung function. If the patient is under 70 and 
has a good lung function, the recommended active treatment is neoadjuvant 
chemotherapy with resective intent. However, if the patient is over 70 and with a 
poor lung function, the recommended active treatment is concurrent chemo-
radiotherapy. The patient in this case study inhabits a blurred area between both 
recommendations. The decision is then preference-sensitive and the use of a PDA to 
make this decision is appropriate. 
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Chapter 2: Using Expert Choice and Annalisa in Elicia to develop, 
with clinicians in the Spanish NHS, a patient decision aid for the 
clinical management of Stage IIIA3 non-small cell lung cancer. 
 
This chapter explains the methods and results related to Objective 1 of this thesis, 
i.e.: 
- To assess the use with clinicians in the Spanish NHS of two alternative MCDA 
software applications which implement dissimilar MCDA techniques in the 
development of a PDA in routine clinical practice. 
The chapter begins with a justification for the choice of software applications (from 
now on referred to simply as “templates”) Expert Choice and Annalisa in Elicia 
(ALEL) for the development of a Stage IIIA3 non-small cell lung cancer clinical 
management PDA. It then presents an overview of the methods used to develop the 
PDA using Expert Choice in hospital H1 and ALEL in hospital H2. The chapter then 
describes step-by-step the development of the two template-based PDAs. The results 
and the corresponding commentary are presented at the end of the chapter. 
1. Rationale for choosing Expert Choice and ALEL as the basis for the lung 
cancer management PDA. 
The author of this research chose, for the development and implementation of the 
lung cancer management patient decision aid (PDA), two templates. The selection 
was made on the basis of three criteria. First, the two templates should implement 
methods previously explored in medical decision-making situations. Second, the two 
templates should be relatively easy to use. Third, with a view towards subsequent 
evaluation using Decision Resources-Decision Effectiveness Analysis (DRDEA), the 
two templates should differ in terms of the likely benefits (decision effectiveness) 
and the likely costs (decision resources). 
1.1. Expert Choice. 
The first chosen template is Expert Choice. Expert Choice implements the Analytic 
Hierarchy Process (AHP) MCDA approach. The use of the AHP in medical decision 
making has been described in several studies, e.g. in the choice of best screening test 
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for colorectal cancer [18, 179], the choice of antimicrobial therapy for pyelonephritis 
[236], and the choice of whether or not to undergo prostate cancer screening [194]. 
The AHP has been described as useful for patient decision support due to the ease of 
use of its pair-wise comparisons elicitation procedure and due to the strength of 
measurement of the AHP methodology [116].  
1.2. ALEL. 
The second chosen template is ALEL. ALEL implements SAW, a simple method, via 
the software Annalisa. The use of SAW via Annalisa in medical decision making has 
been described e.g. in Masya et al. [175] for the choice of colorectal cancer treatment 
and by Cunich et al. [176] for deciding whether or not to take a prostate screening 
test. ALEL was explicitly designed to be of practical use [19]. 
1.3. Different benefits and costs in Expert Choice and ALEL.   
Expert Choice and ALEL differ between them in the likely benefits (i.e. decision 
effectiveness) and costs (i.e. decision resources) associated with their use in the 
development and delivery of a PDA. First of all, Expert Choice is a hierarchical 
MCDA template, while ALEL is not. In this sense, under the assumption that for a 
complex clinical decision question such as the choice of lung cancer treatment the 
decision model is highly likely to be a hierarchy of decision criteria, Expert Choice 
has the benefit over ALEL that it allows for a more thorough representation of all the 
aspects of the decision. Other things being equal, this is likely to come at a cost. A 
hierarchical PDA is likely to take more time to deliver in a clinical consultation than 
a non-hierarchical PDA. Second of all, the procedure used to elicit patient 
preferences with Expert Choice (pair-wise comparisons of relative importance of the 
criteria) has higher costs and higher benefits than that used with ALEL (direct weight 
elicitation). On the cost side, the pair-wise comparisons with Expert Choice are 
likely to require more time than the direct criteria weight elicitation using ALEL. On 
the benefit side, the AHP verifies the consistency of the user’s pair-wise comparison 
judgments, which is not possible with direct weight elicitation in ALEL. 
In summary, Expert Choice and ALEL have a track record in medical decision-
making, both are easy to use and both differ between them in the likely benefits 
(decision effectiveness) and costs (decision resources). The next section explains the 
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methods used to develop the lung cancer management PDA using Expert Choice and 
using ALEL. 
2. Overview of methods. 
This section describes how each of the two MCDA templates (Expert Choice and 
ALEL) was used to develop a lung cancer clinical management PDA with a team of 
clinicians from a hospital in the Spanish NHS. The two chosen hospitals were: 
- Hospital Germans Trias I Pujol (from now on hospital H1), in Badalona, a large 
town in the outskirts of Barcelona 
- Hospital Reina Sofia (from now on hospital H2), in Cordoba. 
In each of the two hospitals, three clinicians were recruited by the present author: one 
pulmonologist (referred throughout as clinician 1), one oncologist (referred 
throughout as clinician 2) and one thoracic surgeon (referred throughout as clinician 
3). The rationale for this choice is that pulmonologists, thoracic surgeons and 
oncologists are the three medical specialists who are typically most heavily involved 
in the clinical management of non-small cell lung cancer patients. It was deemed 
important to incorporate the clinical perspectives of these three clinical 
specialisations in the process of PDA development.  
The Expert Choice-based PDA was developed in close collaboration with the team of 
three clinicians recruited from hospital H1. The ALEL-based PDA was developed in 
close collaboration with the team of three clinicians recruited from hospital H2. 
Recall from Chapter 1 that the hypothetical patient is a 69 year-old patient recently 
diagnosed with stage IIIA3 non-small cell lung cancer (TNM stage T2N2M0) and 
with the following comorbidities: 1) light chronic obstructive pulmonary disease 
(COPD) with a good lung function; 2) myocardial infarction treated three years back 
with stent surgery. 
The development of the Expert Choice-based PDA in hospital H1 and the ALEL-
based PDA in hospital H2 was divided into the following three stages of the MCDA 
process:  
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STAGE 1. Determining the relevant options for the clinical management of the 
hypothetical lung cancer patient; 
STAGE 2: Determining the criteria relevant to the patient for choosing between the 
options; 
STAGE 3: Calculating the scores of the options on the criteria; 
The processes associated with developing the Expert Choice-based PDA (in H1) and 
the ALEL-based PDA (in H2) were strongly context led. Aiming at generating 
knowledge in the practical context of day-to-day clinical practice, these processes 
were led by the present author, but evolved based on the opinions of the clinicians 
and in response to the constraints confronted by these clinicians. One constraint that 
shaped these processes was the limited time that the clinicians had to participate in 
this research project due to their highly demanding clinical work. 
3. Developing the Expert Choice-based PDA and the ALEL-based PDA. 
3.1. STAGE 1: determining the options for the clinical management of the 
hypothetical lung cancer patient 
This stage was undertaken by the present author, based on 1) a review of non-small 
cell lung cancer clinical guidelines [235, 237]  and 2) on extensive one-on-one 
discussions with the pulmonologists from hospitals H1 and H2. The options are 
common to both the Expert Choice-based PDA (in H1) and to the ALEL-based PDA 
(in H2). They are: 
Option 𝐀𝟏: neoadjuvant chemotherapy with resective intent. 
With this option, the hypothetical patient is initially treated with neoadjuvant 
chemotherapy with the aim that the NSCLC is down-staged so that the patient’s 
tumour can be surgically removed. The chemotherapy is termed “neoadjuvant” 
because it is given prior to the main treatment. The main treatment is tumour 
resection in the form of lobectomy if a number of conditions are met after the patient 
has been given the neoadjuvant chemotherapy. Figure 2.1 illustrates the pathway of 
possible clinical interventions associated with this option. The elements of the 
pathway highlighted in red indicate cancer recurrence. 
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Figure 2.1. Pathway of possible clinical interventions under option 𝐴1, neoadjuvant 
chemotherapy with resective intent. 
 
 
Option 𝐀𝟐: concurrent chemo-radiotherapy  
With this option, the hypothetical patient is not considered for surgery. He is initially 
treated with concurrent-chemotherapy with the aim to stop disease progression. The 
subsequent interventions under this option are dependent on the uncertain success of 
the chemo-radiotherapy at reversing the cancer. Figure 2.2 illustrates the pathway of 
possible clinical interventions associated with this option. The elements of the 
pathway highlighted in red indicate cancer recurrence. 
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Figure 2.2. Pathway of possible clinical interventions under option 𝐴2, concurrent 
chemo-radiotherapy. 
 
Option 𝐀𝟑: best supportive care.  
Best supportive care, or palliative care, consists in providing the hypothetical patient 
with 1) good communication to facilitate decision-making, 2) symptoms control, 
psychosocial support (during the disease and in the last days of life), and physical 
care in the last days of life [238]. 
Apart from options 𝐴1, 𝐴2, and 𝐴3, no additional clinical management options were 
considered available for the patient by the clinicians in either hospital.  
Once the options were determined, the second stage in PDA development was to 
determine the criteria relevant for the decision for 1) the Expert Choice-based PDA 
and 2) the ALEL-based PDA. This stage is described below. 
3.2. STAGE 2: Determining the relevant criteria for choosing between the 
options. 
This stage was initially undertaken separately for the Expert Choice-based PDA (in 
H1) and the ALEL-based PDA (in H2) during several group meetings between the 
author of this research and each team of clinicians.  
  
115 
 
3.2.1. Initial sets of criteria. 
In each hospital, the same procedure was initially used to define the criteria for the 
PDA: the present author met with the three specialists and asked them to agree on a 
set of criteria that the hypothetical lung cancer patient would consider relevant for 
the decision. In each hospital the clinicians considered the same five relevant criteria: 
1. The duration of life, i.e. the life expectancy; 
2. The burden of treatment, i.e. the treatment-related adverse effects; 
3. The quality of life in the medium term, where medium term was defined as two 
years after the start of treatment; 
4. The financial burden in the medium term, i.e. the financial problems derived, two 
years after the start of treatment, from 1) direct expenditures related with the disease 
and/or the treatment, and from 2) the opportunity cost of not being able to earn a 
living as a result of being ill;  
5. The quality of the health care experience (i.e. those aspects of the health care 
delivery which are positive for one’s well-being as a patient) from the start of 
treatment until the medium term (i.e. 2 years after the start of treatment). 
In each hospital, the team of clinicians defined a set of sub-criteria for: quality of life 
in the medium term (criterion 3 above), and quality of the health care experience 
(criterion 5 above). For quality of life in the medium term, in both hospitals the team 
of clinicians opted for using the items of the European Organisation for Research and 
Treatment of Cancer (EORTC) QLQ-C30 questionnaire [239, 240] as the basis for 
the relevant sub-criteria. For quality of the health care experience, the team of 
clinicians using Expert Choice opted to define the following four sub-criteria: 1) 
visits to the health services/ hospital inpatient stays, 2) waiting time due to waiting 
lists between interventions, 3) duration of treatment by the same team of clinicians, 
4) personalised care. For quality of the health care experience, the team of clinicians 
using ALEL opted, given the impossibility of using a hierarchy of criteria in ALEL, to 
represent this dimension using only one criterion. The chosen criterion was: visits to 
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the health services/ hospital inpatient stays from the start of treatment until the 
medium term (i.e. two years after starting the treatment).  
The criteria hierarchies initially built with each team of clinicians (shown in 
Appendix 1) relied greatly in the items of the EORTC QLQ-C30 questionnaire. The 
present author considered this was problematic. First, the EORTC QLQ-C30 
instrument uses interval scales to score its items. These scores are incompatible with 
the AHP which requires scores to be measured on ratio scales. It was considered 
confusing to provide ratio scores for the same items which are measured on interval 
scales in an instrument which is furthermore subject to copyright. Second, the author 
of this researcher considered that many of the criteria of these initial hierarchies were 
not mutually preference independent. After discussing this issue in a group meeting 
with each team, in both cases the initial hierarchy was discarded. 
3.2.2. Final set of criteria. 
Although in each hospital the initial hierarchy of criteria proposed by each team 
clinicians was discarded, the information contained in each hierarchy was used by 
the present author to build a single hierarchy for both the Expert Choice-based PDA 
(in H1) and the ALEL-based PDA (in H2). This hierarchy was presented to each of 
the two teams of clinicians in a further group meeting and unanimously considered 
an adequate representation of the decision problem. The hierarchy is presented in 
Figure 2.3 (see Appendix 2 for a definition of the items in the hierarchy). 
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Figure 2.3. Final hierarchy of criteria for the Expert Choice-based PDA and the 
ALEL-based PDA 
 
In Figure 2.3, note that the goal is choosing the best clinical management strategy for 
the hypothetical patient. The criteria shaded in grey are top-level criteria composed 
of sub-criteria. The criteria shaded in light red are bottom-level criteria of the 
hierarchy. There are twenty-four bottom-level criteria, each with the mathematical 
notation 𝐶𝑘(𝑏) (𝑘 = 1,2 … 24). 
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3.2.3. Representing the hierarchy of criteria in the PDA. 
At this stage of the development of the two PDAs, the issue arose of representing the 
hierarchy of criteria during the delivery of the PDA in consultations. Both teams of 
clinicians considered that the hierarchy was too large to display fully to a patient. In 
both teams of clinicians it was agreed that only the top-level criteria (i.e. the criteria 
on Level 1 of the hierarchy) would be represented in the PDA. 
Once the criteria were defined and the clinicians agreed to represent in the PDA only 
the top-level criteria of the hierarchy, the final stage in PDA development was to 
calculate the scores of the three options on the top-level criteria for 1) the Expert 
Choice-based PDA in hospital H1 and for 2) the ALEL-based PDA in hospital H2. 
This stage is described below.   
3.3. STAGE 3: Calculating the scores of the options on the top-level criteria. 
This stage was undertaken separately for the Expert Choice-based PDA (in H1) and 
for the ALEL-based PDA (in H2). They are presented separately below.  
3.3.1. STAGE 3 for the Expert Choice-based PDA: Calculating the scores (or 
priorities) of the options on the top-level criteria of the hierarchy. 
Recall from Chapter 1 that to avoid rank reversals, the ideal AHP should be used 
whenever options can be added to or removed from the option set. In this research 
project, the ideal AHP is used to allow for the eventuality of adding or removing 
options. 
Two steps were required using the ideal AHP to calculate the scores (from now on 
termed priorities for consistency with AHP nomenclature) of the three clinical 
management options on the top-level criteria of the hierarchy. The first step was 
calculating the priorities of the options on the bottom-level criteria of the hierarchy. 
The second step was assigning weights to these bottom-level criteria so that the 
bottom-criteria priorities can be propagated up the hierarchy. These two steps are 
described below. 
  
119 
 
3.3.1.1. Calculating the priorities of the options on the bottom-level criteria for 
the Expert Choice-based PDA. 
The calculation of the priorities of the options on the bottom-level criteria required 
two additional steps: 1) deciding with the three clinicians in hospital H1 how to 
measure the priorities of the options on the bottom-level criteria, and 2) actually 
calculating these priorities. The first step is presented in section 3.3.1.1.1. The 
second step is presented in section 3.3.1.1.2. 
3.3.1.1.1. Deciding how to calculate the priorities of the options on the bottom-
level criteria for the Expert Choice-based PDA. 
In Expert Choice using the ideal AHP, the calculation of the priorities of the options 
on a particular bottom-level criterion can be done using two approaches: 1) making 
pair-wise comparisons of judgments of relative performance between options on that 
criterion, or 2) directly entering data in the appropriate format. In the first case, the 
priorities of the options on each criterion are calculated using the eigenvector 
method. In the second case, the priorities are obtained in two steps: 1) measuring the 
performance levels of the options on the criteria, 2) transforming these levels into 0-1 
priorities on a ratio scale. In both cases, each priority of each option on each criterion 
is then idealised - that is, normalised by the priorities of the highest performing 
option on that criterion. 
It was proposed by the present author and agreed in a group meeting with the three 
clinicians in hospital H1 to calculate the priorities of the three options on the twenty-
four bottom-level criteria of the hierarchy (i.e. the criteria shaded in light red in 
Figure 2.3) using both approaches described in the previous paragraph. Pairwise 
comparisons of relative performance between options were to be used with four 
criteria: 𝐶3(𝑏)-𝐶6(𝑏). Direct data were to be estimated for the remaining twenty 
criteria: 𝐶1(𝑏), 𝐶2(𝑏), and 𝐶7(𝑏)-𝐶24(𝑏)). Table 2.1 describes the mechanics of the 
pair-wise comparisons for the first set of criteria; Table 2.2 describes the variables 
used to measure the levels of performance 𝑥𝑖,𝑘 of the options 𝐴𝑖(𝑖 = 1,2,3) on the 
second set of criteria, i.e. the criteria 𝐶𝑘(𝑏) (𝑘 = 1,2,7,8 … 24). In Table 2.2, note 
that criteria 𝐶11(𝑏)-𝐶19(𝑏) are all criteria reflecting what the clinicians in hospital H1 
considered were the main adverse effects of the options. To define the possible levels 
120 
 
of these criteria, it was agreed to use the grading system of the National Cancer 
Institute Common Terminology Criteria for Adverse Effects (CTCAE) [241] in its 
version 4 [242]. Table 2.1 and Table 2.2 are self-explanatory and will not be 
explained further in the main body of the text.  
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Table 2.1.  Description of the pair-wise comparisons used to obtain the priorities of 
the options on criteria 𝐶3(𝑏)-𝐶6(𝑏)  
Criterion 
𝑪𝒌(𝒃) 
 
Description of the pair-wise comparisons of relative dominance of 
the options 𝑨𝒊 (𝒊 = 𝟏 … 𝟑) with respect to each criterion 
Disease-
related 
pain 
𝐶3(𝑏) 
 
The matrix of comparative consequence judgments for each criterion 
𝐶𝑘(𝑏) is: 
𝐶𝑀(𝐶𝑘(𝑏)) = (
𝑐(𝑘)𝐴1,𝐴1 𝑐(𝑘)𝐴1,𝐴2 𝑐(𝑘)𝐴1,𝐴3
𝑐(𝑘)𝐴2,𝐴1 𝑐(𝑘)𝐴2,𝐴2 𝑐(𝑘)𝐴2,𝐴3
𝑐(𝑘)𝐴3,𝐴1 𝑐(𝑘)𝐴3,𝐴2 𝑐(𝑘)𝐴3,𝐴3
) 
As was shown in Chapter 1, the elements of  matrix 𝐶𝑀(𝐶𝑘(𝑏)) are the 
comparative judgments of dominance 𝑐(𝑘)𝐴𝑖,𝐴𝑗 of every alternative 
𝐴𝑖  (𝑖 = 1 … 3) with respect to every other alternative 𝐴𝑗 (𝑖 = 1 … 3). 
The elements of the diagonal of the matrix are all equal to 1. The 
elements below the diagonal of the matrix are the reciprocals of their 
corresponding elements above the diagonal. It is necessary to calculate 
the three following elements above the diagonal of the matrix: 
1. 𝑐(𝑘)𝐴1,𝐴2: The comparative judgment of dominance, on a scale 
between 1 and 9, of option 𝐴1 (neoadjuvant chemotherapy with resective 
intent) compared to option 𝐴2  (concurrent chemo-radiotherapy) with 
respect to criterion 𝐶𝑘(𝑏) 
2. 𝑐(𝑘)𝐴1,𝐴3: The comparative judgment of dominance, on a scale 
between 1 and 9, of option 𝐴1 (neoadjuvant chemotherapy with resective 
intent) compared to option 𝐴3(best supportive care)  with respect to 
criterion 𝐶𝑘(𝑏) 
3. 𝑐(𝑘)𝐴2,𝐴3: The comparative judgment of dominance, on a scale 
between 1 and 9, of option 𝐴2 (concurrent chemo-radiotherapy) 
compared to option 𝐴3 (best supportive care)  with respect to criterion 
𝐶𝑘(𝑏) 
Disease-
related 
dyspnoea 
𝐶4(𝑏) 
 
Disease-
related 
asthenia 
𝐶5(𝑏) 
Disease-
related 
emotional 
problems 
𝐶6(𝑏) 
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Table 2.2. Description of the variables used to measure the levels of performance 
𝑥𝑖,𝑘 of the options 𝐴𝑖(𝑖 = 1,2,3) on criteria 𝐶𝑘(𝑏) (𝑘 = 1,2,7,8 … 24) 
Criterion 
𝑪𝒌(𝒃) 
 
Measure of the levels 
of each option on each 
criterion 
Minimum (Min) 
and maximum 
(Max) levels of each 
consequence  
Variable measuring 
the levels of the 
options 𝑨𝒊 (𝒊 = 𝟏 … 𝟑) 
on each criterion 
 
Cure 
𝐶1(𝑏)                 
Probability that there is 
no tumour activity 5 
years after starting 
treatment  
 
Min: 0  
Max: 1 
𝑥𝑖,1 ∈ [0,1] ⊂ ℝ
+   
 
Life 
Expectancy 
 𝐶2(𝑏) 
Survival in years Min: 0 years  
Max: 𝐿𝐸(𝑚𝑎𝑥), 
which is the highest 
estimated survival 
under the most 
efficacious of the 
three options 
𝑥𝑖,2 ∈ [0, 𝐿𝐸(max)] ⊂ ℝ
+ 
Self-care 
𝐶7(𝑏) 
Probability that the 
patient will, in the 
medium term, be able to 
take care of himself 
without help from 
others 
  
Min: 0  
Max: 1 
𝑥𝑖,7 ∈ [0,1] ⊂ ℝ
+   
 
Work a 
normal 
week 
𝐶8(𝑏) 
Probability that the 
patient will, in the 
medium term*, be able 
to work a normal week 
(i.e. 40 hours in a week)  
 
Min: 0  
Max: 1 
𝑥𝑖,8 ∈ [0,1] ⊂ ℝ
+   
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Table 2.2 (cont.). Description of the variables used to measure the levels of 
performance 𝑥𝑖,𝑘 of the options 𝐴𝑖(𝑖 = 1,2,3) on criteria 𝐶𝑘(𝑏) (𝑘 = 1,2,7,8 … 24) 
Criterion 
𝑪𝒌(𝒃) 
 
Measure of the levels 
of each option on each 
criterion 
Minimum (Min) 
and maximum 
(Max) levels of each 
consequence  
Variable measuring 
the levels of the 
options 𝑨𝒊 (𝒊 = 𝟏 … 𝟑) 
on each criterion 
 
Interference 
of the 
disease with 
family life 
or with 
social 
activities  
𝐶9(𝑏) 
Probability that the 
disease will, in the 
medium term*, interfere 
from moderately to 
extremely in the 
patient’s family life and 
in his family and social 
relations  
 
Min: 0  
Max: 1 
 
 
𝑥𝑖,9 ∈ [0,1] ⊂ ℝ
+   
 
Disease-
related 
financial 
burden in 
the 
medium 
term* 
𝐶10(𝑏) 
 
Probability that the 
disease will, in the 
medium term*, cause 
the patient form 
moderate to severe 
financial difficulties  
 
Min: 0  
Max: 1 
 
 
𝑥𝑖,10 ∈ [0,1] ⊂ ℝ
+   
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Table 2.2 (cont.). Description of the variables used to measure the levels of 
performance 𝑥𝑖,𝑘 of the options 𝐴𝑖(𝑖 = 1,2,3) on criteria 𝐶𝑘(𝑏) (𝑘 = 1,2,7,8 … 24) 
 
Criterion  
𝑪𝒌(𝒃) 
 
 
Measure of the levels of 
each option on each 
criterion 
 
Minimum 
(Min) and 
maximum 
(Max) levels 
of each 
consequence 
  
 
Variable 
measuring the 
levels of the 
options  
𝑨𝒊 (𝒊 = 𝟏 … 𝟑) on  
each criterion. 
 
 
Treatment-related 
dyspnoea as a 
consequence of 
pneumonitis or 
pulmonary 
fibrosis 
𝐶11(𝑏) 
 
Probability that the patient 
will have any of the following 
moderate to extremely severe 
grades of dyspnoea as a 
consequence of treatment-
related pneumonitis and/or 
pulmonary fibrosis: 
 
- grade 2 (dyspnoea with 
minimal exertion) 
- grade 3 (dyspnoea at rest) 
- grade 4 (dyspnoea with life-
threatening consequences)  
 
 
 
 
 
 
 
Min: 0  
Max: 1 
 
 
 
 
 
 
 
𝑥𝑖,11 ∈ [0,1] ⊂ ℝ
+   
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Table 2.2 (cont.). Description of the variables used to measure the levels of 
performance 𝑥𝑖,𝑘 of the options 𝐴𝑖(𝑖 = 1,2,3) on criteria 𝐶𝑘(𝑏) (𝑘 = 1,2,7,8 … 24) 
 
Criterion  
𝑪𝒌(𝒃) 
 
 
Measure of the levels of 
each option on each 
criterion 
 
Minimum 
(Min) and 
maximum 
(Max) levels 
of each 
consequence 
  
 
Variable 
measuring the 
levels of the 
options  
𝑨𝒊 (𝒊 = 𝟏 … 𝟑) on  
each criterion. 
 
 
Treatment-related 
dysphagia as a 
consequence of 
oesophagitis 
𝐶12(𝑏) 
 
Probability that the patient 
will have any of the following 
moderate to extremely severe 
grades of dysphagia as a 
consequence of treatment-
related oesophagitis: 
 
- grade 2 (symptomatic and 
altered eating/swallowing) 
- grade 3 (severely altered 
eating/swallowing requiring 
tube feeding) 
- grade 4 (dysphagia with life-
threatening consequences)  
 
 
 
 
 
 
Min: 0  
Max: 1 
 
 
 
 
 
 
𝑥𝑖,12 ∈ [0,1] ⊂ ℝ
+   
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Table 2.2 (cont.). Description of the variables used to measure the levels of 
performance 𝑥𝑖,𝑘 of the options 𝐴𝑖(𝑖 = 1,2,3) on criteria 𝐶𝑘(𝑏) (𝑘 = 1,2,7,8 … 24) 
 
Criterion  
𝑪𝒌(𝒃) 
 
 
Measure of the levels of 
each option on each 
criterion 
 
Minimum 
(Min) and 
maximum 
(Max) levels 
of each 
consequence 
  
 
Variable 
measuring the 
levels of the 
options  
𝑨𝒊 (𝒊 = 𝟏 … 𝟑) on  
each criterion. 
 
 
Treatment-related 
infection due to 
immunodeficiency 
𝐶13(𝑏) 
 
Probability that the patient 
will have any of the following 
moderate to extremely severe 
grades of treatment-related 
infection as a consequence of 
immunodeficiency: 
 
- grade 2 (requiring 
antibiotics) 
- grade 3 (requiring, in 
addition to antibiotics, 
radiologic or operative 
intervention) 
- grade 4 (infection with life-
threatening consequences)  
 
 
 
 
 
 
 
Min: 0  
Max: 1 
 
 
 
 
 
 
𝑥𝑖,13 ∈ [0,1] ⊂ ℝ
+   
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Table 2.2 (cont.). Description of the variables used to measure the levels of 
performance 𝑥𝑖,𝑘 of the options 𝐴𝑖(𝑖 = 1,2,3) on criteria 𝐶𝑘(𝑏) (𝑘 = 1,2,7,8 … 24) 
Criterion  
𝑪𝒌(𝒃) 
 
Measure of the levels of each option 
on each criterion 
Minimu
m (Min) 
and 
maximu
m (Max) 
levels of 
each 
conseq. 
Variable 
measuring the 
levels of the 
options  
𝑨𝒊 (𝒊 = 𝟏 … 𝟑) on  
each criterion. 
 
 
Treatment-
related 
diarrhoea 
𝐶14(𝑏) 
 
Probability that the patient will have 
any of the following moderate to 
extremely severe grades of treatment-
related diarrhoea: 
- grade 2 (increase of 4 to 6 stools per 
day over baseline) 
- grade 3 (increase of 7 or more stools 
per day over baseline, incontinence, 
limiting self-care, requires 
hospitalisation) 
- grade 4 (diarrhoea with life-
threatening consequences)  
 
 
 
 
 
 
 
Min: 0  
Max: 1 
 
 
 
 
 
 
𝑥𝑖,14 ∈ [0,1] ⊂ ℝ
+   
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Table 2.2 (cont.). Description of the variables used to measure the levels of 
performance 𝑥𝑖,𝑘 of the options 𝐴𝑖(𝑖 = 1,2,3) on criteria 𝐶𝑘(𝑏) (𝑘 = 1,2,7,8 … 24) 
Criterion  
𝑪𝒌(𝒃) 
 
Measure of the levels of each 
option on each criterion 
Minimum 
(Min) and 
maximum 
(Max) levels 
of each 
conseq. 
Variable 
measuring the 
levels of the 
options  
𝑨𝒊 (𝒊 = 𝟏 … 𝟑) on  
each criterion. 
 
 
Treatment-
related 
vomiting  
𝐶15(𝑏) 
 
Probability that the patient will 
have any of the following 
moderate to extremely severe 
grades of treatment-related 
vomiting: 
 
- grade 2 (3-5 episodes separated 
by 5 minutes in 24 hours) 
- grade 3 (6 or more episodes 
separated by 5 minutes in 24 
hours, requires tube feeding and 
hospitalisation) 
- grade 4 (vomiting with life-
threatening consequences) 
  
 
 
 
 
 
 
Min: 0  
Max: 1 
 
 
 
 
 
 
𝑥𝑖,15 ∈ [0,1] ⊂ ℝ
+   
 
 
Treatment-
related  
alopecia 
𝐶16(𝑏) 
 
Probability that the patient will 
have the following moderate grade 
of treatment-related alopecia*:  
- grade 2 (loss of 50% or more of 
one’s hair associated with 
psychosocial impact)  
 
 
 
 
Min: 0  
Max: 1 
 
 
 
𝑥𝑖,16 ∈ [0,1] ⊂ ℝ
+   
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Table 2.2 (cont.). Description of the variables used to measure the levels of 
performance 𝑥𝑖,𝑘 of the options 𝐴𝑖(𝑖 = 1,2,3) on criteria 𝐶𝑘(𝑏) (𝑘 = 1,2,7,8 … 24) 
Criterion  
𝑪𝒌(𝒃) 
 
Measure of the levels of each 
option on each criterion 
Minimum 
(Min) and 
maximum 
(Max) levels 
of each 
conseq. 
Variable 
measuring the 
levels of the 
options  
𝑨𝒊 (𝒊 = 𝟏 … 𝟑) on  
each criterion. 
 
 
Treatment-
related 
paraesthesia 
𝐶17(𝑏) 
 
Probability that the patient will 
have any of the following 
moderate to severe grades of 
treatment-related paraesthesia*: 
- Grade 2 (moderate paraesthesia) 
- Grade 3 (severe paraesthesia 
limiting self-care)  
 
 
 
 
Min: 0  
Max: 1 
 
 
 
𝑥𝑖,17 ∈ [0,1] ⊂ ℝ
+   
 
 
Treatment-
related 
fatigue 
𝐶18(𝑏) 
 
Probability that the patient will 
have any of the following 
moderate to severe grades of 
treatment-related fatigue*: 
 
- Grade 2 (fatigue not relieved by 
rest) 
- Grade 3 (fatigue not relieved by 
rest, limiting self-care)  
 
 
 
 
 
Min: 0  
Max: 1 
 
 
 
 
 
𝑥𝑖,18 ∈ [0,1] ⊂ ℝ
+   
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Table 2.2 (cont.). Description of the variables used to measure the levels of 
performance 𝑥𝑖,𝑘 of the options 𝐴𝑖(𝑖 = 1,2,3) on criteria 𝐶𝑘(𝑏) (𝑘 = 1,2,7,8 … 24) 
Criterion  
𝑪𝒌(𝒃) 
 
Measure of the levels of each 
option on each criterion 
Minimum (Min) 
and maximum 
(Max) levels of 
each conseq. 
Variable 
measuring the 
levels of the 
options  
𝑨𝒊 (𝒊 = 𝟏 … 𝟑) on  
each criterion. 
 
 
Treatment-
related 
anorexia 
𝐶19(𝑏) 
 
Probability that the patient will 
have any of the following 
moderate to extremely severe 
grades of treatment-related 
anorexia: 
 
- Grade 2 (oral intake altered 
without significant weight loss 
or malnutrition requiring oral 
nutritional supplements) 
- Grade 3 (significant weight 
loss or malnutrition, requiring 
tube feeding) 
- Grade 4 (anorexia with life 
threatening consequences 
  
 
 
 
 
 
 
 
Min: 0  
Max: 1 
 
 
 
 
 
 
 
 
𝑥𝑖,19 ∈ [0,1] ⊂ ℝ
+   
 
 
  
131 
 
Table 2.2 (cont.). Description of the variables used to measure the levels of 
performance 𝑥𝑖,𝑘 of the options 𝐴𝑖(𝑖 = 1,2,3) on criteria 𝐶𝑘(𝑏) (𝑘 = 1,2,7,8 … 24) 
Criterion  
𝑪𝒌(𝒃) 
 
Measure of the levels of 
each option on each 
criterion 
Minimum (Min) 
and maximum 
(Max) levels of 
each conseq. 
Variable 
measuring the 
levels of the 
options  
𝑨𝒊 (𝒊 = 𝟏 … 𝟑) on  
each criterion. 
 
 
Visits to the 
health 
services  
𝐶20(𝑏) 
 
Total number of cancer-
related visits to any 
outpatient health service from 
the start of treatment until the 
medium term**  
 
Min: 0  
Max: 𝑉(𝑚𝑎𝑥), 
which is the 
highest number of 
visits incurred in 
with any of the 
three options 
 
 
 
 
𝑥𝑖,20
∈ {1,2, … 𝑉(max)}
⊂ ℕ+ 
 
 
 
Hospital in-
patient stays 
𝐶21(𝑏) 
 
 
Total number of days spent 
by the patient in the hospital 
due to  cancer-related 
hospitalisation from the start 
of treatment until the medium 
term** 
 
 
Min: 0  
Max: 𝐷(𝑚𝑎𝑥), 
which is the 
highest number of 
days spent in 
hospital due to a 
cancer-related 
hospitalisation out 
of any of the three 
options 
 
 
 
 
𝑥𝑖,21
∈ {1,2, … 𝐷(max)}
⊂ ℕ+ 
 
* In the CTCAE version 4 system severity grades higher than grade 3 are not defined for fatigue  
** The medium term is defined as 2 years after the start of treatment 
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Table 2.2 (cont.). Description of the variables used to measure the levels of 
performance 𝑥𝑖,𝑘 of the options 𝐴𝑖(𝑖 = 1,2,3) on criteria 𝐶𝑘(𝑏) (𝑘 = 1,2,7,8 … 24) 
 
Criterion 
𝑪𝒌(𝒃) 
 
 
Measure of the levels 
of each option on 
each criterion 
 
Minimum 
(Min) and 
maximum 
(Max) levels of 
each 
consequence  
 
 
Variable measuring  
the levels of the options  
𝑨𝒊 (𝒊 = 𝟏 … 𝟑) on the 
criterion. 
 
 
Waiting time 
(due to 
waiting lists) 
between 
interventions 
𝐶22(𝑏) 
 
Total number of days 
over the optimal 
calendar required to 
continue treating the 
patient due to waiting 
lists from the start of 
treatment until the 
medium term* 
 
Min: 0  
Max: 𝑊(𝑚𝑎𝑥), 
which is the 
highest number 
of days required 
to continue 
treating the 
patient due to 
waiting lists 
from the start of 
treatment until 
the medium 
term out of any 
of the three 
options 
 
 
 
 
 
 
𝑥𝑖,22 ∈ {1,2, … 𝑊(max)}ℕ
+ 
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Table 2.2 (cont.). Description of the variables used to measure the levels of 
performance 𝑥𝑖,𝑘 of the options 𝐴𝑖(𝑖 = 1,2,3) on criteria 𝐶𝑘(𝑏) (𝑘 = 1,2,7,8 … 24) 
 
Criterion 
𝑪𝒌(𝒃) 
 
 
Measure of the levels 
of each option on 
each criterion 
 
Minimum 
(Min) and 
maximum 
(Max) levels of 
each 
consequence  
 
 
Variable measuring  
the levels of the options  
𝑨𝒊 (𝒊 = 𝟏 … 𝟑) on the 
criterion. 
 
 
Treatment 
by the same 
team of 
clinicians 
𝐶23(𝑏) 
 
Whether or not the 
patient will be treated 
by the same clinician 
or by the same team of 
clinicians from the 
start of treatment until 
the medium term*: 
No=0 
Yes=1 
 
 
 
 
 
Min: 0 (No) 
Max: 1 (Yes) 
 
 
 
 
𝑥𝑖,23 ∈ {0,1} ⊂ ℕ 
 
 
Attentive 
care 
𝐶24(𝑏) 
 
Whether or not the 
patient will always be 
treated by his 
clinician(s) in a caring 
and considerate 
fashion from the start 
of treatment until the 
medium term: 
No=0 
Yes=1 
 
 
 
 
 
Min: 0 (No) 
Max: 1 (Yes) 
 
 
 
 
𝑥𝑖,24 ∈ {0,1} ⊂ ℕ 
 
* The medium term is defined as 2 years after the start of treatment. 
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Figure 2.4 shows the transformation of the pairwise comparisons of relative 
performance between the options into priorities using the eigenvector method. Figure 
2.5 shows the transformations of the performance levels 𝑥𝑖,𝑘 of the options 𝐴𝑖(𝑖 =
1,2,3) on criteria 𝐶𝑘(𝑏) (𝑘 = 1,2,7,8 … 24) into priorities 𝑠𝑖,𝑘. The transformations 
from Figure 2.4 are self-explanatory and will not be explained further in the main 
body of the text. The transformations from Figure 2.5 are explained immediately 
after Figure 2.5 in the main body of the text. 
 
Figure 2.4. Calculation of the priorities 𝑠𝑖,𝑘 of the options 𝐴𝑖(𝑖 = 1,2,3) on criteria 
𝐶𝑘(𝑏) (𝑘 = 3,4,5,6) (Expert Choice-based PDA) 
 
  
C3(b):Disease-related pain
C4(b):Disease-related dyspnoea
C6(b):Disease-related emotional 
problems
C5(b):Disease-related asthenia
Matrix of 
comparative consequence 
judgments of the three options 
on the cancer-related pain 
criterion
Matrix of 
comparative consequence 
judgments of the three options 
on the cancer-related dyspnoea 
criterion
Matrix of 
comparative consequence 
judgments of the three options 
on the cancer-related asthenia 
criterion
Matrix of 
comparative consequence 
judgments of the three options 
on the cancer-related emotional 
problems criterion
MATRICES OF 
COMPARATIVE 
CONSEQUENCE 
JUDGMENTS 
ON EACH OF THE 
CRITERIA 
CALCULATION OF 
PRIORITIES 
The AHP uses 
the eigenvector
method to 
transform the 
matrices of 
comparative
judgments into 
priorities 
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Figure 2.5. Transformation of the levels of performance 𝑥𝑖,𝑘 of the options 𝐴𝑖(𝑖 =
1,2,3) on criteria 𝐶𝑘(𝑏) (𝑘 = 1,2,7,8 … 24) into priorities 𝑠𝑖,𝑘 (Expert Choice-based 
PDA) 
 
  
C7(b):Self-care
C8(b):Work a normal week
C9(b):Interference of the disease with 
family life and/or other social 
activities
C15(b):Treatment-related vomiting
C16(b):Treatment-related alopecia
C18(b):Treatment-related fatigue
C17(b):Treatment-related paraesthesia
C11(b):Treatment-related dyspnoea 
due to pneumonitis or pulmonary 
fibrosis 
C12(b):Treatment-related dysphagia 
due to oesophagitis
C14(b):Treatment-related diarrhoea
C13(b):Treatment-related infection 
due to immunodeficiency
C19(b):Treatment-related anorexia
C20(b):Visits to the health services
C23(b):Treatment by the same team 
of clinicians
C22(b):Waiting time (due to waiting 
lists) between interventions 
C24(b):Attentive care
C21(b):Hospital inpatient stays
C1(b):Cure for the cancer
C2(b):Life expectancy
C10(b):Disease-related financial 
difficulties in 
the medium term
EACH 
CRITERION 
probabilities of cure
years of life expectancy
probabilities of being able 
to take care of oneself in the 
medium term
probabilities of being able 
to work a normal week in the 
medium term
probabilities of the disease 
interfering with the family life 
and other social relations in the 
medium term
probabilities of disease-
related financial difficulties in 
the medium term
probabilities of 
treatment-related dyspnoea
probabilities of 
treatment-related dysphagia
probabilities of 
treatment-related infections 
due to immunodeficiency
probabilities of 
treatment-related diarrhoea
probabilities of 
treatment-related vomiting
probabilities of 
treatment-related alopecia
probabilities of treatment-
related paraesthesia
probabilities of treatment-
related fatigue
probabilities of treatment-
related anorexia
number of cancer-related 
days of hospital inpatient days 
from the beginning of treatment 
until the medium term
number of cancer-related 
visits to health services from the 
beginning of treatment until the 
medium term
number of days of waiting 
over the normal schedule from 
the beginning of treatment until 
the medium term
Is the patient treated by 
the same team of clinicians 
throughout?
Is the patient treated in 
considerately  by his clinicians 
throughout?
First, transform the probabilities
into odds :
Second, divide each odd by the
sum of the odds:
First, calculate 
Second, divide each level 
By the highest of the three
First, calculate the complementary
probability :
Second, transform into 
odds:
Third, divide each odds by the sum
of odds:
First, calculate the reciprocals
performance levels 
Second, divide each reciprocal
performance level by the highest
reciprocal*
Third, divide each odds by the sum
of odds:
*If then 
If the level is 1, then
If the level is 0, then
TRANSFORMATION OF THE 
LEVELS INTO PRIORITIES 
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Figure 2.5 describes the calculations for transforming the performance levels 𝑥𝑖,𝑘 of 
the three clinical management options 𝐴𝑖 (𝑖 = 1,2,3) on the criteria 𝐶𝑘(𝑏) (𝑘 =
1,2,7,8 … 24) into priorities 𝑠𝑖,𝑘 on a ratio scale, which was the type of scale required 
by the AHP. From Figure 2.5 note five types of transformations, each highlighted 
with a colour code. Each of these transformations is explained below: 
1. Transformation of performance levels 𝑥𝑖,𝑘 on criteria 𝐶𝑘(𝑏) (𝑘 = 1,7,8), 
respectively cure for cancer, being able to take care of oneself in the medium term 
(i.e. two years after the start of treatment), and being able to work a normal week in 
the medium term (i.e. two years after the start of treatment), colour coded in purple 
in Figure 2.5. These performance levels were, respectively, the probability of cure, 
the probability of being able to take care of oneself in the medium term, and the 
probability of being able to work a normal week in the medium term under each 
clinical management strategy. These probabilities needed to be transformed into 
priorities on a ratio scale so that a higher priority indicated a better outcome and a 
lower priority indicated a worse outcome. To transform probabilities into priorities 
closely resembling the AHP ratio scale, the odds related with these probabilities were 
then calculated, as indicated by Dolan [236]. With the above odds calculations, the 
transformation of 1) a probability of avoiding adverse effects equal to 0 and of 2) a 
probability of avoiding an adverse effect equal to 1 into odds was not possible. To 
circumvent this issue, it was decided to assign probabilities of 0 a very low but 
positive odds (i.e. 0.001) and to assign probabilities of 1 an odds close to 1 but below 
1 (0.999). The procedure is explained in the purple box in Figure 2.5; 
2. Transformation of performance levels 𝑥𝑖,𝑘 on criterion 𝐶2(𝑏), life expectancy, 
colour-coded in brown in Figure 2.5. Life expectancy was measured in years. The 
transformation of years of life expectancy into priorities on a ratio scale such that a 
higher priority reflected higher life expectancy and a lower priority reflected lower 
life expectancy was achieved by dividing the years of life expectancy for each option 
by the life expectancy of the highest performing option, as shown in the brown box 
in Figure 2.5; 
3. Transformation of performance levels 𝑥𝑖,𝑘 on criteria 𝐶𝑘(𝑏) (𝑘 = 9 … 19), adverse 
effects of the clinical management options, colour-coded in red in Figure 2.5. These 
performance levels were all probabilities of adverse effects due to the clinical 
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management options. They needed to be transformed into priorities on a ratio scale 
so that a higher priority indicated a better outcome (i.e. less adverse effects) and a 
lower priority indicated a worse outcome (i.e. more adverse effects). The first step to 
calculate the priorities for the options was to transform the probabilities of adverse 
effects the probabilities of avoiding adverse effects. This was achieved by calculating 
the complementary probabilities, as indicated in the red box in Figure 2.5. The 
second step involved expressing these probabilities as ratio comparisons by 
calculating the odds related with these probabilities as was explained in point 1.  
4. Transformation of performance levels 𝑥𝑖,𝑘 on criteria 𝐶𝑘(𝑏) (𝑘 = 20,21,22), visits 
to the health services, hospital inpatient stays, and waiting time (due to waiting lists) 
between interventions, colour-coded in green in Figure 2.5. These performance levels 
were measured respectively as the number of visits to the health services, the number 
of days in hospital, and the number of days of waiting time (due to waiting lists) 
between interventions with each option. The transformation of these performance 
levels into priorities on a ratio scale such that a higher priority reflected a better 
outcome and a lower priority reflected a worse outcome requires two steps. First, the 
reciprocals of these performance levels were calculated. Second, they were 
transformed into priorities by dividing the performance level for each option by the 
performance of the highest performing option on each criterion, as shown in the 
green box in Figure 2.5; 
5. Transformation of performance levels 𝑥𝑖,𝑘 on criteria 𝐶𝑘(𝑏) (𝑘 = 23,24), 
treatment by the same team of clinicians and attentive care (colour-coded in orange 
in Figure 2.5). These performance levels were measured by dichotomous 1/0 
variables (corresponding to statements “yes”/”no”). The transformation of the 
performance levels of the options into priorities was done simply by assigning a 
performance level of 1 a priority of 1 and assigning a performance level of 0 a 
priority of 0, as is shown in the orange box in Figure 2.5. 
The above transformations completed the procedure agreed with the clinicians in 
hospital H1 for scoring the performance of the three clinical management options on 
the bottom-level criteria for the Expert Choice-based PDA. The next step was 
actually calculating these priorities. 
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3.3.1.1.2. Calculating the priorities of the options on the bottom-level criteria for 
the Expert Choice-based PDA. 
Once the procedure to calculate the priorities of the performance levels of the options 
– recall, neoadjuvant chemotherapy with resective intent (𝐴1), concurrent chemo-
radiotherapy (𝐴2) and best supportive care (𝐴3)- on the bottom-level criteria of the 
hierarchy was agreed with the clinicians, the next step in quantifying the evidence 
was calculating these priorities. This required two additional steps. First, obtaining 
estimates for the performance levels 𝑥𝑖,𝑘 of the options 𝐴𝑖(𝑖 = 1,2,3) on each of the 
bottom-level criteria 𝐶𝑘(𝑏) (𝑘 = 1,2 … 24). Second, transforming these performance 
levels into priorities using the procedures outlined in Figure 2.5 and described in the 
previous section. The first step requires explanation, the second is immediate 
applying the relevant formulas in Figure 2.5, and will not be further described in the 
main body of the text.   
To calculate the performance levels of the options on the bottom-level criteria, the 
most evident approach would have been performing a series of literature reviews of 
the published scientific literature regarding these consequences. This posed one 
immediate problem. The two teams of clinicians did not have time to undertake any 
literature reviews due to their busy working schedules. As the research was aimed at 
generating knowledge regarding the use of MCDA templates for the development 
and delivery of a PDA in the practical context of day-to-day clinical practice, the 
present author felt that it was important to take the time constraints of the clinicians 
into account - hence, it was decided that the methods for developing the Expert 
Choice-based and the ALEL-based Stage IIIA3 NSCLC PDAs would not resort to 
literature reviews as a source of evidence information.  
The present author did undertake a literature review of the evidence regarding the 
levels of the three options on the bottom-level criteria to get a general understanding 
of the availability of information regarding these consequences. The review resulted 
in a perhaps unsurprising dearth of evidence (see Appendix 3). 
Considering the time constraints that the three clinicians from hospital H1 
confronted, the chosen source of the evidence information for the Expert Choice-
based PDA was the clinicians’ judgments, i.e. their expert opinion. These judgments 
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were elicited for each of the three clinicians - the pulmonologist (clinician 1), the 
oncologist (clinician 2), and the thoracic surgeon (clinician 3).  
To elicit these judgments, a questionnaire were developed by the present author 
using the ELICIA online survey functionality [20]. 
The questionnaire, termed the Expert Choice-based PDA evidence generation 
questionnaire (EC-EGQ) was composed of 112 questions. It was developed to elicit, 
from each of the three clinicians in hospital H1, two types of judgments: 
- First, judgments about the levels 𝑥𝑖,𝑘 (𝑖 = 1 … 3; 𝑘 = 1,2,7 … 24) of the options 
𝐴𝑖  (𝑖 = 1 … 3) on the criteria 𝐶1(𝑏), 𝐶2(𝑏), and 𝐶7(𝑏)-𝐶24(𝑏) 
- Second, pair-wise comparisons of the perceived dominance of each of the options 
𝐴𝑖  (𝑖 = 1 … 3) with respect to each other option on criteria 𝐶3(𝑏)-𝐶6(𝑏).  
Each of the three clinicians from hospital H1 was asked to fill in the EC-EGQ 
questionnaire online. Three sets of responses were obtained, one set for each 
clinician 
Appendix 4 presents the EC-EGQ and the judgments elicited from each of the three 
clinicians. For most criteria, the performance levels of the options on the criteria 
were directly obtained from the questionnaire responses. There was one criterion, 
however, for which this was not so. In order to measure the levels 𝑥𝑖,2 (𝑖 = 1 … 3) of 
the options 𝐴𝑖 (𝑖 = 1 … 3) on criterion life expectancy (𝐶2(𝑏)), the present author 
decided to use a Markov model. The description of the Markov model and how it 
was used is provided now. 
Markov models are useful tools for modelling disease progression. In a Markov 
model, a disease (e.g. lung cancer) is represented mathematically by a succession of 
mutually exclusive health states through which a patient transitions over time until 
he/she reaches an absorbing state (e.g. death). The basic functioning of a Markov 
model involves the following steps. First, mapping out the disease states and the 
possible transitions that a patient can undergo from one state to another; second, 
calculating the probabilities of these different transitions (i.e. calculating the matrix 
of transition probabilities); third, based on the matrix of transition probabilities, 
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simulating a cohort of patients transitioning over time through the different disease 
states. The average time spent by the cohort of simulated patients transitioning 
between the different disease states is calculated by the model. This is the average 
life expectancy of a typical patient with the disease. 
A schematic representation of the Markov model used to represent disease 
progression for a cohort of Stage IIIA3 non-small cell lung cancer patients is shown 
in Figure 2.6. In the model, each time cycle at which transitions between states occur 
was set at six months.  
Figure 2.6. Schematic representation of the Stage IIIA3 non-small cell lung cancer 
Markov model  
  
 
 
In Figure 2.6, a cohort of patients begins their journey through the model at “Stage 
IIIA3 NSCLC diagnosis”. In the first six months, patients can either transition to a 
situation of no disease progression (a situation with no changes, with respect to the 
diagnosis in terms of the extent of the cancerous lesions), transition to a situation of 
disease progression, or die. If they transition to no disease progression, then every six 
months after that the patients may either remain in a situation of no disease 
progression, transition to disease progression, or die. If the patients transition to 
disease progression, then every six months after that the patients may either remain 
in a situation of disease progression or die. 
The transitions of the cohort of patients between the disease states in Figure 2.6 are 
governed by the following matrix of transition probabilities 𝑇𝑃: 
              1.STAGE IIIA3 
              NSCLC DIAGNOSIS
2.NO PROGRESSION
4.DEATH
3.PROGRESSION
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𝑇𝑃 = (
𝑝1,1 𝑝1,2 𝑝1,3 𝑝1,4
𝑝2,1 𝑝2,2 𝑝2,3 𝑝2,4
𝑝3,1 𝑝3,2 𝑝3,3 𝑝3,4
) = (
0 𝑝1,2 𝑝1,3 𝑝1,4
0 𝑝2,2 𝑝2,3 𝑝2,4
0 0 𝑝3,3 𝑝3,4
) 
(2.1) 
Each element in matrix 𝑇𝑃 above describes the transitions between the four 
following states: 1) Stage IIIA3 NSCLC diagnosis, 2) no progression, 3) progression, 
4) death.  
The matrix of transition probabilities from expression (2.1) is not the same if the 
patients in the cohort are undergoing neoadjuvant chemotherapy with resective intent 
(option A1), concurrent chemo-radiotherapy (option A2) or best supportive care 
(option A3). To calculate the average life expectancy of a patient with Stage IIIA3 
non-small cell lung cancer under each option, a matrix of transition probabilities 
needs to be estimated for each option and then entered into the Markov model. 
Estimates of the three matrices of transition probabilities corresponding to the three 
clinical management options were obtained from each of the three clinicians in 
hospital H1 using the same online questionnaire (the EC-EGQ) that was used for 
obtaining the performance levels of the options on the remaining criteria. The 
questions asked to each of the clinicians, the resulting matrices of transition 
probabilities and the resulting estimates of life expectancy under each option are 
shown in Appendix 4. 
The use of the Markov model to generate estimates of life expectancy for the 
hypothetical patient under each clinical management strategy is justified under the 
assumption that if the matrices of transition probabilities elicited from the clinicians 
are reasonably accurate, then the life expectancy calculated by the Markov model is a 
reasonable approximation of the actual life expectancy of the hypothetical patient. 
Once all the information on the performance of the three clinical management 
options on each bottom-level criterion of the hierarchy was elicited from each of the 
three clinicians in hospital H1, the clinician-specific priorities of the options on each 
of these criteria were calculated (as specified in section 3.3.1.1.1 and Figure 2.5). 
These priorities are shown in Appendix 4.  
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To calculate the priorities of the three options on the top-level criteria of the 
hierarchy, the next step was propagating the priorities of the options on the bottom-
level criteria up the hierarchy. This procedure is explained in the next section 
3.3.1.2. Propagating the priorities of the options on the bottom-level criteria up 
the hierarchy for the Expert Choice-based PDA. 
Figure 2.7 below shows that three of the criteria in the hierarchy are parent criteria 
with sub-criteria. They are: cancer-related symptoms (on Level 2 of the hierarchy), 
quality of life in the medium term (on Level 1 of the hierarchy), treatment-related 
adverse effects, and quality of the health care experience from the start of treatment 
until the medium term (Level 1 of the hierarchy). Expert Choice automatically 
calculated the priorities of the options on each parent criterion only once weights 
have been assigned to all its children criteria. This is illustrated in Figure 2.7. 
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Figure 2.7. Calculating the priorities of the options on the top-level criteria (Expert 
Choice-based PDA) 
 
Once the weights were assigned to all the children criteria of every parent criterion, 
Expert Choice calculated the priorities of the options in the top-level criteria by 
propagating the priorities of the options on these criteria up the hierarchy. 
To avoid injecting preferences into the calculations, equal weights were assigned to 
all the children criteria of each parent criterion. This provided the priorities shown in 
Figure 2.8. These priorities were the priorities to be presented to proxy patients 
To calculate the priorities of the options on 
criterion quality of the health care experience 
from the start of treatment until the medium 
term, assign weights to its children criteria: C20(b), 
C21(b), C22(b), C23(b), C24(b) 
To calculate the priorities of the options on 
criterion treatment-related adverse effects, assign 
weights to its children criteria: C11(b), C12(b), 
C13(b), C14(b), C15(b), C16(b), C17(b), C18(b), C19(b) 
To calculate the priorities of the options on 
criterion health-related quality of life in the 
medium term, assign weights to its children 
criteria: cancer-related symptoms, C7(b), C8(b), 
C9(b), C11(b) 
Health-related quality of 
life in the medium term
Cancer-related 
symptoms
C3(b):Disease-related pain
C4(b):Disease-related dyspnoea
C6(b):Disease-related emotional 
problems
C5(b):Disease-related asthenia
C7(b):Self-care
C8(b):Work a normal week
C9(b):Interference of the disease with 
family life and/or other social 
activities
C1(b):Cure for the cancer
C2(b):Life expectancy
C10(b):Disease-related 
financial difficulties in 
the medium term
Treatment-related 
adverse effects
Quality of the health care 
experience from the start 
of treatment until the 
medium term
C15(b):Treatment-related vomiting
C16(b):Treatment-related alopecia
C18(b):Treatment-related fatigue
C17(b):Treatment-related paraesthesia
C11(b):Treatment-related dyspnoea 
due to pneumonitis or pulmonary 
fibrosis 
C12(b):Treatment-related dysphagia 
due to oesophagitis
C14(b):Treatment-related diarrhoea
C13(b):Treatment-related infection 
due to immunodeficiency
C19(b):Treatment-related anorexia
C20(b):Visits to the health services
C23(b):Treatment by the same team 
of clinicians
C22(b):Waiting time (due to waiting 
lists) between interventions 
C24(b):Attentive care
What is the best clinical 
management strategy for 
a Stage IIIA3 NSCLC 
patient?
HIERARCHY
LEVEL 1
HIERARCHY
LEVEL 2
HIERARCHY
LEVEL 3
C21(b):Hospital inpatient stays
To calculate the priorities of the options on 
criterion cancer-related symptoms, assign 
weights to its children criteria: C3(b), C4(b), 
C5(b), C6(b) 
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during the delivery of the Expert Choice-based PDA in clinical consultations. Note 
from Figure 2.8 that in Expert Choice the priorities are normalised to sum to unity. 
Figure 2.8. Priorities of the options on the top-level criteria (Expert Choice-based 
PDA) 
 
 
3.3.1.3. Summary of STAGE 3 for the Expert Choice-based PDA: calculating the 
priorities of the options on the top-level criteria of the hierarchy. 
Having established the three clinical management strategies for the Stage IIIA3 non-
small cell lung cancer hypothetical patient in STAGE 1 - neoadjuvant chemotherapy 
with resective intent (A1), concurrent chemo-radiotherapy (A2) and best supportive 
care (A3)-  and the hierarchy of criteria relevant for the decision in STAGE 2 (see 
Figure 2.4), STAGE 3 of the co-development with clinicians in hospital H1 of the 
Expert Choice-based PDA involved calculating the priorities of the three options on 
the top-level criteria of the hierarchy. The steps for this calculation involved: 
1. Deciding how to calculate the priorities of the options on the bottom-level criteria. 
It was agreed with the three clinicians that pairwise comparisons of relative 
WHAT IS THE BEST 
CLINICAL MANAGEMENT 
OPTION FOR A MALE 69-
YEAR OLD STAGE IIIA3 
PATIENT WITH 
CARDIOVASCULAR AND 
LUNG COMORBIDITIES?
1. CURE FOR THE 
CANCER
2. LIFE EXPECTANCY
3. QUALITY OF LIFE IN 
THE MEDIUM TERM
4. DISEASE-RELATED 
FINANCIAL BURDEN 
IN THE MEDIUM 
TERM
5. TREATMENT-
RELATED ADVERSE 
EFFECTS
6. QUALITY OF THE 
HEALTH CARE 
EXPERIENCE FROM 
THE START OF 
TREATMENT UNTIL 
THE MEDIUM TERM
Clinician 1 Clinician 2 Clinician 3
0.67 0.22. 0.11.
0.43 0.42. 0.15.
0.72 0.24. 0.04.
0.80 0.13. 0.07.
0.12 0.11. 0.77.
0.31 0.28. 0.41.
0.69. 0.31. 0.00.
0.56 0.31. 0.13.
0.68 0.26. 0.06.
0.69 0.26. 0.05.
0.90 0.90. 0.81.
0.28 0.30. 0.42.
0.65. 0.35. 0.00.
0.63 0.30. 0.07.
0.68 0.30. 0.02.
0.19 0.04. 0.77.
0.30 0.28. 0.42.
0.68 0.32. 0.00.
OPTION A1:
NEOADJUVANT 
CHEMOTHERAPY WITH 
RESECTIVE INTENT
OPTION A2:
CONCURRENT CHEMO-
RADIOTHERAPY
OPTION A3:
BEST SUPPORTIVE 
CARE
HOSPITAL H1
NORMALISED PRIORITIES OF THE OPTIONS ON THE CRITERIA
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performance between the options would be used to calculate these priorities for the 
following criteria: disease-related pain, disease-related dyspnoea, disease-related 
asthenia and disease-related emotional problems. Direct data would be used to 
calculate the performance levels of the options on all remaining criteria, for which a 
number of quantitative variables were defined. 
2. Calculating the priorities of the options on the bottom-level criteria. This step 
involved, first, eliciting judgments from each of the three clinicians to estimate the 
performance levels of the three options on all the bottom-level criteria of the 
hierarchy. To calculate the performance levels of the options on criterion life 
expectancy, a Markov model was used, the inputs of which were based on clinicians’ 
judgments. These performance levels were transformed into AHP priorities using the 
procedures described in Figure 2.5. 
3. Finally, the priorities of the options on the bottom-level criteria were propagated 
up the hierarchy using equal weights for all the children criteria of each top-level 
criterion to obtain the priorities in Figure 2.8. 
The next section describes STAGE 3 of the PDA development process for the ALEL-
based PDA. 
3.3.2. STAGE 3: Calculating the scores of the options on the top-level criteria 
for the ALEL-based PDA. 
As with the Expert Choice-based PDA, two steps were required using ALEL to 
calculate the scores (from now on termed ratings for consistency with the Annalisa 
nomenclature) of the three clinical management options on the top-level criteria of 
the hierarchy. The first step was calculating the ratings of the options on the bottom-
level criteria of the hierarchy. The second step was propagating the ratings of the 
options on the bottom-level criteria up the hierarchy for the ALEL-based PDA. These 
steps are explained below.  
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3.3.2.1. Calculating the ratings of the options on the bottom-level criteria for the 
ALEL-based PDA. 
The calculation of the ratings of the options on the bottom-level criteria required two 
steps: 1) deciding with the three clinicians in hospital H2 how to measure the ratings, 
and 2) actually calculating these ratings. The first step is presented in section 
2.3.2.1.1. The second step is presented in section 2.3.2.1.2. 
3.3.2.1.1. Deciding how to calculate the ratings of the options on the bottom-level 
criteria for the ALEL-based PDA. 
To calculate the ratings of the options on the bottom-level criteria with ALEL, which 
implements the SAW MCDA approach, two steps were required: 1) measuring the 
performance levels of the options on the criteria, 2) transforming these levels into 0-1 
ratings on ratio scales. Each option rating on each criterion was then idealised - that 
is, normalised by the rating of the highest performing option on that criterion. 
In a meeting with the three clinicians from hospital H2, the present author proposed 
and the clinicians agreed to use the same variables measuring the performance levels 
of the options on the bottom-level criteria that were used for the Expert Choice-based 
PDA in hospital H1 for criteria 𝐶1(𝑏), 𝐶2(𝑏), and 𝐶7(𝑏)-𝐶24(𝑏). The descriptions of 
these variables have already been provided in Table 2.1. For criteria 𝐶3(𝑏)-𝐶6(𝑏), 
new variables measuring option performance were defined for the ALEL-based PDA, 
as pairwise comparisons between options could not be used. Table 2.3, which is self-
explanatory, describes these variables.  
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Table 2.3. Description of the variables measuring the levels of the options on the 
criteria 𝐶3(𝑏)-𝐶6(𝑏) (ALEL-based PDA)  
Criterion 
𝑪𝒌(𝒃) 
 
Measure of the 
levels of each option 
on each criterion 
Minimum (Min) 
and maximum 
(Max) levels of 
each consequence  
Variable measuring  
the levels of the options  
𝑨𝒊 (𝒊 = 𝟏 … 𝟑) on the 
criterion. 
 
 
Disease-
related  
pain 
𝐶3(𝑏) 
 
Intensity of disease-
related pain in the 
medium term* on a 
scale between 1 and 
9, where: 
No pain=1 
Extreme pain=9 
 
 
 
 
Min:  No pain 
Max: Extreme pain 
 
 
 
 
𝑥𝑖,3 ∈ {1,2,3,4,5,6,7,8,9} ⊂ ℕ
+ 
 
Disease-
related 
dyspnoea 
𝐶4(𝑏) 
 
 
Intensity of disease-
related dyspnoea in 
the medium term* on 
a scale between 1 
and 9, where: 
No dyspnoea=1 
Extreme dyspnoea=9 
 
 
 
 
Min:  No dyspnoea 
Max: Extreme 
dyspnoea 
 
 
 
 
𝑥𝑖,4 ∈ {1,2,3,4,5,6,7,8,9} ⊂ ℕ
+ 
 
Disease-
related 
asthenia 
𝐶5(𝑏) 
 
Intensity of disease-
related asthenia in 
the medium term* on 
a scale between 1 
and 9, where: 
No asthenia=1 
Extreme asthenia=9 
 
 
 
 
Min:  No asthenia 
Max: Extreme 
asthenia 
 
 
 
 
 
𝑥𝑖,5 ∈ {1,2,3,4,5,6,7,8,9} ⊂ ℕ
+ 
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Table 2.3 (cont.). Description of the variables measuring the levels of the options on 
the criteria 𝐶3(𝑏)-𝐶6(𝑏) (ALEL-based PDA)  
Criterion 
𝑪𝒌(𝒃) 
 
Measure of the 
levels of each option 
on each criterion 
Minimum (Min) 
and maximum 
(Max) levels of 
each consequence  
Variable measuring  
the levels of the options  
𝑨𝒊 (𝒊 = 𝟏 … 𝟑) on the 
criterion. 
 
 
Disease-
related 
emotional 
problems 
𝐶6(𝑏) 
 
Intensity of disease-
related emotional 
problems (depression 
and/or irritability 
and/or worry) in the 
medium term* on a 
scale between 1 and 
9, where: 
No emotional 
problems=1 
Extreme emotional 
problems=9 
 
 
 
 
 
 
Min:  No emotional 
problems 
Max: Extreme 
emotional problems 
 
 
 
 
 
 
 
𝑥𝑖,6 ∈ {1,2,3,4,5,6,7,8,9} ⊂ ℕ
+ 
 
Once the variables used to measure the performance levels of the options on the 
bottom-level criteria of the hierarchy were defined, the next step was rating these 
performance levels. Figure 2.9 describes the procedures used for transforming option 
performance levels into ratings for criteria 𝐶𝑘(𝑏) (𝑘 = 1,2,7,8 … 24). Figure 2.10 
describes the procedures used for transforming option performance levels into ratings 
for criteria 𝐶𝑘(𝑏) (𝑘 = 3,4,5,6). 
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Figure 2.9. Transformation of the levels of performance 𝑥𝑖,𝑘 of the options 𝐴𝑖(𝑖 =
1,2,3) on criteria 𝐶𝑘(𝑏) (𝑘 = 1,2,7,8 … 24) into ratings 𝑠𝑖,𝑘 (ALEL-based PDA) 
  
C7(b):Self-care
C8(b):Work a normal week
C9(b):Interference of the disease with 
family life and/or other social 
activities
C15(b):Treatment-related vomiting
C16(b):Treatment-related alopecia
C18(b):Treatment-related fatigue
C17(b):Treatment-related paraesthesia
C11(b):Treatment-related dyspnoea 
due to pneumonitis or pulmonary 
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C12(b):Treatment-related dysphagia 
due to oesophagitis
C14(b):Treatment-related diarrhoea
C13(b):Treatment-related infection 
due to immunodeficiency
C19(b):Treatment-related anorexia
C20(b):Visits to the health services
C23(b):Treatment by the same team 
of clinicians
C22(b):Waiting time (due to waiting 
lists) between interventions 
C24(b):Attentive care
C21(b):Hospital inpatient stays
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From Figure 2.9, note five types of transformations, each highlighted with a colour 
code. Each of these transformations is explained below: 
1. Transformation of performance levels 𝑥𝑖,𝑘 on criteria 𝐶𝑘(𝑏) (𝑘 = 1,7,8), 
respectively cure for cancer, being able to take care of oneself in the medium term 
(i.e. two years after the start of treatment), and being able to work a normal week in 
the medium term (i.e. two years after the start of treatment), colour coded in purple 
in Figure 2.9. These performance levels were, respectively, the probability of cure, 
the probability of being able to take care of oneself in the medium term, and the 
probability of being able to work a normal week in the medium term with each 
option. Higher probabilities indicated better outcomes. In SAW, these probabilities 
did not need transformation to be used as ratings, as is illustrated in the purple box in 
Figure 2.9; 
2. Transformation of performance levels 𝑥𝑖,𝑘 on criterion 𝐶2(𝑏), life expectancy, 
colour-coded in brown in Figure 2.9. Life expectancy was measured in years. In 
order to transform years of life expectancy into ratings such that a higher rating 
reflected higher life expectancy and a lower rating reflected lower life expectancy, 
this was achieved by dividing the years of life expectancy for each option by the life 
expectancy of the highest performing option, as shown in the brown box in Figure 
2.9; 
3. Transformation of performance levels 𝑥𝑖,𝑘 on criteria 𝐶𝑘(𝑏) (𝑘 = 9 … 19), adverse 
effects of the clinical management options, colour-coded in red in Figure 2.9. These 
performance levels were all probabilities of adverse effects due to the clinical 
management options. Their transformation into ratings so that a higher rating 
indicated a better outcome (i.e. less adverse effects) and a lower rating indicated a 
worse outcome (i.e. more adverse effects) was done by transforming the probabilities 
of adverse effects into the probabilities of avoiding adverse effects. This is achieved 
by calculating the complementary probabilities, as indicated in the red box in Figure 
2.9.  
4. Transformation of performance levels 𝑥𝑖,𝑘 on criteria 𝐶𝑘(𝑏) (𝑘 = 20,21,22), visits 
to the health services, hospital inpatient stays, and waiting time (due to waiting lists) 
between interventions, colour-coded in green in Figure 2.9. These performance levels 
were measured respectively as the number of visits to the health services, the number 
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of days in hospital, and the number of days of waiting time (due to waiting lists) 
between interventions. The transformation of these performance levels into ratings 
such that a higher rating reflected a better outcome and a lower rating reflected a 
worse outcome required two steps. First, the reciprocals of these performance levels 
were calculated. Second, they were transformed into ratings by dividing the 
performance level for each option by the performance of the highest performing 
option on each criterion, as shown in the green box in Figure 2.9; 
5. Transformation of performance levels 𝑥𝑖,𝑘 on criteria 𝐶𝑘(𝑏) (𝑘 = 23,24), 
treatment by the same team of clinicians and attentive care (colour-coded in yellow 
in Figure 2.9). These performance levels were measured by dichotomous 1/0 
variables (corresponding to statements “yes”/”no”). The transformation of these 
performance levels into ratings was done simply by assigning a performance level of 
1 a rating of 1 and assigning a performance level of 0 a rating of 0. 
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Figure 2.10. Transformation of the levels of performance 𝑥𝑖,𝑘 of the options 𝐴𝑖(𝑖 =
1,2,3) into ratings on 𝐶3(𝑏)- 𝐶6(𝑏) (ALEL-based PDA) 
 
 
 
From Figure 2.10, the performance levels on criteria 𝐶𝑘(𝑏) (𝑘 = 3,4,5,6), disease-
related pain, disease-related dyspnoea, disease-related asthenia, and disease-related 
emotional problems were nine possible levels of severity. To calculate the rating for 
each of the three clinical management strategies on each of these criteria, each 
option’s level on each criterion was mapped on a scale, as shown at the top of the red 
box in Figure 2.10. The scale was then inverted. 
The above transformations completed the procedure agreed with the clinicians in 
hospital H2 for rating the performance levels of the three clinical management 
C3(b):Disease-related pain
C4(b):Disease-related dyspnoea
C6(b):Disease-related emotional 
problems
C5(b):Disease-related asthenia
EACH 
CRITERION 
Nine possible levels of 
severity of disease-related pain 
in the medium term
Nine possible levels of 
severity of disease-related 
dyspnoea in the medium term
Nine possible levels of 
severity of disease-related 
asthenia in the medium term
Nine possible levels of 
severity of disease-related 
emotional problems in the 
medium term
TRANSFORMATION OF THE 
LEVELS INTO RATINGS 
Nine possible levels of severity
are defined for
each criterion. Each level of
severity is assigned a
rating on a scale 
between 0 and 1:
S                  
1                     0
2                     0.125
3                     0.250
4                     0.375
5                     0.5
6                     0.625
7                     0.75
8 0.875
9 1
The rating scale is then inverted
To obtain the final severity
ratings 
S                     
1                     1
2                     0.875
3                     0.75
4                     0.625
5                     0.5
6                     0.375
7                     0.25
8                     0.125
9 0
For example, 
Then 
And 
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options on the bottom-level criteria for the ALEL-based PDA. The next step was 
actually calculating these ratings. 
3.3.2.1.2. Calculating the ratings of the options on the bottom-level criteria for 
the ALEL-based PDA. 
Once the procedure to rate the performance levels of the options – recall, 
neoadjuvant chemotherapy with resective intent (𝐴1), concurrent chemo-
radiotherapy (𝐴2) and best supportive care (𝐴3)- on the bottom-level criteria of the 
hierarchy was agreed with the clinicians in hospital H2, the next step in quantifying 
the evidence was calculating these ratings. This required two additional steps. First, 
obtaining estimates for the performance levels 𝑥𝑖,𝑘 of the options 𝐴𝑖(1,2,3) on each 
of the bottom-level criteria 𝐶𝑘(𝑏) (𝑘 = 1,2 … 24). Second, transforming these 
performance levels into ratings using the procedures outlined in the previous section. 
The first step is explained below, the second is immediate applying the relevant 
formulas in Figure 2.9, and will not be further described in the main body of the text.   
Considering the time constraints that the three clinicians from hospital H2 
confronted, the chosen source of the evidence information for the ALEL-based PDA 
was, as with the Expert Choice-based PDA in hospital H1, the clinicians’ judgments. 
These judgments were elicited for each of the three clinicians (the pulmonologist, the 
oncologist, the thoracic surgeon).  
To elicit these judgments, a questionnaire was developed by the present author using 
the ELICIA online survey functionality. The questionnaire, termed the ALEL-based 
PDA evidence generation questionnaire (ALEL-EGQ) was composed of 88 
questions. It was developed to elicit, from each of the three clinicians in hospital H2, 
two types of judgments: 
- First, judgments about the levels 𝑥𝑖,𝑘 (𝑖 = 1 … 3; 𝑘 = 1,3,4 … 24) of the options 
𝐴𝑖  (𝑖 = 1 … 3) on the criteria 𝐶1(𝑏), and 𝐶3(𝑏)-𝐶24(𝑏); 
- Second, matrices of transition probabilities for input into a Markov model to 
calculate the levels 𝑥𝑖,2 (𝑖 = 1 … 3; 𝑘 = 2) on criterion 𝐶2(𝑏), i.e. the life expectancy 
of the hypothetical patient with each of the three clinical management strategies; 
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Each of the three clinicians from hospital H2 was asked to fill in the ALEL-EGQ 
questionnaire online. Three sets of responses were obtained, one set for each 
clinician. 
Appendix 5 presents the ALEL-EGQ, the judgments elicited from each of the three 
clinicians, and the corresponding ratings of the options on the bottom-level criteria, 
calculated as described in Figures 2.9 and 2.10. 
The next step was calculating the ratings of the three options on the top-level criteria 
of the hierarchy using ALEL. This procedure is explained in the next section 
3.3.2.2. Propagating the ratings of the options on the bottom-level criteria up the 
hierarchy for the ALEL-based PDA. 
Figure 2.11 below shows that three of the criteria in the hierarchy were parent criteria 
with sub-criteria. They are: cancer-related symptoms (on Level 2 of the hierarchy), 
quality of life in the medium term (on Level 1 of the hierarchy), treatment-related 
adverse effects, and quality of the health care experience from the start of treatment 
until the medium term (Level 1 of the hierarchy). ALEL, unlike Expert Choice, did 
not automatically calculate the ratings of the options on each parent criterion once 
weights were assigned to all its children criteria. Instead, a weighted sum had to be 
calculated for each group of children criteria. This is illustrated in Figure 2.11. 
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Figure 2.11: Weighted sums required in order to calculate the ratinss of the options 
on the parent top-level criteria (ALEL-based PDA) 
 
 
From Figure 2.11, to calculate the rating of each option on a parent criterion, the 
weighted-sum of the ratings of that option on its children criteria needed to be 
calculated. Once the weighted-sums were calculated for each group of children 
criteria, the ratings of the options on the top-level criteria were calculated. These 
ratings, presented in Figure 2.12, were those to be presented to patients during the 
To calculate the score of each option on criterion 
quality of the health care experience from the 
start of treatment until the medium term, 
calculate the weighted sum of the scores of each 
option on its children criteria: C20(b), C21(b), C22(b), 
C23(b), C24(b) assigning equal weights to the 
children criteria
To calculate the score of each option on criterion 
treatment-related adverse effects, calculate the 
weighted sum of the scores of each option on its 
children criteria: C11(b), C12(b), C13(b), C14(b), C15(b), 
C16(b), C17(b), C18(b), C19(b) assigning equal weights 
to the children criteria
To calculate the score of each option on criterion 
health-related quality of life in the medium term 
calculate the weighted sum of the scores of each 
option on its children criteria: cancer-related 
symptoms, C7(b), C8(b), C9(b), C11(b) assigning 
equal weights to the children criteria
Health-related quality of 
life in the medium term
Cancer-related 
symptoms
C3(b):Disease-related pain
C4(b):Disease-related dyspnoea
C6(b):Disease-related emotional 
problems
C5(b):Disease-related asthenia
C7(b):Self-care
C8(b):Work a normal week
C9(b):Interference of the disease with 
family life and/or other social 
activities
C1(b):Cure for the cancer
C2(b):Life expectancy
C10(b):Disease-related 
financial difficulties in 
the medium term
Treatment-related 
adverse effects
Quality of the health care 
experience from the start 
of treatment until the 
medium term
C15(b):Treatment-related vomiting
C16(b):Treatment-related alopecia
C18(b):Treatment-related fatigue
C17(b):Treatment-related paraesthesia
C11(b):Treatment-related dyspnoea 
due to pneumonitis or pulmonary 
fibrosis 
C12(b):Treatment-related dysphagia 
due to oesophagitis
C14(b):Treatment-related diarrhoea
C13(b):Treatment-related infection 
due to immunodeficiency
C19(b):Treatment-related anorexia
C20(b):Visits to the health services
C23(b):Treatment by the same team 
of clinicians
C22(b):Waiting time (due to waiting 
lists) between interventions 
C24(b):Attentive care
What is the best clinical 
management strategy for 
a Stage IIIA3 NSCLC 
patient?
HIERARCHY
LEVEL 1
HIERARCHY
LEVEL 2
HIERARCHY
LEVEL 3
C21(b):Hospital inpatient stays
To calculate the score of each option on 
criterion cancer-related symptoms, calculate 
the weighted sum of the scores of each 
option on its children criteria: C3(b), C4(b), 
C5(b), C6(b) assigning equal weights to the 
children criteria
156 
 
delivery of the ALEL-based PDA in clinical consultations. Note from Figure 2.12 
that the option ratings were idealised. 
Figure 2.12. Calculating the ratings of the options on the top-level criteria (ALEL-
based PDA) 
 
 
3.3.2.3. Summary of STAGE 3 for the ALEL-based PDA: calculating the ratings 
of the options on the top-level criteria of the hierarchy. 
Having established the three clinical management strategies for the Stage IIIA3 non-
small cell lung cancer hypothetical patient in STAGE 1 - neoadjuvant chemotherapy 
with resective intent (A1), concurrent chemo-radiotherapy (A2) and best supportive 
care (A3)-  and the hierarchy of criteria relevant for the decision in STAGE 2 (see 
Figure 2.4), STAGE 3 of the co-development with clinicians in hospital H2 of the 
ALEL-based PDA involved calculating the ratings of the three options on the top-
level criteria of the hierarchy. The steps for this calculation involved: 
WHAT IS THE BEST 
CLINICAL MANAGEMENT 
STRATEGY FOR A MALE 
69-YEAR OLD STAGE IIIA3 
PATIENT WITH 
CARDIOVASCULAR AND 
LUNG COMORBIDITIES?
1. CURE FOR THE 
CANCER
2. LIFE EXPECTANCY
3. QUALITY OF LIFE IN 
THE MEDIUM TERM
4. DISEASE-RELATED 
FINANCIAL BURDEN 
IN THE MEDIUM 
TERM
5. TREATMENT-
RELATED ADVERSE 
EFFECTS
6. QUALITY OF THE 
HEALTH CARE 
EXPERIENCE FROM 
THE START OF 
TREATMENT UNTIL 
THE MEDIUM TERM
Clinician 1 Clinician 2 Clinician 3
1.00 0.33. 0.01.
1.00 0.64. 0.61.
1.00 0.41. 0.40.
1.00 0.89. 1.00.
0.86 0.65. 1.00.
0.61 0.54. 1.00.
1.00. 0.63. 0.00.
1.00 0.62. 0.34.
1.00 0.75. 0.40.
1.00 0.80. 0.40.
0.76 0.62. 1.00.
0.89 0.72. 1.00.
1.00. 0.60. 0.00.
1.00 0.61. 0.19.
1.00 0.67. 0.14.
0.80 0.70. 1.00.
0.86 0.69. 1.00.
1.00 0.60. 0.40.
OPTION A1:
NEOADJUVANT 
CHEMOTHERAPY WITH 
RESECTIVE INTENT
OPTION A2:
CONCURRENT CHEMO-
RADIOTHERAPY
OPTION A3:
BEST SUPPORTIVE 
CARE
HOSPITAL H2
IDEALISED RATINGS OF THE OPTIONS ON THE CRITERIA
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1. Deciding how to calculate the ratings of the options on the bottom-level criteria. It 
was agreed with the three clinicians to define a number of quantitative variables for 
each bottom-level criterion to measure the performance levels of the options on these 
variables and then transform these into ratings; 
2. Calculating the ratings of the options on the bottom-level criteria. This step 
involved, first, eliciting judgments from each of the three clinicians to estimate the 
performance levels of the three options on all the bottom-level criteria of the 
hierarchy. To calculate the performance levels of the options on criterion life 
expectancy, a Markov model was used, the inputs of which were based on clinicians’ 
judgments. These performance levels were transformed into ratings using the 
procedures described in Figure 2.9. 
3. Finally, the ratings of the options on the bottom-level criteria were propagated up 
the hierarchy calculating weighted sums of all the children criteria of each parent 
criterion as described in Figure 2.12. 
The next section provides an analysis of the results of using Expert Choice to 
develop the Stage IIIA3 non-small cell lung cancer PDA in hospital H1 and of using 
ALEL to develop the same PDA in hospital H2. 
3.4. Analysis. 
3.4.1. Comparing the process of developing the Stage IIIA3 non-small cell lung 
cancer PDA with clinicians in hospital H1 and in hospital H2. 
The process of development of the PDA with clinicians using Expert Choice in 
hospital H1 and using ALEL in hospital H2 had both similarities and differences, 
described for each stage of PDA development below. 
3.4.1.1. STAGE 1: determining the relevant options for the clinical management 
of the hypothetical lung cancer patient. 
The process of determining the relevant options for the clinical management of a 
hypothetical 69 year-old State IIIA3 (TNM stage T2N2M0) non-small cell lung 
cancer patient was common to both hospital H1 and hospital H2. It was based on this 
author’s review of current clinical guidelines for the treatment of non-small cell lung 
cancer and adapted by individual contributions of the three clinicians in each 
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hospital. This led to the same three options in each of the two hospitals: neoadjuvant 
chemotherapy (option A1) with resective intent, concurrent chemo-radiotherapy 
(option A2) and best supportive care (option A3). The first two options were 
composed of active treatments (e.g. chemotherapy, surgery and/or radiotherapy), the 
third option is palliative. The pathway of interventions (each dependent on an 
uncertain event, see Figures 2.1 and 2.2) within each of the two active clinical 
management strategies was also common to both hospitals. This highlights the 
similarities in the treatment protocols across hospitals.  
With respect to the third option, best supportive care, it was defined in both hospitals 
in broad terms. This is because it is composed of a sequence of on-demand, 
piecemeal interventions. Each team of three clinicians confirmed that the palliative 
care protocols applied in their respective hospitals were based on current guidelines. 
In addition, the author of this study verified that the mode of provision of best 
supportive care did not differ much across the two hospitals. Hospital Germans Trias 
I Pujol (hospital H1) in Badalona has a unit of integrated palliative care. The regional 
government of Catalonia has a programme of home care (Programa de atencio 
domiciliaria i equips de support, PADES [243]) which is active in the catchment area 
of hospital H1. Doctors, nurses and social workers from PADES coordinate their 
activities with the palliative care unit of hospital H1. Hospital Reina Sofia (hospital 
H2) in Cordoba also has unit of palliative care, which provides home care for 
patients in need. From the above it is assumed that the definition of best supportive 
care (option A3) did not differ substantially across the two hospitals.  
3.4.1.2. STAGE 2: determining the criteria relevant for the hypothetical patient 
for choosing between the three options. 
In each of the two hospitals, the three clinicians jointly determined, with guidance 
from this researcher, the hierarchy of criteria considered relevant for a hypothetical 
Stage IIIA3 lung cancer patient in making the choice between the three clinical 
management options. In both cases, the chosen criteria were remarkably similar. In 
both cases the team of clinicians initially proposed to use the EORTC QDQ-C30 
items as the basis for the quality of life sub-criteria. The resulting hierarchy (see 
Figure 2.3) was modified by this author to 1) avoid using the EORTC QDQ-C30, 2) 
to minimise its size and 3) in an attempt to minimise the number of criteria which 
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were not preference independent while respecting the choice of criteria made by the 
clinicians. 
The final hierarchy of criteria had twenty-four bottom-level criteria. In hospital H1, 
using the Expert Choice template as the basis for the lung cancer PDA, the three 
clinicians considered that although the template allowed for a hierarchical 
representation of the decision problem to the hypothetical patient the hierarchy was 
too large to be communicated to the patient during a standard clinical consultation. 
For this reason, the clinicians decided that only the six top-level criteria would be 
presented in the PDA. In hospital H2, the hierarchical representation of the decision 
problem was not a choice, as ALEL does not allow for such a hierarchical 
representation. The implications are clear: lack of time did not allow to take full 
advantage of the capacity of Expert Choice to represent the decision problem in all 
its richness via the presentation of the full hierarchy of decision criteria.  
3.4.1.3. STAGE 3: Calculating the scores of the options on the top-level criteria 
for the Expert Choice-based PDA and the ALEL-based PDA. 
The calculation of the single-criterion scores of the three clinical management 
options on the six top-level criteria followed in general the same approaches in both 
hospital H1 and H2: 1) defining and agreeing with the clinicians variables for 
measuring the performance levels of the options on the bottom-level criteria, 2) 
measuring the levels of the options on these criteria based on individual clinician 
judgments, 3) transforming these levels into scores (priotities for the Expert Choice-
based PDA, ratings for the ALEL-based PDA), and 4) propagating these scores up the 
hierarchy without injecting preferences. 
For the Expert Choice-based PDA, the calculation of the priorities of the options on 
twenty of the twenty-four bottom-level criteria used direct data based on clinician 
judgments instead of pairwise comparisons of relative performance of the options. 
This was done in order to avoid asking the clinicians in hospital H1 to make an 
unreasonable (about four hundred) pairwise comparisons. Instead, they were asked to 
make one hundred and eighteen judgments. For the ALEL-based PDA, eighty-eight 
judgments were required from each of the clinicians in hospital H2 to obtain the 
ratings of the options on the twenty-four bottom-level criteria. This exercise of expert 
judgment elicitation was a feasible way to obtain the evidence for input in the model 
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without having to review the literature, a task for which neither team of clinicians 
had time. 
Figure 2.13 displays in blue/orange stacked bars the lowest/highest six scores 
corresponding to the lowest/highest performing options on the six top-level criteria 
according to the judgments of 1) the three clinicians in hospital H1 (for the Expert 
Choice PDA) and of 2) the three clinicians in hospital H2 (for the ALEL-based PDA). 
The red line shows the six scores on the six top-level criteria corresponding to the 
mid-performing option according to the judgments of 1) the three clinicians in 
hospital H1 (for the Expert Choice PDA) and of 2) the three clinicians in hospital H2 
(for the ALEL-based PDA).  
Figure 2.13. Visual representation of the scores (priorities/ratings) of the options on 
the six top-level criteria 
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From Figure 2.13, focusing on the red lines in both graphs, there is more variation in 
the single-criterion scores of the mid-performing options for the Expert Choice-based 
PDA than for the ALEL-based PDA. Focusing on the stacked bars, note that the 
closer the highest and lowest scores of the lowest/highest performing options are for 
each criterion the more similar the blue and orange bars will be in size. The highest 
and lowest scores of the lowest/highest performing options are more dissimilar in 
size for the Expert Choice-based PDA than for the ALEL-based PDA. 
In short, from Figure 2.13, the priorities of the options on the six top-level criteria for 
the Expert Choice-based PDA are more scattered than the ratings of the options on 
the six top-level criteria for the ALEL-based PDA. To get an indication of to what 
extent this is due to differences in clinicians’ judgments and to what extent it is due 
to the procedures used to transform the performance levels into priorities/ratings, it is 
useful to compare the performance levels of the options and their scores (i.e. 
priorities/ratings) for the bottom-level criteria. Figure 2.14 shows this comparison. 
Figure 2.14. Comparing the performance levels and the scores (priorities/ratings) of 
the options on the bottom-level criteria  
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From Figure 2.14, notice that for the Expert Choice-based PDA the transformation of 
the performance levels into priorities creates a distortion in a number of outcomes, 
while this is not the case with the ALEL-based PDA. This distortion in the Expert 
Choice-based PDA occurs for the criteria where the performance levels of the 
options are measured as probabilities and which are then transformed into priorities 
using the odds transformation. 
3.4.2. Estimating the reliability of clinicians’ judgments for the Expert Choice-
based PDA (hospital H1) and for the ALEL-based PDA (hospital H2). 
The inter-rater reliability in the judgments about the performance levels of the 
clinical management strategies on the bottom-level criteria of the hierarchy was 
estimated by calculating for the Expert Choice-based PDA (hospital H1) and for the 
ALEL-based PDA (hospital H2) the Intraclass Correlation Coefficient (ICC) for each 
option via a random effects two-way analysis of variance (ANOVA) for a random 
sample of three clinicians scoring twenty items, as indicated by Schrout and Fleiss 
[244]. The unit of analysis is a single rater. Table 2.4 shows the results of the 
analysis. Appendix 10 (Panel 1) shows the results of the analysis, which was 
undertaken using STATA 14 [245]. 
Table 2.4. Inter-rater reliability 
 Expert Choice-based PDA (H1) ALEL-based PDA (H2) 
Option ICC CI*(-) CI*(+) ICC CI*(-) CI*(+) 
A1 0.67 0.44 0.84 0.68 0.45 0.84 
A2 0.62 0.38 0.81 0.88 0.78 0.95 
A3 0.63 0.38 0.81 0.34 0.08 0.62 
*95% Confidence interval 
From Table 2.4, the ICC was above 0.6 for the three clinical management strategies 
in hospital H1 and for two (option A1 and option A2) clinical management strategies 
in hospital H2. The ICC was 0.34 for option A3 in hospital H2. Following Landis 
[246] and Fleiss and Cohen [247], in the first case (ICC>0.6) the agreement between 
clinicians can be considered substantial and in the second case (ICC=0.34) low.  
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3.4.3. Comparing the scores on the top-level criteria for the Expert Choice-based 
PDA (hospital H1) and for the ALEL-based PDA (hospital H2). 
In order to identify if, jointly evaluated, there were differences in the average scores 
(priorities in the Expert Choice-based PDA/ratings in the ALEL-based PDA) on the 
top-level criteria by clinician, option, and criterion, multiple linear regression 
analysis was used. Two regression models were fit, one for each PDA/hospital. The 
dependent variable was the score (priority/rating). The independent variables were 1) 
the clinician, 2) the option, and 3) each of the six top-level criteria. Appendix 10 
(Panel 2) shows the outputs of the analyses, undertaken using STATA 14. The output 
shows the coefficients, comparing each level of the independent variables with the 
reference level. The Wald test was used to verify if there were differences in the 
scores (priorities/ratings) between levels of the independent variables. 
In hospital H1, there was a problem of colinearity. Hence, one option was eliminated 
from the analysis (option A3, best supportive care). Including only options A1 and A2 
in the regression, the above regression model was appropriate to explain the 
variations in priorities (F=11.64, p=0.0000). The average priorities differed across 
options and across criteria, but not across clinicians.  
In hospital H2, there was no colinearity. The appropriateness of the above regression 
model was confirmed (F=4.13, p=0.0007). The average ratings differed across 
options, possibly across criteria (p=0.055), but not across clinicians). 
In other words, the clinicians were consistent in scoring across options and criteria. 
These results are consistent with the inter-rater agreement observed across clinicians.  
3.4.4. Implications for clinical practice. 
The case for this research study, a hypothetical 69 year old patient with Stage IIIA3 
(TNM stage T2N2M0) non-small cell lung cancer with lung and cardiovascular 
comorbidities is a good example of a difficult, preference-sensitive decision. For 
such a patient, the extension of the disease is in the frontier between localised and 
systemic disease. The frequency of presentation of this type of case in day-to-day 
clinical practice is low: lung cancer nowadays is usually diagnosed at earlier stages. 
This circumstance is likely to be reflected in the limited scientific evidence that this 
researcher found regarding the performance of the three clinical management options 
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on the large number of specific criteria considered by the clinicians relevant for the 
decision. The lack of evidence highlights the role of clinical expertise (i.e. expert 
opinion) in the provision of information for this type of decision model. The finding 
that there was considerable agreement between clinicians in the elicitation of 
judgments in this sense is encouraging. 
The clinicians participating in this study had never been involved in the development 
of a PDA and they had never used MCDA as the basis of a PDA. They greatly 
valued how MCDA involved the explicit and systematic expression of all the 
relevant elements of a complex decision. For example, the definition of the uncertain 
pathways of interventions of which each active clinical management strategy was 
composed. This raised the issue of how to best represent these clinical management 
strategies in the PDAs. The choice of communicating the options in broad terms was 
pragmatic, motivated overall by the time constraints of clinicians. This aspect of the 
development of the Expert Choice-based and the ALEL-based PDAs highlights the 
importance of taking uncertainty into account in the development of PDAs for the 
clinical management of Stage IIIA3 lung cancer.   
The clinicians also valued greatly the requirement in MCDA of developing a 
hierarchy of criteria which considered all the aspects of importance to the 
hypothetical lung cancer patient in making the choice of clinical management 
strategy. The two PDAs included clinical outcomes of the interventions, but also 
outcomes related with the quality of care, and outcomes related with the patient’s 
broader quality of life (e.g. being able to work a normal week, or interference of the 
disease with the patient’s family life and other social activities). By explicitly taking 
into account all of these aspects, the Expert Choice-based PDA and the ALEL-based 
PDA provided an accurate and explicit representation of the overall implications of 
the different clinical management strategies for the patient. This is important for such 
a condition as lung cancer where the condition and the treatments impact deeply on 
many aspects of the patient’s life. 
The strong time constraints confronted by clinicians in the development of the Expert 
Choice-based PDA and the ALEL-based PDA meant that the input of this researcher 
in the development of both PDAs was large. This highlights the role of external 
support to clinicians in the development of these tools. In this sense, the presence of 
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a decision analyst to aid clinicians in the development of MCDA-based PDAs for 
complex decisions such as the clinical management of lung cancer is desirable. Both 
hospital H1 and hospital H2 are tertiary hospitals from the Spanish NHS. In these 
hospitals, there exist structures that can provide additional support for the 
development of such PDAs. For example, hospital tumour committees. These 
committees are multidisciplinary groups of clinicians which meet regularly with, 
among other tasks, the task of refining existing cancer clinical care protocols. The 
outputs of these committees (e.g. clinical practice guidelines) are disseminated 
rapidly and generally accepted by clinicians from other hospitals.  
Among other constraints, the lack of awareness in clinicians regarding PDAs, their 
lack of time, and the lack of financial compensation are important barriers for the 
development of these tools by clinicians as part of their day-to-day workload. This 
researcher considers that the feasibility of this task would be greatly increased with 
support from the health system. In the Spanish NHS there are research structures 
with the capacity to provide such support. For example, the Thematic Networks for 
Cooperative Research (RETICS [248]) or the Centres for Networked Biomedical 
Research (CIBER [249]), one of which is dedicated to diseases of the lung. 
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Chapter 3: Using Expert Choice and Annalisa in Elicia to deliver, 
with clinicians in the Spanish NHS, a patient decision aid for the 
clinical management of Stage IIIA3 non-small cell lung cancer in an 
environment replicating actual clinical consultations.  
 
Chapter 2 described the methods and results related with Objective 1 of this thesis:  
assessing the use with clinicians in the Spanish NHS of two alternative software 
applications which support dissimilar MCDA techniques in the development of a 
PDA in routine clinical practice. Two software applications (i.e. templates) were 
used to develop a PDA for the choice of best clinical management strategy in Stage 
IIIA3 non-small cell lung cancer: Expert Choice (with three clinicians in hospital 
H1), and Annalisa in Elicia (with three clinicians in hospital H2). Expert Choice 
supports the AHP MCDA approach and Annalisa in Elicia (ALEL) supports the 
SAW MCDA approach. The process of development the Expert Choice-based PDA 
and the ALEL-based PDA resulted in: 
1. Three options for inclusion in each version of the lung cancer PDA: neoadjuvant 
chemotherapy with resective intent (option 𝐴1), concurrent chemo-radiotherapy 
(option 𝐴2), and 3) best supportive care (option 𝐴3); 
2. A common set of six top-level decision criteria for inclusion in both versions of 
the lung cancer clinical management PDA: 1) cure from the cancer, 2) life 
expectancy, 3) quality of life in the medium term, 4) disease-related financial burden 
in the medium term, 5) treatment-related adverse effects, 6) quality of the health care 
experience between the start of treatment and the medium term; 
 3. Three different sets of scores for inclusion in each version of the PDA reflecting 
the consequences of the options on the six decision criteria. Each set of priorities for 
the Expert Choice-based PDA was based on the judgments of each participating 
clinician (one pulmonologist, one oncologist, one thoracic surgeon) from hospital 
H1. Each set of ratings for the ALEL-based PDA was based on the judgments of each 
participating clinician (one pulmonologist, one oncologist, one thoracic surgeon) 
from hospital H2 
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This chapter explains the methods and results related to Objective 2 of this thesis, 
i.e.: 
- To assess the use with clinicians in the Spanish NHS of the two alternative MCDA 
software applications in the implementation of a PDA in an environment replicating 
actual clinical consultations. 
The chapter begins with an overview of the methods used to implement, i.e. deliver, 
the two PDAs in an environment replicating actual clinical consultations. It then 
describes the process of delivering the Expert Choice-based PDA in hospital H1. 
This is followed by a description of the process of delivering the ALEL-based PDA 
in hospital H2. The results and the corresponding commentary are presented at the 
end of the chapter. 
1. Overview of methods. 
The decision of implementing, i.e. delivering, the Expert Choice-based PDA and the 
ALEL-based PDA in an environment replicating actual clinical consultations was 
motivated by the shared decision-making (SDM) paradigm. SDM can be 
conceptualised as a continuum with patient-led decision making at one end and 
physician-led decision making at the other end [250]. In patient-led decision making 
the clinician provides expert knowledge to the patient but makes no 
recommendations about the choice [250]. Based on patient-led decision making, the 
delivery of the Expert Choice-based PDA in hospital H1 and the delivery of the 
ALEL-based PDA in hospital H2 were structured by setting up in each of the two 
hospitals a number of hypothetical consultations. Each hypothetical consultation 
simulated an actual consultation between 1) a pulmonologist and 2) a patient with 
Stage IIIA3 (TNM stage T2N2M0) non-small cell lung cancer and lung and 
cardiovascular comorbidities in which the pulmonologist guides the patient through 
the PDA but the patient makes the choice of clinical management strategy. 
To deliver the Expert Choice-based PDA, three hypothetical consultations were set 
up in hospital H1. In each consultation, one of the three clinicians - the 
pulmonologist (clinician 1), the oncologist (clinician 2) and the thoracic surgeon 
(clinician 3) individually guided, with support from the author of this study, a proxy 
patient (a non-clinical member of hospital staff) through the PDA. Similarly, to 
168 
 
deliver the ALEL-based PDA, three hospital consultations were set up in hospital H2 
between each individual clinician and a proxy patient. At the end of each 
hypothetical consultation in both hospital H1 and hospital H2, both the clinician and 
the proxy patient were asked to assess the quality of the decision using the “My 
Decision Quality” (MDQ) instrument [21]. The process of delivery of both the 
Expert Choice-based PDA and the ALEL-based PDA in the hypothetical 
consultations was documented. 
In the process of delivery of the Expert Choice-based PDA (in hospital 1) and the 
ALEL-based PDA (in hospital H2) to the proxy patient, the author of this research 
identified the following steps (not necessarily in the order presented): 1) 
communication of the criteria, 2) communication of the options, 3) communication 
of the evidence (i.e. communication of the scores of the options on each of the 
criteria), 4) preference elicitation (i.e. criteria weight elicitation), 5) communication 
of the results of the decision to the patient, and 6) sensitivity analysis of the criteria 
weights. To deliver the two PDAs, the first decision confronted by the clinicians and 
the present author was the choice of desired sequence of delivery steps. After group 
discussions with both teams of clinicians, in both teams it was agreed that the 
following sequence was appropriate (see Figure 3.1): 
Figure 3.1. Sequence of delivery steps of the Expert Choice-based and ALEL-based 
PDAs 
 
 
  
1. COMMUNICATION 
OF THE CRITERIA
2. PREFERENCE 
ELICITATION
4. COMMUNICATION 
OF THE RESULTS OF 
THE DECISION
5. COMMUNICATION 
OF THE EVIDENCE
3. COMMUNICATION 
OF THE OPTIONS
6. SENSITIVITY 
ANALYSIS OF THE 
CRITERIA WEIGHTS
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From Figure 3.1., note that the first step in the delivery of either PDA in the 
hypothetical consultation was the communication of the criteria to the proxy patient, 
immediately followed by the elicitation of proxy patient preferences (i.e. the 
elicitation of criteria weights). Next came the communication of the options, 
followed by the communication of the results of the decision, the communication of 
the evidence and the sensitivity analysis of criteria weights. 
Eliciting proxy patient preferences before communicating information about the 
options is justified to 1) help the proxy patient focus on the different aspects of 
importance to him before focusing on any other aspect of the decision, and to 2) 
reduce the chance of bias in the elicitation of the proxy patient’s preferences due to 
knowledge about the options. Communicating the results of the decision before 
communicating the evidence was felt by the clinicians as a good way for the proxy 
patient to understand this evidence. This is because communicating the results before 
the evidence allows the proxy patient to ask the question of how these results came 
about, focusing attention on how the options perform on the different criteria. 
Sensitivity analysis on criteria weights then allowed to focus on the imprecision of 
the weight estimates during the elicitation of the proxy patient’s preferences. 
Section 2 explains the steps of delivering the Expert Choice-based PDA in 
hypothetical consultations in hospital H1. Section 3 explains the steps of delivering 
the ALEL-based PDA in hypothetical consultations in hospital H2. 
2. Delivering the Expert Choice-based PDA in hypothetical clinical consultations 
in hospital H1. 
A group meeting with the clinicians in hospital H1 was set up to decide how to 
implement the agreed sequence of delivery steps in a hypothetical consultation using 
the Expert Choice-based PDA. In this meeting, it was also agreed that each clinician 
would guide the proxy patient through the PDA. In the case of Expert Choice, this 
guidance involved helping the proxy patient move through the different Expert 
Choice menus to be able to access each screen relevant for each particular delivery 
step. It was agreed that the proxy patient could ask questions at any point during the 
delivery of the PDA. 
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2.1. Communication of the criteria 
Recall that the criteria to be presented in the Expert Choice-based PDA were the six 
top-level criteria of the agreed hierarchy (see Figure 2.3): 1) cure from cancer, 2) life 
expectancy, 3) quality of life in the medium term, 4) disease-related financial burden 
in the medium term, 5) treatment-related adverse effects, and 6) quality of the health 
care experience from the start of treatment until the medium term. The team of 
clinicians in hospital H1 suggested that the six criteria should be communicated in 
the PDA using the easiest language possible. Table 3.1 shows the language agreed 
between the three clinicians and the author of this study to communicate the criteria 
to the proxy patient.  
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Table 3.1. Communication of the criteria to the proxy patient (Expert Choice-based 
PDA)3 
 
Criterion 
 
 
Language used for communication to the patient 
 
Cure 
 
 
To get cured 
 
Life Expectancy 
 
 
To live longer, independently of my state of health 
 
Quality of life in 
the medium 
term* 
 
 
To have a good quality of life two years from now.  I will have a good quality 
of life two years from now if, after two years: 
 
1) I do not have the following symptoms of cancer: pain, shortness of breath, 
loss of weight and extreme tiredness, and emotional problems such as 
depression and irritability 
 
2) I am able to take care of myself without help from others, I can work a 
normal forty-hour week, and my condition does not interfere with my family 
life and other social relations 
 
 
Disease-related 
financial burden 
in the medium 
term* 
 
 
To avoid having financial difficulties due to my condition two years from now 
 
Treatment-
related adverse 
effects 
 
 
To avoid the adverse effects due to the treatment. If I take the treatment I can 
have the following adverse effects: breathlessness, problems swallowing, 
infections due to a drop in my defences, diarrhoea and vomiting, loss of hair, a 
prickling or burning sensation (especially in the hands and feet), fatigue, and 
loss of weight. All of these adverse effects with the exception of the loss of 
hair can be serious enough to require that I am admitted to hospital 
 
 
Quality of the 
health care 
experience from 
the start of 
treatment until 
the medium 
term* 
 
 
To have a good experience of the health care received in the next two years. I 
will have a good experience of the health care received if 1) I have to go to the 
outpatient clinics as little as possible, if 2) I have to be admitted to hospital as 
few times as possible, 3) I do not have to wait unnecessarily to receive 
treatment, 4) I am always treated by the same clinician or clinicians, 5) I am 
treated in an attentive and considerate manner by my clinicians 
 
                                                          
3 See Appendix 8 for the Spanish criteria names 
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In each hypothetical consultation, the communication of the criteria to the proxy 
patient was made by letting the patient read through the criteria in the Tree View 
screen of Expert Choice (see Figure A6.1 in Appendix 6 for an illustration). Once the 
proxy patient considered that he had understood the criteria, the clinician helped the 
patient to access the screen for preference elicitation. 
2.2. Preference elicitation. 
Proxy patient preferences for the different criteria were elicited using pairwise 
comparisons of relative importance between the criteria. For these pairwise 
comparisons, the standard 1-9 AHP scale was used (see Table 3.2). The clinicians 
were given the option of using either numbers, verbal expressions or sliding bars to 
elicit proxy patient preferences in Expert Choice. They all agreed to use sliding bars 
because they thought the sliding bars were visually intuitive to express the pairwise 
comparisons (see Figure A6.2 in Appendix 6 for an illustration).  
 
Table 3.2. 1-9 AHP scale of intensity of dominance. 
Intensity of dominance Definition 
1 Equal intensity of dominance 
2 Weak intensity of dominance 
3 Moderate intensity of dominance 
4 Moderate plus intensity of dominance 
5 Strong intensity of dominance 
6 Strong-plus intensity of dominance 
7 Very strong intensity of dominance 
8 Very, very strong intensity of dominance 
9 Extreme intensity of dominance 
 
The preference elicitation was conducted in each hypothetical consultation as 
follows. First, the clinician explained to the proxy patient how to perform a pairwise 
comparison of relative importance between criteria. Each proxy patient had to make 
fifteen of these pairwise comparisons. Any inconsistencies in the proxy patient’s 
judgements were highlighted in real time in Expert Choice by a visual display of the 
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inconsistency index which was monitored by the clinician. A consistency index 
higher than the (more or less arbitrary) value of 0.1 required a reassessment of the 
pair-wise comparisons. Interestingly, in hospital H1 the pulmonologist raised the 
issue that perhaps the threshold of the consistency index should be increased from 
0.1 to 0.2. The reason for this was, according to the pulmonologist, that expecting 
high consistency in the pair-wise comparison judgments of a real lung cancer patient 
was perhaps expecting too much. For this clinician’s hypothetical consultation, the 
consistency index threshold was raised to 0.15 to accommodate his views.  
Once the criteria weights were obtained, the clinician helped the patient to access the 
screen for the communication of the options. 
2.3. Communication of the options. 
This step of PDA delivery involved describing to the proxy patient the three clinical 
management options, i.e. neoadjuvant chemotherapy with resective intent (option 
𝐴1), concurrent chemo-radiotherapy (option 𝐴2), and best supportive care (option 
𝐴3). This was a challenging task, as the actual sequence of interventions within each 
strategy is uncertain (see Figures 2.1 and 2.2 in Chapter 2). The clinicians and this 
researcher agreed to describe the options in terms of a broad outline of the 
interventions that could occur within each option.  
Table 3.3 shows the textual content of the three descriptions. Note that each 
description is in the first person, for consistency with the textual description of the 
criteria shown in Table 3.1. Each option was communicated to the proxy patient by 
letting the patient read the textual content from Table 3.3 for each option using 
Expert Choice’s information document screen (for an illustration, see Figure A6.3 in 
Appendix 6).  
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Table 3.3. Textual content of the three option descriptions (Expert Choice-based 
PDA)4  
 
Option 
 
Description 
 
 
 
Neoadjuvant 
chemotherapy 
with resective 
intent       
(Option 𝐴1) 
 
1. Neoadjuvant chemotherapy with resective intent. This treatment consists in 
injecting me a medicine (chemotherapy) that kills the cancer cells. The goal is 
to reduce the size and extent of the tumour enough that it can be taken out 
using surgery. This treatment has several steps. First, I am given the 
chemotherapy in several sessions over a month or so. If, after a scan, it looks 
like the chemotherapy is successful at reducing the size and extent of the 
tumour so that it can be removed, then I will have a small chest intervention 
called mediastinoscopy to confirm that this is the case. If the mediastinoscopy 
confirms that this is indeed the case, then I will have the surgery to remove the 
tumour. The surgery consists in removing the part of the lung where the 
tumour is lodged. If the chemotherapy is not successful at reducing the size and 
extent of the tumour, I will not have surgery. Instead, I will be given 
chemotherapy along with radiotherapy. Radiotherapy consists in using a 
machine that sends rays to burn the cells of the tumour. If after either of these 
treatments the tumour comes back, which is likely, I will be given 
chemotherapy again; 
 
Concurrent 
chemotherapy 
(Option 𝐴2) 
 
2. Concurrent chemo-radiotherapy. This treatment consists in giving me 
alternatively chemotherapy and radiotherapy for several weeks with the goal of 
eliminating the tumour. If after the treatment the tumour comes back, I will be 
given chemotherapy again; 
 
Best supportive 
care        
(Option 𝐴3) 
 
3. Best supportive care. This treatment is not directed at curing the tumour, but 
at eliminating the symptoms of the cancer. I will be given, if and when I 
require it, the following treatments: physiotherapy, psychotherapy, treatment 
against pain, treatment against breathlessness, treatment against loss of weight, 
etc. 
 
 
  
                                                          
4 See Appendix 8 for the Spanish option names 
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Once the proxy patient considered that he had understood the options, the clinician 
helped the patient to access the screen for communicating the results of the decision. 
2.4. Communication of the results of the decision 
This stage in the delivery of the Expert Choice-based PDA involved communicating 
to the proxy patient the three overall scores of the three options and their ranking 
from best to worst. The communication of the results of the decision was done using 
the Synthesise screen in Expert Choice (see Figure A6.4 in Appendix 6 for an 
illustration). This screen consists of three horizontal bars reflecting the overall 
priorities (normalised to sum to one) of the three options. In the Synthesise screen, 
the options are ranked from best to worst from the top-down. Once the proxy patient 
considered that he had understood the overall scores of the options and the ranking of 
the options, the clinician asked the proxy patient if he wanted to see the evidence (i.e. 
the priorities) of the options on the individual criteria. If the answer was “yes”, the 
clinician helped the patient to access the screen for visualising the evidence. If the 
answer was “no”, the clinician moved to the sensitivity analysis screen. In the three 
hypothetical consultations in hospital H1 all three proxy patients wanted to see the 
evidence. 
2.5. Communication of the evidence. 
This stage in the delivery of the Expert Choice-based PDA involved showing the 
proxy patient the priorities (normalised to sum to one) of the three clinical 
management strategies on each of the six decision criteria.  
The communication of the evidence was done using the criterion window in Expert 
Choice (see Figure A6.5 in Appendix 6 for an illustration). The clinician explained to 
the proxy patient that the priorities of the options on each criterion reflected how 
much better each option was with respect to each other option in terms of achieving 
that criterion. Once the proxy patient considered that he had understood the evidence, 
the clinician helped him to access the sensitivity analysis screen. 
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2.6. Sensitivity analysis of the criteria weights. 
The final stage in the delivery of the Expert Choice-based PDAs was the sensitivity 
analysis on the criteria weights elicited from the proxy patient. The sensitivity 
analysis assessed the robustness of the overall results (in terms of the ranking of the 
options) to changes in the criteria weights. One approach to such a sensitivity 
analysis involves varying the criteria weights over a range. This was the approach 
used in each hypothetical consultation. Each of the six criteria weights was varied 
over a range of plus/minus 20%. 
To undertake the sensitivity analysis, the three clinicians chose to use the dynamic 
sensitivity analysis screen (see Figure A6.6 in Appendix 6), as they felt it was easy to 
use for patients. This screen displays on the left side the weights of the decision 
criteria as sliding horizontal bars, and on the right side the aggregate scores of the 
three options also as horizontal bars. As each criterion weight is changed, the overall 
scores of the options change correspondingly. The sensitivity analysis was done for 
each criterion by the clinician and communicated verbally to the proxy patient. If 
there was a change in the ranking of the options as a result of any of these weight 
changes, the patient was asked to state whether or not he felt that the weight of that 
criterion could vary over the range that induced a change in the ranking of the 
options. 
After the sensitivity analysis, the delivery of the Expert Choice-based PDA ended. 
The clinician and the proxy patient then proceeded to answer to the MDQ decision 
quality questionnaire.  
2.7. Summary of delivery steps for the Expert Choice PDA. 
To deliver the Expert Choice-based Stage IIIA3 non-small cell lung cancer PDA in 
hospital H1, three hypothetical consultations were set up. In each hypothetical 
consultation, one of the three clinicians the pulmonologist (clinician 1), the 
oncologist (clinician 2), and the thoracic surgeon (clinician 2) guided a proxy patient 
(a non-clinical member of hospital staff), with support from the author of this thesis, 
through the following PDA delivery steps: 1) communication of the criteria (in 
simple language) using the template’s TreeView screen, 2) criteria weight elicitation 
(including the verification of the consistency of the proxy patient’s judgments) using 
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the graphical pairwise comparisons screen and a 1-9 intensity of dominance scale, 3) 
communication of the options (describing each of the options in terms of a broad 
outline) with the template’s information document screen, 4) communication of the 
results using the template’s graphical Synthesise screen, 5) communication (if 
desired by the proxy patient) of the priorities of the options on each of the criteria on 
a separate criterion window, and 6) sensitivity analysis of the proxy patient’s weights 
varying each weight over a ±20% using the dynamic sensitivity screen.  
3. Delivering the ALEL-based PDA in hypothetical clinical consultations 
As with the Expert Choice-based PDA, a group meeting was organised with the 
clinicians in hospital H2 to decide how to implement the agreed sequence of delivery 
steps (see Figure 3.1) using the ALEL-based PDA in a hypothetical consultation. In 
this meeting, it was also agreed that each clinician would guide the proxy patient 
through the PDA. ALEL allows to tailor the sequence of screens to be presented to 
the proxy patient. There are two types of screens in ALEL: 1) the Elicia screens and 
2) the Annalisa topic screens. The Elicia screens both present information and elicit 
information from the user. The Annalisa topic screens constitute the decision making 
interface of ALEL. A typical Annalisa topic screen is structured in three panels: 1) 
the ratings panel at the bottom of the screen, which includes the names of the options 
and a visual representation (in horizontal sliding bars) of the rating of each option on 
each criterion, 2) the weights panel in the middle of the screen including the names 
of the criteria and a visual representation in horizontal sliding bars of the weights 
assigned by the patient to each of the criteria, and 3) the scores panel at the top of the 
screen, including a visual representation of the overall scores of the options. The 
ratings/weights/scores panels can be hidden from view at any point. For example, 
when eliciting criteria weights using the horizontal sliding bars, the ratings panel and 
the scores panel can be hidden. The ALEL-based PDA was purposefully built by this 
researcher using a sequence of Elicia screens and Annalisa topic screens guiding the 
proxy patient through the PDA delivery steps. It was agreed with the clinicians that 
the proxy patient could ask questions at any point of the PDA delivery. 
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3.1. Communication of the criteria 
As with the Expert Choice-based PDA, the criteria presented in the ALEL-based 
PDA were: 1) cure from cancer, 2) life expectancy, 3) quality of life in the medium 
term, 4) disease-related financial burden in the medium term, 5) treatment-related 
adverse effects, and 6) quality of the health care experience from the start of 
treatment until the medium term. The clinicians in hospital H2 were of the opinion 
that the criteria should be communicated to the proxy patient in the easiest way 
possible. The chosen textual content of the criteria communication screen was 
similar as for the Expert Choice-based PDA (see Table 3.1), but expressed in second 
person singular instead of in first person singular. For example, for criterion quality 
of life in the medium term (third row in Table 3.1), instead of displaying “I will have 
a good quality of life in the medium term if…” as in the Expert Choice-based PDA, 
the ALEL-based PDA displayed “you will have a good quality of life in the medium 
term if…”. 
In each hypothetical consultation, the communication of the criteria was made to the 
proxy patient using an Elicia screen which was accessible from the welcome screen 
of the PDA (see Figure A7.1 in Appendix 7). Once the proxy patient considered that 
he had understood the criteria, he moved to the preference elicitation screen by 
clicking on a button in the Elicia screen. 
3.2. Preference elicitation. 
The preference elicitation (i.e. the elicitation of criteria weights) for the ALEL-based 
PDA was undertaken in each hypothetical consultation using a two-step process. 
First, the proxy patient was prompted by an Elicia screen to assess the relative 
importance of the six criteria on five verbal levels of importance (see Table 3.4, first 
column). As shown in Table 3.4, each level of importance was assigned a weight 
between 0 and 1. For an illustration of the screen used to elicit these weights see 
Figure A7.2 in Appendix 7.  
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Table 3.4. Levels of criterion importance and associated weights (ALEL-based PDA) 
Levels of importance Weights 
Not important at all 𝑤(not important at all) = 0 
A little bit important 𝑤(a little bit important) = 0.25 
Moderately important 𝑤(moderately important) = 0.5 
Very important 𝑤(very important) = 0.75 
Extremely important 𝑤(extremely important) = 1 
 
Second, upon clicking on a button in the Elicia screen the proxy patient was 
informed that in the next screen he would visualise in sliding bars the weights 
corresponding to the verbal levels of importance assigned to each of the criteria. He 
was advised to modify these weights using the sliding bars until they represented 
adequately his relative preferences for the different criteria (see Figure A7.3 in 
Appendix 7). Upon clicking on a button in the Elicia screen the proxy patient was 
directed to an Annalisa topic screen where he could change the weights that he had 
previously assigned verbally if he so wished. The weighting panel in the Annalisa 
topic screen is unique in that when the cursor is dragged across each criterion name a 
pop-up appears with information about the criterion. Advantage was taken of this 
feature to include information about each criterion in the weightings panel. Table 3.5 
provides a description of the information included in the criteria pop-ups. 
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Table 3.5. Content of the criterion information pop-ups (ALEL-based PDA) 
 
Criterion (SHORT NAME) 
 
Content of the pop-up  
 
Cure (CURE) 
 
Shows how important it is for you to get cured  
 
Life expectancy (TIME ALIVE) 
 
Shows how important it is for you to live longer, 
independently of the state of health you are in 
 
Quality of life in the medium term 
(QUAL.LIFE) 
 
Shows how important it is for you to have a good quality of 
life two years from now 
 
Financial burden due to the disease 
in the medium term (FIN.DIFF) 
 
Shows how important it is for you to avoid the financial 
difficulties due to the disease two years from now 
 
Treatment-related adverse effects 
(ADV.EFF) 
 
Shows how important it is for you to avoid the treatment-
related adverse effects 
 
Quality of the health care 
experience (QUAL.CARE) 
 
Shows how important it is for you to have a good 
experience of the health care received during the next two 
years  
 
Once the proxy patient assigned weights to the criteria, the PDA prompted him to 
move to the options communication screen by pressing a button. 
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3.3. Communication of the options. 
The communication of the options for the ALEL-based PDA was done in a similar 
fashion as for the Expert Choice-based PDA. The textual content of the option 
descriptions was almost identical to that of Table 3.3, except that it was expressed in 
the second person singular. The information was presented to the proxy patient using 
an Elicia screen (see A7.4 in Appendix 7 for illustration). Once the proxy patient 
considered that he understood the options, he moved to the results communication 
screen by clicking on a button. 
3.4. Communication of the results of the decision 
This stage in the delivery of the ALEL-based PDA involved explaining to the proxy 
patient the three overall scores of the three options and their ranking from best to 
worst. The communication of the results of the decision was done using an Annalisa 
topic screen displaying the overall scores panel and the weightings panel (see Figure 
A7.5 in Appendix 7 for an illustration). The scores panel consists of three horizontal 
bars reflecting the overall scores of the three options. Once the proxy patient 
considered that he understood the overall scores of the options and the ranking of the 
options, the clinician asked the proxy patient if he wanted to see the evidence of the 
consequences of the options on the criteria. If the answer was “yes”, the patient 
moved to the evidence communication screen by clicking on a button. If the answer 
was “no”, the clinician stepped in and clicked ahead to the sensitivity analysis screen. 
3.5. Communication of the evidence 
This stage in the delivery of the Expert Choice-based PDA involved showing the 
proxy patient the ratings of the three clinical management strategies on the six 
decision criteria. In ALEL it was possible to simultaneously visualise all the evidence 
(i.e. all the ratings of the three options on all the criteria) on the screen. The 
communication of the evidence was done using the ratings panel of an Annalisa topic 
screen (see Figure A7.6 in Appendix 7). Once the proxy patient considered that he 
had understood the evidence, he moved to the sensitivity analysis screen by clicking 
on a button.  
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3.6. Sensitivity analysis of the criteria weights 
The final stage in the delivery of the ALEL-based PDAs was the sensitivity analysis 
on the criteria weights elicited from the proxy patient. ALEL allows for performing 
sensitivity analyses on the criteria weights within the same Annalisa topic screen as 
long as the screen is displaying both the weights and the scores panel. In order to 
perform this sensitivity analysis, the weights assigned by the proxy patient to each of 
the different criteria were modified by the clinician by an amount of plus/minus 20%. 
If the ranking of the options changed as a result of a particular criterion weight 
change, the proxy patient was asked by the clinician to reconsider that criterion 
weight. 
After the sensitivity analysis, the delivery of the Expert Choice-based PDA ended. 
The clinician and the proxy patient then proceeded to answer to the MDQ decision 
quality questionnaire.  
3.7. Summary of delivery steps for the ALEL PDA. 
To deliver the ALEL-based Stage IIIA3 non-small cell lung cancer PDA in hospital 
H2, three hypothetical consultations were set up. In each hypothetical consultation, 
one of the three clinicians - the pulmonologist (clinician 1), the oncologist (clinician 
2), the thoracic surgeon (clinician 3) guided a proxy patient (a non-clinical member 
of hospital staff), with support from the author of this thesis, through the following 
PDA delivery steps: 1) communication of the criteria (in simple language) using an 
Elicia screen, 2) criteria weight elicitation using first verbal statements and then 
using an Annalisa topic screen displaying only the weights panel, 3) communication 
of the options (describing each of the options in terms of a broad outline) with an 
Elicia screen, 4) communication of the results using an Annalisa topic screen 
displaying only the overall scores panel and the weights panel, 5) communication (if 
desired by the proxy patient) of the ratings of the options on all the criteria on the 
same Annalisa topic screen of the results communication step but now displaying the 
ratings panel, and 6) sensitivity analysis of the proxy patient’s weights varying each 
weight over a range of  ±20%.  
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The next section describes the use of the “My Decision Quality” (MDQ) after each 
hypothetical consultation to assess each clinician’s and proxy patient’s perception of 
the quality of decision-making using the template-based PDAs. 
4. Assessing decision quality using the “My Decision Quality” (MDQ) tool. 
The MDQ instrument [21], currently implemented using the ALEL template, 
combines 1) a decision maker’s ratings on eight decision-making quality criteria with 
2) the weights assigned by the decision maker to these criteria to calculate a score 
measuring the quality of the subject’s decision-making. The eight MDQ criteria are, 
from the perspective of the decision maker, the following [21]: 
1) Being clear about the possible options for him/her and what they involve;   
2) Being clear about the possible effects and outcomes of each option for him/her; 
3) Being clear about the relative importance to him/her of the different possible 
effects and outcomes;  
4) Being clear about the chances of the different effects and outcomes happening to 
him/her, including the uncertainties surrounding the best estimates of them; 
5) Being able to trust that the information given to him/her was the best possible;  
6) Feeling that he/she has received the level of support and consideration wanted 
throughout the decision making process, especially in regard to communicating at his 
level; 
7) Feeling that he/she is in control of the decision to the extent he/she wished;  
8) Being committed to acting on the decision taken. 
To calculate the MDQ score associated with the delivery of a template-based PDA, 
the subject is first asked to weigh, on a 0-10 scale, the importance to him/her of each 
of the above eight criteria. The 10 possible levels of importance for each MDQ 
decision quality criterion, from “not important” to “extremely important” and the 
related weights are shown in Table 3.6. 
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Table 3.6. Possible levels of importance and corresponding weights of the decision 
quality criteria (MDQ) 
 
Levels of importance 
 
 
Weights 
 
Not important (=0) 
 
 
0 
 
1 
 
 
0.1 
 
2 
 
 
0.2 
 
3 
 
 
0.3 
 
4 
 
 
0.4 
 
Moderately important (=5) 
 
 
0.5 
 
6 
 
 
0.6 
 
7 
 
 
0.7 
 
8 
 
 
0.8 
 
9 
 
 
0.9 
 
Extremely important (=10) 
 
 
1 
 
Next, the subject is asked to rate how well the use of the PDA has achieved each 
MDQ criterion, on a scale between 0 and 10, where 0 is “extremely poorly” and 10 is 
“extremely well” (see Table 3.7). 
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Table 3.7. Ratings on the decision criteria (MDQ) 
 
How well has the PDA achieved each 
criterion? 
 
 
Ratings 
 
Extremely poorly (=0) 
 
 
0 
 
1 
 
 
0.1 
 
2 
 
 
0.2 
 
3 
 
 
0.3 
 
4 
 
 
0.4 
 
Moderately (=5) 
 
 
0.5 
 
6 
 
 
0.6 
 
7 
 
 
0.7 
 
8 
 
 
0.8 
 
9 
 
 
0.9 
 
Extremely well (=10) 
 
 
1 
 
 
Multiplying each weight by each rating for each MDQ criterion and adding across 
criteria, the MDQ score is calculated. The MDQ score ranges between 0 and 1. 
In each hypothetical consultation in hospitals H1 and H2, both the proxy patient and 
the clinician used the MDQ instrument to assess the quality of the proxy patient’s 
decision using the relevant template-based PDA.  
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5. Results of delivering the template-based PDAs in the hypothetical 
consultations. 
This section summarizes the results of 1) delivering the Expert Choice-based PDA in 
three hypothetical consultations in hospital H1 and of 2) delivering the ALEL-based 
PDAs in three hypothetical consultations in hospital H2. For each hypothetical 
consultation, the results reported include: 1) The aggregate scores of the three 
options and their ranking, 2) the weights assigned by the proxy patient to the criteria, 
3) the time required to implement each delivery step of the relevant PDA, 4) the 
results of the sensitivity analysis, 5) the MDQ scores elicited from the clinician and 
the proxy patient 
Figures 3.2-3.4 show the results of delivering the Expert Choice-based PDA in the 
three hypothetical consultations in hospital H1. Figures 3.5-3.7 show the results of 
delivering the ALEL-based PDA in the three hypothetical consultations in hospital 
H2.   
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Figure 3.2. Results of delivering the Expert Choice-based PDA in hypothetical 
consultation 1 with Clinician 1 and a proxy patient (hospital H1) 
 
DECISION QUALITY:
- The clinician’s MDQ score was 0.67.  
- The proxy patient’s MDQ score was 0.75 
SENSITIVITY ANALYSIS:
- The ranking of the treatment options was 
not altered by a change of plus/minus 20% in 
each of the weights
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Figure 3.3. Results of delivering the Expert Choice-based PDA in hypothetical 
consultation 2 with Clinician 2 and a proxy patient (hospital H1) 
 
DECISION QUALITY:
- The clinician’s MDQ score was 0.77.  
- The proxy patient’s MDQ score was 0.70. 
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Figure 3.4. Results of delivering the Expert Choice-based PDA in hypothetical 
consultation 3 with Clinician 3 and a proxy patient (hospital H1) 
 
DECISION QUALITY:
- The clinician’s MDQ score was 0.60;  
- The proxy patient’s MDQ score was 0.78 
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Figure 3.5. Results of delivering the ALEL-based PDA in hypothetical consultation 1 
with Clinician 1 and a proxy patient (hospital H2) 
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Figure 3.6. Results of delivering the ALEL-based PDA in hypothetical consultation 2 
with Clinician 2 and a proxy patient (hospital H2) 
 
DECISION QUALITY:
- The clinician’s MDQ score was 0.88.  
- The proxy patient’s MDQ score was 0.87 
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Figure 3.7. Results of delivering the ALEL-based PDA in hypothetical consultation 3 
with Clinician 3 and a proxy patient (hospital H2) 
 
DECISION QUALITY:
- The clinician’s MDQ score was 0.75.  
- The proxy patient’s MDQ score was 0.81 
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6. Analysis. 
6.1. Comparing the process of delivering the Stage IIIA3 non-small cell PDA 
with clinicians in hypothetical consultations in hospital H1 and in hospital H2. 
The process of delivering the PDA with clinicians using Expert Choice in hospital 
H1 and using ALEL in hospital H2 had both similarities and differences. These 
similarities and differences are presented for each of the PDA delivery steps: 1) 
communication of the criteria, 2) preference elicitation, 3) communication of the 
options, 4) communication of the results, 5) communication of the evidence (if 
desired by the proxy patient), and 6) sensitivity analysis on criteria weights 
One initial, important, difference in the delivery of the PDAs was the level of 
guidance through each PDA that was required from the clinicians. In the three 
hypothetical consultations in hospital H1, the clinicians had to switch between 
Expert Choice screens to help the proxy patient through the different PDA delivery 
steps. This was not the case in the ALEL-based PDA. The reason is that the ALEL-
based PDA was tailored to easily move between screens in a step-by-step manner. 
Using the Elicia survey functionality, on-screen instructions and information were 
provided for each delivery step. The proxy patient only had to click on a button to 
move to the next step. This unique feature in ALEL ensured a smooth user experience 
in the case of the ALEL-based PDA. 
The communication of the criteria was similar in terms of the criteria described to the 
proxy patient (the top-level criteria of the hierarchy) and in terms of the language 
used to describe these criteria. No advantage was taken of the additional functionality 
available in Expert Choice with respect to ALEL in terms of being able to present 
information about all of the criteria in the hierarchy. This is because the three 
clinicians in hospital H1 considered there would not be enough time to present all the 
information pertaining to all the criteria during the time available in a standard 
consultation with a hypothetical lung cancer patient. For the Expert Choice-based 
PDA the time required for the communication of the criteria was, in all hypothetical 
consultations, longer than for the ALEL-based PDA. The reason is that with Expert 
Choice the clinician had to switch between criterion screens (one screen per 
criterion), while with ALEL all the criterion information was presented in the same 
screen. 
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The preference elicitation was remarkably different across PDAs. Using the Expert 
Choice-based PDA, each clinician had to first explain to the proxy patient how to do 
pairwise comparisons of relative importance between criteria using the application’s 
graphical interface. Then, the proxy patient had to perform fifteen pairwise 
comparisons. In two hypothetical consultations there were inconsistencies in the 
pairwise comparisons, which required a reassessment of these pairwise comparisons. 
The advantage of the pairwise comparisons was that consistency between judgments 
of relative importance was achieved in all cases. The disadvantage of Expert Choice 
is double. First, the process of making fifteen pairwise comparisons of relative 
importance between criteria is long. Second, the interpretation of the six criteria 
weights was not straightforward. In the Analytic Hierarchy Process (AHP), the 
MCDA approach supported by Expert Choice, each weight should be interpreted as 
an average score across options for each criterion, a concept that this researcher 
found difficult to explain in the hypothetical consultations. The time taken for 
preference elicitation varied across the hypothetical consultations between a 
minimum of twelve and a maximum of twenty-two minutes. 
Using the ALEL-based PDA, the preference elicitation was done in two steps in each 
hypothetical consultation: first, assigning verbal levels of importance to each of the 
six top-level criteria using an Elicia screen; then, visualizing these weights as sliding 
bars on an Annalisa screen to allow for their adjustment. All proxy patients adjusted 
the criteria weights by small amounts. The interpretation of the weights was that each 
criterion weight expressed the relative importance of that criterion with respect to the 
other criteria. The proxy patients had no trouble understanding this definition of 
weights. During the preference elicitation, the proxy patients made use of the 
criterion information pop-ups to remember the basic definitions of each of the 
criteria. The time taken for preference elicitation varied across the hypothetical 
consultations between a minimum of four and a maximum of six minutes, 
substantially less than for the Expert Choice-based PDA. 
The communication of the options was similar for both PDAs in terms of the textual 
content. The main difference in this stage was that for the Expert Choice-based PDA 
the clinician had to switch across screens to display the information for each option, 
while in ALEL all the information was presented in one Elicia screen. The time taken 
to complete this stage of PDA delivery varied from a minimum of six minutes to a 
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maximum of seven minutes for the Expert Choice-based PDA and from a minimum 
of three minutes to a maximum of ten minutes for the ALEL-based PDA. 
The communication of the results was similar using both PDAs, as both Expert 
Choice and ALEL use horizontal bars expressing the overall scores (priorities and 
ratings, respectively) of the options. Expert Choice allows to rank the options on 
screen, which was found to be a useful feature that all proxy patients took advantage 
of in the hypothetical consultations in hospital H1. The interpretation of these scores 
was similar for both Expert Choice and ALEL. Each option’s overall score is the sum 
of the weighted performances of that option across the six criteria. This was 
understood clearly by all proxy patients.  
All patients chose to visualize the evidence, i.e. the individual scores of the options 
across the top-level criteria, in all hypothetical consultations. In the Expert Choice-
based PDA, the priority of each option on a criterion is interpreted as the contribution 
of the option to the achievement of the criterion, a concept that all proxy patients 
understood. In ALEL, the score or rating of an option on a criterion is the 
performance of that option relative to the highest performing option, which all proxy 
patients also understood. The time required for communication of the evidence was 
between a minimum of seven minutes and a maximum of eight minutes for the 
Expert Choice-based PDA and between four minutes and seven minutes for the 
ALEL-based PDA. 
Finally, the sensitivity analysis was performed in a very similar way across 
hypothetical consultations with the Expert Choice-based PDA and the ALEL-based 
PDA. The main difference was that in the hypothetical consultation using Expert 
Choice the clinicians had to switch to a specific sensitivity analysis screen (the 
Dynamic sensitivity analysis screen), while using ALEL the sensitivity analysis was 
performed directly on the same Annalisa topic screen used for the presentation of the 
evidence. 
6.2. Comparing the quality of the decision across clinicians and proxy patients 
for the Expert Choice-based PDA and the ALEL-based PDA. 
As mentioned before, after each hypothetical consultation with the Expert Choice-
based PDA and the ALEL-based PDA, both the proxy patient and the clinician were 
asked to complete the “My Decision Quality” (MDQ) instrument. MDQ produces a 
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score between 0 and 1 such that a higher score implies higher decision quality. The 
MDQ score is preference-sensitive, i.e. it depends on the weights assigned by the 
decision maker to each of the MDQ dimensions. In each hypothetical consultation, 
the clinician was explicitly asked to complete the MDQ instrument for the proxy 
patient’s decision. In assigning weights for each of the MDQ dimensions, the 
clinician was asked to consider his own preferences. For example, for the second 
dimension of the MDQ, “being clear about the possible effects and outcomes of each 
option for him/her”, the clinician was asked to assess how important it was for 
him/her (i.e. the clinician) that the patient was “clear about the possible effects and 
outcomes of each option for the patient”. Figure 3.8 plots, for each hypothetical 
consultation, the MDQ score for each proxy patient against the MDQ score of the 
corresponding clinician. The red points correspond in Figure 3.8 correspond to the 
MDQ scores for the hypothetical consultations in hospital H1 using the Expert 
Choice-based PDA. The yellow points in Figure 3.8 correspond to the MDQ scores 
for the hypothetical consultations in hospital H2 using the ALEL-based PDA. Points 
along the diagonal line in Figure 3.8 represent for each hypothetical consultation 
equal MDQ scores for the clinician and the proxy patient. The dashed lines divide the 
plot into four quadrants. Points on the top-right quadrant represent levels of decision 
quality above 0.5 (on a total scale between 0 and 1) for both the proxy patient and the 
clinician. 
Figure 3.8. Plot of the MDQ scores (Expert Choice-based PDA and ALEL-based 
PDA) 
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From Figure 3.8, note that in five out of six hypothetical consultations the MDQ 
scores for both the proxy patients and the clinicians were above the mid-point of the 
MDQ scale, indicating relatively high levels of perceived decision quality. The 
highest levels of decision quality corresponded to two of the hypothetical 
consultations using the ALEL-based PDA. From Figure 3.8, note also that four out of 
the six points lie above the diagonal line. That is, in four out of six hypothetical 
consultations (two using the Expert Choice-based PDA and two using the ALEL-
based PDA) the proxy patients perceived higher levels of decision quality than did 
the corresponding clinicians. 
6.3. Comparing the overall results in the hypothetical consultations with the 
Expert Choice-based PDA and the ALEL-based PDA. 
Table 3.8 presents the overall results and rankings of the options on the criteria. 
From Table 3.8, in five out of six hypothetical consultations neoadjuvant 
chemotherapy with resective intent (option A1) was the preferred option, followed by 
concurrent chemo-radiotherapy (option A2) and followed by best supportive care. 
The exception was hypothetical consultation 1 in hospital H2 using the ALEL-based 
PDA. In this consultation, the second most preferred option by the proxy patient was 
best supportive care. 
Table 3.8. Overall scores (ranking of options) for the options in hypothetical 
consultations 
 
Hypothetical consultations in 
Hospital H1 
Hypothetical consultations in 
hospital H2 
1 2 3 1 2 3 
 
Option A1 
0.55 (1) 0.61 (1) 0.57 (1) 0.88 (1) 0.94 (1) 0.92 (1) 
 
Option A2 
0.25 (2) 0.29 (2) 0.29 (2) 0.52 (3) 0.69 (2) 0.66 (2) 
 
Option A3 
0.20 (3) 0.10 (3) 0.14 (3) 0.66 (2) 0.53 (3) 0.51 (3) 
 
To understand these results it is useful to take a closer look at the highest scoring 
option on each of the six criteria for each hypothetical consultation and to the 
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weights assigned to each of these criteria by each proxy patient. This information is 
shown, respectively, in Table 3.9 and in Figure 3.9. 
Table 3.9. Highest scoring option on each criterion for each hypothetical 
consultations 
 
Hypothetical consultations in 
Hospital H1 (Expert Choice-
based PDA) 
Hypothetical consultations in 
hospital H2 (ALEL-based 
PDA) 
 
1 
 
2 3 1 2 3 
 
Cure for cancer 
 
A1 A1 A1 A1 A1 A1 
 
Life expectancy 
 
A1 A1 A1 A1 A1 A1 
 
Quality of life in the 
medium term 
 
A1 A1 A1 A1 A1 A1 
 
Disease-related financial 
burden in the medium 
term 
 
A1 A1/A2 A1 A1 A1 A1/A3 
 
Treatment-related 
adverse effects 
 
A3 A3 A3 A3 A3 A3 
Quality of the health 
care experience from 
start of treatment until 
the medium term 
A3 A3 A3 A3 A3 A3 
 
From Table 3.9, for criteria cure for cancer, life expectancy, and quality of life in the 
medium term option A1 is systematically the highest performing option. For criterion 
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disease-related financial burden in the medium term, this is the case in four out of 
seven consultations. Conversely, for criteria treatment-related adverse effects and 
quality of the health care experience from start of treatment until the medium term 
option A3 is systematically the highest performing option. Except for disease-related 
financial burden in the medium term, option A2 systematically scores between option 
A1 and option A3.  
From the above information, the ranking of the options will depend on the relative 
weights assigned by each proxy patient to the criteria. This information is described 
in Figure 3.9. 
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Figure 3.9. Criteria weights assigned by the proxy patients in the hypothetical 
consultations 
 
 
From Figure 3.9, top panel, the proxy patients using the Expert Choice-based PDA in 
hospital H1 assigned lower weights to the criteria for which option A3 was the most 
preferred, and higher weights to the criteria for which option A1 was the most 
preferred. Hence the resulting rankings. From Figure 3.9, bottom panel, the weights 
assigned to the criteria by the proxy patients using the ALEL-based PDA in hospital 
H2 were more evenly distributed, increasing the likelihood that option A3 was ranked 
highest compared to the hypothetical consultations in hospital H1. In particular, 
proxy patient 1 assigned comparatively high weights to two criteria, quality of the 
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health care experience between the start of treatment and the medium term and 
treatment-related adverse effects, for which option A3 was the most preferred. This 
led to A3 ranking higher than A2 in the case of this proxy patient. 
6.4. Exploring the robustness of the overall results in the Expert Choice-based 
PDA and the ALEL-based PDA to the independence of irrelevant alternatives. 
Recall from Chapter 1 that MCDA approaches such as the AHP and SAW which rely 
on the normalization of single-criterion scores could lead to rank reversals when 
options are added to or subtracted from the set of options under consideration. Since 
both the Expert Choice-based PDA and the ALEL-based PDA rely on such 
normalization procedures, it is important to test the impact of adding and subtracting 
alternatives on the ranking and the overall scores of the options.  
Following Belton and Gear [188], an exact copy of option A2, concurrent chemo-
radiotherapy, termed option A2* was added to each of the models used in the 
hypothetical consultations. The impact of this addition on the ranking of the options 
and on their overall scores were explored. In addition, the impact of subsequently 
eliminating option A2 and option A3, best supportive care, on the rankings and 
overall scores was also explored. The results of these three tests are described in, 
respectively, Table 3.10, Table 3.11 and Table 3.12. 
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Table 3.10. Impact on rankings and overall scores of adding option A2* to the set of 
options 
 Hypothetical 
consultations in Hospital 
H1 
Hypothetical 
consultations in hospital 
H2 
 
1 
 
2 
 
3 
 
1 
 
2 
 
3 
 
Alteration in original 
ranking 
 
 
None 
 
None 
 
None 
 
None 
 
None 
 
None 
 
% change in relative 
overall score of option A2 
with respect to option A1 
 
 
-1.2% 
 
-0.3% +0.0% +0.0% +0.0% +0.0% 
 
% change in relative 
overall score of option A3 
with respect to option A1 
 
+2.3% +7.7% -2.6% +0.0% +0.0% +0.0% 
 
From Table 3.10, the addition of an exact copy of Option A2 did not have any 
undesirable effect on the original rankings of the options obtained in the hypothetical 
consultations. For the Expert Choice-based PDA (implementing the AHP), the 
relative overall scores of options A2 and A3 with respect to option A1 changed by 
small amounts. For the ALEL-based PDA (implementing SAW with Annalisa), there 
were no changes in the relative overall scores of options A2 and A3 with respect to 
option A1 
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Table 3.11. Impact on rankings and overall scores of subtracting option A2 from the 
set of options 
 Hypothetical consultations 
in Hospital H1 
Hypothetical consultations 
in hospital H2 
 
1 
 
2 
 
3 
 
1 
 
2 
 
3 
 
Alteration in original 
ranking 
 
None None None None None None 
 
% change in relative 
overall score of option 
A3 with respect to 
option A1 
 
 
+3% 
 
+9% -2.1% -2.0% +0.0% -5% 
 
From Table 3.11, the deletion of option A2, concurrent chemo-radiotherapy, did not 
affect the original rankings in any of the hypothetical consultations. The relative 
score of option A3 with respect to A1 changed over a larger range for the Expert 
Choice-based PDA than for the ALEL-based PDA. 
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Table 3.12. Impact on rankings and overall scores of subtracting option A3 from the 
set of options 
 Hypothetical 
consultations in Hospital 
H1 
Hypothetical 
consultations in hospital 
H2 
 
1 
 
2 
 
3 
 
1 
 
2 
 
3 
 
Alteration in original ranking 
 
 
None 
 
None 
 
None 
 
None 
 
None 
 
None 
 
% change in relative overall 
score of option A2 with respect 
to option A1 
-3% -1% +0% +6.5% +1% +1.7% 
 
From Table 3.12, the deletion of option A2, concurrent chemo-radiotherapy, did not 
affect the original rankings in any of the hypothetical consultations. The relative 
score of option A3 with respect to A1 changed over a larger range for the ALEL-based 
PDA than for the Expert Choice-based PDA. 
Overall, the tests performed show that in this study the results were robust to the 
addition of an irrelevant alternative and to the subtraction of options. However, there 
were some changes in the relative scores of the options in the set under consideration 
when options were added to or subtracted from to the set of options. While this did 
not lead to illogical results in this particular study, such illogical results could arise in 
situations where the overall scores of the options are very similar. Note that in the 
AHP and SAW with Annalisa, the scales on which the overall scores of the options 
are defined are ratio scales, not interval scales. With ratio scales, differences in 
overall scores are not meaningful so preference differences of the remaining 
alternatives were not calculated. 
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6.5. Implications for clinical practice. 
In this study, the delivery of the Expert Choice-based PDA and of the ALEL-based 
PDA in clinical consultations was undertaken with proxy patients (non-clinical 
members of hospital staff) who were healthy individuals. This fact may have biased 
the choice of clinical management strategy towards the most “aggressive” option, i.e. 
neoadjuvant chemotherapy with resective intent (option A1). Option A1 was the 
option which performed best out of the three clinical management options in criteria 
such as cure for cancer, life expectancy or disease-related quality of life. It was also 
the option which had the strongest treatment-related side effects. The weights 
assigned by the proxy patients to avoiding adverse effects may have underestimated 
the weights assigned by actual Stage IIIA3 non-small cell lung cancer patients to that 
criterion. This possibility helps to highlight that the results of the hypothetical 
consultations (i.e. the scores and rankings of the options) in hospital H1 and hospital 
H2 are not directly relevant to clinical practice.  
Even though the results of the hypothetical consultations cannot be extrapolated to a 
real clinical setting, the experience of delivering the Expert Choice-based PDA and 
the ALEL-based PDA in hypothetical consultations in hospital H1 and hospital H2 
has implications for clinical practice. First, it is feasible to deliver MCDA-based 
PDAs for the clinical management of Stage IIIA3 non-small cell lung cancer in 
routine clinical consultations. However, the delivery steps of the PDAs need to be 
adapted to fit in the time available for consultation with patients. In addition, the 
amount of information presented in the PDA should be limited to a relatively small 
number of criteria in order to facilitate understanding. In this study, information on 
six criteria was well processed by proxy patients. 
The introduction of a MCDA-based PDA for the clinical management of lung cancer 
in routine clinical practice in Spanish NHS hospitals involves a considerable change 
in the way patients make these decisions with support from their clinicians. 
Currently, the prevalent mode of decision making is some form of verbal deliberation 
between the clinician and the patient. With a MCDA-based PDA, all the elements of 
the decision are made explicit in a quantitative fashion. The patient, with support 
from the clinician, follows in a step-wise fashion the MCDA process. Patients are not 
used to make decisions using such a structured, explicit and quantitative decision 
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technologies. The patients will need to be tutored in the basics of the MCDA 
approach, with the subsequent implications in terms of time and other resources. A 
patient recently diagnosed with lung cancer is likely to experience high levels of 
anxiety, which does not facilitate the tutoring process. Issues of limited health 
literacy in older patients (recall that they hypothetical patient is a 69 year old 
individual) will make the tutoring process more difficult. 
In the patient-centered mode of shared decision making, the perspective taken in this 
study, the clinician does not make recommendations, only presents information to the 
patient using the MCDA-based PDA. Using these tools, clinicians will see their role 
as agents for the patient diminish, which will not be acceptable to some of them. 
Patients will see their role as decision makers enhanced, which will not be acceptable 
to some of them. In general, patients expect a personal interaction with the clinician 
(this was highlighted several times by the clinicians participating in this study). Some 
patients will mistrust the use of the MCDA-based PDAs to make such important 
decisions. 
The issues mentioned above place important demands on clinicians. First, they 
require good clinician-patient communication. Second, they require that clinicians 
invest time in supporting patients to make decisions using these tools. Considering 
the workload that clinicians are subject to in routine clinical practice in the Spanish 
NHS, this is likely to limit the feasibility of implementing MCDA-based PDAs in 
practice. 
MCDA is a resource intensive decision technology. It requires more cognitive effort 
and time than verbal deliberation to be implemented, particularly for such a complex 
decision as the clinical management of Stage IIIA3 lung cancer. The limited 
resources available in routine clinical practice may negatively affect the quality of 
decision-making if a particular MCDA-based PDA is not delivered ensuring that 
patients understand well all that is required to help them make the relevant decision 
using this tool.  
The step of preference elicitation is a key part of PDA delivery, as it determines the 
final ranking of the options. Hence, the impact of imprecise weight estimates on the 
overall results should be carefully assessed during the PDA delivery process. 
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Sensitivity analysis plays a very important role in exploring the robustness of the 
results of the decision to imprecise patient preferences.   
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Chapter 4: Using a meta-multi-criteria decision model to make the 
choice between alternative templates for developing and delivering a 
patient decision aid in routine clinical practice. 
 
Chapter 3 described the methods and results related with Objective 2 of this project: 
using two MCDA software applications or templates (i.e. Expert Choice and 
Annalisa in Elicia) differing in the MCDA approach in order to implement, i.e. 
deliver, a PDA in an environment replicating actual clinical consultations. This 
chapter explains the methods and results related with Objective 3 of this research 
project:  
- To build a meta-multi-criteria decision model based on the DRDEA framework and 
assess the use of this model by clinicians in the Spanish NHS to make the choice 
between the two MCDA software applications as the basis for a PDA.  
The Chapter begins with a justification and an overview of the use of the Decision 
Resources-Decision Effectiveness Analysis (DRDEA) framework as the basis for 
choosing the best template for developing and implementing a PDA in routine 
clinical practice. It then presents an overview of the methods used to develop and 
implement, with clinicians in the Spanish NHS, a DRDEA-based meta-decision 
model for the choice between the templates Expert Choice and ALEL for developing 
and delivering a Stage IIIA3 non-small cell lung cancer PDA in the context of routine 
clinical practice. The chapter then describes the process of developing and 
implementing the DRDEA-based meta-model. It ends with a presentation of the 
results of the model implementation and the subsequent commentary. 
1. Decision Resources- Decision Effectiveness Analysis. 
The application of the Decision Resources-Decision Effectiveness Analysis 
(DRDEA) framework to the choice of MCDA software application or template 
proposes that the question of choosing one from a set of templates can be framed as a 
meta-decision problem which is specific to the particular context where the decision 
is made [19]. The decision problem can be represented by two types of criteria: 1) 
decision resources (DR) criteria reflecting the resource requirements associated with 
using each template (e.g. time or cognitive effort required to use the template, as well 
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as the financial cost associated with implementing the template)[19] and 2) decision 
effectiveness (DE) criteria expressing the benefits of using the template (e.g. 
theoretical grounding of the decision-making paradigm underlying the template, or 
strength and coverage of the evidence included in the template) [19]. In DRDEA, the 
decision of choosing between alternative templates is preference sensitive and the 
appropriate analytical technique for making this decision is Multi-Criteria Decision 
Analysis (MCDA) [19]. 
The author of this thesis acknowledges that there are other approaches than DRDEA 
for the task of selecting decision support software applications. For example, those of 
Le Blanc and Jelassi [231], Ossadnik and Lange [232] and Phillips-Wren et al. [233], 
all of which have been described in Chapter 1. DRDEA however, is appropriate in 
the context of this research study because it highlights that the choice between 
templates for developing and implementing a PDA in routine clinical practice can 
involve making trade-offs between DR and DE criteria. To illustrate with a basic 
example, consider the choice, for that task, between a template implementing Multi-
Attribute Utility Theory (MAUT) a la Keeney and Raiffa [11] and a template 
implementing Simple Additive Weighting (SAW). The first template will achieve 
high levels of DE as it has a strong grounding in axioms of rational decision making, 
while the second will achieve low levels of DE as it does not have such axiomatic 
grounding. At the same time, the elicitation of inputs to the decision model in the 
case of the first template will require a substantial amount of cognitive effort and 
time, while this will not be the case in the case of the second template. In a context, 
such as that of routine clinical practice, where time and other resources are scarce, 
exploring these trade-offs is important.  
There are parallels between DRDEA and cost-effectiveness analysis (CEA) [19]. 
CEA explores the trade-off between cost and effectiveness for the “adoption 
decision”, i.e. for choosing which health care interventions a health system should 
adopt. DRDEA explores trade-offs between decision resources and decision 
effectiveness for the “decision decision”, i.e. deciding how to decide.  
  
210 
 
2. Overview of methods. 
The development and implementation of a DRDEA-based meta-decision model for 
the choice between Expert Choice and Annalisa in Elicia (ALEL) as the basis for 
developing and implementing a Stage IIIA3 non-small cell lung cancer PDA 
followed the following steps:  
1. Three clinicians - one pulmonologist (clinician 1), one oncologist (clinician 2), one 
thoracic surgeon (clinician 3) were recruited from hospital Son Dureta (hospital H3) 
in Palma de Mallorca; 
2. The author of this study, with support from the three clinicians, developed the 
DRDEA-based meta-decision model using Multi-Attribute Value Theory (MAVT) 
and the template HiView 3; 
3. The DRDEA MAVT model was implemented with the three clinicians from 
hospital H3. 
The DRDEA-based meta-MCDM was developed as proof of concept. The purpose 
was to test the feasibility of the DRDEA framework in its application to the choice of 
decision support system. 
3. Developing and implementing the meta-decision model. 
3.1. Developing the meta-decision model. 
As mentioned in the previous section, the meta-decision model was developed using 
Multi-Attribute Value Theory (MAVT) and the template HiView 3. The decision 
maker was a hypothetical clinician in charge of developing a PDA, assumed to be the 
head of a clinical department in a hospital of the Spanish NHS.  
The decision question was: 
- Which is the best template to develop and deliver a MCDA-based PDA for treating 
a 69 year old male patient with Stage IIIA3 NSCLC (TNM stage T2N2M0) and 
cardiovascular and lung comorbidities? 
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The local decision options under consideration were: Expert Choice (option A1) and 
Annalisa in Elicia (ALEL) (option A2).  
The global decision options included options 𝐴1, 𝐴2 and the following frequently 
used templates: Logical Decisions, HiView 3, V.I.S.A. Decisions and Web-HIPRE.  
The first step in developing the meta-MCDM was defining the relevant hierarchy of 
decision effectiveness (DE) and decision resources (DR) criteria for choosing 
between the alternative templates. This step was entirely undertaken by the present 
author. For this proof-of-concept meta-model, the present author decided that no 
more than eleven bottom-level DE and DR criteria were to be used in the decision 
hierarchy of the meta-decision model.  
The second step in developing the meta-decision model was calculating the value 
scores of the two templates on each of the bottom-level criteria of the defined 
hierarchy. For some of the DE and DR criteria, the scoring of the options was 
undertaken by the researcher. For some of the DE and DR criteria, this step was 
undertaken by this researcher in collaboration with each of the three clinicians from 
hospital H3. Global scales were used to define each of the single-attribute value 
functions of the bottom-level criteria of the hierarchy. The use of global scales 
defined each single-attribute value function in tems of the global options considered 
in the previous section. This ensured that the meta-decision model could be used 
with decision options other than (or in addition to) Expert Choice and ALEL.  
The following sections describe in detail the resulting meta-decision model. 
3.1.1. Determining the relevant decision effectiveness and decision resources 
criteria 
One decision effectiveness criterion and three decision resources criteria were used 
in the meta-decision model: 
1. Normativity in the development of the PDA (DE criterion); 
2. Practicality in the delivery of the of the PDA (DR criterion); 
3. Ease of use of the template (DR criterion); 
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4. Acceptability of the PDA (DR criterion). 
Each of these four criteria were defined in terms of sub-criteria, as described below. 
3.1.1.1. Defining normativity in the development of the MCDA-based PDA. 
This DE criterion was defined in terms of a hierarchy of sub-criteria with two levels. 
Level 1 of the hierarchy was composed of three sub-criteria:  
1. Normativity in the structure of the decision model. This sub-criterion is defined as 
the extent to which the MCDA template is able to incorporate a well-constructed set 
of criteria in the PDA, i.e. a set of criteria built according to best practice standards. 
These best practice standards require the criteria to fulfil the properties of 
completeness, operationality, decomposability, absence of redundancy, and 
minimum size. For a complex decision like the choice of Stage IIIA3 non-small cell 
lung cancer treatment, it is very likely that a well-constructed set of criteria will be 
hierarchical.  
2. Normativity in the preference elicitation, defined as the extent to which the 
template is able to incorporate in the PDA a preference elicitation methodology 
which reaches normative standards of quality. This criterion was defined in terms of 
the following two sub-criteria: 
2.1. Logical consistency of the preferences, defined as the extent to which the 
template is able to incorporate in the PDA a preference elicitation technique which 
produces preferences that are logically consistent.  
Logically consistent preferences are generated by preference elicitation techniques 
which are based on models consistent with rational axioms of decision making. For 
example, preference elicitation techniques based on MAVT/MAUT. For an in-depth 
description of these axioms, see Dyer and Keeney and Raiffa; 
2.2. Empirical accuracy of the preferences, defined as the extent to which the 
template is able to incorporate in the PDA a preference elicitation technique which 
produces preferences that are empirically accurate.  
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Empirically accurate preferences are obtained by a preference elicitation technique 
when these preferences correspond to the decision maker’s true preferences. 
However, it is very difficult to objectively know a decision maker’s true preferences 
as they are inherently subjective. In addition, they may not be defined or stable. They 
may indeed be constructed as the decision maker considers a specific decision 
situation. Assuming that these true preferences exist, establishing their empirical 
accuracy is not a straightforward task because it is difficult to find external/objective 
criteria for validating a given preference elicitation procedure. There are different 
approaches to testing the experimental validity of multi-criteria preference elicitation 
procedures using second-best strategies to objective empirical validation, such as 
convergent, predictive and axiomatic validation. von Winterfeldt and Edwards 
provide a summary of these approaches as they were used to test the experimental 
validity of MAUT.  
The use of second-best experimental validation approaches such as those mentioned 
above has shown that MAUT approaches have at least partial experimental validity 
A similar case is argued by Saaty for the AHP However, these approaches have not 
set a gold standard for which preference elicitation method yields empirical accuracy 
of the preferences. In a sense, it remains to the decision maker to determine this gold 
standard, and to measure against this gold standard the extent to which a given 
template is able to incorporate into the PDA a preference elicitation procedure that 
achieves (or is close to) this standard. For the purposes of this thesis, the opinion of 
this researcher is that MAVT/MAUT, due to a more detailed exploration of the 
decision maker’s preferences compared to AHP, is the best practice standard 
regarding the empirical accuracy of the preferences. 
3. Normativity in the evidence generation/ representation, defined as the extent to 
which the template is able to represent in the PDA the best available evidence in 
detail for all the bottom-level decision criteria of a decision hierarchy. The best 
estimates of the impact of the clinical options on the decision criteria might come, for 
different criteria, from different sources. Highest quality sources include clinical 
trials and systematic reviews/meta-analyses. For some (perhaps many) criteria there 
will be no such high quality (or indeed lower quality) studies that may supply these 
evidence estimates. In these cases, the best available evidence comes from 
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methodologically sound approaches to eliciting the relevant estimates from experts. 
Templates that score highly in this criterion must be able to represent the best 
evidence of the decision alternatives in detail for all the bottom-level decision criteria 
of a decision hierarchy. These templates will be hierarchical templates. 
Figure 4.1 shows the parent criterion normativity in the development of a template-
based PDA and its sub-criteria. 
Figure 4.1. Normativity in the development of a MCDA-based PDA: parent criterion 
and sub-criteria 
 
 
3.1.1.2. Defining practicality in the delivery of the template-based PDA. 
The DR criterion practicality in the delivery of the template-based PDA was defined 
in terms the following three sub-criteria:  
1. Practicality in the communication of the model structure and outputs, defined as 
the extent to which it is practical, using the template-based PDA, to explain to the 
patient the model structure (i.e. the set of decision criteria relevant for the clinical 
decision) and the model outputs (i.e. the aggregate scores of the options) within the 
constraints of the time available in the consultation. 
2. Practicality in the preference elicitation, defined as the extent to which it is 
practical, using the template-based PDA, to elicit the patient’s preferences for the 
different criteria within the time constraints of a clinical consultation. 
Normativity in the 
development of the 
template-based PDA
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preferences
Empirical accuracy of the 
preferences
𝐶4
𝑏  
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Normativity in the evidence 
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3. Practicality in the communication of the evidence, defined as the extent to which 
the evidence can be explained to the patient using the template-based PDA within the 
time constraints of a clinical consultation. 
Figure 4.2 shows the parent criterion practicality in the delivery of the template-
based PDA and its sub-criteria. 
Figure 4.2. Practicality in the delivery of the template-based PDA: parent criterion 
and sub-criteria 
 
3.1.1.3. Defining ease of use of the template interface.  
Ease of use of the template interface, a DR criterion, was defined in terms of the 
following sub-criteria: 
1. Ease of use of the template interface by clinicians, defined as the extent to which 
clinicians will be able to use the interface of a PDA developed using the template 
with a reasonable and acceptable amount of training; 
2. Ease of use of the template interface by patients, similarly defined as the extent to 
which patients will be able to use the interface of a PDA developed using the 
template with a reasonable and acceptable amount of training. 
Figure 4.3 shows the parent criterion ease of use of the template interface and its sub-
criteria. 
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Figure 4.3. Ease of use of the template interface: parent criterion and sub-criteria 
 
 
3.1.1.4. Defining acceptability of the template-based PDA. 
Acceptability of the template-based DA, another DR criterion, is defined in terms of 
two sub-criteria: 
1) Cost of the template, in terms of the cost of a single-user license. 
2) Organisational fit of the template-based PDA. This criterion is defined as the 
extent to which other clinicians in the department perceive that a PDA based on the 
template will be suited for use in day-to-day clinical practice. 
Figure 4.4 shows the parent criterion acceptability of the template-based PDA and its 
sub-criteria. 
Figure 4.4. Acceptability of the template-based PDA: parent criterion and sub-
criteria 
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3.1.1.5. Full hierarchy of decision criteria for the meta-decision model. 
Figure 4.5 shows the final model structure for the meta-decision model. In Figure 
4.5, note that the eleven bottom-level criteria are highlighted in red colour and 
assigned the notation 𝐶𝑘(𝑏)(𝑘 = 1 … 11). 
Figure 4.5. Full hierarchy of decision criteria for the meta-decision model 
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3.2. Calculating the value scores of the two templates on the bottom-level 
criteria 
The scores of the two templates 𝐴𝑖  (𝑖 = 1,2), that is Expert Choice and ALEL, on the 
eleven bottom-level criteria 𝐶𝑘(𝑏) (𝑘 = 1 … 11) were value scores 𝑣𝑖,𝑘 (𝑖 = 1,2; 𝑘 =
1 … 11) on eleven single-criterion value functions. The first stage in calculating these 
scores for each bottom-level criterion was to build the relevant single-criterion value 
function. This required the following steps: 
1. Defining the variable 𝑥𝑖,𝑘 (𝑖 = 1 … 𝑛) describing the levels of all templates 𝐴𝑖  (𝑖 =
1 … 𝑛) available locally or globally on criterion 𝐶𝑘(𝑏); 
2. Assigning value scores 𝑣𝑖,𝑘 (𝑖 = 1 … 𝑛) to all the levels of any template 𝐴𝑖 (𝑖 =
1 … 𝑛) available locally or globally on criterion 𝐶𝑘(𝑏). 
For ease of explanation, each single-criterion value function will be illustrated using 
a diagram. The generic elements of each diagram are illustrated in Figure 4.6. 
Figure 4.6. Example of a diagram illustrating each of the single-criterion value 
functions for criteria 𝐶𝑘(𝑏)(𝑘 = 1 … 11) 
 
Criterion name 
1 = LOW
2 = INTERMEDIATE
3 = HIGH
V(1) = v(LOW) =0
V(2) = v(INTERMEDIATE) = 0.5
V(3) = v(HIGH) =1 1
0
0.5
Variable describing the possible levels 
of all locally and globally available MCDA templates
on criterion .
For example, for a variable describing three possible
levels on criterion (low, intermediate, high), 
then 
Possible levels
on criterion .
V
of the possible levels on 
criterion .
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As shown in Figure 4.6, at the top of each diagram describing each criterion’s single-
attribute value function is the variable defining the possible levels on that criterion. 
Below it on the left is a description of these different levels. Below it on the right is a 
description (including a 0-1 numerical scale) of the value scores associated with 
these levels. 
The second step in calculating the value scores of the two MCDA templates 𝐴𝑖(𝑖 =
1,2) on each criterion 𝐶𝑘(𝑏) involved calculating the levels 𝑥𝑖,𝑘 (𝑖 = 1,2) of the two 
options. Mapping these performance levels on the relevant value function led 
immediately to the value scores 𝑣𝑖,𝑘 (𝑖 = 1,2) of the two options.  
The process is now described for each bottom-level criterion. 
3.2.1. Normativity in the model structuring (𝑪𝟏(𝒃)). 
Normativity in the model structuring was previously defined as the extent to which a 
template allowed to incorporate in the PDA a well-constructed hierarchy according 
to the best practice standards. These best practice standards require the set of 
decision criteria to fulfil the properties of completeness, operationality, 
decomposability, absence of redundancy, and minimum size. To achieve 
decomposability, it is important that the template allows for 1) preferences to be 
expressed for different levels of any particular criterion (as is done in 
MAUT/MAVT) and for 2) the set of criteria to be expressed as a hierarchy. Figure 
4.7 shows the value function for this criterion. 
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Figure 4.7. Value function for criterion normativity in the model structuring (𝐶1(𝑏))  
 
 
Looking at Figure 4.7, note that Expert Choice is a hierarchical template but not 
MAUT/MAVT-based, and that ALEL is neither. Table 4.1 shows the corresponding 
levels of the two templates on this criterion and their value scores.  
Table 4.1. Levels 𝑥𝑖,1(𝑖 = 1,2) and value scores 𝑣𝑖,1(𝑖 = 1,2) of the two templates 
𝐴𝑖  (𝑖 = 1,2) on criterion normativity in the model structuring (𝐶1(𝑏)) 
  
Option 
 
 
𝒙𝒊,𝟏 
 
𝒗𝒊,𝟏 
 
Expert Choice (𝐴1) 
 
 
2 
 
0.5 
 
ALEL (𝐴2) 
 
 
 
1 
 
0 
 
  
1 = LOW
The template does not satisfy 
either P1 or P2
2 = INTERMEDIATE
The template satisfies either P1 
or P2, but not both
3 = HIGH
The template satisfies both of 
the following properties:
P1) It is a hierarchical template
P2) It is based on MAUT/MAVT 
V(1) = v(LOW) =0
V(2) = v(INTERMEDIATE) = 0.5
V(3) = v(HIGH) =1 1
0
0.5
Possible levels
on criterion .
V
of the possible levels on 
criterion .
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3.2.2. Logical consistency of the preferences (𝑪𝟐(𝒃))  
Logical consistency of the preferences was defined as the extent to which a template 
allowed to incorporate in the PDA a preference elicitation technique which is in 
accordance with the best standards of decision making. Such standards are the 
axioms of rational behaviour of MAUT/MAVT. Figure 4.8 shows the value function 
for this criterion. 
Figure 4.8. Value function for criterion logical consistency of the preferences  
(𝐶2(𝑏))  
 
 
Expert Choice’s preference elicitation technique (pair-wise comparisons of relative 
importance of the criteria) is based on rules of rational behaviour that ensure the 
consistency of the patient’s preferences (as measured by the consistency index) but 
not on the axioms of MAUT/MAVT. ALEL’s relative importance weight elicitation 
technique is based on no explicit rules of rational behaviour. Table 4.2 shows the 
corresponding levels and value scores of the two templates on this criterion.  
  
1 = LOW
The template uses a PE which is 
not based on any explicit rule of 
rational behaviour 
2 = INTERMEDIATE
The template uses a PE which is 
based on rules of rational 
behaviour but nor on the axioms 
of MAUT/MAVT 
3 = HIGH
The template uses a preference 
elicitation technique (PE) which is 
based on the axioms of rational 
behaviour of MAUT/MAVT 
V(1) = v(LOW) =0
V(2) = v(INTERMEDIATE) = 0.5
V(3) = v(HIGH) =1 1
0
0.5
Possible levels
on criterion .
V
of the possible levels on 
criterion .
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Table 4.2. Levels 𝑥𝑖,2(𝑖 = 1,2) and value scores 𝑣𝑖,2(𝑖 = 1,2) of the two templates 
𝐴𝑖  (𝑖 = 1,2) on criterion logical consistency of the preferences  (𝐶2(𝑏)) 
  
Option 
 
 
𝒙𝒊,𝟐 
 
𝒗𝒊,𝟐 
 
Expert Choice (𝐴1) 
 
 
2 
 
0.5 
 
ALEL (𝐴2) 
 
 
 
1 
 
0 
 
3.2.3. Empirical accuracy of the preferences (𝑪𝟑(𝒃)).  
This criterion was defined as the extent to which a template allows to incorporate in 
the PDA a preference elicitation technique which is empirically accurate. The 
empirical accuracy of the preferences is a concept not possible to measure directly. 
This researcher considered that one first level of empirical accuracy of the 
preferences was determined by whether or not there was some (indirectly measured) 
published evidence that a particular preference elicitation technique generated 
reasonably accurate preferences. This was the case for the preference elicitation 
techniques of MAUT/MAVT and the AHP. To discriminate whether MAUT/MAVT 
generated more empirically accurate judgments than AHP (or other approaches) was 
only possible making a subjective judgment. This researcher considered that 
MAUT/MAVT preference elicitation techniques generate more empirically accurate 
preferences because they explore patient preferences more thoroughly than other 
methods. Figure 4.9 shows the value function for this criterion. 
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Figure 4.9. Value function for criterion empirical accuracy of the preferences  
(𝐶3(𝑏))  
 
 
While there is some evidence in the literature that the preferences generated by the 
AHP (which is used by Expert Choice) are empirically accurate there is not for 
ALEL. Table 4.3 shows the corresponding levels and value scores of the two 
templates.  
Table 4.3. Levels 𝑥𝑖,3(𝑖 = 1,2) and value scores 𝑣𝑖,3(𝑖 = 1,2) of the two templates 
𝐴𝑖  (𝑖 = 1,2) on empirical accuracy of the preferences  (𝐶3(𝑏))   
  
Option 
 
 
𝑥𝑖,3 
 
𝑣𝑖,3 
 
Expert Choice (𝐴1) 
 
 
2 
 
0.5 
 
ALEL (𝐴2) 
 
 
 
1 
 
0 
 
1 = LOW
The template uses a PE for which 
there is no evidence available that 
it generates empirically accurate 
preferences 
2 = INTERMEDIATE
The template uses a PE for which 
there is some evidence in the 
literature that it generates 
empirically accurate preferences 
3 = HIGH
The template uses a preference 
elicitation technique (PE) which is 
based on MAUT/MAVT 
V(1) = v(LOW) =0
V(2) = v(INTERMEDIATE) = 0.5
V(3) = v(HIGH) =1 1
0
0.5
Possible levels
on criterion .
V
of the possible levels on 
criterion .
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3.2.4. Normativity in the evidence generation/ representation (𝑪𝟒(𝒃))  
This criterion was defined as the extent to which a template allows for the 
representation, in the PDA, of the best available evidence on all the bottom-level 
criteria of the decision model structure. The requirement to achieve this is that the 
template is hierarchical. Figure 4.10 shows the value function for this criterion. 
Figure 4.10. Value function for criterion normativity in the evidence generation/ 
representation (𝐶4(𝑏))  
 
While Expert Choice is a hierarchical template, ALEL is not. The corresponding 
levels and value scores are shown in Table 4.4.  
Table 4.4. Levels 𝑥𝑖,4(𝑖 = 1,2) and value scores 𝑣𝑖,4(𝑖 = 1,2) of the two templates 
𝐴𝑖  (𝑖 = 1,2) on normativity in the evidence generation/ representation (𝐶4(𝑏))   
  
Option 
 
 
𝑥𝑖,4 
 
𝑣𝑖,4 
 
Expert Choice (𝐴1) 
 
 
2 
 
1 
 
ALEL (𝐴2) 
 
1 
 
0 
 
1 = LOW
The template is not hierarchical 
2 = HIGH
The template is hierarchical 
V(1) = v(LOW) =0
V(2) = v(HIGH) =1 1
0
0.5
V
of the possible levels on 
criterion .
Possible levels
on criterion .
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3.2.5. Practicality in the communication of the model structure and outputs, or 
CMSO (𝑪𝟓(𝒃))  
This criterion measured the degree to which it is practical, during the delivery of the 
PDA, to use a template for explaining to the patient the set of decision criteria and 
the aggregate scores of the options. This depends on the time it takes to perform this 
task. Figure 4.11 shows the value function for this criterion. 
Figure 4.11. Value function for criterion practicality in the communication of the 
model structure and outputs (𝐶5(𝑏))  
 
 
In Figure 4.11, note that there are no specific time durations assigned to each of the 
possible levels on this criterion. Each clinician from hospital H3 was asked to supply 
his/her own estimates of what time duration would make the communication of the 
model structure and outputs 1) highly practical, 2) reasonably practical and 3) 
impractical. From each clinician’s judgments three value functions with three 
different time durations were generated for each level (see Figure 4.12). 
  
1 = LOW
Time duration of the CMSO which 
would be impractical  
3 = HIGH
Time duration of the 
communication of the model 
structure and outputs (CMSO) 
which would be highly practical 
V(1) = v(LOW) =0
V(3) = v(HIGH) =1 1
0
0.5
Possible levels
on criterion .
V
of the possible levels on 
criterion .
2 = HIGH
Time duration of the CMSO which 
would be reasonably practical  
V(2) = v(INTERMEDIATE) =0.5
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Figure 4.12. Clinician-specific value functions for criterion practicality in the 
communication of the model structure and outputs (𝐶5(𝑏))  
 
 
 
1 = LOW
The CMSO is impractical if its time 
duration is more than 8 minutes
3 = HIGH
The communication of the model 
structure and outputs (CMSO) is 
highly practical if its time duration 
is less than 5 minutes 
V(1) = v(LOW) =0
V(3) = v(HIGH) =1 1
0
0.5
Possible levels
on criterion .
V
of the possible levels on 
criterion .
2 = INTERMEDIATE
The CMSO is reasonably practical 
if its time duration is between 5 
minutes and 8 minutes
V(2) = v(INTERMEDIATE) =0.5
1 = LOW
The CMSO is impractical if its time 
duration is more than 10 minutes
3 = HIGH
The communication of the model 
structure and outputs (CMSO) is 
highly practical if its time duration 
is less than 7 minutes 
V(1) = v(LOW) =0
V(3) = v(HIGH) =1 1
0
0.5
2 = INTERMEDIATE
The CMSO is reasonably practical 
if its time duration is between 7 
minutes and 10 minutes
V(2) = v(INTERMEDIATE) =0.5
CLINICIAN 1
CLINICIAN 2
1 = LOW
The CMSO is impractical if its time 
duration is more than 15 minutes
3 = HIGH
The communication of the model 
structure and outputs (CMSO) is 
highly practical if its time duration 
is less than 10 minutes 
V(1) = v(LOW) =0
V(3) = v(HIGH) =1 1
0
0.5
2 = INTERMEDIATE
The CMSO is reasonably practical 
if its time duration is between 10 
minutes and 15 minutes
V(2) = v(INTERMEDIATE) =0.5CLINICIAN 3
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As a proxy of the levels of the two templates on this criterion, the following were 
used: 1) the hypothetical duration of the CMSO using the Expert Choice-based PDA 
if instead of six top-level criteria all of the criteria had been included in the PDA; 2) 
the duration of the CMSO using the ALEL-based PDA. 
With respect to 1) the hypothetical duration of the CMSO using the Expert Choice-
based PDA if instead of six top-level criteria all of the criteria had been included in 
the PDA, from Chapter 3, the CMSO for the Expert Choice-based PDA (with six 
criteria) took twelve, fourteen, and ten minutes in the hypothetical consultations in 
hospital H1. These time durations would be at least double if the Expert Choice-
based PDA included all twenty four criteria. Such time durations would be 
impractical according to the three clinicians from hospital H3 (see Figure 4.12). 
With respect to 2) the duration of the CMSO using the ALEL-based PDA, the CMSO 
for the ALEL-based PDA took seven, eight, and nine minutes in each of the three 
hypothetical consultations in hospital H2. That is, an average of 8 minutes. From 
Figure 4.11, the level of practicality corresponding to eight minutes was judged by 
each of the three clinicians in H3 to be, respectively, reasonably practical, reasonably 
practical and highly practical (see Figure 4.12).    
Table 4.5 shows the levels of practicality above and the associated value scores. 
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Table 4.5. Levels 𝑥𝑖,5(𝑖 = 1,2) and value scores 𝑣𝑖,5(𝑖 = 1,2) of the two templates 
𝐴𝑖  (𝑖 = 1,2) on criterion practicality in the communication of the model structure 
and outputs (𝐶5(𝑏))  
  
Option 
 
 
𝑥𝑖,5 
 
𝑣𝑖,5 
  
Clinician 1 
 
 
Clinician 2 
 
Clinician 3 
 
Clinician 1 
 
Clinician 2 
 
Clinician 3 
 
Expert 
Choice (𝐴1) 
 
 
1 
 
1 
 
1 
 
0 
 
0 
 
0 
 
ALEL (𝐴2) 
 
 
2 
 
 
 
2 
 
3 
 
0.5 
 
0.5 
 
1 
 
3.2.6. Practicality in the preference elicitation, or PE (𝑪𝟔(𝒃))  
This criterion was defined as the degree to which it is practical to use a template for 
eliciting the patient’s preferences for the different criteria. This depends on the time 
it takes to perform the preference elicitation task during the delivery of the template-
based PDA. Each clinician from hospital H3 was asked to supply his/her own 
estimates of what time duration would make the preference elicitation 1) highly 
practical, 2) reasonably practical and 3) impractical. The three resulting value 
functions are shown in Figure 4.13. 
 
  
229 
 
Figure 4.13. Clinician-specific value functions for criterion practicality in the 
preference elicitation ((𝐶6(𝑏)) 
 
 
As before, 1) the hypothetical duration of the PE using the Expert Choice-based PDA 
if instead of six top-level criteria all of the criteria had been included in the PDA and 
1 = LOW
The CMSO is impractical if its time 
duration is more than 8 minutes
3 = HIGH
The preference elicitation (PE) is 
highly practical if its time duration 
is less than or equal to 5 minutes 
V(1) = v(LOW) =0
V(3) = v(HIGH) =1 1
0
0.5
2 = INTERMEDIATE
The PE is reasonably practical if its 
time duration is more than 5 
minutes and less than or equal to 
8 minutes
V(2) = v(INTERMEDIATE) =0.5
1 = LOW
The PE is impractical if its time 
duration is more than 10 minutes
3 = HIGH
The preference elicitation (PE) is 
highly practical if its time duration 
is less than or equal to 5 minutes 
V(1) = v(LOW) =0
V(3) = v(HIGH) =1 1
0
0.5
2 = INTERMEDIATE
The PE is reasonably practical if its 
time duration is more than 5 
minutes and less than or equal to 
10 minutes  
V(2) = v(INTERMEDIATE) =0.5
CLINICIAN 1
CLINICIAN 2
1 = LOW
The PE is impractical if its time 
duration is more than 15 minutes
3 = HIGH
The preference elicitation (PE) is 
highly practical is less than or 
equal to 10 minutes 
V(1) = v(LOW) =0
V(3) = v(HIGH) =1 1
0
0.5
2 = INTERMEDIATE
The PE is reasonably practical if its 
time duration is more than 10 
minutes and less than or equal to 
15 minutes
V(2) = v(INTERMEDIATE) =0.5CLINICIAN 3
Possible levels
on criterion .
V
of the possible levels on 
criterion .
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2) the duration of the PE using the ALEL-based PDA were used as proxies for the 
level of the two templates on this criterion. 
From Chapter 3, the PE for the Expert Choice-based PDA (with six criteria) took 
twenty, twelve, and twenty-two minutes in the hypothetical consultations in hospital 
H1. These time durations would be much higher if the twenty-four criteria of the 
Stage IIIA3 NSCLC clinical management decision hierarchy were included in the 
PDA. According to the three clinicians from hospital H3, such time durations are 
impractical (see Figure 4.13). 
In the hypothetical consultations with the ALEL-based PDA in hospital H2, the time 
duration of the PE was four, five, and six minutes (or five minutes on average). The 
three clinicians in H3 judged such a time duration to be highly practical.    
The levels of practicality above and the associated value scores are shown in Table 
4.6. 
Table 4.6. Levels 𝑥𝑖,6(𝑖 = 1,2) and value scores 𝑣𝑖,6(𝑖 = 1,2) of the two templates 
𝐴𝑖  (𝑖 = 1,2) on criterion practicality in the preference elicitation ((𝐶6(𝑏)) 
  
Option 
 
 
𝑥𝑖,6 
 
𝑣𝑖,6 
  
Clinician 1 
 
 
Clinician 2 
 
Clinician 3 
 
Clinician 1 
 
Clinician 2 
 
Clinician 3 
 
Expert 
Choice (𝐴1) 
 
 
1 
 
1 
 
1 
 
0 
 
0 
 
0 
 
ALEL (𝐴2) 
 
 
3 
 
3 
 
3 
 
1 
 
1 
 
1 
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3.2.7. Practicality in the evidence communication, or EC (𝑪𝟕(𝒃))  
This criterion measured the degree to which it is practical, during the delivery of the 
PDA, to use a template for explaining to the patient the levels of the options on the 
criteria. Practicality depends on the time it takes to perform this task during the 
delivery of the template-based PDA. Each clinician from hospital H3 was asked to 
supply his/her own estimates of what time duration would make the communication 
of the evidence 1) highly practical, 2) reasonably practical and 3) impractical. Figure 
4.14 shows the three clinician-specific value functions. 
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Figure 4.14. Clinician-specific value functions for criterion practicality in the 
preference elicitation ((𝐶7(𝑏)) 
 
 
The levels of the two templates on this criterion were measured using two proxies: 1) 
the hypothetical time duration of the EC in the delivery of the Expert Choice-based 
1 = LOW
The EC is impractical if its time 
duration is more than 15 minutes
3 = HIGH
The evidence communication (EC) 
is highly practical if its time 
duration is less than or equal to 
12 minutes 
V(1) = v(LOW) =0
V(3) = v(HIGH) =1 1
0
0.5
2 = INTERMEDIATE
The EC is reasonably practical if its 
time duration is more than 12 
minutes and less than or equal to 
15 minutes
V(2) = v(INTERMEDIATE) =0.5
1 = LOW
The EC is impractical if its time 
duration is more than 10 minutes
3 = HIGH
The evidence communication (EC) 
is highly practical if its time 
duration is less than or equal to 5 
minutes 
V(1) = v(LOW) =0
V(3) = v(HIGH) =1 1
0
0.5
2 = INTERMEDIATE
The EC is reasonably practical if its 
time duration is more than 5 
minutes and less than or equal to 
10 minutes  
V(2) = v(INTERMEDIATE) =0.5
CLINICIAN 1
CLINICIAN 2
1 = LOW
The EC is impractical if its time 
duration is more than 15 minutes
3 = HIGH
The evidence communication (EC) 
is highly practical if its time 
duration is less than or equal to 
10 minutes 
V(1) = v(LOW) =0
V(3) = v(HIGH) =1 1
0
0.5
2 = INTERMEDIATE
The EC is reasonably practical if its 
time duration is more than 10 
minutes and less than or equal to 
15 minutes
V(2) = v(INTERMEDIATE) =0.5CLINICIAN 3
Possible levels
on criterion .
V
of the possible levels on 
criterion .
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PDA if the evidence had been explained for all the bottom-level criteria and 2) the 
time duration of the EC in the delivery of the ALEL-based PDA.  
From Chapter 3, the time duration of the EC in the delivery of the Expert Choice-
based PDA (with six criteria) was, for each of the three hypothetical consultations in 
H1, seven, seven and eight minutes. With twenty-four bottom-level criteria it would 
be about four times as much, a time considered impractical by the three clinicians in 
hospital H3. The time duration of the EC in the delivery of the ALEL-based PDA 
was, in each of the three hypothetical consultations in hospital H2, four, seven and 
six minutes, or approximately six minutes on average. This time duration was 
considered, respectively, highly, reasonably, and highly practical by the three 
clinicians in hospital H3. 
Table 4.7 shows the levels of practicality above and the associated value scores. 
Table 4.7. Levels 𝑥𝑖,7(𝑖 = 1,2) and value scores 𝑣𝑖,7(𝑖 = 1,2) of the two templates 
𝐴𝑖  (𝑖 = 1,2) on criterion practicality in the preference elicitation ((𝐶7(𝑏)) 
  
Option 
 
 
𝑥𝑖,7 
 
𝑣𝑖,7 
  
Clinician 1 
 
 
Clinician 2 
 
Clinician 3 
 
Clinician 1 
 
Clinician 2 
 
Clinician 3 
 
Expert 
Choice (𝐴1) 
 
 
1 
 
1 
 
1 
 
0 
 
0 
 
0 
 
ALEL (𝐴2) 
 
 
 
3 
 
2 
 
3 
 
1 
 
0.5 
 
1 
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3.2.8. Ease of use of the template interface by clinicians (𝑪𝟖(𝒃))  
This criterion was defined as the degree to which, during the delivery of the PDA, a 
template interface is easy to use by the clinicians. Figure 4.15 shows the value 
function for this criterion. 
Figure 4.15. Value function for criterion ease of use of the template interface by 
clinicians (𝐶8(𝑏))  
 
 
To estimate the levels of the two templates on this criterion, each of the three 
clinicians in hospital H3 was asked to state the percentage of clinicians treating non-
small cell lung cancer (NSCLC) who would be able to use Expert Choice and ALEL 
in the delivery of a Stage IIIA3 NSCLC PDA with a reasonable and acceptable 
amount of training. 
The levels of ease of use for clinicians and their associated value scores are shown in 
Table 4.8. 
  
MINIMUM:
0% of the clinicians treating 
NSCLC would be able to use the 
template interface with 
reasonable and acceptable 
training
MAXIMUM:
100% of the clinicians treating 
NSCLC would be able to use the 
template interface with 
reasonable and acceptable 
training
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on criterion .
V
of the possible levels on 
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Table 4.8. Levels 𝑥𝑖,8(𝑖 = 1,2) and value scores 𝑣𝑖,8(𝑖 = 1,2) of the two templates 
𝐴𝑖  (𝑖 = 1,2) on criterion ease of use of the template interface by clinicians (𝐶8(𝑏))  
  
Option 
 
 
𝑥𝑖,8 
 
𝑣𝑖,8 
  
Clinician 1 
 
 
Clinician 2 
 
Clinician 3 
 
Clinician 1 
 
Clinician 2 
 
Clinician 3 
 
Expert 
Choice (𝐴1) 
 
 
60% 
 
60% 
 
60% 
 
0.6 
 
0.6 
 
0.6 
 
ALEL (𝐴2) 
 
 
 
80% 
 
70% 
 
75% 
 
0.8 
 
0.7 
 
0.7 
 
3.2.9. Ease of use of the template interface by patients (𝑪𝟗(𝒃))  
This criterion was defined as the degree to which, during the delivery of the PDA, a 
template interface is easy to use by the Stage IIIA3 NSCLC patients. Figure 4.16 
shows the value function for this criterion. 
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Figure 4.16. Value function for criterion ease of use of the template interface by 
patients (𝐶9(𝑏))  
 
 
Each of the three clinicians in hospital H3 was asked to state the percentage of Stage 
IIIA3 NSCLC patients who would be able to use Expert Choice and ALEL in the 
delivery of a Stage IIIA3 NSCLC clinical management PDA with a reasonable and 
acceptable amount of training. Table 4.9 shows the levels of ease of use for patients 
and their associated value scores. 
  
MINIMUM:
0% of the Stage IIIA3 NSCLC 
patients would be able to use the 
template interface with 
reasonable and acceptable 
training
MAXIMUM:
100% of the Stage IIIA3 NSCLC 
patients would be able to use the 
template interface with 
reasonable and acceptable 
training
Possible levels
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V
of the possible levels on 
criterion .
0
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Table 4.9. Levels 𝑥𝑖,9(𝑖 = 1,2) and value scores 𝑣𝑖,9(𝑖 = 1,2) of the two templates 
𝐴𝑖  (𝑖 = 1,2) on criterion ease of use of the template interface by patients (𝐶9(𝑏))  
  
Option 
 
 
𝑥𝑖,9 
 
𝑣𝑖,9 
  
Clinician 1 
 
 
Clinician 2 
 
Clinician 3 
 
Clinician 1 
 
Clinician 2 
 
Clinician 3 
 
Expert 
Choice (𝐴1) 
 
 
20% 
 
20% 
 
40% 
 
0.2 
 
0.2 
 
0.4 
 
ALEL (𝐴2) 
 
 
50% 
 
30% 
 
50% 
 
0.5 
 
0.3 
 
0.5 
 
3.2.10. Cost of the template (𝑪𝟏𝟎(𝒃)).  
This criterion was defined as the cost of one user’s license of a template. Table 4.10 
shows the MCDA templates that were taken into account as global options to 
develop the value function for this criterion. 
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Table 4.10. Single user standard licenses available and their cost for six commonly 
used MCDA templates (in year 2013) 
 
MCDA template 
 
 
Type of single-user license 
  
Cost (GBP) 
 
Logical Decisions 
 
 
Full license for version 7.1 
 
577 
 
HiView 3 
 
 
Full license for version 3.2.0.7 
with 1-year user support 
 
 
950 
 
V.I.S.A 
 
 
Full license for V.I.S.A 
standard version 
 
 
295 
 
Expert Choice 
 
 
Full license to Expert Choice 
Desktop 
 
 
1770 
 
ALEL 
 
 
1- year managed hosting 
access to ALEL 
 
 
648 
 
Web-HIPRE 
 
 
No license required 
 
0 
 
Figure 4.17 shows the value function for this criterion. Note that this value function 
is linear. 
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Figure 4.17. Value function for criterion cost of the template (𝐶10(𝑏))  
 
 
Table 4.11 shows the levels of cost and their associated value scores for the Expert 
Choice and ALEL templates. 
Table 4.11. Levels 𝑥𝑖,10(𝑖 = 1,2) and value scores 𝑣𝑖,10(𝑖 = 1,2) of the two 
templates 𝐴𝑖  (𝑖 = 1,2) on criterion cost of the template (𝐶10(𝑏)) 
  
Option 
 
 
𝑥𝑖,10 
 
𝑣𝑖,10 
 
Expert 
Choice (𝐴1) 
 
 
1770 
 
0 
 
ALEL (𝐴2) 
 
647.88 
 
0.63 
 
3.2.11. Organisational fit (𝑪𝟏𝟏(𝒃))  
This criterion is defined as the extent to which clinicians would find it acceptable to 
use a template-based Stage IIIA3 NSCLC clinical management PDA in day-to-day 
clinical practice. To calculate the value scores of the two templates on this criterion, 
each of the three clinicians in hospital H3 was asked to state the percentage of 
clinicians involved in treating NSCLC in their hospital who would find it acceptable 
MINIMUM:
0 GBP (the cost of Web-HIPRE)
MAXIMUM:
1770 GBP (the cost of a full 
license to Expert Choice Desktop)
Possible levels
on criterion .
V
of the possible levels on 
criterion .
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to use an Expert Choice-based and an ALEL-based Stage IIIA3 NSCLC clinical 
management PDA in day-to-day clinical practice. Figure 4.18 shows the value 
function for this criterion. 
Figure 4.18. Value function for criterion organisational fit (𝐶11(𝑏))  
 
 
Table 4.12 shows the levels of organisational fit and their associated value scores for 
the Expert Choice and ALEL templates. 
  
MINIMUM:
0% of the clinicians treating 
NSCLC would find it acceptable to 
use the template-based PDA in 
day-to-day clinical practice 
MAXIMUM:
100% of the clinicians treating 
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use the template-based PDA in 
day-to-day clinical practice
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Table 4.12. Levels 𝑥𝑖,11(𝑖 = 1,2) and value scores 𝑣𝑖,11(𝑖 = 1,2) of the two 
templates 𝐴𝑖  (𝑖 = 1,2) on criterion organisational fit (𝐶11(𝑏)) 
 
Option 
 
 
𝑥𝑖,11 
 
𝑣𝑖,11 
  
Clinician 1 
 
 
Clinician 2 
 
Clinician 3 
 
Clinician 1 
 
Clinician 2 
 
Clinician 3 
 
Expert 
Choice (𝐴1) 
 
 
25% 
 
10% 
 
50% 
 
0.25 
 
0.10 
 
0.50 
 
ALEL (𝐴2) 
 
 
60% 
 
40% 
 
70% 
 
0.60 
 
0.40 
 
0.70 
 
4. Results of solving the meta-MCDM with the three clinicians in hospital H3 
Once the hierarchy of decision effectiveness and decision resource criteria was 
determined and the scores of the two templates were calculated, both were entered 
into HiView 3. There were three versions of the meta-decision model, one for each of 
the three clinicians in hospital H3 – the pulmonologist (clinician 1), the oncologist 
(clinician 2) and the thoracic surgeon (clinician 3). The meta-decison was then 
solved by each of the three clinicians in an individual meeting with this researcher. 
Their task was to assess the swing weights of the criteria. Figures 4.18, 4.19 and 4.20 
show the results of solving the meta-MCDM for each of the three clinicians.  
In the figures, the names of the four top-level criteria of the meta-MCDM hierarchy 
are shortened in the way shown in Table 4.13. 
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Table 4.13. Short names of the meta-decision model criteria 
 
Top-level criteria names 
 
 
Short name 
 
Normativity in the development of the 
template-based PDA 
 
 
NORM_DEV 
 
Practicality in the delivery of the template-
based PDA 
 
 
PRACT_DEL 
 
Ease of use of the template 
 
 
EASE_USE 
 
Acceptability of the template-based PDA 
 
 
ACCEPT 
 
Figure 4.19. Results of the meta-decision model (clinician 1) 
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0.6
0.7
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1 Weighted scores  of the templates on the top-level 
criteria
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Clinician 1 preferred ALEL over Expert Choice to develop and deliver a Stage IIIA3 
non-small cell lung cancer clinical management PDA, although not by a large 
margin. The most important criterion for clinician 1 was normativity in the 
development of the PDA. In Figure 4.19, the bottom left hand panel shows the 
weighted scores of each of the two templates on the top-level criteria. These 
weighted scores combine 1) the weights assigned by clinician 1 to the children 
criteria of these top-level criteria with 2) the scores of the templates on the bottom-
level criteria. Note how Expert Choice greatly outscores (0.64 to 0) ALEL in terms of 
decision effectiveness (represented by the normativity in the development of the 
PDA) while ALEL greatly outscores Expert Choice for two resource criteria 
(practicality in the delivery of the PDA, acceptability by clinicians of a template 
based PDA in day-to-day clinical practice) and somewhat less in the third decision 
resource criterion (ease of use in the template). The bottom-right hand panel in 
Figure 4.19 shows the contribution of each top-level criterion to the final score of the 
template. In switching from one template to another, there is a trade-off between 
normativity in the development of the PDA and practicality in the delivery of the 
PDA. Switching from ALEL to Expert Choice involves forfeiting practicality in the 
delivery of the PDA in exchange for higher normativity. The results were robust to a 
sensitivity analysis on the weights of all the bottom-level decision criteria. 
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Figure 4.20. Results of the meta-decision model (clinician 2) 
 
The results of the meta-decision model using clinician 2’s preferences and value 
functions (where relevant) were quite similar to the results using clinician 1’s 
preferences and value functions (where relevant). From Figure 4.20, top left hand 
panel, ALEL was preferred over Expert Choice, although not by a large margin. 
Again normativity in the development of the PDA was the most important criterion 
in the choice of template. Again a trade-off was evidenced between the decision 
effectiveness criterion and the decision resource criteria when switching across 
templates. Perhaps the main difference was that clinician 2 did not consider that the 
two templates were similar in terms of ease of use in the delivery of the template-
based PDA. The results of the meta-decision model for clinician 2 were robust to 
changes in the weights of the bottom-level criteria. 
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Figure 4.21. Results of the meta-decision model (clinician 3) 
 
 
The pattern that was seen for clinicians 1 and 2 was repeated for clinician 3. ALEL 
was preferred over Expert Choice, although in this case by a larger margin than 
clinician 1 and clinician 2. Interestingly, although clinician 3 attached the highest 
weight of the three clinicians to criterion normativity in the development of the 
template-based PDA, he also attached the highest weight of the three to criterion 
practicality in the delivery of the template-based PDA. In the bottom right hand 
panel of Figure 4.21 note how much criterion practicality in the delivery of the PDA 
contributes to the score of the ALEL template. The results of the meta-decision model 
for clinician 3 were robust to changes in the weights of the bottom-level criteria. 
5. Implications for clinical practice. 
From the above results, the MCDA formulation of the Decision Resources-Decision 
Effectiveness Analysis (DRDEA) framework can be useful to help clinicians choose 
between alternative templates to develop and deliver a Stage IIIA3 non-small cell 
lung cancer PDA in the context of day-to-day clinical practice in the Spanish NHS. 
Specifically, the results of developing and implementing the DRDEA-based meta-
decision model showed with three clinicians from hospital H3 show that the choice 
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of template to develop and implement a PDA indeed involves making trade-offs 
between decision effectiveness and decision resources. This is not a surprising result 
considering the time and other resource constraints that clinicians face in the 
workplace. 
The three clinicians with which the meta-decision model was developed and 
implemented found the use of MAVT with swing weights via the template HiView 3 
straightforward and informative. There is no reason to assume that this approach 
cannot be used by other clinicians for choosing the most appropriate template as the 
basis for a PDA. MAVT is a MCDA methodology with solid axiomatic grounding in 
rational decision making. It is recommended here a “best practice” approach for the 
application of DRDEA to the choice of template as the basis of a PDA. 
The three clinicians from hospital H3 considered that the most important criterion for 
choosing between templates was the normativity in the development of the MCDA-
based PDA. Assuming that other clinicians express similar preferences to the 
clinicians in hospital H3, it is likely that, if resource constraints were not an issue, 
clinicians would choose templates which implement MCDA approaches that allow 
for high level of normativity in the development of a MCDA-based PDA. As defined 
in the proof of concept meta-MCDA model, best practice standards of normativity in 
the development of a MCDA-based PDA correspond to templates which implement 
MAVT/MAUT at the same time that they allow for a hierarchical representation of 
the decision problem. Templates of this type include HiView 3, Logical Decisions, 
and V.I.S.A Decisions. 
However, decision resources as defined in the meta-decision model may impose 
constraints to the desired levels of decision effectiveness in routine clinical practice. 
This may be particularly relevant in the case of complex decisions such as the 
clinical management of cancer. For the particular example researched in this thesis, 
the clinical management of Stage IIIA3 non-small cell lung cancer, the large number 
of criteria considered relevant to the decision by clinicians in hospitals H1 and H2 
was one of the main sources (although not the only one) of decision resource 
constraints. This was evidenced by some of the opinions expressed by the clinicians 
in hospital H3. For example, in terms of practicality in the delivery of the lung cancer 
PDA, the three clinicians in hospital H3 considered that it was impractical to 
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communicate to the patient the twenty-four bottom-level criteria of the hierarchy 
using the Expert Choice-based PDA during the time available in clinical 
consultations. In contrast, two of the clinicians considered that it was reasonably 
practical to communicate the six top-level criteria of the hierarchy using the ALEL-
based PDA, and one considered that it was highly practical. With respect to the 
practicality in the preference elicitation, the three clinicians considered that it was 
impractical for the patient to perform all the required pairwise comparisons for the 
full hierarchy of decision criteria for the Expert Choice-based PDA during the time 
available in a clinical consultation. They considered, however, that it was highly 
practical to elicit preferences over the six top-level criteria of the hierarchy using the 
approach described in the ALEL-based PDA (i.e. first assigning verbal levels of 
importance to the criteria and then adjusting the resulting criteria using sliding bars). 
From these comments it seems clear that developing a hierarchy of criteria of 
minimum size which is still relevant to the decision problem might alleviate some of 
the decision resources constraints imposed on the development and delivery of 
MCDA-based PDAs in routine clinical practice. 
With respect to the ease of use (or lack thereof) of the templates, the three clinicians 
considered that 1) a substantial percentage of clinicians treating non-small cell lung 
cancer (40%) would not find the Expert Choice interface easy to use even with 
training and that 2) between 20% and 30% of clinicians treating non-small cell lung 
cancer would not find the ALEL interface easy to use even with training. These 
percentages increased for the case of patients. The three clinicians considered that 1) 
between 60% and 80% of Stage IIIA3 non-small cell lung cancer patients would not 
find the Expert Choice interface easy to use even with training and that 2) between 
30% and 50% of these patients would not find the ALEL interface easy to use even 
with training. This may indicate that there is more to the use of a MCDA-based PDA 
than adequate and acceptable training in its use. Training in the basic concepts of 
MCDA might also be important. 
Finally, with respect to the acceptability of the templates for use by clinicians in their 
consultations, the three clinicians considered that between 50% and 90% of 
clinicians treating non-small cell lung cancer would not find it acceptable to use the 
Expert Choice PDA in their day-to-day clinical practice. The same three clinicians 
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considered that between 30% and 60% of clinicians treating non-small cell lung 
cancer would not find it acceptable to use the ALEL template in their day-to-day 
clinical practice. Unfortunately, the implications of these statements could not be 
explored with the three clinicians due to lack of time to participate in this project 
beyond the implementation of the meta-decision model. From the literature, there are 
a number of barriers to the implementation of PDAs in clinical practice which could 
play a part in the acceptability of these tools. Clinicians cite scepticism about the 
content of PDAs [105], lack of training in shared decision-making and in the use of 
PDAs [7], concerns about the adequacy of PDAs for some groups of patients (e.g. 
vulnerable patients such as the elderly or patients with little education) [7], and 
competing demands and time constraints [105].  
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Chapter 5: Discussion  
 
1. Main findings 
Undertaken in close collaboration with clinicians in the Spanish NHS, the research 
undertaken in this study established that MCDA is a potentially useful technique for 
the development and implementation, i.e. delivery, using dissimilar templates, of 
MCDA-based interactive patient decision aids. This conclusion was based on the co-
development and co-delivery, with two teams of clinicians from the Spanish NHS, of 
a PDA for the clinical management of Stage IIIA3 (TNM stage T2N2M0) non-small 
cell lung cancer patients using the templates Expert Choice and Annalisa in Elicia 
(ALEL).  
These two versions of the lung cancer PDAs, although based on large hierarchies of 
decision criteria, were successfully developed and delivered, as proof-of-concept, in 
hypothetical consultations replicating actual clinical consultations. 
However, the major but not unsuspected finding was that the use by clinicians of 
alternative templates implementing dissimilar MCDA methods was heavily 
influenced by the resource constraints inherent to day-to-day clinical practice. There 
is a fairly direct  relationship between  higher levels of decision effectiveness (DE) – 
a term which is defined here as the achievement of  normative standards in the 
resulting PDA produced using a specific template, and higher levels of decision 
resources (DR), such as the time and cognitive effort required to deliver the PDA 
produced using that template. The choice by clinicians between 1) templates with 
higher DE/ higher DR (such as Logical Decisions, HiView, or Expert Choice) and 
MCDA templates with lower DE/ lower DR (such as ALEL) may require clinicians to 
trade off DE with DR. Decision Resources-Decision Effectiveness (DRDEA) 
Analysis – a simple transposition of multi-criteria Cost-Effectiveness Analysis to the 
decision process - proposes that this choice can be characterised as a ‘meta-decision’ 
of how to decide to decide. It can therefore be made using a meta-multi-criteria 
decision model (meta-MCDM) comprising a number of relevant DE and DR criteria.  
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To explore the trade-offs made by clinicians between DE and DR in day-to-day 
clinical practice, a DRDEA Multi-attribute Value Theory (MAVT) meta-MCDM 
was developed, as proof of concept, using the MCDA template HiView 3 and was 
solved by three clinicians in the Spanish NHS in the context of a choice between the 
Expert Choice and ALEL templates for developing a PDA for the clinical 
management of Stage IIIA3 non-small cell lung cancer. The application of the 
resulting meta-MCDM with each of the three clinicians from hospital H3 in the 
Spanish NHS showed that the choice between Expert Choice and ALEL for 
developing a non-small cell lung cancer PDA did depend on the preferences of the 
clinicians for trading off 1) decision effectiveness (DE), i.e. the extent to which 
Expert Choice (ALEL) facilitates normativity in the model structuring, the preference 
elicitation, and the evidence generation/ representation incorporated in the eventual 
PDA, in relation to the decision resources (DR), i.e. the practicality, ease of use, and 
acceptability to the organisation of an Expert Choice (ALEL)-based PDA. 
Developing the insights provided by this result we can suggest that clinicians seeking 
to use MCDA templates with higher DE (that is, ones that facilitate the achievement 
of normative standards in the resulting PDA) will confront a ceiling of DR and that 
this ceiling may be too high for some templates to be implementable in their full 
functionality in day-to-day clinical practice. In this research project this was evident 
in the use of Expert Choice to develop a PDA with the team of clinicians from 
hospital H1. To result in a practical, easy to use, and acceptable PDA, the original 
hierarchy of decision criteria had to be collapsed into its top-level criteria (effectively 
paralleling the non-hierarchical template ALEL). The inclusion of the entire 
hierarchy, instead of only its top-level criteria, in the PDA would have accrued a 
higher level of DE in the use of Expert Choice. Perhaps not so much in terms of the 
normativity of the decision model structure (which was not necessarily well-
constructed according to MAVT/MAUT standards – the aim of clinicians being to 
build a model structure that included as many decision criteria as were thought to be 
relevant for the decision problem), but certainly in terms of normativity in the 
preference elicitation and the evidence generation/ representation. With respect to the 
first, the inclusion of the hierarchy in the PDA would have allowed patients to 
express their preferences via pair-wise comparisons of relative importance (a 
preference elicitation technique which generates preferences with reasonable logical 
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consistency and reasonable empirical accuracy) for all pairs of relevant criteria of the 
decision from the bottom-level upwards, rather than just for the top-level criteria. 
With respect to the second, the PDA would have included the evidence of the 
different options with respect to the wider range of bottom-level decision criteria. 
Neither of these potential gains in DE was realisable within the DR threshold (i.e. the 
time constraints of a standard clinical consultation) in the research setting. 
Conceptually, the use of a higher DE template to develop a PDA with a DR threshold 
would only be feasible by sacrificing DE unless clinicians were able to 
operationalize the maximum DE possible within a level of DR that is below the DR 
threshold. This would require clinicians to build a MCDM structure (i.e. a hierarchy 
of decision criteria) with the highest possible level of “best practice” or 
“normativity” in the model structuring achievable by the template which, while 
containing all the relevant criteria for the patient to make the clinical decision, would 
be of a small enough size to result in a PDA that can be deliverable within the 
duration of a clinical consultation, easy enough to use by patients, and acceptable to 
other clinicians.  
In terms of the MAUT formulation of DRDEA, these two approaches to using a high 
DE template – one involving a sacrifice in DE, one not - to develop a PDA with a 
DR threshold can be represented in Figures 5.1 and 5.2 – a DRDEA version of the 
standard Cost-Effectiveness plane. 
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Figure 5.1. DRDEA MAUT formulation. Using high DE templates to develop a PDA: 
sacrifice in DE  
 
 
In Figure 5.1, the existence of a ceiling of DR in the use of alternative templates to 
develop a PDA in the context of clinical practice is represented by a maximum 
possible level of incremental DR (iDR) in switching from the potentially lowest DE/ 
lowest DR template (ALEL) to a higher DE/ higher DR template (the dashed line 
marked “Max iDR”). Below the maximum possible level of iDR, the switch from 
ALEL to a higher DE MCDA template will depend on the IDRDER (Incremental 
DRDE Ratio) threshold (the blue line in Figure 5.1), the slope of which represents 
the maximum level of additional DR that clinicians consider worth investing per unit 
of DE gained by making that switch. For MCDA templates below the IDRDER 
threshold, the switch will be DR-effective. For MCDA templates above the IDRDER 
threshold, the switch will not be DR-effective. Above the maximum possible level of 
iDR, the switch from ALEL to a higher level DE template is not justifiable. It will 
only be possible if the iDR required to make that switch is reduced to a level that is 
lower than the maximum possible level of iDR (as shown in Figure 5.1 with the 
green arrows). This requires a sacrifice in DE (as shown in Figure 5.1 using the red 
arrows). For the higher DE MCDA template to be DR-effective, the sacrifice in DE 
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has to be small enough to be worth the investment in DR made by switching from a 
lower DE MCDA template (such as ALEL) to that the higher DE template. 
Figure 5.2. DRDEA MAUT formulation. Using high DE templates to develop a PDA: 
no sacrifice in DE  
 
 
In Figure 5.2, the switch from ALEL to a higher DE template would be possible 
without incurring in an iDR which is higher than the maximum possible level of iDR. 
This is because clinicians would “save” DR by being able to operationalize, for each 
of the higher DE templates shown in Figure 5.2, the maximum DE possible accruable 
by the MCDA template.  
In the specific context of this research, sacrifices in DE were required. This was 
primarily due to the large number of criteria (twenty-four) which the clinicians in 
both hospital H1 and hospital H2 considered were relevant for the decision. The 
model structure built by the team of clinicians that used the high DE template Expert 
Choice (the team from hospital H1) was too large to result in a PDA with a level of 
DR below the DR threshold. Although, admittedly, this MCDM structure was not 
built by the clinicians within an explicit DRDEA framework and could potentially be 
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reduced by combining some criteria, this was appropriate to the comparative 
evaluation.  
How can templates with the highest possible DE be used to develop and implement 
MCDA-based PDAs in routine clinical practice with the absolute minimum sacrifice 
in DR? One answer may lie in the work by Edwards and Barron [121], who 
developed the Simple Multiattribute Rating Technique with Swings (SMARTS) and 
SMART Exploiting Ranks (SMARTER) partly in response to the difficulty of the 
indifference judgments required from the decision maker in order to construct 
multiattribute preference structures using the best practice standards of 
MAVT/MAUT proposed by Keeney and Raiffa [11]. Edwards and Barron suggested 
the use of a “strategy of heroic approximation” [121] to identify “the simplest 
possible judgments that have any hope of meeting the underlying requirements of 
multiattribute utility measurement, and try to determine whether they will lead to 
substantial suboptimal choices in the problem at hand” [121]. If they do not lead to 
suboptimal choices (which Edwards and Barron suggest in many decision situations 
will be the case), a quick and easy to implement nine-step procedure (see Chapter 1, 
section 8.2.1.1) can be used to solve a multi-criterion decision problems according to 
prescriptive standards. Templates such as Logical Decisions and HiView 3 may be 
used to implement SMARTS as the basis of MAVT-based PDAs in routine clinical 
practice. Templates such as Logical Decisions and Web-HIPRE may be used to 
implement SMARTER for the same task. 
2. Study limitations.  
The potential weaknesses of the methods used in this research project need to be 
highlighted. The project was undertaken in close collaboration with clinicians in the 
Spanish NHS with a view to understanding how the use of MCDA in developing and 
delivering interactive patient decision aids is affected by the actual context of day-to-
day clinical practice. For that reason, the methods were context-led, that is, they were 
adapted to the clinicians’ point of views and daily routines during the course of the 
study which partook of many of the qualities of ‘action research’. In this sense the 
clinicians’ preferences with regards to the content of the Expert Choice-based PDA 
and the ALEL-based PDAs, as well as in regard to the inputs of the meta-decision 
model, were accepted independently of any considerations of methodological rigour, 
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as were the clinicians’ strong time constraints on participation in this research. The 
potential weaknesses of the methods need to be interpreted within this necessarily 
context-led approach. 
2.1. Limitations in the development and delivery of the Expert Choice-based 
and the ALEL-based M-IPDAs. 
2.1.1. The hierarchy of criteria for the Expert Choice-based and the ALEL-
based PDAs 
In both hospital H1 and hospital H2, the processes of building the final hierarchy of 
decision criteria was researcher- and clinician-led and did not seek to adopt the 
patient-centred perspective with patient involvement in the determination of patient-
important outcomes and criteria.  
The final set of decision criteria was comprehensive as far as the clinicians were 
concerned. In terms of model structuring, however, this led to a decision hierarchy 
which was not, strictly speaking, well-structured according to normative standards of 
decision theory. In particular, several bottom-level criteria were arguably not 
preference independent. In this case, strict normativity was sacrificed to the 
clinicians’ desire for subjective comprehensiveness in the model structuring. This 
can be reasonably justified from a practical point of view. The lack of value 
independence does not necessarily invalidate the use of value dependent decision 
criteria in MCDA [251]. However, it could have been desirable to engage with the 
clinicians in a requisite decision modelling [212] exercise in this respect. 
Such an exercise would have consisted in a consultative and iterative process 
between the clinicians and the present author with the aim of modifying the model 
structure to be 1) more in line with the normative axioms of decision theory while 
containing 2) the relevant content to the clinicians for helping patients make the 
decision. However such a modelling exercise was not possible in either hospital H1 
or hospital H2 due to time constraints on the side of the clinicians derived from their 
clinical duties. 
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2.1.2. Generating the evidence 
For both the Expert Choice-based and the ALEL-based PDA, the evidence of the 
performance of the lung cancer clinical management options on the bottom-level 
decision criteria was generated in a highly pragmatic way that respected the time 
constraints of the clinicians involved in this research - eliciting their expert opinion 
by asking them to state their estimates of the options’ performance levels. 
Furthermore, for all the quality of life criteria, the estimates of the performance 
levels of the decision alternatives were limited to one point in time – 2 years after the 
start of treatment.  
The performance levels resulting from the elicitation of the clinicians’ expert opinion 
differed, in some cases substantially, across clinicians. There are at least three 
possible reasons for these differences: 
1) The large uncertainty inherent to the raw performance levels being assessed from 
the clinicians, as these raw performance levels depend on a series of probabilistic 
events. For example, the level of pain that a NSCLC patient is expected to have two 
years after starting treatment with neoadjuvant chemotherapy depends on his health 
state 2 years after starting treatment which depends, among other probabilities, on 
the probability that 1) the neoadjuvant chemotherapy treatment has been successful 
at downstaging the tumour, 2) the probability that the surgical resection is complete, 
and 3) the probability that, if the surgical resection is not complete, after further 
chemo-radiotherapy there is a local or advanced recurrence;  
2) Differing clinician beliefs. There is evidence in the lung cancer literature that lung 
cancer clinicians express beliefs (i.e. subjective probabilities) regarding the outcomes 
of lung cancer treatments that differ substantially from both their peers and with 
respect to the published evidence [252], an argument which resonates with the results 
of other research suggesting that in general experts predict poorly [253]; 
3) Lack of accuracy of the methods used in this research project to obtain the raw 
performance levels.  
With more time and financial resources (unavailable to the clinicians in this research 
project), clinicians could attempt to improve the quality of the estimates of the 
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evidence by undertaking a review of the scientific literature regarding the impact of 
each treatment option on each bottom-level decision criterion of the Expert Choice-
based and the ALEL-based PDAs. The aim of these literature reviews would be to 
find the best available published evidence of the performance levels, from the start of 
treatment until death, of the clinical management options on each of these criteria. 
The best available published evidence should come from high quality sources (e.g. 
clinical trials, systematic reviews and/or meta-analyses), but it is vital to emphasise 
that this evidence is likely to be unavailable for many of the decision criteria and for 
many individualised cases within a condition. A review of the medical literature 
undertaken by the present author revealed no studies comparing, head to head, the 
lifetime clinical (or other) outcomes of the three non-small cell lung cancer treatment 
options (neoadjuvant chemotherapy, concurrent chemo-radiotherapy and best 
supportive care). Some studies evaluating the outcomes of these options were found, 
but they generally related to patients in more than one stage of non-small cell lung 
cancer, and often to interventions that are dissimilar to the three clinical management 
options considered in this research project.  
Best practice modelling by ‘practice –normative’ standards requires clinicians to 
input into the decision model the “best estimates available now” (BEANs) for the 
raw performance levels on the relevant decision criteria. The BEANs will most likely 
come from expert opinion elicitation, although a few may be available from 
published scientific papers based on higher quality sources. It is of course arguable 
that the expert judgments of clinicians are made in the light of familiarity with this 
literature as modified by their clinical experience. Elicitation of expert opinion 
should be undertaken using best practice methods such as those described in von 
Winterfeldt and Edwards [151]. 
2.1.3. Format and content of the Expert Choice-based and the ALEL-based 
PDAs 
Neither of the two PDAs was developed to achieve all of the best practice standards 
of format and content required by the International Patient Decision Aids Standards 
[67]. Notwithstanding the criticisms made to these standards by, among others, 
McDonald and Charles [89] and Bekker [87], the main reason for not focusing on 
these standards to develop the Expert Choice-based and the ALEL-based PDAs was 
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that, in this particular research project, the objective was not to develop two PDAs 
that met abstract external standards of format and content quality. Rather, it was to 
develop two PDAs that could potentially improve the quality of patient decision 
making in clinical consultations with respect to current practice (that is, with respect 
to verbal reasoning). This is not to say that it is not desirable to develop these two 
tools with reference to external standards as targets, but not as evaluation checklists 
as such.  
2.1.4. Possible bias in the delivery of the M-IPDAs in clinical consultations 
With respect to the delivery of the two PDAs, due to time constraints, neither the 
clinicians nor the proxy patients had training in the use of the two templates. In fact, 
the hypothetical consultations were followed using a script and strong support from 
the researcher. This is likely to have introduced a bias in the interaction between the 
clinician and the proxy patient. It certainly did not allow for a proper assessment of 
the fluidity of the communication between clinicians and proxy patients using the 
PDAs.  
2.1.5. Proxy patients versus real patients in the delivery of the M-IPDAs 
Perhaps the greatest limitation in the delivery of the two MCDA-based PDAs was the 
use of proxy patients and hypothetical consultations instead of real patients and real 
consultations. There is a large gap between hypothetical consultations and real 
consultations. Proxy cancer patients are very different from real cancer patients. 
Anxiety, a frequent response to cancer diagnosis [254] is likely to interfere with the 
patient’s ability to communicate with his/her physician to discuss the information 
necessary to make a balanced treatment decision. Although there is some evidence 
that the exposure to PDAs does not increase anxiety in patients [255, 256] it is likely 
that actual lung cancer patients, especially if they have relatively low educational and 
computer-literacy levels, will find, within a generally anxious state of mind, the use 
of the PDAs more challenging than proxy patients. Nevertheless it is important not to 
stereotype or pre-judge individual patients in this respect and an important step to 
understand the impact of delivering the Expert Choice-based PDA and the ALEL-
based PDA in the context of clinical practice is to pilot the use of these tools in actual 
day-to-day consultations with real Stage IIIA3 non-small cell lung cancer patients. 
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Given the heterogeneity of patients, the average results from such piloting need 
careful interpretation. 
2.2. Limitations in the development and delivery of the DRDEA meta- decision 
model. 
2.2.1. The scope of the DRDEA meta-decision model. 
The main limitation of the meta-MCDM was its limited scope. In total, 11 decision 
effectiveness (DE) and decision resources (DR) criteria were included in the model. 
Although the inclusion of 11 criteria was justified by the 1) proof-of-concept 
approach and 2) the time constraints of clinicians in hospital H3 to participate in this 
research project, the meta-decision model can be extended to include other important 
DE and DR criteria. In terms of DE, for example, an important criterion for inclusion 
in further versions of the meta-decision model is the DE in the delivery of the PDA, 
e.g. the extent to which the use of a template in the delivery of a PDA increases the 
quality of the decision. In term of DR, an important criterion for inclusion in further 
versions of the meta-decision model is the practicality in the development of a PDA, 
which can be defined as the extent to which it is practical to develop a PDA based on 
a particular template within the time and organisational constraints available to 
clinicians for that task. The development of a PDA can require a large amount of 
time and other resources if, for example, in order to build a well-structured decision 
hierarchy, clinicians hire a decision analyst. Or if clinicians engage in time-
consuming reviews of the literature and/or modelling exercises to generate the 
evidence of the clinical options on the decision criteria. 
Two other types of DE and DR criteria that could also be considered for inclusion in 
future versions of the meta-decision model are 1) in relation to DE, the improved 
health outcomes associated with using a particular template to deliver a PDA and 2) 
in relation to DR, the changes in health care expenditures, associated with using a 
template to deliver a PDA.  
With respect to the first of these two criteria, several studies have evaluated the 
actual impact of (non-MCDA-based) patient decision aids on health outcomes. For 
example, Barry et al [257] in a randomised controlled trial evaluating the impact of a 
multimedia decision aid on the risks and benefits of different treatments for benign 
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prostatic hyperplasia, measured urinary symptoms at 3 months after the use of the 
decision aid via a urinary symptoms index measure. In another study, Deyo et al. 
[258] carried out a trial of the impact on an array of outcomes of an interactive video 
disk giving information about alternative treatments for back injuries. The authors 
measured, among others, back pain severity at one year after patients were exposed 
to the decision aid. They found a statistically significant effect (a reduction in back 
pain severity) of the intervention compared with the control (no videodisk). Murray 
et al [259] conducted a clinical trial to evaluate the impact of 1) a clinical decision 
aid consisting of an interactive multimedia program accompanied by a booklet 
describing hormone replacement therapy risks and benefits versus 2) no clinical 
decision aid on, among other outcomes, self-assessed health status using both the 
EuroQoL EQ-5D quality of life questionnaire and the SF-36 quality of life 
questionnaire. 205 menopausal women were randomised to the intervention and 
control. Health-related quality of life was assessed at 3 and 9 months after using the 
decision aid. The authors found no significant changes in the baseline health status 
scores over time in either of the two groups. Finally, Kennedy et al [104] used the 
SF-36 questionnaire to evaluate the impact of two decision aid tools, 1) a booklet and 
accompanying videotape and 2) the same booklet and videotape plus a preference 
elicitation interview- versus 3) no decision aid on the quality of life of women with 
uncomplicated menorrhagia. 894 women were randomly allocated across the three 
groups, and asked to fill in the SF-36 questionnaire at 2-year follow-up. At this time, 
there was a statistically significant difference between group 2) and the other 2 
groups in the SF-36 role function score. 
With respect to the second criterion, the impact of introducing patient decision aids 
on health service costs has been evaluated albeit in too few studies to draw 
substantive conclusions. To mention a study which achieved positive results, 
Kennedy et al [104] performed a cost analysis of the impact of using 1) a booklet + 
videotape and 2) booklet + videotape + preference elicitation interview as decision 
aids for women with menorrhagia. The cost perspective was the UK NHS 
perspective. The authors calculated the resources used during the development and 
production of the interventions, including 1) the duration of time devoted by nurses 
during the preference elicitation technique (if any), 2) use by the women in the study 
of health services, including tests and other procedures, medications for menorrhagia, 
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inpatient days in hospital and outpatient and family physician visits (if any) at 6, 12, 
and 24 months after the interventions. The effective life of the interventions was 
estimated at 3 years. Costs per patient were calculated by dividing the total cost of 
each intervention by the number of patients in each intervention group. Both 
intervention groups showed major mean cost savings compared to the control group. 
2.2.2. Evaluating the performance of alternative MCDA templates on the 
criteria of the meta-decision model. 
One of the main concerns that arose in the development of the meta-decision model 
was providing the estimates of the performance levels of the proposed PDAs on the 
meta-decision criteria. Because making the decision of what type of template to use 
in the development and delivery of a PDA has to be made ex ante, it is not possible 
to accurately measure many of these performance levels – e.g. the impact of using 
this MCDA template on criteria of DE in the delivery of this M-IPDA. This is of 
course a universal problem in decision making and decision support and one that is 
simply made more obvious in, but not created by, developing an meta-decision 
model. One productive route would involve moving from evaluating the templates as 
such to evaluating their use in particular ways and within particular constraints. For 
example one option in this more refined meta-model might be: “Expert Choice being 
used to produce a PDA that can be delivered in less than 1 hour, is easy to use by 
patients after approximately 30 minutes of training and that 90% of clinicians in the 
hospital will consider suitable for use in their clinical consultations”. 
Using the “best evidence available now” (BEANs) standard, in order to learn the 
extent of DE accrued and DR consumed developing and delivering PDAs, 
information is required from the BEANs. Currently, there is little information in the 
literature about the impact of PDAs produced using the different templates reviewed 
in this research in terms of practicality in the preference elicitation or organisational 
fit, but hopefully this will change in the future as the use of templates to develop and 
deliver MCDA-based PDAs becomes more widespread. The BEANs will then be 
based on more robust study designs. In the absence of such evidence from the 
literature, the performance of alternative templates in terms of DE and DR needs to 
be estimated using best practice expert opinion elicitation methods as in the decision 
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modelling itself. The need to make a meta-decision can no more be postponed than 
the decision itself. 
3. Generalizability of results and implications for public health. 
The work undertaken in this study is a proof-of-concept study exploring 1) the 
potential of using MCDA in the development and implementation of PDAs in routine 
clinical practice and 2) the potential for the application of the Decision Resources- 
Decision Effectiveness Analysis (DRDEA) MCDA framework to the choice by 
clinicians of MCDA template as the basis for a PDA. The context in which this 
proof-of-concept study was carried out was that of Spanish NHS tertiary hospitals, so 
the generalisability of the results to other health care settings is limited to hospitals 
with similar characteristics. The teams of clinicians who participated in this study 
were selected by this researcher based on prior experience doing research together. 
They are all highly specialised, highly motivated clinicians. In this sense, they may 
not be representative of the population of all clinicians. 
The implementation of the Expert Choice-based PDA and the ALEL-based PDA in 
hypothetical consultations replicating actual clinical consultations was done with 
proxy patients who were healthy individuals. The results of these consultations 
cannot be generalised to actual lung cancer patients. 
In terms of generalisability to other therapeutic areas, the decision of what is the best 
clinical management strategy for a Stage IIIA3 non-small cell lung cancer patient has 
several particular characteristics. First of all, it is a very complex decision problem. 
The options are composed of uncertain interventions which vary depending on the 
evolution of the patient. Both the condition and the clinical management options 
affect many aspects of the patient’s well-being. The decision is fateful, so the PDA 
delivery is likely to cause high level of anxiety to the patients. In many other 
therapeutic areas, the decision problem is likely to be more straightforward and the 
applicability of MCDA easier. It is in this sense that the methods used to develop and 
deliver the Expert Choice-based PDA and the ALEL-based PDA with clinicians in 
the Spanish NHS is likely to be applicable to many other clinical decisions. With 
respect to the trade-offs between decision resources and decision effectiveness, it is 
also likely that for other therapeutic areas in which the decision problem is easier to 
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conceptualise (e.g. clearer options, less relevant criteria) these trade-offs will be less 
important, facilitating the use of templates which implement high DE MCDA 
methods (such as MAVT). 
In terms of the public health implications of this research, Stage IIIA3 non-small cell 
lung cancer is a rare condition. Implementing MCDA-based PDAs for the clinical 
management of this condition is not likely to have much importance to public health 
in terms of burden of disease. However, the active treatment options for this 
condition are very expensive. Allowing patients to make values-based choices in this 
realm is likely to have cost implications. For example, if more patients choose, based 
on their values, best supportive care than they would having not been exposed to the 
PDA. One of the original motivations for the development of PDAs was to help 
reduce unwarranted variations in the provision of health care (i.e. variations in the 
provision of care that could not be explained by the need for these interventions). In 
this sense, PDAs aim to spur patient self-interest in avoiding such interventions [23]. 
The clinical management of Stage IIIA3 is a case in point: patients with strong 
preferences for avoiding the many adverse effects of the active treatments may 
decide that it is best for them to receive best supportive care.  
4. Suggestions for further research. 
1) There is a need for more research on the use of high DE, low DR templates to 
develop PDAs with clinicians using prescriptive MCDA approaches such as 
SMARTS/SMARTER; 
2) There is a need for more research to identify best practice approaches to delivering 
prescriptive MCDA-based PDAs to patients; 
3) There is a need for more research to identify best practice methods for developing 
and delivering prescriptive MCDA-based PDAs for clinical management decisions in 
oncology within the constraints imposed by the decision resources relevant for the 
particular decision at hand. Decisions about the clinical management of oncological 
conditions can be fateful, are often characterised by uncertainty, and often result in 
recurrence of disease. How should patients be supported to make these decisions 
using prescriptive MCDA considering the levels of anxiety that patients can be in? 
How can uncertainty be modelled into these PDAs so that it is understood by 
264 
 
patients? When should these PDAs be delivered? In oncology, there are particular 
points of time in the evolution of the disease whe MCDA might be more appropriate 
than at other moments; 
4) What is the role of decision analysts in supporting both the development of 
prescriptive MCDA-based PDAs with clinicians and their implementation with 
patients? This role is likely to vary with the particular condition under consideration. 
For less fateful, less uncertain, less complex decisions with few decision criteria 
decision analysts may have a less crucial role than for fateful, uncertain, complex 
decisions; 
5) What are the most appropriate decision support software interfaces to provide 
decision support for prescriptive MCDA-based PDAs? These software applications 
should implement prescriptive MCDA approaches with the highest possible level of 
decision effectiveness but with the lowest possible requirements in terms of time and 
cognitive effort. 
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Appendix 1: Initial hierarchies of criteria for the Expert Choice-
based PDA and the ALEL-based PDA. 
Figure A1.1. Initial hierarchy of criteria for the Expert Choice-based PDA 
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Figure A1.2. Initial hierarchy of criteria for the ALEL-based PDA 
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Appendix 2: Description of the criteria of the final hierarchy 
common to the Expert Choice-based PDA and the ALEL-based PDA. 
The final hierarchy of criteria was common to the Expert Choice-based PDA and the 
ALEL-based PDA. The six top-level criteria of this common hierarchy were: 
1. Cure from cancer, i.e. how likely it is to get cured from Stage IIIA3 NSCLC  
2. The duration of life, i.e. the life expectancy 
3. The quality of life in the medium term, where medium term is defined as two 
years after the start of treatment 
4. The disease-related financial burden in the medium term, i.e. the financial 
problems derived, two years after the start of treatment, from 1) direct expenditures 
related with the disease and/or the treatment, and from 2) the opportunity cost of not 
being able to earn a living as a result of being ill 
5. The treatment-related adverse effects 
6. The quality of the health care experience (i.e. those aspects of the health care 
delivery which are positive for one’s well-being as a patient) from the start of 
treatment until the medium term. 
Note that, compared to the initial set of decision-relevant aspects from Appendix 1, 
an additional aspect was included in the final decision hierarchy: cure from cancer. 
This criterion was added after informal conversations between the present author and 
two of the participating clinicians. In these conversations, held after the two model-
building exercises, both clinicians pointed out that it was indeed possible (albeit 
unlikely) for the hypothetical Stage IIIA3 non-small cell lung cancer patient to get 
cured if the patient chose to undergo one of the two active treatment strategies, 
particularly option 𝐴1 (neo-adjuvant chemotherapy with respective intent). Cure 
from Stage IIIA3 NSCLC was not an easy concept to define for the hypothetical 
patient, as there is always the chance that metastatic lesions may recur. In this 
project, the clinicians agreed to define cure from cancer as the absence of any tumour 
activity after 5 years of starting the treatment. 
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Three top-level criteria (cure for cancer, duration of life, and disease-related financial 
burden in the medium term) were defined as stand-alone criteria. The three 
remaining top-level criteria (quality of life in the medium term, treatment-related 
adverse effects, and quality of the health care experience from the start of treatment 
until the medium term) were defined in terms of sub-criteria. These are explained 
below. 
A2.1. Defining quality of life in the medium term in terms of a sub-hierarchy of 
sub-criteria  
In the final hierarchy of criteria common to both the Expert Choice-based PDA and 
the ALEL-based PDA, quality of life in the medium term (i.e. after 2 years of starting 
treatment) was defined in terms of a sub-hierarchy of sub-criteria. Level 1 of the sub-
hierarchy was defined by four sub-criteria characterising quality of life in the 
medium term: 1) cancer-related symptoms, 2) self-care (i.e. being able to take care of 
oneself without help from others), 3) being able to work a standard working week 
(i.e. 40 hours), 4) interference of the disease with family life and/or other social 
activities. Level 2 of the sub- hierarchy was composed of four cancer-related 
symptoms children criteria. These sub-criteria were considered to be by the two 
teams of clinicians the symptoms due to the disease that most commonly occur in 
Stage IIIA3 NSCLC patients in the medium term. They were: 1) disease-related pain, 
2) disease-related dyspnoea (difficulty breathing), 3) disease-related asthenia (feeling 
of weakness), and 4) disease-related emotional problems (i.e. anxiety and/or 
depression). Figure A2.1 shows this sub-hierarchy of quality of life in the medium 
term sub-criteria.  
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Figure A2.1. Sub-hierarchy of quality of life in the medium term sub-criteria (Expert 
Choice-based PDA and ALEL-based PDA)  
 
A2.2. Defining treatment-related adverse effects in terms of a sub-hierarchy of 
sub-criteria  
The treatment-related adverse effects criterion was defined as a one-level sub-
hierarchy of sub-criteria. Deciding what these sub-criteria should be was not an easy 
task, as more than five hundred cancer treatment-related adverse effects have been 
described in the literature (these are detailed and graded, in terms of severity, in the 
National Cancer Institute Common Terminology Criteria for Adverse Effects 
(CTCAE) grading system). For practical reasons, the approach taken by this 
researcher to select these sub-criteria was to reach a consensus with both teams of 
clinicians about which were the nine most common adverse effects associated with 
the treatment of the Stage IIIA3 NSCLC patient. The nine treatment-related adverse 
effects sub-criteria were 1) dyspnoea as a consequence of pneumonitis or pulmonary 
fibrosis, 2) dysphagia (i.e. problems swallowing) as a consequence of oesophagitis, 
3) infection as a consequence of immunodeficiency, 4) diarrhoea, 5) vomiting, 6) 
alopecia (hair loss), 7) paraesthesia (feelings of tickling, burning, or numbness in the 
skin), 8) fatigue, and 9) anorexia (loss of appetite). Figure A2.2 shows the sub-
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Figure A2.2. Sub-hierarchy of treatment-related adverse effects sub-criteria (Expert 
Choice-based PDA and ALEL-based PDA)  
 
A2.3. Defining quality of the health care experience from the start of treatment 
until the medium term in terms of a sub-hierarchy of sub-criteria  
This criterion was defined as a one-level sub-hierarchy of sub-criteria. The chosen 
sub-criteria were 1) visits to the health services, 2) hospital in-patient stays, 3) 
waiting time (due to waiting lists) between interventions, 4) treatment by the same 
team of clinicians (that is, whether or not the same clinician or clinicians follow-up 
the patient throughout time), 5) attentive care (that is, whether or not the patient is 
always treated by his clinicians in a considerate and caring fashion). Figure A2.3 
shows the sub-hierarchy. 
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Figure A2.3. Sub-hierarchy of health care experience between the start of treatment 
and the medium term sub-criteria (Expert Choice-based PDA and ALEL-based PDA)  
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Appendix 3: Literature search of published clinical studies 
evaluating the outcomes of the three clinical decision options. 
The purpose of this literature search was solely to identify the types of outcomes that 
are measured in existing clinical studies evaluating the impact of the clinical 
management strategies used in this research as decision options for both the Expert 
Choice and the ALEL Stage IIIA3 NSCLC treatment PDAs, i.e. chemotherapy with 
resective intent (𝐴1), concurrent chemo-radiotherapy (𝐴2), and best supportive care 
(𝐴3). Identifying these outcomes was important to understand how likely it was that 
the currently existing evidence regarding the impact of these three decision options 
on the bottom-level criteria 𝐶𝑘(𝑏) (𝑘 = 1 … 24) of the full final decision hierarchy 
for the two PDAs (shown in Figure A3.1, where the relevant criteria are highlighted 
in red colour) could be used to inform the calculation of the scores of the three 
decision options on these twenty-four criteria.  
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Figure A3.1. Full final hierarchy of criteria for the Expert Choice-based PDA and 
the ALEL-based PDA 
 
The literature search, which was done in PUBMED. It was designed to identify all 
the clinical trials, comparative studies, evaluation studies, meta-analyses, reviews 
and systematic reviews published in English in the last seven years (i.e. since January 
1, 2006) which would be specific to patients with stage IIIA3 non-small cell lung 
cancer over sixty-five years of age and which would include, either as the main 
treatment or as a comparator, the following options: 
1. Neoadjuvant chemotherapy followed by surgery with one of the chemotherapy 
agents being either cisplatin or carboplatin 
Quality of life in the 
medium term
Cancer-related 
symptoms
C3(b):Disease-related pain
C4(b):Disease-related dyspnoea
C6(b):Disease-related emotional 
problems
C5(b):Disease-related asthenia
C7(b):Self-care
C8(b):Work a normal week
C9(b):Interference of the disease with 
family life and/or other social 
activities
C1(b):Cure for the cancer
C2(b):Life expectancy
C10(b):Disease-related 
financial burden in 
the medium term
Treatment-related 
adverse effects
Quality of the health care 
experience from the start 
of treatment until the 
medium term
C15(b):Treatment-related vomiting
C16(b):Treatment-related alopecia
C18(b):Treatment-related fatigue
C17(b):Treatment-related paraesthesia
C11(b):Treatment-related dyspnoea 
due to pneumonitis or pulmonary 
fibrosis 
C12(b):Treatment-related dysphagia 
due to oesophagitis
C14(b):Treatment-related diarrhoea
C13(b):Treatment-related infection 
due to immunodeficiency
C19(b):Treatment-related anorexia
C20(b):Visits to the health services
C23(b):Treatment by the same team 
of clinicians
C22(b):Waiting time (due to waiting 
lists) between interventions 
C24(b):Attentive care
What is the best 
treatment for a Stage 
IIIA3 NSCLC patient?
HIERARCHY
LEVEL 1
HIERARCHY
LEVEL 2
HIERARCHY
LEVEL 3
C21(b):Hospital inpatient stays
274 
 
2. Concurrent chemotherapy with one of the chemotherapy agents being either 
cisplatin or carboplatin 
3. Best supportive care  
The search strategy, including the search terms and the number of published articles 
associated with each search term are shown in Table A3.1. 
Table A3.1: Search strategy 
Individual search 
identification 
number 
Search terms Number of 
articles found in 
the database 
#1 
 
Cancer* OR carcinoma* OR neoplasm* 2,433,263 
#2 
 
Non-small cell OR non small cell 232,018 
 
#3 
 
Lung OR pulmonary 952,371 
#4 
 
#1 AND #2 AND #3 44,631 
 
#5 
 
T2N2M0 OR IIIA3 OR 3A3 OR IIIA OR 3A 
OR locally advanced 
 
 
52,556 
#6 
 
#4 AND #5 3,354 
#7 Induction chemotherapy OR neoadjuvant 
chemotherapy 
 
38,656 
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Table A3.1 (cont.): Search strategy  
Individual 
search 
identification 
number 
Search terms Number of 
articles found in 
the database 
#8 
 
#6 AND #7 863 
#9 
 
Cisplatin OR carboplatin 58,527 
 
#10 
 
#8 AND #9 494 
#11 
 
Lobectomy OR surgical resection OR tumour 
resection OR surgery 
 
44,631 
#12 
 
#10 AND #11 
 
303 
 
#13 
 
Limit #12 to: 7 last years; patients aged 65 or 
older; clinical trials, comparative studies, 
evaluation studies, meta-analyses, reviews and 
systematic reviews  
 
40 
 
#14 
 
Concurrent chemo-radiotherapy OR concurrent 
radio-chemotherapy OR concurrent chemo 
radiotherapy or concurrent radio chemotherapy 
OR (chemotherapy AND radiotherapy) 
 
 
85,259 
#15 #9 AND #14 10.523 
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Table A3.1 (cont.): Search strategy 
Individual 
search 
identification 
number 
Search terms Number of 
articles found in 
the database 
 
#17 
 
Limit #16 to: 7 last years; patients aged 65 or 
older; clinical trials, comparative studies, 
evaluation studies, meta-analyses, reviews and 
systematic reviews 
 
123 
#18 
 
No active treatment OR best supportive care 
OR palliative care NOT (chemotherapy OR 
radiotherapy) 
163,383 
#19 
 
#6 AND #18 16 
 
 
#20 
 
Limit #19 to: 7 last years; patients aged 65 or 
older; clinical trials, comparative studies, 
evaluation studies, meta-analyses, reviews and 
systematic reviews 
2 
 
Using the search strategy shown in Table A3.1, forty articles were found that 
potentially described the outcomes of neoadjuvant chemotherapy with resective 
intent (see search #13) in Stage IIIA3 non-small cell lung cancer patients. In addition, 
a hundred and twenty-three articles were found which potentially described the 
outcomes of concurrent chemo-radiotherapy (see search #17) in the same type of 
patients. Finally, two articles were found which potentially described the outcomes 
of best supportive care (see search #20) in those patients. The abstracts of all these 
articles were reviewed. An article was selected for review if, of all the patients 
treated with the relevant option in the study, the group of patients with Stage IIIA3 
non-small cell lung cancer was the most numerous. If it was not possible to know 
from the article the number of Stage IIIA3 patients treated with the relevant option, 
the article was selected for review if the number of Stage IIIA patients treated with 
the relevant option in the study was more than 50% of all the patients described in 
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the article. The rationale for this was to ensure that the evidence retrieved from the 
literature referred as much as possible to the same type of patient who would be 
engaged in decision making with the Expert Choice or ALEL PDAs – i.e. patients 
with Stage IIIA3 NSCLC. 
With the above criteria for article selection, seven (out of the original forty) articles 
were found describing the outcomes of neoadjuvant chemotherapy with resective 
intent in Stage IIIA3 non-small cell lung cancer patients (see Table A3.2). With the 
same criteria, five articles (out of one hundred and twenty-three) were found 
describing the outcomes of concurrent chemo-radiotherapy in Stage IIIA3 non-small 
cell lung cancer patients (see Table A3.3). No articles were found describing the 
outcomes of best supportive care in Stage IIIA3 non-small cell lung cancer patients. 
Table A3.2 presents, for each of the seven articles selected for review regarding the 
outcomes of neoadjuvant chemotherapy with resective intent (𝐴1) for Stage IIIA3 
NSCLC patients, a brief description of the type of study, the main treatment and 
comparators described, and the outcomes reported. 
Table A3.2: Results of the literature search. Treatment option: neoadjuvant 
chemotherapy with resective intent (𝐴1) 
Article 
  
Type of study Main treatment/ 
comparator (if any) 
Outcome(s) reported 
Brunelli, A., et al., 
Gemcitabine-cisplatin 
chemotherapy before lung 
resection: a case-matched 
analysis of early outcome. The 
Annals of Thoracic Surgery, 
2006. 81: p. 1963-1968 
Observation
al study 
Main treatment: 
Neoadjuvant 
chemotherapy 
(cisplatin + 
gemcitabine) with 
surgery 
Comparator: Only 
surgery 
Cardiopulmonary 
morbidity/ mortality/ 
Perioperative blood 
transfusion/ 
emergency ICU 
admissions/ length of 
postoperative stay/ 
bronchopleural 
fistula/ prolongued 
air leak/ empyema      
   
 
  
278 
 
Table A3.2 (cont.): Results of the literature search. Treatment option: neoadjuvant 
chemotherapy with resective intent (𝐴1) 
Article 
  
Type of study Main treatment/ 
comparator (if any) 
Outcome(s) reported 
Esteban, E., J. de Sande, and N. 
Villanueva, Cisplatin 
plus gemcitabine with 
or without vinorelbine 
as induction 
chemotherapy prior to 
radical locoregional 
treatment for patients 
with stage III non-
small-cell lung cancer 
(NSCLC): results of a 
prospective 
randomized study. 
Lung Cancer, 2007. 
55: p. 173-180. 
 
Clinical trial Main treatment: 
Neoadjuvant 
chemotherapy 
(cisplatin + 
gemcitabine) with 
surgery (if 
downstaging) or 
radiotherapy (if no 
downstaging) 
Comparator: 
Neoadjuvant 
chemotherapy 
(cisplatin + 
gemcitabine + 
vinorelbine) with 
surgery (if 
downstaging) or 
radiotherapy (if no 
downstaging) 
 
Tumour response/ 
survival/ stable 
disease/ disease 
progression/ anaemia/ 
neutropenia/ 
thrombocytopenia/ 
infection/ fever/ 
nausea and vomiting/ 
asthenia/ alopecia 
Gottfried, M., R. Ramlau, and 
M. Krzakowski, 
Cisplatin-based three 
drugs combination 
(NIP) as induction and 
adjuvant treatment in 
locally advanced non-
small cell lung cancer. 
Journal of Thoracic 
Oncology, 2008. 3: p. 
152-157. 
Clinical trial Main treatment: 
Neoadjuvant 
chemotherapy 
(cisplatin + 
vinorelbine + 
ifosfamide/mesna) 
with surgery and 
post-surgical 
chemotherapy 
Comparator: 
Neoadjuvant 
chemotherapy 
(cisplatin + 
vinorelbine + 
ifosfamide/mesna) 
with surgery  
   
Tumour response/ 
survival/ disease 
progression/ anemia/ 
neutropenia/ 
thrombocytopenia/ 
death due to toxicity/ 
nausea and vomiting/ 
diarrhoea/ alopecia/ 
infection/ asthenia/ 
pain/ anorexia 
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Table A3.2 (cont.): Results of the literature search. Treatment option: neoadjuvant 
chemotherapy with resective intent (𝐴1) 
Article 
  
Type of study Main treatment/ 
comparator (if any) 
Outcome(s) reported 
Katakami, N., H. Tada, and T. 
Mitsudomi, A phase 3 
study of induction 
treatment with 
concurrent 
chemoradiotherapy 
versus chemotherapy 
before surgery in 
patients with 
pathologically 
confirmed N2 stage 
IIIA nonsmall cell lung 
cancer (WJTOG9903). 
Cancer, 2012. 118: p. 
6126-6135. 
 
Clinical trial Main treatment: 
Neoadjuvant 
chemo-radiotherapy 
(carboplatin + 
docetaxel) and 
surgery 
Comparator: 
Neoadjuvant 
chemotherapy 
(carboplatin + 
docetaxel) and 
surgery 
Tumour response/ 
survival/ disease 
progression/ nausea/ 
vomiting/ fever/ 
dyspnoea/ infection/ 
peripheral 
neuropathy/ allergic 
reaction/ dysphagia/ 
leukopenia/ 
neutropenia/ anemia/ 
thrombocytopenia/ 
increased 
transaminase/ 
increased creatinine 
Kolek, V., I. Grygarkova, and 
M. Hajduch, Long term 
follow-up of 
neoadjuvant-adjuvant 
combination 
treatments of IIIA 
stage non-small cell 
lung cancer: results of 
neoadjuvant 
carboplatin/ 
vinorelbine and 
carboplatin/ paclitaxel 
regimens combined 
with selective adjuvant 
chemotherapy 
according to in vitro 
chemo-resistance test. 
Biomedical Papers, 
2008. 152: p. 259-266. 
 
Clinical trial Main treatment: 
Neoadjuvant 
chemotherapy 
(carboplatin + 
vinorelbine) with 
surgery and post-
surgical 
chemotherapy 
Comparator: 
Neoadjuvant 
chemotherapy 
(carboplatin + 
paclitaxel) with 
surgery and post-
surgical 
chemotherapy 
 
Downstaging/ 
complete resection/ 
stable disease/ 
disease progression/ 
survival/ overall 
toxicity/ 
thrombocytopenia/ 
myalgia/ arthralgia/ 
anorexia 
Nagai, K., R. Tsuchiya, and T. 
Mori, A randomized 
trial comparing 
induction 
chemotherapy followed 
by surgery with 
surgery alone for 
patients with stage IIIA 
N2 non–small cell lung 
cancer (JCOG 9209). 
The Journal of 
Thoracic and 
Cardiovascular 
Surgery, 2003. 125: p. 
254-260. 
Clinical trial Main treatment: 
Neoadjuvant 
chemotherapy 
(cisplatin + 
vindesine) with 
surgery 
Comparator: 
Surgery alone 
 
Tumour response/ 
stable disease/ 
progressive disease/ 
survival/ 
leukocytopenia/ 
anaemia/ vomiting 
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From the last column of Table A3.2, the evidence from the literature can be directly 
used to inform the calculation of the scores of neoadjuvant chemotherapy with 
resective intent on only a subset of the bottom-level criteria of the decision hierarchy 
shown in Figure A3.1. Specifically, on the following eleven criteria: 
- Life expectancy (𝐶2(𝑏))  
- Asthenia (𝐶5(𝑏)) 
- Treatment-related dyspnoea due to pneumonitis or pulmonary fibrosis (𝐶11(𝑏)) 
- Treatment-related dysphagia due to oesophagitis (𝐶12(𝑏)) 
- Treatment-related infection due to immunodeficiency (𝐶13(𝑏)) 
- Treatment-related diarrhoea (𝐶14(𝑏)) 
- Treatment-related vomiting (𝐶15(𝑏)) 
- Treatment-related alopecia (𝐶16(𝑏)) 
- Treatment-related paraesthesia (𝐶17(𝑏)) 
- Treatment-related anorexia (𝐶19(𝑏)) 
- Hospital inpatient stays (𝐶21(𝑏)) 
From the above results, it is likely that the evidence available from the published 
literature cannot inform the calculation of the scores of this treatment option on the 
remaining fourteen criteria. Other sources of evidence, in particular clinical expert 
opinion, are required to calculate these scores. 
Table A3.3 presents the outcomes of concurrent chemotherapy (𝐴2) for Stage IIIA3 
NSCLC patients resulting from the five articles selected for review. The table 
provides, for each article, a brief description of the type of study, the main treatment 
and comparators described, and the outcomes reported. 
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Table A3.3: Results of the literature search. Treatment option: concurrent chemo-
radiotherapy (𝐴2) 
Article 
  
Type of study Main treatment/ 
comparator (if any) 
Outcome(s) 
reported 
Auperin, A., et al., 
Concomitant radio-
chemotherapy based on platin 
compounds in patients with 
locally advanced non-small 
cell lung cancer (NSCLC): a 
meta-analysis of individual 
data from 1764 patients. 
Annals of Oncology, 2006. 
17(3): p. 473-483 
Meta-analysis 
Main treatment: 
radiotherapy with 
concomitant platin-
based chemotherapy 
Comparator: 
radiotherapy alone 
 
Survival/ event-
free survival 
Govindan, R., J. Bogard, and 
T. Stinchcombe, Randomized 
phase II study of pemetrexed, 
carboplatin, and thoracic 
radiation with or without 
cetuximab in patients with 
locally advanced unresectable 
non–small-cell lung cancer: 
cancer and leukemia group B 
trial 30407. Journal of Clinical 
Oncology, 2011. 29: p. 3120-
3125. 
 
Phase II 
clinical trial 
Main treatment: 
chemotherapy 
(carboplatin + paclitaxel 
+ cetuximab) with 
concurrent radiotherapy  
Main treatment: 
chemotherapy 
(carboplatin + paclitaxel 
+ cetuximab) with 
concurrent radiotherapy  
 
Tumour response/ 
survival/ anaemia/ 
neutropenia/ 
febrile 
neutropenia/ 
thrombocytopenia/ 
dehydration/ 
dysphagia/ 
dyspnoea/  
esophagitis/ 
fatigue/ 
hypokalemia/ 
nausea and 
vomiting/ 
pneumonitis/ rash 
Gridelli, C., C. Langer, and P. 
Maione, Lung cancer in the 
elderly. Journal of Clinical 
Oncology, 2007. 25(1898-
1907). 
 
Literature 
review 
Range of treatments 
described: radiotherapy/ 
concurrent chemo-
radiotherapy/ sequential 
chemoradiotherapy 
Survival, quality-
adjusted survival/ 
toxicity 
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Table A3.3 (cont.). Results of the literature search. Treatment option: concurrent 
chemo-radiotherapy (𝐴2) 
Article 
  
Type of study Main treatment/ 
comparator (if any) 
Outcome(s) 
reported 
Hirose, T., Y. Mizutani, and T. 
Ohmori, The combination of 
cisplatin and vinorelbine with 
concurrent thoracic radiation 
therapy for locally advanced 
stage IIIA or IIIB non-small-
cell lung cancer. Cancer 
Chemotherapy and 
Pharmacology, 2006. 58: p. 
361-367. 
Observational 
study 
Main treatment: 
chemotherapy (cisplatin 
+ vinorelbine) with 
concurrent radiotherapy  
Comparator: N/A 
 
Tumour response/ 
survival/ 
leukopenia/ 
neutropenia/ 
thrombocytopenia/ 
anaemia/ nausea/ 
vomiting/ 
diarrhoea/ 
infection/ 
esophagitis/ 
pneumonitis/ 
gastric ulcer/ 
elevation of 
transaminase/ 
elevation of 
creatinine/ 
neurological 
peripheral 
symptoms 
Uitterhoeve, A., M. Koolen, 
and R. van Os, Accelerated 
high-dose radiotherapy alone 
or combined with either 
concomitant or sequential 
chemotherapy; treatments of 
choice in patients with non-
small cell lung cancer. 
Radiation Oncology, 2007. 2: 
p. 27-36. 
Retrospective 
stud 
Main treatment: 
chemotherapy (cisplatin) 
with concurrent 
radiotherapy 
Comparator 1: 
chemotherapy (cisplatin 
+ gemcitabine) with 
sequential radiotherapy 
Comparator 2: only 
radiotherapy 
Survival/ 
pulmonary 
toxicity/ 
oesophageal 
toxicity/ cardiac 
toxicity/ 
neuropathy 
 
From the last column of Table A3.3, the evidence from the literature can be directly 
used to inform the calculation of the scores of concurrent chemo-radiotherapy on an 
even smaller subset of criteria as was the case for neoadjuvant chemotherapy with 
resective intent. Specifically, on the following seven criteria: 
- Life expectancy (𝐶2(𝑏))   
- Treatment-related dyspnoea due to pneumonitis or pulmonary fibrosis (𝐶11(𝑏)) 
- Treatment-related dysphagia due to oesophagitis (𝐶12(𝑏)) 
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- Treatment-related infection due to immunodeficiency (𝐶13(𝑏)) 
- Treatment-related diarrhoea (𝐶14(𝑏)) 
- Treatment-related vomiting (𝐶15(𝑏)) 
- Treatment-related paraesthesia (𝐶17(𝑏)) 
As before, it is likely that the evidence available from the published literature cannot 
inform the calculation of the scores of this treatment option on the remaining 
fourteen criteria. Other sources of evidence, in particular clinical expert opinion, are 
required to calculate these scores. 
No articles were found to inform the calculation of the scores of the option best 
supportive care (𝐴3) on any of the criteria of the decision hierarchy. 
To summarise the results of this literature review, it seems likely that the calculation 
of the scores of the three treatment options - neoadjuvant chemotherapy with 
resective intent (𝐴1), concurrent chemo-radiotherapy (𝐴2) and best supportive care 
(𝐴3) on the majority of the bottom-level criteria of the decision hierarchy of the 
Expert Choice-based and the ALEL-based PDAs will generally rely on clinical expert 
opinion. 
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Appendix 4: Expert Choice Evidence-Generation Questionnaire (EC-
EGQ), clinicians’ judgments about the performance levels of the 
options on the bottom-level criteria of the hierarchy and single-
criterion scores of the options on these criteria for hospital H1 
Table A4.1: Expert Choice Evidence Generation Questionnaire (EC-EGC) 
 
Introduction. Welcome. Jose is a sixty-nine year old male recently diagnosed with non-small cell 
lung cancer stage T2N2M0 (IIIA3). The tumour is in the lower left lobe and the mediastinal 
involvement is limited to one paratracheal lymph node. Jose has mild chronic obstructive 
pulmonary disease (COPD) and three years ago he suffered a hear infarction that was treated with 
a stent. 
 
The objective of this questionnaire is to measure the likely impact of the three treatment options 
available at hospital H1 for this patient on a number of criteria that you have considered of 
importance to him. The three options are: 
 
Option 1: neoadjuvant chemotherapy with resective intent. 
Option 2: concurrent chemo-radiotherapy 
Option 3: best supportive care 
 
Please answer the following questions. Many thanks in advance for your time and your answers 
 
Question 1. Of 100 patients identical to Jose who start treatment with (Option 1/ Option 2/ Option 
3), how many of these patients will get “cured”? Cure is defined as absence of tumour activity 
after 5 years of the start of treatment 
 
Suppose that Jose can be in one of the three states of tumour response: 1) “no progression” (the 
cancerous lesions do not extend and may even respond partially to the treatment), 2) 
“progression” (the cancerous lesions extend without question), and 3) “death”.  
 
Question 2.  
 
2.1. Imagine 100 patients identical to Jose who start treatment with (Option 1/ Option 2/ Option 
3). 
2.1.1. How many of these patients will be in state “no progression” 6 months after starting 
treatment? 
2.1.2. How many of these patients will be in state “progression” 6 months after starting treatment? 
2.1.3. How many of these patients will be in state “death” 6 months after starting treatment? 
 
2.2. Suppose now that Jose, 6 months after starting treatment with (option 1/ Option 2/ Option 3) 
is in state “no progression”. Imagine 100 patients identical to Jose.  
2.2.1. How many of these patients will be in state “no progression” 12 months after starting 
treatment? 
2.2.2. How many of these patients will be in state “progression” 12 months after starting 
treatment? 
2.2.3. How many of these patients will be in state “death” 12 months after starting treatment? 
 
2.3. Suppose now that Jose, 6 months after starting treatment with (option 1/ Option 2/ Option 3) 
is in state “progression”. Imagine 100 patients identical to Jose.  
2.3.1. How many of these patients will still be in state “progression” 12 months after starting 
treatment? 
2.3.2. How many of these patients will be in state “death” 12 months after starting treatment? 
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Table A4.1 (cont.): Expert Choice Evidence Generation Questionnaire (EC-EGC) 
 
Question 3. This question is designed to measure Jose’s quality of life in the medium term (two 
years after starting treatment) under each of the three treatment options. To measure this quality of 
life, it is important to assume that Jose, at two years after starting treatment, is not suffering any of 
the adverse effects associated with the treatments. In particular, that Jose is not suffering the 
adverse effects typically associated with chemotherapy or radiotherapy. 
 
3.1. Disease-related pain. 
3.1.1. Indicate, on a scale between 1 and 9, how much better is Option 1 over Option 2 (or Option 
2 over Option 1) in terms of disease related pain two years after Jose starts treatment 
3.1.2. Indicate, on a scale between 1 and 9, how much better is Option 2 over Option 3 (or Option 
3 over Option 2) in terms of disease related pain two years after Jose starts treatment 
3.1.3. Indicate, on a scale between 1 and 9, how much better is Option 1 over Option 3 (or Option 
3 over Option 1) in terms of disease related pain two years after Jose starts treatment 
 
3.2. Disease-related dyspnoea. 
3.2.1. Indicate, on a scale between 1 and 9, how much better is Option 1 over Option 2 (or Option 
2 over Option 1) in terms of disease related dyspnoea two years after Jose starts treatment 
3.2.2. Indicate, on a scale between 1 and 9, how much better is Option 2 over Option 3 (or Option 
3 over Option 2) in terms of disease related dyspnoea two years after Jose starts treatment 
3.2.3. Indicate, on a scale between 1 and 9, how much better is Option 1 over Option 3 (or Option 
3 over Option 1) in terms of disease related dyspnoea two years after Jose starts treatment 
 
3.3. Disease-related asthenia. 
3.3.1. Indicate, on a scale between 1 and 9, how much better is Option 1 over Option 2 (or Option 
2 over Option 1) in terms of disease related asthenia two years after Jose starts treatment 
3.3.2. Indicate, on a scale between 1 and 9, how much better is Option 2 over Option 3 (or Option 
3 over Option 2) in terms of disease related asthenia two years after Jose starts treatment 
3.3.3. Indicate, on a scale between 1 and 9, how much better is Option 1 over Option 3 (or Option 
3 over Option 1) in terms of disease related asthenia two years after Jose starts treatment 
 
3.4. Disease-related emotional problems. 
3.4.1. Indicate, on a scale between 1 and 9, how much better is Option 1 over Option 2 (or Option 
2 over Option 1) in terms of disease related emotional problems two years after Jose starts 
treatment 
3.4.2. Indicate, on a scale between 1 and 9, how much better is Option 2 over Option 3 (or Option 
3 over Option 2) in terms of disease related emotional problems two years after Jose starts 
treatment 
3.4.3. Indicate, on a scale between 1 and 9, how much better is Option 1 over Option 3 (or Option 
3 over Option 1) in terms of disease related emotional problems two years after Jose starts 
treatment 
 
 
Question 4. Imagine 100 patients identical to Jose who are alive two years after starting treatment 
with (Option 1/ Option 2/ Option 3). How many of these patients will be able to take care of 
themselves without help from others? 
 
 
Question 5. Imagine 100 patients identical to Jose who are alive two years after starting treatment 
with (Option 1/ Option 2/ Option 3). How many of these patients will be able to work a standard 
working week (i.e. 40 hours)? 
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Table A4.1 (cont.): Expert Choice Evidence Generation Questionnaire (EC-EGC) 
Question 6. Imagine 100 patients identical to Jose who are alive two years after starting treatment 
with (Option 1/ Option 2/ Option 3). How many of these patients will be able to work a standard 
working week (i.e. 40 hours)? 
 
Question 7. Imagine 100 patients identical to Jose who are alive two years after starting treatment 
with (Option 1/ Option 2/ Option 3). In how many of these patients will the disease interfere from 
moderately to extremely in their family life and in their family and social relations? 
 
 
Question 8. Imagine 100 patients identical to Jose who are alive two years after starting treatment 
with (Option 1/ Option 2/ Option 3). In how many of these patients will the disease cause 
moderate to severe financial difficulties? 
 
 
Question 9. This question is designed to measure the impact of the treatment-related adverse 
effects on Jose with each of the three treatment options from the start of treatment until death.  
 
Out of 100 patients identical to Jose who start treatment with (Option 1/ Option 2/ Option 3): 
9.1. How many will suffer grade 2,3, or 4 dyspnoea as a consequence of treatment-related 
pneumonitis and/or pulmonary fibrosis? 
9.2. How many will suffer grade 2,3, or 4 dysphagia as a consequence of treatment-related 
esophagitis? 
9.3. How many will suffer grade 2,3, or 4 infection as a consequence of immunodeficiency? 
9.4. How many will suffer grade 2,3, or 4 treatment-related diarrhoea? 
9.5. How many will suffer grade 2,3, or 4 treatment-related vomiting? 
9.6. How many will suffer grade 2 alopecia? 
9.7. How many will suffer grade 2 or grade 3 paraesthesia? 
9.8. How many will suffer grade 2 or grade 3 fatigue? 
9.9. How many will suffer grade 2, 3, or 4 anorexia?    
 
 
Question 10. This question is designed to measure the quality of the health care experience for 
Jose, from the start of treatment with (Option 1/ Option 2/ Option 3) until two years after the start 
of treatment.  
 
10.1. On average, what is the total number of visits that Jose will make to any outpatient health 
service during this period? 
10.2. On average, what is the total number of days spent by Jose in the hospital due to a cancer-
related hospitalisation during this period? 
10.3. On average, what is the total number of days over the optimal calendar required to continue 
treating Jose due to waiting lists during this period? 
10.4. Will Jose be treated by the same clinician or team of clinicians during this period? 
10.5. Will Jose be treated by his clinician or team of clinicians in a caring and considerate fashion 
during this period? 
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Table A4.2. Levels of the three options 𝐴𝑖  (𝑖 = 1 … 3) on the bottom-level criteria of 
the full final hierarchy for each of the three clinicians (Expert Choice-based PDA) 
 
 
Criterion  
𝑪𝒌(𝒃) 
 
 
Level 𝒙𝒊,𝒌  
 
or  
 
Matrix of 
comparative 
consequence 
judgments 
𝑪𝑴(𝑪𝒌(𝒃)) 
 
 
Clinician 1 
 
 
Clinician 2 
 
Clinician 3 
 
 
 
𝐴1 
 
 
 
𝐴2 
 
 
 
𝐴3 
 
 
 
𝐴1 
 
 
 
𝐴2 
 
 
 
𝐴3 
 
 
 
𝐴1 
 
 
 
𝐴2 
 
 
 
𝐴3 
 
Cure 
𝐶1(𝑏) 
 
𝑥𝑖,1 
 
0.25 
 
 
 
0.10 
 
0.05 
 
0.20 
 
0.10 
 
0.00 
 
0.40 
 
0.27 
 
0.00 
 
Life 
Expectancy 
 𝐶2(𝑏) 
 
 
 
𝑥𝑖,2 
 
 
5.15 
 
 
5.05 
 
 
1.75 
 
 
2.43 
 
 
1.34 
 
 
0.55 
 
 
6.49 
 
 
3.13 
 
 
0.73 
 
Disease-
related pain 
𝐶3(𝑏) 
 
 
𝐶𝑀(𝐶3(𝑏)) 
 
(
1 3 5
1/4 1 4
1/5 1/3 1
) 
 
 
(
1 4 3
1/4 1 1
1/3 1 1
) 
 
 
(
1 3 7
1/3 1 5
1/7 1/5 1
) 
 
 
Disease-
related 
dyspnoea 
𝐶4(𝑏) 
 
 
𝐶𝑀(𝐶4(𝑏)) 
 
(
1 3 5
1/3 1 4
1/5 1/4 1
) 
 
 
(
1 4 5
1/4 1 3
1/5 1/3 1
) 
 
 
(
1 1 8
1 1 7
1/8 1/7 1
) 
 
 
Disease-
related 
asthenia 
𝐶5(𝑏) 
 
 
𝐶𝑀(𝐶5(𝑏)) 
 
(
1 3 5
1/3 1 4
1/5 1/4 1
) 
 
 
(
1 4 3
1/4 1 2
1/3 1/2 1
) 
 
 
(
1 1 9
1 1 9
1/9 1/9 1
) 
 
 
Disease-
related 
emotional 
problems 
𝐶6(𝑏) 
 
 
 
𝐶𝑀(𝐶6(𝑏)) 
 
(
1 5 5
1/5 1 2
1/5 1/2 1
) 
 
(
1 4 5
1/4 1 3
1/5 1/3 1
) 
 
(
1 3 8
1/3 1 6
1/8 1/6 1
) 
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Table A4.2 (cont). Levels of the three options  𝐴𝑖  (𝑖 = 1 … 3) on the bottom-level 
criteria of the full final hierarchy for each of the three clinicians (Expert Choice-
based PDA) 
 
 
Criterion  
𝑪𝒌(𝒃) 
 
 
Level 𝒙𝒊,𝒌  
 
or  
 
Matrix of 
comparative 
consequence 
judgments 
𝑪𝑴(𝑪𝒌(𝒃)) 
 
 
Clinician 1 
 
Clinician 2 
 
Clinician 3 
 
 
 
𝐴1 
 
 
 
𝐴2 
 
 
 
𝐴3 
 
 
 
𝐴1 
 
 
 
𝐴2 
 
 
 
𝐴3 
 
 
 
𝐴1 
 
 
 
𝐴2 
 
 
 
𝐴3 
 
Self-care 
𝐶7(𝑏) 
 
 
𝑥𝑖,7 
 
0.90 
 
 
 
0.80 
 
0.30 
 
0.90 
 
0.80 
 
0.10 
 
0.85 
 
0.60 
 
0.10 
 
Work a normal 
week 
𝐶8(𝑏) 
 
 
 
𝑥𝑖,8 
 
 
0.25 
 
 
0.05 
 
 
0.00 
 
 
0.80 
 
 
0.60 
 
 
0.20 
 
 
0.75 
 
 
0.55 
 
 
0.00 
 
Interference of 
the disease with 
family life or 
with social 
activities  
𝐶9(𝑏) 
 
 
 
 
 
𝑥𝑖,9 
 
 
 
 
0.20 
 
 
 
 
0.40 
 
 
 
 
0.90 
 
 
 
 
0.20 
 
 
 
 
0.40 
 
 
 
 
0.80 
 
 
 
 
0.15 
 
 
 
 
0.30 
 
 
 
 
0.99 
 
Disease-related 
financial burden 
in the medium 
term* 
𝐶10(𝑏) 
 
 
 
 
𝑥𝑖,10 
 
 
 
0.60 
 
 
 
0.90 
 
 
 
0.95 
 
 
 
 
0.20 
 
 
 
 
 
0.40 
 
 
 
0.80 
 
 
 
0.20 
 
 
 
0.35 
 
 
 
0.99 
 
Treatment-
related 
dyspnoea as a 
consequence of 
pneumonitis or 
pulmonary 
fibrosis 
𝐶11(𝑏) 
 
 
 
 
 
𝑥𝑖,11 
 
 
 
 
0.20 
 
 
 
 
0.50 
 
 
 
 
0.00 
 
 
 
 
0.10 
 
 
 
 
0.40 
 
 
 
 
0.00 
 
 
 
 
0.02 
 
 
 
 
0.04 
 
 
 
 
0.00 
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Table A4.2(cont). Levels of the three options 𝐴𝑖  (𝑖 = 1 … 3) on the bottom-level 
criteria of the full final hierarchy for each of the three clinicians (Expert Choice-
based PDA) 
 
 
Criterion 
𝑪𝒌(𝒃) 
 
 
 
Level 𝒙𝒊,𝒌  
 
 
 
Clinician 1 
 
Clinician 2 
 
Clinician 3 
 
𝐴1 
 
 
𝐴2 
 
𝐴3 
 
𝐴1 
 
𝐴2 
 
𝐴3 
 
𝐴1 
 
𝐴2 
 
𝐴3 
 
Treatment-
related 
dysphagia as a 
consequence of 
oesophagitis 
𝐶12(𝑏) 
 
 
 
 
𝑥𝑖,12 
 
 
 
0.10 
 
 
 
0.20 
 
 
 
0.00 
 
 
 
0.15 
 
 
 
0.40 
 
 
 
0.00 
 
 
 
0.02 
 
 
 
0.15 
 
 
 
0.00 
 
Treatment-
related infection 
due to immuno-
deficiency 
𝐶13(𝑏) 
 
 
 
 
𝑥𝑖,13 
 
 
 
0.20 
 
 
 
0.20 
 
 
 
0.10 
 
 
 
0.20 
 
 
 
0.30 
 
 
 
0.00 
 
 
 
0.02 
 
 
 
0.20 
 
 
 
0.00 
 
Treatment-
related 
diarrhoea 
𝐶14(𝑏) 
 
 
 
𝑥𝑖,14 
 
 
0.20 
 
 
0.20 
 
 
0.10 
 
 
0.10 
 
 
 
0.10 
 
 
0.05 
 
 
0.20 
 
 
0.30 
 
 
0.05 
 
Treatment-
related 
vomiting  
𝐶15(𝑏) 
 
 
 
𝑥𝑖,15 
 
 
 
0.20 
 
 
0.20 
 
 
0.10 
 
 
0.15 
 
 
0.10 
 
 
0.05 
 
 
0.15 
 
 
0.60 
 
 
0.20 
 
Treatment-
related  
alopecia 
𝐶16(𝑏) 
 
 
 
𝑥𝑖,16 
 
 
 
0.10 
 
 
0.10 
 
 
0.00 
 
 
0.20 
 
 
0.20 
 
 
0.00 
 
 
0.05 
 
 
0.60 
 
 
0.00 
 
Treatment-
related 
paraesthesia 
𝐶17(𝑏) 
 
 
 
𝑥𝑖,17 
 
 
0.05 
 
 
0.05 
 
 
0.00 
 
 
0.10 
 
 
0.10 
 
 
0.00 
 
 
0.10 
 
 
0.50 
 
 
0.00 
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Table A4.2 (cont). Levels of the three options  𝐴𝑖  (𝑖 = 1 … 3) on the bottom-level 
criteria of the full final hierarchy for each of the three clinicians (Expert Choice-
based PDA) 
 
 
Criterion  
𝑪𝒌(𝒃) 
 
 
 
Level 𝒙𝒊,𝒌  
 
 
 
Clinician 1 
 
Clinician 2 
 
Clinician 3 
 
𝐴1 
 
 
𝐴2 
 
𝐴3 
 
𝐴1 
 
𝐴2 
 
𝐴3 
 
𝐴1 
 
𝐴2 
 
𝐴3 
 
Treatment-
related  
fatigue 
𝐶18(𝑏) 
 
 
 
𝑥𝑖,18 
 
 
0.40 
 
 
0.50 
 
 
0.20 
 
 
0.40 
 
 
0.60 
 
 
0.05 
 
 
0.02 
 
 
0.30 
 
 
0.00 
 
Treatment-
related  
anorexia 
𝐶19(𝑏) 
 
 
 
𝑥𝑖,19 
 
 
0.40 
 
 
0.40 
 
 
0.00 
 
 
0.60 
 
 
0.80 
 
 
0.00 
 
 
0.02 
 
 
0.30 
 
 
0.00 
 
Visits to the 
health services  
𝐶20(𝑏) 
 
 
 
𝑥𝑖,20 
 
 
20 
 
 
20 
 
 
10 
 
 
46 
 
 
 
76 
 
 
20 
 
 
13 
 
 
31 
 
 
4 
 
Hospital in-
patient stays 
𝐶21(𝑏) 
 
 
 
𝑥𝑖,21 
 
 
30 
 
 
20 
 
 
10 
 
 
15 
 
 
10 
 
 
10 
 
 
14 
 
 
14 
 
 
21 
Waiting time 
(due to waiting 
lists) between 
interventions 
𝐶22(𝑏) 
 
 
𝑥𝑖,22 
 
 
10 
 
 
20 
 
 
10 
 
 
45 
 
 
50 
 
 
15 
 
 
30 
 
 
15 
 
 
0 
 
Treatment by 
the same team 
of clinicians 
𝐶23(𝑏) 
 
 
 
𝑥𝑖,23 
 
 
1 
 
 
1 
 
 
1 
 
 
1 
 
 
1 
 
 
1 
 
 
1 
 
 
1 
 
 
1 
 
Attentive care 
𝐶24(𝑏) 
 
 
𝑥𝑖,24 
 
1 
 
1 
 
 
1 
 
1 
 
1 
 
 
1 
 
1 
 
1 
 
 
1 
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Table A4.3. Transition probability matrices for the Stage IIIA3 NSCLC Markov 
model elicited from the three clinicians in hospital H1 (Expert Choice-based PDA) 
 
Option 
𝑨𝒊 (𝒊 = 𝟏 … 𝟑) 
 
 
Clinician 1 
 
Clinician 2 
 
Clinician 3 
 
Neoadjuvant 
chemotherapy 
with resective 
intent (𝐴1) 
 
 
(
0 0.80 0.15 0.05
0 0.80 0.15 0.05
0 0 0.90 0.10
) 
 
(
0 0.90 0.08 0.02
0 0.70 0.20 0.10
0 0 0.50 0.50
) 
 
(
0 0.95 0.05 0
0 0.92 0.04 0.04
0 0 0.90 0.10
) 
 
Chemo-
radiotherapy 
(𝐴2) 
 
 
(
0 0.70 0.25 0.05
0 0.80 0.15 0.05
0 0 0.90 0.10
) 
 
(
0 0.70 0.20 0.10
0 0.50 0.30 0.20
0 0 0.20 0.80
) 
 
(
0 0.95 0.04 0.01
0 0.75 0.20 0.05
0 0 0.60 0.40
) 
 
Best supportive 
care (𝐴3) 
 
 
(
0 0.20 0.70 0.10
0 0.30 0.40 0.30
0 0 0.70 0.30
) 
 
(
0 0.10 0.45 0.45
0 0.02 0.18 0.80
0 0 0.05 0.95
) 
 
(
0 0.20 0.55 0.25
0 0.05 0.55 0.40
0 0 0.10 0.90
) 
 
Table A4.4. Levels 𝑥𝑖,2 (𝑖 = 1 … 3) of the three options 𝐴𝑖  (𝑖 = 1 … 3) on criterion 
life expectancy 𝐶2(𝑏), in years (Expert Choice-based PDA) 
 
Option 
𝑨𝒊 (𝒊 = 𝟏 … 𝟑) 
 
 
Clinician 1 
 
Clinician 2 
 
Clinician 3 
 
Neoadjuvant 
chemotherapy with 
resective intent (𝐴1) 
 
 
 
𝑥1,2 = 5.15 
 
 
𝑥1,2 = 2.43 
 
 
𝑥1,2 = 6.49 
 
Chemo-radiotherapy 
(𝐴2) 
 
 
𝑥2,2 = 5.05 
 
𝑥2,2 = 1.34 
 
𝑥2,2 = 3.13 
 
Best supportive care 
(𝐴3) 
 
 
𝑥3,2 = 1.75 
 
𝑥3,2 = 0.55 
 
𝑥3,2 = 0.73 
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Table A4.5. Non-idealised scores (idealised scores) of the options 𝐴𝑖(𝑖 = 1 … 3) on 
the bottom-level criteria 𝐶𝑘(𝑏)(𝑘 = 1 … 24) resulting from clinicians’ judgments 
(Expert Choice-based PDA) 
 
Criterion 𝑪𝒌(𝒃) 
Clinician 1 Clinician 2 Clinician 3 
𝐴1 𝐴2 𝐴3 𝐴1 𝐴2 𝐴3 𝐴1 𝐴2 𝐴3 
 
Cure 
𝐶1(𝑏) 
 
0.33 
(1.00) 
 
 
0.11 
(0.33) 
 
0.05 
(0.16) 
 
0.69 
(1) 
 
 
0.31 
(0.44) 
 
0.00 
(0.00) 
 
0.64 
(1.00) 
 
 
0.36 
(0.55) 
 
0.00 
(0.00) 
 
Life 
Expectancy 
 𝐶2(𝑏) 
 
 
 
1.00 
(1.00) 
 
 
0.98 
(0.98) 
 
 
0.34 
(0.34) 
 
 
1.00 
(1.00) 
 
 
0.55 
(0.55) 
 
 
0.23 
(0.23) 
 
 
1.00 
(1.00) 
 
 
0.48 
(0.48) 
 
 
0.11 
(0.11) 
 
Disease-related pain 
𝐶3(𝑏) 
 
 
0.67 
(1.00) 
 
 
0.23 
(0.34) 
 
0.10 
(0.15) 
 
0.63 
(1.00) 
 
 
0.17 
(0.28) 
 
0.19 
(0.30) 
 
0.65 
(1.00) 
 
 
0.28 
(0.43) 
 
0.07 
(0.11) 
 
Disease-related 
dyspnoea 
𝐶4(𝑏) 
 
 
0.63 
(1.00) 
 
 
0.28 
(0.44) 
 
0.09 
(0.14) 
 
0.67 
(1.00) 
 
 
0.23 
(0.32) 
 
0.10 
(0.15) 
 
0.48 
(1.00) 
 
 
0.46 
(0.96) 
 
0.06 
(0.13) 
 
Disease-related 
asthenia 
𝐶5(𝑏) 
 
 
0.63 
(1.00) 
 
 
0.28 
(0.44) 
 
0.09 
(0.14) 
 
0.63 
(1.00) 
 
 
0.22 
(0.35) 
 
0.15 
(0.24) 
 
0.47 
(1.00) 
 
 
0.47 
(1.00) 
 
0.05 
(0.11) 
 
Disease-related 
emotional problems 
𝐶6(𝑏) 
 
 
0.71 
(1.00) 
 
 
0.18 
(0.25) 
 
0.11 
(0.16) 
 
0.67 
(1.00) 
 
 
0.23 
(0.32) 
 
0.10 
(0.15) 
 
0.65 
(1.00) 
 
 
0.29 
(0.44) 
 
0.06 
(0.10) 
 
Self-care 
𝐶7(𝑏) 
 
 
0.67 
(1.00) 
 
 
0.30 
(0.45) 
 
0.03 
(0.05) 
 
0.69 
(1.00) 
 
 
0.31 
(0.44) 
 
0.01 
(0.01) 
 
0.78 
(1.00) 
 
 
0.21 
(0.26) 
 
0.02 
(0.02) 
 
Work a normal week 
𝐶8(𝑏) 
 
 
0.86 
(1.00) 
 
 
0.14 
(0.16) 
 
0.00 
(0.00) 
 
0.70 
(1.00) 
 
 
0.26 
(0.38) 
 
0.04 
(0.06) 
 
0.71 
(1.00) 
 
 
0.29 
(0.41) 
 
0.00 
(0.00) 
 
Interference of the 
disease with family 
life or with social 
activities  
𝐶9(𝑏) 
 
 
 
0.71 
(1.00) 
 
 
 
0.27 
(0.38) 
 
 
0.02 
(0.03) 
 
 
0.70 
(1.00) 
 
 
 
0.26 
(0.38) 
 
 
0.04 
(0.06) 
 
 
0.71 
(1.00) 
 
 
 
0.29 
(0.41) 
 
 
0.00 
(0.00) 
Disease-related 
financial burden in the 
medium term 
𝐶10(𝑏) 
 
 
0.80 
(1.00) 
 
 
 
0.13 
(0.16) 
 
 
0.06 
(0.08) 
 
 
0.70 
(1.00) 
 
 
 
0.26 
(0.38) 
 
 
0.04 
(0.06) 
 
 
0.68 
(1.00) 
 
 
 
0.32 
(0.46) 
 
 
0.00 
(0.00) 
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Table A4.5 (cont): Non-idealised scores (idealised scores) of the options 𝐴𝑖(𝑖 = 1 … 3) on 
the bottom-level criteria 𝐶𝑘(𝑏)(𝑘 = 1 … 24) resulting from clinicians’ judgments (Expert 
Choice-based PDA) 
 
Criterion  
𝑪𝒌(𝒃) 
 
Clinician 1 Clinician 2 Clinician 3 
𝐴1 𝐴2 𝐴3 𝐴1 𝐴2 𝐴3 𝐴1 𝐴2 𝐴3 
 
Treatment-related 
dyspnoea as a 
consequence of 
pneumonitis or 
pulmonary fibrosis 
𝐶11(𝑏) 
 
 
 
 
0.04 
(0.04) 
 
 
 
 
0.01 
(0.01) 
 
 
 
0.95 
(1.00) 
 
 
 
0.01 
(0.09) 
 
 
 
 
0.08 
(0.02) 
 
 
 
0.90 
(1.00) 
 
 
 
0.28 
(0.49) 
 
 
 
 
0.14 
(0.24) 
 
 
 
0.58 
(1.00) 
 
Treatment-related 
dysphagia as a 
consequence of 
oesophagitis 
𝐶12(𝑏) 
 
 
 
0.08 
(0.09) 
 
 
0.04 
(0.04) 
 
 
0.88 
(1.00) 
 
 
0.05 
(0.06) 
 
 
0.01 
(0.02) 
 
 
0.93 
(1.00) 
 
 
0.32 
(0.49) 
 
 
0.04 
(0.06) 
 
 
0.64 
(1.00) 
 
Treatment-related 
infection due to 
immuno-deficiency 
𝐶13(𝑏) 
 
 
0.04 
(0.04) 
 
 
0.04 
(0.04) 
 
0.92 
(1.00) 
 
0.02 
(0.02) 
 
 
0.04 
(0.04) 
 
0.94 
(1.00) 
 
0.04 
(0.04) 
 
 
0.02 
(0.02) 
 
0.94 
(1.00) 
 
Treatment-related 
diarrhoea 
𝐶14(𝑏) 
 
 
0.24 
(0.46) 
 
 
0.24 
(0.46) 
 
0.54 
(1.00) 
 
0.24 
(0.46) 
 
 
0.24 
(0.46) 
 
0.54 
(1.00) 
 
0.16 
(0.21) 
 
 
0.09 
(0.12) 
 
0.75 
(1.00) 
 
Treatment-related 
vomiting  
𝐶15(𝑏) 
 
 
0.24 
(0.46) 
 
 
0.24 
(0.46) 
 
0.53 
(1.00) 
 
0.17 
(0.30) 
 
 
0.27 
(0.47) 
 
0.56 
(1.00) 
 
0.02 
(0.02) 
 
 
0.00 
(0.00) 
 
0.98 
(1.00) 
 
Treatment-related  
alopecia 
𝐶16(𝑏) 
 
 
0.00 
(0.00) 
 
 
0.00 
(0.00) 
 
1.00 
(1.00) 
 
0.00 
(0.00) 
 
 
0.00 
(0.00) 
 
1.00 
(1.00) 
 
0.00 
(0.00) 
 
 
0.00 
(0.00) 
 
1.00 
(1.00) 
 
Treatment-related 
paraesthesia 
𝐶17(𝑏) 
 
 
0.00 
(0.00) 
 
 
0.00 
(0.00) 
 
1.00 
(1.00) 
 
0.00 
(0.00) 
 
 
0.00 
(0.00) 
 
1.00 
(1.00) 
 
0.00 
(0.00) 
 
 
0.00 
(0.00) 
 
1.00 
(1.00) 
 
Treatment-related  
fatigue 
𝐶18(𝑏) 
 
 
0.23 
(0.37) 
 
 
0.15 
(0.24) 
 
0.62 
(1.00) 
 
0.07 
(0.08) 
 
 
0.03 
(0.04) 
 
0.90 
(1.00) 
 
0.33 
(0.50) 
 
 
0.02 
(0.02) 
 
0.66 
(1.00) 
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Table A4.5 (cont): Non-idealised scores (idealised scores) of the options 𝐴𝑖(𝑖 = 1 … 3) on 
the bottom-level criteria 𝐶𝑘(𝑏)(𝑘 = 1 … 24) resulting from clinicians’ judgments (Expert 
Choice-based PDA) 
 
Criterion  
𝑪𝒌(𝒃) 
 
Clinician 1 Clinician 2 Clinician 3 
𝐴1 𝐴2 𝐴3 𝐴1 𝐴2 𝐴3 𝐴1 𝐴2 𝐴3 
 
Treatment-related  
anorexia 
C19(b) 
 
 
0.00 
(0.00) 
 
 
0.00 
(0.00) 
 
1.00 
(1.00) 
 
0.00 
(0.00) 
 
 
0.00 
(0.00) 
 
1.00 
(1.00) 
 
0.33 
(0.50) 
 
 
0.02 
(0.02) 
 
0.66 
(1.00) 
 
Visits to the health 
services  
𝐶20(𝑏) 
 
 
0.25 
(0.50) 
 
 
0.25 
(0.50) 
 
0.50 
(1.00) 
 
0.26 
(0.43) 
 
 
0.15 
(0.26) 
 
0.59 
(1.00) 
 
0.21 
(0.31) 
 
 
0.09 
(0.13) 
 
0.70 
(1.00) 
 
Hospital in-patient 
stays 
𝐶21(𝑏) 
 
 
0.18 
(0.33) 
 
 
0.27 
(0.49) 
 
0.55 
(1.00) 
 
0.25 
(0.67) 
 
 
0.38 
(1.00) 
 
0.38 
(1.00) 
 
0.37 
(1.00) 
 
 
0.38 
(1.00) 
 
0.25 
(0.67) 
Waiting time (due 
to waiting lists) 
between 
interventions 
𝐶22(𝑏) 
 
0.40 
(1.00) 
 
 
0.20 
(0.50) 
 
0.40 
(1.00) 
 
0.20 
(0.33) 
 
 
0.18 
(0.30) 
 
0.62 
(1.00) 
 
0.00 
(0.00) 
 
 
0.01 
(0.01) 
 
0.99 
(1.00) 
 
Treatment by the 
same team of 
clinicians 
𝐶23(𝑏) 
 
 
1.00 
(1.00) 
 
 
1.00 
(1.00) 
 
1.00 
(1.00) 
 
1.00 
(1.00) 
 
 
1.00 
(1.00) 
 
1.00 
(1.00) 
 
1.00 
(1.00) 
 
 
1.00 
(1.00) 
 
1.00 
(1.00) 
 
Attentive care 
𝐶24(𝑏) 
 
 
1.00 
(1.00) 
 
 
1.00 
(1.00) 
 
1.00 
(1.00) 
 
1.00 
(1.00) 
 
 
1.00 
(1.00) 
 
 
1.00 
(1.00) 
 
1.00 
(1.00) 
 
1.00 
(1.00) 
 
 
1.00 
(1.00) 
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Appendix 5: ALEL Evidence-Generation Questionnaire (ALEL-
EGQ), clinicians’ judgments about the performance levels of the 
options on the bottom-level criteria of the hierarchy and single-
criterion scores of the options on these criteria for ALEL-based PDA 
Table A5.1. ALEL-based evidence generation questionnaire (ALEL-EGC) 
 
Introduction. Welcome. Jose is a sixty-nine year old male recently diagnosed with non-small cell 
lung cancer stage T2N2M0 (IIIA3). The tumour is in the lower left lobe and the mediastinal 
involvement is limited to one paratracheal lymph node. Jose has mild chronic obstructive 
pulmonary disease (COPD) and three years ago he suffered a hear infarction that was treated with 
a stent. 
 
The objective of this questionnaire is to measure the likely impact of the three treatment options 
available at hospital H1 for this patient on a number of criteria that you have considered of 
importance to him. The three options are: 
 
Option 1: neoadjuvant chemotherapy with resective intent. 
Option 2: concurrent chemo-radiotherapy 
Option 3: best supportive care 
 
Please answer the following questions. Many thanks in advance for your time and your answers 
 
Question 1. Of 100 patients identical to Jose who start treatment with (Option 1/ Option 2/ Option 
3), how many of these patients will get “cured”? Cure is defined as absence of tumour activity 
after 5 years of the start of treatment 
 
Suppose that Jose can be in one of the three states of tumour response: 1) “no progression” (the 
cancerous lesions do not extend and may even respond partially to the treatment), 2) 
“progression” (the cancerous lesions extend without question), and 3) “death”.  
 
Question 2.  
 
2.1. Imagine 100 patients identical to Jose who start treatment with (Option 1/ Option 2/ Option 
3). 
2.1.1. How many of these patients will be in state “no progression” 6 months after starting 
treatment? 
2.1.2. How many of these patients will be in state “progression” 6 months after starting treatment? 
2.1.3. How many of these patients will be in state “death” 6 months after starting treatment? 
 
2.2. Suppose now that Jose, 6 months after starting treatment with (option 1/ Option 2/ Option 3) 
is in state “no progression”. Imagine 100 patients identical to Jose.  
2.2.1. How many of these patients will be in state “no progression” 12 months after starting 
treatment? 
2.2.2. How many of these patients will be in state “progression” 12 months after starting 
treatment? 
2.2.3. How many of these patients will be in state “death” 12 months after starting treatment? 
 
2.3. Suppose now that Jose, 6 months after starting treatment with (option 1/ Option 2/ Option 3) 
is in state “progression”. Imagine 100 patients identical to Jose.  
2.3.1. How many of these patients will still be in state “progression” 12 months after starting 
treatment? 
2.3.2. How many of these patients will be in state “death” 12 months after starting treatment? 
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Table A5.1 (cont.). ALEL-based evidence generation questionnaire (ALEL-EGC) 
 
Question 3. This question is designed to measure Jose’s quality of life in the medium term (two 
years after starting treatment) under each of the three treatment options. To measure this quality of 
life, it is important to assume that Jose, at two years after starting treatment, is not suffering any of 
the adverse effects associated with the treatments. In particular, that Jose is not suffering the 
adverse effects typically associated with chemotherapy or radiotherapy. 
 
3.1. Indicate, on a scale between 1 and 9 where 1 is “no pain” and 9 is “extreme pain”, the 
intensity of disease-related pain that Jose will experience two years after the start of treatment 
with (Option 1/ Option 2/ Option 3)  
3.2. Indicate, on a scale between 1 and 9 where 1 is “no dyspnoea” and 9 is “extreme dyspnoea”, 
the intensity of disease-related dyspnoea that Jose will experience two years after the start of 
treatment with (Option 1/ Option 2/ Option 3)   
3.3. Indicate, on a scale between 1 and 9 where 1 is “no asthenia” and 9 is “extreme asthenia”, the 
intensity of disease-related asthenia that Jose will experience two years after the start of treatment 
with (Option 1/ Option 2/ Option 3)   
3.4. Indicate, on a scale between 1 and 9 where 1 is “no emotional problems” and 9 is “extreme 
emotional problems”, the intensity of disease-related emotional problems that Jose will experience 
two years after the start of treatment with (Option 1/ Option 2/ Option 3)   
  
 
 
Question 4. Imagine 100 patients identical to Jose who are alive two years after starting treatment 
with (Option 1/ Option 2/ Option 3). How many of these patients will be able to take care of 
themselves without help from others? 
 
 
Question 5. Imagine 100 patients identical to Jose who are alive two years after starting treatment 
with (Option 1/ Option 2/ Option 3). How many of these patients will be able to work a standard 
working week (i.e. 40 hours)? 
 
 
Question 6. Imagine 100 patients identical to Jose who are alive two years after starting treatment 
with (Option 1/ Option 2/ Option 3). How many of these patients will be able to work a standard 
working week (i.e. 40 hours)? 
 
Question 7. Imagine 100 patients identical to Jose who are alive two years after starting treatment 
with (Option 1/ Option 2/ Option 3). In how many of these patients will the disease interfere from 
moderately to extremely in their family life and in their family and social relations? 
 
 
Question 8. Imagine 100 patients identical to Jose who are alive two years after starting treatment 
with (Option 1/ Option 2/ Option 3). In how many of these patients will the disease cause 
moderate to severe financial difficulties? 
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Table A5.1 (cont.): ALEL-based evidence generation questionnaire (ALEL-EGC) 
 
Question 9. This question is designed to measure the impact of the treatment-related adverse 
effects on Jose with each of the three treatment options from the start of treatment until death.  
 
Out of 100 patients identical to Jose who start treatment with (Option 1/ Option 2/ Option 3): 
9.1. How many will suffer grade 2,3, or 4 dyspnoea as a consequence of treatment-related 
pneumonitis and/or pulmonary fibrosis? 
9.2. How many will suffer grade 2,3, or 4 dysphagia as a consequence of treatment-related 
esophagitis? 
9.3. How many will suffer grade 2,3, or 4 infection as a consequence of immunodeficiency? 
9.4. How many will suffer grade 2,3, or 4 treatment-related diarrhoea? 
9.5. How many will suffer grade 2,3, or 4 treatment-related vomiting? 
9.6. How many will suffer grade 2 alopecia? 
9.7. How many will suffer grade 2 or grade 3 paraesthesia? 
9.8. How many will suffer grade 2 or grade 3 fatigue? 
9.9. How many will suffer grade 2, 3, or 4 anorexia?    
 
 
Question 10. This question is designed to measure the quality of the health care experience for 
Jose, from the start of treatment with (Option 1/ Option 2/ Option 3) until two years after the start 
of treatment.  
 
10.1. On average, what is the total number of visits that Jose will make to any outpatient health 
service during this period? 
10.2. On average, what is the total number of days spent by Jose in the hospital due to a cancer-
related hospitalisation during this period? 
10.3. On average, what is the total number of days over the optimal calendar required to continue 
treating Jose due to waiting lists during this period? 
10.4. Will Jose be treated by the same clinician or team of clinicians during this period? 
10.5. Will Jose be treated by his clinician or team of clinicians in a caring and considerate fashion 
during this period? 
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Table A5.2. Levels of the three options 𝐴𝑖  (𝑖 = 1 … 3) on the bottom-level criteria of 
the full final hierarchy for each of the three clinicians (ALEL-based PDA) 
 
 
Criterion  
𝑪𝒌(𝒃) 
 
 
 
Level 𝒙𝒊,𝒌  
 
 
 
Clinician 1 
 
Clinician 2 
 
Clinician 3 
 
𝐴1 
 
𝐴2 
 
𝐴3 
 
𝐴1 
 
𝐴2 
 
𝐴3 
 
𝐴1 
 
𝐴2 
 
𝐴3 
 
 
Cure 
𝐶1(𝑏) 
 
𝑥𝑖,1 
 
0.30 
 
0.10 
 
0.03 
 
0.40 
 
0.25 
 
0.00 
 
0.25 
 
 
 
0.15 
 
0.00 
 
Life 
Expectancy 
 𝐶2(𝑏) 
 
 
 
𝑥𝑖,2 
 
 
1.85 
 
 
1.19 
 
 
1.12 
 
 
2.08 
 
 
1.28 
 
 
0.70 
 
 
2.01 
 
 
1.23 
 
 
0.38 
 
Disease-
related pain 
𝐶3(𝑏) 
 
 
 
𝑥𝑖,3 
 
 
3 
 
 
4 
 
 
4 
 
 
5 
 
 
6 
 
 
7 
 
 
2 
 
 
 
3 
 
 
4 
 
Disease-
related 
dyspnoea 
𝐶4(𝑏) 
 
 
 
𝑥𝑖,4 
 
 
4 
 
 
6 
 
 
 
4 
 
 
5 
 
 
6 
 
 
7 
 
 
2 
 
 
5 
 
 
7 
 
Disease-
related 
asthenia 
𝐶5(𝑏) 
 
 
 
𝑥𝑖,5 
 
 
4 
 
 
6 
 
 
8 
 
 
3 
 
 
4 
 
 
6 
 
 
2 
 
 
4 
 
 
7 
 
Disease-
related 
emotional 
problems 
𝐶6(𝑏) 
 
 
 
 
𝑥𝑖,6 
 
 
4 
 
 
6 
 
 
8 
 
 
3 
 
 
3 
 
 
6 
 
 
2 
 
 
4 
 
 
6 
 
Self-care 
𝐶7(𝑏) 
 
 
𝑥𝑖,7 
 
0.60 
 
0.35 
 
 
 
0.05 
 
0.70 
 
0.50 
 
0.25 
 
0.80 
 
0.60 
 
 
0.10 
 
Work a 
normal 
week 
𝐶8(𝑏) 
 
 
 
𝑥𝑖,8 
 
 
0.40 
 
 
0.20 
 
 
0.05 
 
 
0.30 
 
 
0.20 
 
 
0.10 
 
 
0.80 
 
 
0.70 
 
 
0.10 
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Table A5.2 (cont.). Levels of the three options  𝐴𝑖  (𝑖 = 1 … 3) on the bottom-level 
criteria of the full final hierarchy for each of the three clinicians (ALEL-based PDA) 
 
 
Criterion  
𝑪𝒌(𝒃) 
 
 
 
Level 𝒙𝒊,𝒌  
 
 
 
Clinician 1 
 
Clinician 2 
 
Clinician 3 
 
𝐴1 
 
 
𝐴2 
 
𝐴3 
 
𝐴1 
 
𝐴2 
 
𝐴3 
 
𝐴1 
 
𝐴2 
 
𝐴3 
 
Interference of 
the disease with 
family life or 
with social 
activities  
𝐶9(𝑏) 
 
 
 
 
𝑥𝑖,9 
 
 
 
0.40 
 
 
 
0.65 
 
 
 
0.05 
 
 
 
0.50 
 
 
 
0.60 
 
 
 
0.80 
 
 
 
0.80 
 
 
 
 
 
0.70 
 
 
 
0.50 
 
Disease-related 
financial burden 
in the medium 
term* 
𝐶10(𝑏) 
 
 
 
 
𝑥𝑖,10 
 
 
 
0.10 
 
 
 
0.20 
 
 
 
0.10 
 
 
 
0.50 
 
 
 
0.60 
 
 
 
0.80 
 
 
 
0.10 
 
 
 
0.10 
 
 
 
0.20 
 
Treatment-
related 
dyspnoea as a 
consequence of 
pneumonitis or 
pulmonary 
fibrosis 
𝐶11(𝑏) 
 
 
 
 
 
𝑥𝑖,11 
 
 
 
 
0.05 
 
 
 
 
0.20 
 
 
 
 
0.00 
 
 
 
 
0.50 
 
 
 
 
0.70 
 
 
 
 
0.00 
 
 
 
 
0.15 
 
 
 
 
0.30 
 
 
 
 
0.00 
 
Treatment-
related 
dysphagia as a 
consequence of 
oesophagitis 
𝐶12(𝑏) 
 
 
 
 
𝑥𝑖,12 
 
 
 
0.10 
 
 
 
0.20 
 
 
 
0.00 
 
 
 
0.30 
 
 
 
0.60 
 
 
 
0.00 
 
 
 
0.10 
 
 
 
0.20 
 
 
 
0.00 
 
Treatment-
related infection 
due to immuno-
deficiency 
𝐶13(𝑏) 
 
 
 
 
𝑥𝑖,13 
 
 
 
0.30 
 
 
 
0.50 
 
 
 
0.00 
 
 
 
0.10 
 
 
 
0.20 
 
 
 
0.00 
 
 
 
0.15 
 
 
 
0.30 
 
 
 
0.00 
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Table A5.2 (cont.): Levels of the three options 𝐴𝑖  (𝑖 = 1 … 3) on the bottom-level 
criteria of the full final hierarchy for each of the three clinicians (ALEL-based PDA) 
 
 
Criterion  
𝑪𝒌(𝒃) 
 
 
 
Level 𝒙𝒊,𝒌  
 
 
 
Clinician 1 
 
Clinician 2 
 
Clinician 3 
 
𝐴1 
 
 
𝐴2 
 
𝐴3 
 
𝐴1 
 
𝐴2 
 
𝐴3 
 
𝐴1 
 
𝐴2 
 
𝐴3 
 
Treatment-
related 
diarrhoea 
𝐶14(𝑏) 
 
 
 
𝑥𝑖,14 
 
 
0.10 
 
 
0.20 
 
 
0.10 
 
 
0.10 
 
 
0.10 
 
 
0.10 
 
 
0.10 
 
 
 
 
0.10 
 
 
0.05 
 
Treatment-
related 
vomiting  
𝐶15(𝑏) 
 
 
 
𝑥𝑖,15 
 
 
0.05 
 
 
0.30 
 
 
0.10 
 
 
0.50 
 
 
0.60 
 
 
0.10 
 
 
0.20 
 
 
0.30 
 
 
0.30 
 
Treatment-
related  
alopecia 
𝐶16(𝑏) 
 
 
 
𝑥𝑖,16 
 
 
0.90 
 
 
0.99 
 
 
0.00 
 
 
0.20 
 
 
0.20 
 
 
0.00 
 
 
0.80 
 
 
0.80 
 
 
0.00 
 
Treatment-
related 
paraesthesia 
𝐶17(𝑏) 
 
 
 
𝑥𝑖,17 
 
 
0.10 
 
 
0.50 
 
 
0.00 
 
 
0.20 
 
 
0.20 
 
 
0.00 
 
 
0.70 
 
 
0.70 
 
 
0.00 
 
Treatment-
related  
fatigue 
𝐶18(𝑏) 
 
 
 
𝑥𝑖,18 
 
 
0.20 
 
 
0.40 
 
 
0.60 
 
 
0.40 
 
 
0.60 
 
 
0.15 
 
 
0.15 
 
 
0.25 
 
 
0.50 
 
Treatment-
related  
anorexia 
𝐶19(𝑏) 
 
 
 
𝑥𝑖,19 
 
 
0.20 
 
 
0.50 
 
 
0.00 
 
 
0.15 
 
 
0.40 
 
 
0.00 
 
 
0.30 
 
 
0.50 
 
 
0.00 
 
Visits to the 
health services  
𝐶20(𝑏) 
 
 
 
𝑥𝑖,20 
 
 
8 
 
 
20 
 
 
4 
 
 
20 
 
 
30 
 
 
10 
 
 
15 
 
 
25 
 
 
5 
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Table A5.2 (cont.). Levels of the three options 𝐴𝑖  (𝑖 = 1 … 3) on the bottom-level 
criteria of the full final hierarchy for each of the three clinicians (ALEL-based PDA) 
 
 
Criterion  
𝑪𝒌(𝒃) 
 
 
 
Level 𝒙𝒊,𝒌  
 
 
 
Clinician 1 
 
Clinician 2 
 
Clinician 3 
 
 
 
𝐴1 
 
 
 
𝐴2 
 
 
 
𝐴3 
 
 
 
𝐴1 
 
 
 
𝐴2 
 
 
 
𝐴3 
 
 
 
𝐴1 
 
 
 
𝐴2 
 
 
 
𝐴3 
 
Hospital in-
patient stays 
𝐶21(𝑏) 
 
 
 
𝑥𝑖,21 
 
 
10 
 
 
15 
 
 
4 
 
 
20 
 
 
20 
 
 
30 
 
 
10 
 
 
 
 
15 
 
 
5 
Waiting time 
(due to waiting 
lists) between 
interventions 
𝐶22(𝑏) 
 
 
𝑥𝑖,22 
 
 
30 
 
 
20 
 
 
5 
 
 
15 
 
 
30 
 
 
10 
 
 
5 
 
 
10 
 
 
1 
 
Treatment by 
the same team 
of clinicians 
𝐶23(𝑏) 
 
 
 
𝑥𝑖,23 
 
 
1 
 
 
1 
 
 
1 
 
 
1 
 
 
1 
 
 
1 
 
 
1 
 
 
1 
 
 
1 
 
Attentive care 
𝐶24(𝑏) 
 
 
𝑥𝑖,24 
 
1 
 
1 
 
1 
 
1 
 
1 
 
1 
 
1 
 
1 
 
1 
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Table A5.3. Transition probability matrices for the Stage IIIA3 NSCLC Markov 
model elicited from the three clinicians in hospital H2 (ALEL-based PDA) 
 
Option 
𝑨𝒊 (𝒊 = 𝟏 … 𝟑) 
 
 
Clinician 1 
 
Clinician 2 
 
Clinician 3 
 
Neoadjuvant 
chemotherapy 
with resective 
intent (𝐴1) 
 
 
(
0 0.75 0.18 0.07
0 0.55 0.35 0.10
0 0 0.50 0.50
) 
 
(
0 0.75 0.20 0.05
0 0.70 0.20 0.10
0 0 0.40 0.60
) 
 
(
0 0.80 0.15 0.05
0 0.70 0.20 0.10
0 0 0.80 0.20
) 
 
Chemo-
radiotherapy 
(𝐴2) 
 
 
(
0 0.50 0.35 0.15
0 0.40 0.40 0.20
0 0 0.35 0.65
) 
 
(
0 0.60 0.30 0.10
0 0.50 0.25 0.25
0 0 0.30 0.70
) 
 
(
0 0.60 0.25 0.15
0 0.50 0.30 0.20
0 0 0.20 0.80
) 
 
Best supportive 
care (𝐴3) 
 
 
(
0 0.70 0.20 0.10
0 0.15 0.60 0.25
0 0 0.25 0.75
) 
 
(
0 0.30 0.30 0.40
0 0.30 0.30 0.40
0 0 0.1 0.90
) 
 
(
0 0.05 0.20 0.75
0 0.01 0.04 0.95
0 0 0 1
) 
 
 
Table A5.4. Levels 𝑥𝑖,2 (𝑖 = 1 … 3) of the three options 𝐴𝑖  (𝑖 = 1 … 3) on criterion 
life expectancy 𝐶2(𝑏), in years (ALEL-based PDA) 
 
Option 
𝑨𝒊 (𝒊 = 𝟏 … 𝟑) 
 
 
Clinician 1 
 
Clinician 2 
 
Clinician 3 
 
Neoadjuvant 
chemotherapy with 
resective intent (𝐴1) 
 
 
 
𝑥1,2 = 1.85 
 
 
𝑥1,2 = 2.08 
 
 
𝑥1,2 = 2.01 
 
Chemo-radiotherapy 
(𝐴2) 
 
 
𝑥2,2 = 1.19 
 
𝑥2,2 = 1.24 
 
𝑥2,2 = 1.23 
 
Best supportive care 
(𝐴3) 
 
 
𝑥3,2 = 1.12 
 
𝑥3,2 = 0.70 
 
𝑥3,2 = 0.38 
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Table A5.5. Non-idealised scores (idealised scores) of the options 𝐴𝑖(𝑖 = 1 … 3) on 
the bottom-level criteria 𝐶𝑘(𝑏)(𝑘 = 1 … 24) resulting from clinicians’ judgments 
(ALEL-based PDA) 
 
Criterion 𝑪𝒌(𝒃) 
Clinician 1 Clinician 2 Clinician 3 
𝐴1 𝐴2 𝐴3 𝐴1 𝐴2 𝐴3 𝐴1 𝐴2 𝐴3 
 
Cure 
𝐶1(𝑏) 
 
0.30 
(1.00) 
 
0.10 
(0.33) 
 
0.03 
(0.10) 
 
0.40 
(1.00) 
 
 
0.25 
(0.63) 
 
0.00 
(0.00) 
 
0.25 
(1.00) 
 
 
0.15 
(0.6) 
 
0.00 
(0.00) 
 
Life 
Expectancy 
 𝐶2(𝑏) 
 
 
 
1.00 
(1.00) 
 
 
0.64 
(0.64) 
 
 
0.61 
(0.61) 
 
 
1.00 
(1.00) 
 
 
0.62 
(0.62) 
 
 
0.34 
(0.34) 
 
 
1.00 
(1.00) 
 
 
0.61 
(0.61) 
 
 
0.19 
(0.19) 
 
Disease-related pain 
𝐶3(𝑏) 
 
 
0.75 
(1.00) 
 
 
0.63 
(0.83) 
 
0.63 
(0.83) 
 
0.50 
(1.00) 
 
 
0.38 
(0.75) 
 
0.25 
(0.50) 
 
0.88 
(1.00) 
 
 
0.75 
(0.86) 
 
0.63 
(0.71) 
 
Disease-related 
dyspnoea 
𝐶4(𝑏) 
 
 
0.63 
(1.00) 
 
 
0.38 
(0.60) 
 
0.63 
(1.00) 
 
0.50 
(1.00) 
 
 
0.38 
(0.75) 
 
0.25 
(0.50) 
 
0.88 
(1.00) 
 
 
0.50 
(0.57) 
 
0.25 
(0.29) 
 
Disease-related 
asthenia 
𝐶5(𝑏) 
 
 
0.63 
(1.00) 
 
 
0.38 
(0.60) 
 
0.13 
(0.20) 
 
0.75 
(1.00) 
 
 
0.63 
(0.83) 
 
0.38 
(0.50) 
 
0.88 
(1.00) 
 
 
0.63 
(0.71) 
 
0.25 
(0.29) 
 
Disease-related 
emotional problems 
𝐶6(𝑏) 
 
 
0.63 
(1.00) 
 
 
0.38 
(0.60) 
 
0.13 
(0.20) 
 
0.75 
(1.00) 
 
 
0.75 
(1.00) 
 
0.38 
(0.50) 
 
0.88 
(1.00) 
 
 
0.63 
(0.71) 
 
0.38 
(0.43) 
 
Self-care 
𝐶7(𝑏) 
 
 
0.60 
(1.00) 
 
 
0.35 
(0.58) 
 
0.05 
(0.08) 
 
0.70 
(1.00) 
 
 
0.50 
(0.71) 
 
0.25 
(0.36) 
 
0.80 
(1.00) 
 
 
0.60 
(0.75) 
 
0.10 
(0.13) 
 
Work a normal week 
𝐶8(𝑏) 
 
 
0.40 
(1.00) 
 
 
0.20 
(0.50) 
 
0.05 
(0.13) 
 
0.30 
(1.00) 
 
 
0.20 
(0.67) 
 
0.10 
(0.33) 
 
0.80 
(1.00) 
 
 
0.70 
(0.88) 
 
0.10 
(0.13) 
 
Interference of the 
disease with family 
life or with social 
activities  
𝐶9(𝑏) 
 
 
 
0.60 
(0.63) 
 
 
 
0.35 
(0.37) 
 
 
0.95 
(1.00) 
 
 
0.50 
(1.00) 
 
 
 
0.40 
(0.80) 
 
 
0.20 
(0.40) 
 
 
0.71 
(1.00) 
 
 
 
0.29 
(0.41) 
 
 
0.00 
(0.00) 
 
Disease-related 
financial burden in the 
medium term 𝐶10(𝑏) 
 
 
0.90 
(1.00) 
 
 
 
0.80 
(0.89) 
 
 
0.90 
(1.00) 
 
 
0.50 
(1.00) 
 
 
 
0.40 
(0.80) 
 
 
0.20 
(0.40) 
 
 
0.50 
(1.00) 
 
 
 
0.30 
(0.60) 
 
 
0.20 
(0.40) 
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Table A5.5 (cont.). Non-idealised scores (idealised scores) of the options 𝐴𝑖(𝑖 = 1 … 3) on 
the bottom-level criteria 𝐶𝑘(𝑏)(𝑘 = 1 … 24) resulting from clinicians’ judgments (ALEL-
based PDA) 
 
Criterion  
𝑪𝒌(𝒃) 
 
Clinician 1 Clinician 2 Clinician 3 
𝐴1 𝐴2 𝐴3 𝐴1 𝐴2 𝐴3 𝐴1 𝐴2 𝐴3 
 
Treatment-related 
dyspnoea as a 
consequence of 
pneumonitis or 
pulmonary fibrosis 
𝐶11(𝑏) 
 
 
 
 
0.95 
(0.95) 
 
 
 
 
0.80 
(0.80) 
 
 
 
1.00 
(1.00) 
 
 
 
0.50 
(0.50) 
 
 
 
 
0.30 
(0.30) 
 
 
 
1.00 
(1.00) 
 
 
 
0.85 
(0.85) 
 
 
 
 
0.70 
(0.70) 
 
 
 
1.00 
(1.00) 
 
Treatment-related 
dysphagia as a 
consequence of 
oesophagitis 
𝐶12(𝑏) 
 
 
 
0.90 
(0.90) 
 
 
0.80 
(0.80) 
 
 
1.00 
(1.00) 
 
 
0.70 
(0.70) 
 
 
0.40 
(0.40) 
 
 
1.00 
(1.00) 
 
 
0.90 
(0.90) 
 
 
0.80 
(0.80) 
 
 
1.00 
(1.00) 
 
Treatment-related 
infection due to 
immuno-deficiency 
𝐶13(𝑏) 
 
 
0.70 
(0.70) 
 
 
0.50 
(0.50) 
 
1.00 
(1.00) 
 
0.90 
(0.90) 
 
 
0.80 
(0.80) 
 
1.00 
(1.00) 
 
0.85 
(0.85) 
 
 
0.70 
(0.70) 
 
1.00 
(1.00) 
 
Treatment-related 
diarrhoea 
𝐶14(𝑏) 
 
 
0.90 
(1.00) 
 
 
0.80 
(0.89) 
 
0.90 
(1.00) 
 
0.90 
(1.00) 
 
 
0.90 
(1.00) 
 
0.90 
(1.00) 
 
0.90 
(0.95) 
 
 
0.90 
(0.95) 
 
0.95 
(1.00) 
 
Treatment-related 
vomiting  
𝐶15(𝑏) 
 
 
0.95 
(1.00) 
 
 
0.70 
(0.74) 
 
0.90 
(0.95) 
 
0.50 
(0.55) 
 
 
0.40 
(0.44) 
 
0.90 
(1.00) 
 
0.80 
(1.00) 
 
 
0.70 
(0.88) 
 
0.70 
(0.88) 
 
Treatment-related  
alopecia 
𝐶16(𝑏) 
 
 
0.00 
(0.00) 
 
 
0.00 
(0.00) 
 
1.00 
(1.00) 
 
0.80 
(0.80) 
 
 
0.80 
(0.80) 
 
1.00 
(1.00) 
 
0.20 
(0.20) 
 
 
0.20 
(0.20) 
 
1.00 
(1.00) 
 
Treatment-related 
paraesthesia 
𝐶17(𝑏) 
 
 
0.9 
(0.9) 
 
 
0.5 
(0.5) 
 
1.00 
(1.00) 
 
0.80 
(0.80) 
 
 
0.80 
(0.80) 
 
1.00 
(1.00) 
 
0.30 
(0.30) 
 
 
0.30 
(0.30) 
 
1.00 
(1.00) 
 
Treatment-related  
fatigue 
𝐶18(𝑏) 
 
 
0.80 
(1.00) 
 
 
0.60 
(0.75) 
 
0.40 
(0.5) 
 
0.60 
(0.71) 
 
 
0.40 
(0.47) 
 
0.85 
(1.00) 
 
0.85 
(1.00) 
 
 
0.75 
(0.88) 
 
0.50 
(0.59) 
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Table A5.5 (cont.): Non-idealised scores (idealised scores) of the options 𝐴𝑖(𝑖 = 1 … 3) on 
the bottom-level criteria 𝐶𝑘(𝑏)(𝑘 = 1 … 24) resulting from clinicians’ judgments (ALEL-
based PDA) 
 
Criterion  
𝑪𝒌(𝒃) 
 
Clinician 1 Clinician 2 Clinician 3 
𝐴1 𝐴2 𝐴3 𝐴1 𝐴2 𝐴3 𝐴1 𝐴2 𝐴3 
 
Treatment-related  
anorexia 
𝐶19(𝑏) 
 
 
0.80 
(0.80) 
 
 
0.50 
(0.5) 
 
1.00 
(1.00) 
 
0.85 
(0.85) 
 
 
0.60 
(0.60) 
 
1.00 
(1.00) 
 
0.70 
(0.70) 
 
 
0.50 
(0.50) 
 
1.00 
(1.00) 
 
Visits to the health 
services  
𝐶20(𝑏) 
 
 
0.50 
(0.50) 
 
 
0.20 
(0.20) 
 
1.00 
(1.00) 
 
0.50 
(0.50) 
 
 
0.33 
(0.33) 
 
1.00 
(1.00) 
 
0.07 
(0.33) 
 
 
0.04 
(0.20) 
 
0.20 
(1) 
 
Hospital in-patient 
stays 
𝐶21(𝑏) 
 
 
0.40 
(0.40) 
 
 
0.27 
(0.27) 
 
1.00 
(1.00) 
 
1.00 
(1.00) 
 
 
0.67 
(0.67) 
 
0.67 
(0.67) 
 
0.10 
(0.5) 
 
 
0.07 
(0.33) 
 
0.20 
(1.00) 
Waiting time (due to 
waiting lists) between 
interventions 
𝐶22(𝑏) 
 
0.17 
(0.17) 
 
 
0.25 
(0.25) 
 
1.00 
(1.00) 
 
0.67 
(0.67) 
 
 
0.33 
(0.33) 
 
1.00 
(1.00) 
 
0.20 
(1.00) 
 
 
0.10 
(0.59) 
 
0.10 
(0.50) 
 
Treatment by the 
same team of 
clinicians 
𝐶23(𝑏) 
 
 
1.00 
(1.00) 
 
 
1.00 
(1.00) 
 
1.00 
(1.00) 
 
1.00 
(1.00) 
 
 
1.00 
(1.00) 
 
1.00 
(1.00) 
 
1.00 
(1.00) 
 
 
1.00 
(1.00) 
 
1.00 
(1.00) 
 
Attentive care 
𝐶24(𝑏) 
 
 
1.00 
(1.00) 
 
 
1.00 
(1.00) 
 
 
1.00 
(1.00) 
 
1.00 
(1.00) 
 
 
1.00 
(1.00) 
 
 
1.00 
(1.00) 
 
1.00 
(1.00) 
 
 
1.00 
(1.00) 
 
 
1.00 
(1.00) 
 
  
306 
 
Appendix 6. Visual representation of the sequence of delivery steps 
using the Expert Choice-based PDA (hospital H1) 
 
Figure A6.1. Communication of the criteria  
 
 
Figure A6.2. Pair-wise comparisons screen 
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Figure A6.3. Communication of the options 
 
Figure A6.4. Communication of the results of the decision  
 
Figure A6.5. Communication of the evidence for the quality of life in the medium 
term criterion 
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Figure A6.6. Dynamic sensitivity analysis screen  
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Appendix 7. Visual representation of the sequence of delivery steps 
using the ALEL-based PDA (hospital H2) 
Figure A7.1. Communication of the criteria 
 
Figure A7.2. Elicia screen to assess the criteria weights  
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Figure A7.3. Weightings panel in the Annalisa topic screen 
 
Figure A7.4. Information pop-up for criterion financial burden due to the disease in 
the medium term 
 
Figure A7.5. Communication of the options 
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Figure A7.6. Communication of results 
 
Figure A7.7. Communication of the evidence 
 
Figure A7.8 Sensitivity analysis of the criteria weights 
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Appendix 8: Spanish version of the top-level criteria and of the 
treatment descriptions for the Expert Choice-based PDA  
Table A8.1. Renaming in Spanish the top-level criteria for communication to the 
patient  
 
Top-level criterion 
 
 
Top-level criterion as it was renamed for communication to 
the patient 
 
Curarme 
 
 
Maximizar las opciones de curarme 
 
Esperanza de vida 
 
 
Vivir el mayor tiempo que sea posible, independientemente de que 
mi estado de salud sea bueno o malo 
 
Calidad de vida dentro de 
dos años 
 
 
Tener la major calidad de vida possible dentro de dos años. Esto 
ocurrirá si: 
 
1) Yo no tengo ninguno de los siguientes sintomas típicos del 
cáncer: dolor, sensación de ahogo, astenia, problemas emocionales 
como depresión o irritabilidad 
 
2) Yo soy capaz de cuidar de mi mismo sin necesitar ayuda de 
otros, puedo trabajar una semana laboral normal, y mi enfermedad 
no interfiere de manera notable sobre mi vida familiar y social  
 
 
Problemas económicos 
dentro de dos años 
 
 
Tener los menores problemas económicos posibles por causa de la 
enfermedad dentro de dos años 
 
Efectos adversos derivados 
del tratamiento 
 
 
Padecer los menores efectos adversos derivados del tratamiento 
que sea posible. Entre los efectos adversos más communes están 
los siguientes: sensación de ahogo causada por la inflamación de 
un pulmón, problemas al tragar causados por una inflamación del 
esófago, infecciones causadas por una caída de las defensas, 
diarrea, vómitos, caída del pelo, picores y sensación de temblor en 
las extremidades, cansancio, anorexia. Todos estos efectos 
adversos con la excepción de la caída del pelo pueden llegar a 
requerir ingreso hospitalario  
 
 
Calidad asistencial 
 
 
Tener la mejor calidad asistencial posible durante los primeros dos 
años del tratamiento. Esto ocurrirá si:  
 
1) yo no tengo que realizar visitas al hospital para seguir un 
tratamiento o realizar un chequeo, 2) yo no tengo que ser 
ingresado en el hospital, 3) yo no tengo que estar en lista de espera 
para recibir un tratamiento, 4) yo soy tratado siempre por el 
mismo médico o por el mismo equipo médico, 5) yo soy tratado 
en todo momento de forma personalizada y considerada 
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Table A8.2. Textual content in Spanish of the three treatment descriptions  
 
Treatment 
option 
 
Description 
 
 
 
Neoadjuvant 
chemotherapy 
with resective 
intent       
(Option 𝐴1) 
 
1. Quimioterapia neoadyuvante con intención resectiva. Este tratamiento 
consiste en inyectarme una medicina (quimioterapia) que elimina las células 
del tumor para intentar reducir el tamaño de este y poder quitármelo con 
cirugía. El tratamiento tiene varias etapas: primero se me inyecta la 
quimioterapia en varias sesiones a lo largo de un mes. Si parece que la 
quimioterapia ha tenido éxito en reducir el tumor se me someterá a una 
pequeña intervención quirúrgica llamada mediastinoscopia para verificar que 
esto es así y que se me puede operar el tumor con éxito. Si se me puede operar 
el tumor, se me intervendrá (estaré ingresado aproximadamente una semana). 
Si la quimioterapia no ha tenido éxito en reducir el tumor se me volverá a dar 
quimioterapia a lo largo de unas semanas, esta vez combinada con radioterapia. 
La radioterapia consiste en el uso de una máquina que emite radiación para 
quemar las células del tumor. Si el tumor vuelve, cosa bastante probable, se me 
volverá a tratar con quimioterapia 
 
Concurrent 
chemotherapy 
(Option 𝐴2) 
 
2. Quimio-radioterapia concomitante. Este tratamiento consiste en darme 
quimioterapia combinada con radioterapia a lo largo de unas semanas. Si el 
tumor vuelve, cosa bastante probable, se me volverá a tratar con quimioterapia  
 
Best supportive 
care        
(Option 𝐴3) 
 
3. Tratamiento sintomático. Este tratamiento no va dirigido a eliminar el tumor, 
sino a tratar los síntomas de la enfermedad. Se me dará fisioterapia, 
psicoterapia, medicación para eliminar el dolor, para reducir los problemas 
para respirar, para reducir la náusea y los vómitos, para mejorar mi apetito, 
para eliminar el insomnio, etc 
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Appendix 9: Spanish version of the top-level criteria and of the 
treatment descriptions for the ALEL-based PDA 
Table A9.1: Renaming in Spanish the top-level criteria for communication to the 
patient 
 
Top-level criterion 
 
 
Top-level criterion as it was renamed for communication to 
the patient 
 
Curarme 
 
 
Maximizar las opciones de curarme 
 
Esperanza de vida 
 
 
Vivir el mayor tiempo que sea posible, independientemente de que 
mi estado de salud sea bueno o malo 
 
Calidad de vida dentro de 
dos años 
 
 
Tener la major calidad de vida possible dentro de dos años. Esto 
ocurrirá si: 
 
1) Yo no tengo ninguno de los siguientes sintomas típicos del 
cáncer: dolor, sensación de ahogo, astenia, problemas emocionales 
como depresión o irritabilidad 
 
2) Yo soy capaz de cuidar de mi mismo sin necesitar ayuda de 
otros, puedo trabajar una semana laboral normal, y mi enfermedad 
no interfiere de manera notable sobre mi vida familiar y social  
 
 
Problemas económicos 
dentro de dos años 
 
 
Tener los menores problemas económicos posibles por causa de la 
enfermedad dentro de dos años 
 
Efectos adversos derivados 
del tratamiento 
 
 
Padecer los menores efectos adversos derivados del tratamiento 
que sea posible. Entre los efectos adversos más communes están 
los siguientes: sensación de ahogo causada por la inflamación de 
un pulmón, problemas al tragar causados por una inflamación del 
esófago, infecciones causadas por una caída de las defensas, 
diarrea, vómitos, caída del pelo, picores y sensación de temblor en 
las extremidades, cansancio, anorexia. Todos estos efectos 
adversos con la excepción de la caída del pelo pueden llegar a 
requerir ingreso hospitalario  
 
 
Calidad asistencial 
 
 
Tener la mejor calidad asistencial posible durante los primeros dos 
años del tratamiento. Esto ocurrirá si:  
 
1) yo no tengo que realizar visitas al hospital para seguir un 
tratamiento o realizar un chequeo, 2) yo no tengo que ser 
ingresado en el hospital, 3) yo no tengo que estar en lista de espera 
para recibir un tratamiento, 4) yo soy tratado siempre por el 
mismo médico o por el mismo equipo médico, 5) yo soy tratado 
en todo momento de forma personalizada y considerada 
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Table A9.2: Textual content in Spanish of the three treatment descriptions  
 
Treatment 
option 
 
Description 
 
 
 
Neoadjuvant 
chemotherapy 
with resective 
intent       
(Option 𝐴1) 
 
1. Quimioterapia neoadyuvante con intención resectiva. Este tratamiento 
consiste en inyectarme una medicina (quimioterapia) que elimina las células 
del tumor para intentar reducir el tamaño de este y poder quitármelo con 
cirugía. El tratamiento tiene varias etapas: primero se me inyecta la 
quimioterapia en varias sesiones a lo largo de un mes. Si parece que la 
quimioterapia ha tenido éxito en reducir el tumor se me someterá a una 
pequeña intervención quirúrgica llamada mediastinoscopia para verificar que 
esto es así y que se me puede operar el tumor con éxito. Si se me puede operar 
el tumor, se me intervendrá (estaré ingresado aproximadamente una semana). 
Si la quimioterapia no ha tenido éxito en reducir el tumor se me volverá a dar 
quimioterapia a lo largo de unas semanas, esta vez combinada con radioterapia. 
La radioterapia consiste en el uso de una máquina que emite radiación para 
quemar las células del tumor. Si el tumor vuelve, cosa bastante probable, se me 
volverá a tratar con quimioterapia 
 
Concurrent 
chemotherapy 
(Option 𝐴2) 
 
2. Quimio-radioterapia concomitante. Este tratamiento consiste en darme 
quimioterapia combinada con radioterapia a lo largo de unas semanas. Si el 
tumor vuelve, cosa bastante probable, se me volverá a tratar con quimioterapia  
 
Best supportive 
care        
(Option 𝐴3) 
 
3. Tratamiento sintomático. Este tratamiento no va dirigido a eliminar el tumor, 
sino a tratar los síntomas de la enfermedad. Se me dará fisioterapia, 
psicoterapia, medicación para eliminar el dolor, para reducir los problemas 
para respirar, para reducir la náusea y los vómitos, para mejorar mi apetito, 
para eliminar el insomnio, etc 
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Appendix 10: STATA output. 
Panel 1. Assessment of inter-rater reliability for scores (priorities/ratings) of options 
A1, A2 and A3 on the six top-level criteria: 1) cure for cancer, 2) life expectancy, 3) 
quality of life in the medium term, 4) financial difficulties in the medium term, 5) 
adverse effects of treatment, 6) quality of the health care experience from start of 
treatment until the medium term 
 
. bysort idHosp idTrat: icc punt20C idPunt idClin6 
 
-> idHosp = 1, idTrat = 1 
 
Intraclass correlations 
Two-way random-effects model 
Absolute agreement 
 
Random effects: idPunt           Number of targets =        20 
Random effects: idClin6          Number of raters  =         3 
 
-------------------------------------------------------------- 
               punt20C |        ICC       [95% Conf. Interval] 
-----------------------+-------------------------------------- 
            Individual |   .6678252       .4411757    .8370258 
               Average |   .8577806       .7031244    .9390535 
-------------------------------------------------------------- 
F test that 
  ICC=0.00: F(19.0, 38.0) = 7.02              Prob > F = 0.000 
 
Note: ICCs estimate correlations between individual measurements 
      and between average measurements made on the same target. 
 
 
-> idHosp = 1, idTrat = 2 
 
Intraclass correlations 
Two-way random-effects model 
Absolute agreement 
 
Random effects: idPunt           Number of targets =        20 
Random effects: idClin6          Number of raters  =         3 
 
-------------------------------------------------------------- 
               punt20C |        ICC       [95% Conf. Interval] 
-----------------------+-------------------------------------- 
            Individual |     .62123       .3812422     .809932 
               Average |   .8310918       .6489286    .9274512 
-------------------------------------------------------------- 
F test that 
  ICC=0.00: F(19.0, 38.0) = 6.03              Prob > F = 0.000 
 
Note: ICCs estimate correlations between individual measurements 
      and between average measurements made on the same target. 
 
-------------------------------------------------------------------------------------
-------------------------------------- 
-> idHosp = 1, idTrat = 3 
 
Intraclass correlations 
Two-way random-effects model 
Absolute agreement 
 
Random effects: idPunt           Number of targets =        20 
Random effects: idClin6          Number of raters  =         3 
 
-------------------------------------------------------------- 
               punt20C |        ICC       [95% Conf. Interval] 
-----------------------+-------------------------------------- 
            Individual |   .6257861       .3835051    .8134242 
               Average |   .8337988       .6511085    .9289735 
-------------------------------------------------------------- 
F test that 
  ICC=0.00: F(19.0, 38.0) = 5.91              Prob > F = 0.000 
 
Note: ICCs estimate correlations between individual measurements 
      and between average measurements made on the same target. 
 
-------------------------------------------------------------------------------------
-------------------------------------- 
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-> idHosp = 2, idTrat = 1 
 
Intraclass correlations 
Two-way random-effects model 
Absolute agreement 
 
Random effects: idPunt           Number of targets =        20 
Random effects: idClin6          Number of raters  =         3 
 
-------------------------------------------------------------- 
               punt20C |        ICC       [95% Conf. Interval] 
-----------------------+-------------------------------------- 
            Individual |   .6768686       .4522445    .8423379 
               Average |   .8627156       .7123872    .9412733 
-------------------------------------------------------------- 
F test that 
  ICC=0.00: F(19.0, 38.0) = 7.18              Prob > F = 0.000 
 
Note: ICCs estimate correlations between individual measurements 
      and between average measurements made on the same target. 
 
-------------------------------------------------------------------------------------
-------------------------------------- 
-> idHosp = 2, idTrat = 2 
 
Intraclass correlations 
Two-way random-effects model 
Absolute agreement 
 
Random effects: idPunt           Number of targets =        20 
Random effects: idClin6          Number of raters  =         3 
 
-------------------------------------------------------------- 
               punt20C |        ICC       [95% Conf. Interval] 
-----------------------+-------------------------------------- 
            Individual |   .8890574       .7848056    .9504473 
               Average |   .9600655       .9162541    .9829181 
-------------------------------------------------------------- 
F test that 
  ICC=0.00: F(19.0, 38.0) = 26.32             Prob > F = 0.000 
 
Note: ICCs estimate correlations between individual measurements 
      and between average measurements made on the same target. 
 
-------------------------------------------------------------------------------------
-------------------------------------- 
-> idHosp = 2, idTrat = 3 
 
Intraclass correlations 
Two-way random-effects model 
Absolute agreement 
 
Random effects: idPunt           Number of targets =        20 
Random effects: idClin6          Number of raters  =         3 
 
-------------------------------------------------------------- 
               punt20C |        ICC       [95% Conf. Interval] 
-----------------------+-------------------------------------- 
            Individual |   .3446093       .0805348    .6222834 
               Average |   .6120155       .2080878    .8317196 
-------------------------------------------------------------- 
F test that 
  ICC=0.00: F(19.0, 38.0) = 2.67              Prob > F = 0.005 
 
Note: ICCs estimate correlations between individual measurements 
      and between average measurements made on the same target. 
 
. 
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Panel 2. Comparing the scores (priorities/ratings) of the options on the six top-level 
criteria across clinicians, options and criteria within each hospital. 
1. Hospital H1. 
                                                                     
regress punt6C i.IDTrat i.IDClin3 i.IDcrite if IDhosp==1 & IDTrat<3 
 
 
      Source |       SS           df       MS      Number of obs   =        
36 
-------------+----------------------------------   F(8, 27)        =     
11.64 
       Model |  1.30381113         8  .162976391   Prob > F        =    
0.0000 
    Residual |  .378086126        27   .01400319   R-squared       =    
0.7752 
-------------+----------------------------------   Adj R-squared   =    
0.7086 
       Total |  1.68189726        35  .048054207   Root MSE        =    
.11834 
 
---------------------------------------------------------------------------
--- 
      punt6C |      Coef.   Std. Err.      t    P>|t|     [95% Conf. 
Interval] 
-------------+-------------------------------------------------------------
--- 
    2.IDTrat |  -.2583333    .039445    -6.55   0.000    -.3392678   -
.1773988 
             | 
     IDClin3 | 
          2  |   .0058333   .0483101     0.12   0.905    -.0932908    
.1049575 
          3  |      .0225   .0483101     0.47   0.645    -.0766241    
.1216241 
             | 
     IDcrite | 
          2  |       -.04   .0683208    -0.59   0.563    -.1801827    
.1001827 
          3  |  -.0016667   .0683208    -0.02   0.981    -.1418493     
.138516 
          4  |  -.0016667   .0683208    -0.02   0.981    -.1418493     
.138516 
          5  |      -.375   .0683208    -5.49   0.000    -.5151827   -
.2348173 
          6  |       -.19   .0683208    -2.78   0.010    -.3301827   -
.0498173 
             | 
       _cons |   .6013889   .0591675    10.16   0.000     .4799871    
.7227906 
 
 
Wald test ( Partial F) 
 
. test (2.IDClin3 3.IDClin3) 
 
 ( 1)  2.IDClin3 = 0 
 ( 2)  3.IDClin3 = 0 
 
       F(  2,    27) =    0.12 
            Prob > F =    0.8902 
 
. test (2.IDcrite 3.IDcrite 4.IDcrite 5.IDcrite 6.IDcrite ) 
 
 ( 1)  2.IDcrite = 0 
 ( 2)  3.IDcrite = 0 
 ( 3)  4.IDcrite = 0 
 ( 4)  5.IDcrite = 0 
 ( 5)  6.IDcrite = 0 
 
       F(  5,    27) =   10.00 
            Prob > F =    0.0000 
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2. Hospital H2. 
. regress punt6C i.IDTrat i.IDClin3 i.IDcrite if IDhosp==2 
 
 
      Source |       SS           df       MS      Number of obs   =        
54 
-------------+----------------------------------   F(9, 44)        =      
4.13 
       Model |  2.14989443         9  .238877159   Prob > F        =    
0.0007 
    Residual |  2.54318886        44  .057799747   R-squared       =    
0.4581 
-------------+----------------------------------   Adj R-squared   =    
0.3473 
       Total |  4.69308329        53  .088548741   Root MSE        =    
.24042 
 
---------------------------------------------------------------------------
--- 
      punt6C |      Coef.   Std. Err.      t    P>|t|     [95% Conf. 
Interval] 
-------------+-------------------------------------------------------------
--- 
      IDTrat | 
          2  |  -.2955556   .0801386    -3.69   0.001    -.4570643   -
.1340468 
          3  |  -.3827778   .0801386    -4.78   0.000    -.5442865   -
.2212691 
             | 
     IDClin3 | 
          2  |  -.0011111   .0801386    -0.01   0.989    -.1626198    
.1603976 
          3  |  -.0388889   .0801386    -0.49   0.630    -.2003976    
.1226198 
             | 
     IDcrite | 
          2  |        .16   .1133331     1.41   0.165    -.0684078    
.3884078 
          3  |   .1333333   .1133331     1.18   0.246    -.0950745    
.3617412 
          4  |        .28   .1133331     2.47   0.017     .0515922    
.5084078 
          5  |   .3122222   .1133331     2.75   0.009     .0838144      
.54063 
          6  |   .3044444   .1133331     2.69   0.010     .0760366    
.5328523 
             | 
       _cons |   .7472222   .1034585     7.22   0.000     .5387154    
.9557291 
 
Wald test (partial F) 
 
. test (2.IDTrat 3.IDTrat) 
 
 ( 1)  2.IDTrat = 0 
 ( 2)  3.IDTrat = 0 
 
       F(  2,    44) =   12.53 
            Prob > F =    0.0000 
 
. test (2.IDClin3 3.IDClin3) 
 
 ( 1)  2.IDClin3 = 0 
 ( 2)  3.IDClin3 = 0 
 
       F(  2,    44) =    0.15 
            Prob > F =    0.8589 
 
. test (2.IDcrite 3.IDcrite 4.IDcrite 5.IDcrite 6.IDcrite ) 
 
 ( 1)  2.IDcrite = 0 
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 ( 2)  3.IDcrite = 0 
 ( 3)  4.IDcrite = 0 
 ( 4)  5.IDcrite = 0 
 ( 5)  6.IDcrite = 0 
 
       F(  5,    44) =    2.36 
            Prob > F =    0.0551 
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